0001460602 2024-01-01 2024-12-31 0001460602 2024-06-30 0001460602 2026-03-26 0001460602 2024-12-31 0001460602 2023-12-31 0001460602 us-gaap:RelatedPartyMember 2024-12-31 0001460602 us-gaap:RelatedPartyMember 2023-12-31 0001460602 us-gaap:NonrelatedPartyMember 2024-12-31 0001460602 us-gaap:NonrelatedPartyMember 2023-12-31 0001460602 2023-01-01 2023-12-31 0001460602 us-gaap:CommonStockMember 2023-12-31 0001460602 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001460602 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001460602 us-gaap:TreasuryStockCommonMember 2023-12-31 0001460602 us-gaap:RetainedEarningsMember 2023-12-31 0001460602 us-gaap:ParentMember 2023-12-31 0001460602 us-gaap:NoncontrollingInterestMember 2023-12-31 0001460602 us-gaap:CommonStockMember 2022-12-31 0001460602 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001460602 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001460602 us-gaap:TreasuryStockCommonMember 2022-12-31 0001460602 us-gaap:RetainedEarningsMember 2022-12-31 0001460602 us-gaap:ParentMember 2022-12-31 0001460602 us-gaap:NoncontrollingInterestMember 2022-12-31 0001460602 2022-12-31 0001460602 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001460602 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-12-31 0001460602 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-12-31 0001460602 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-12-31 0001460602 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0001460602 us-gaap:ParentMember 2024-01-01 2024-12-31 0001460602 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-12-31 0001460602 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001460602 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001460602 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0001460602 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-12-31 0001460602 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001460602 us-gaap:ParentMember 2023-01-01 2023-12-31 0001460602 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-12-31 0001460602 us-gaap:CommonStockMember 2024-12-31 0001460602 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001460602 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001460602 us-gaap:TreasuryStockCommonMember 2024-12-31 0001460602 us-gaap:RetainedEarningsMember 2024-12-31 0001460602 us-gaap:ParentMember 2024-12-31 0001460602 us-gaap:NoncontrollingInterestMember 2024-12-31 0001460602 ORGS:OctomeraLLCMember 2024-01-29 0001460602 2024-09-20 2024-09-20 0001460602 ORGS:ORGSMember 2024-12-31 0001460602 srt:MinimumMember ORGS:ProductionFacilityMember 2024-12-31 0001460602 srt:MaximumMember ORGS:ProductionFacilityMember 2024-12-31 0001460602 srt:MinimumMember us-gaap:EquipmentMember 2024-12-31 0001460602 srt:MaximumMember us-gaap:EquipmentMember 2024-12-31 0001460602 srt:MinimumMember us-gaap:OfficeEquipmentMember 2024-12-31 0001460602 srt:MaximumMember us-gaap:OfficeEquipmentMember 2024-12-31 0001460602 ORGS:KnowHowMember 2024-12-31 0001460602 ORGS:TechnologyMember 2024-12-31 0001460602 ORGS:MetalmarkMember ORGS:UnitPurchaseAgreementMember 2024-01-01 2024-12-31 0001460602 ORGS:UnitPurchaseAgreementMember 2024-01-01 2024-12-31 0001460602 ORGS:TenSecuredPromissoryNotesMember 2024-12-31 0001460602 ORGS:OctomeraMember 2024-12-31 0001460602 ORGS:KnowHowTechnologyMember 2024-12-31 0001460602 ORGS:OctomeraMember 2024-01-01 2024-12-31 0001460602 ORGS:OctomeraMember 2023-01-01 2023-12-31 0001460602 ORGS:OctomeraMember 2024-01-01 2024-01-29 0001460602 us-gaap:FairValueInputsLevel3Member 2024-01-29 0001460602 us-gaap:FairValueInputsLevel3Member 2024-12-31 0001460602 ORGS:OctomeraMember us-gaap:MeasurementInputDiscountRateMember 2024-01-29 0001460602 ORGS:OctomeraMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-01-29 0001460602 ORGS:OctomeraMember us-gaap:MeasurementInputLongTermRevenueGrowthRateMember 2024-01-29 0001460602 us-gaap:FairValueInputsLevel3Member ORGS:MeasurementInputStandardDeviationMember 2024-01-29 0001460602 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-01-29 0001460602 us-gaap:FairValueInputsLevel3Member ORGS:MeasurementInputTriggerEventMember 2024-01-29 2024-01-29 0001460602 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputLongTermRevenueGrowthRateMember 2024-01-29 0001460602 us-gaap:FairValueInputsLevel3Member ORGS:MeasurementInputTriggerEventsMember 2024-01-29 0001460602 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputRevenueMultipleMember 2024-01-29 0001460602 2024-01-29 0001460602 ORGS:OctomeraLLCMember 2024-01-31 0001460602 ORGS:ButterflyBiosciencesSarlMember 2023-12-31 0001460602 ORGS:ButterflyBiosciencesSarlMember 2024-12-31 0001460602 ORGS:RevacelSrlMember 2021-12-31 0001460602 ORGS:RevacelSrlMember ORGS:RevatisMember 2021-12-31 0001460602 ORGS:OctomeraLLCMember 2024-01-01 2024-01-31 0001460602 ORGS:OctomeraLLCMember 2023-07-01 2023-12-31 0001460602 ORGS:OctomeraMember 2024-01-01 2024-12-31 0001460602 ORGS:TherapiesMember 2024-01-01 2024-12-31 0001460602 ORGS:EliminationsMember 2024-01-01 2024-12-31 0001460602 ORGS:OctomeraMember 2023-01-01 2023-12-31 0001460602 ORGS:TherapiesMember 2023-01-01 2023-12-31 0001460602 ORGS:EliminationsMember 2023-01-01 2023-12-31 0001460602 ORGS:SecuritiesPurchaseAgreementMember 2023-02-22 2023-02-23 0001460602 ORGS:SecuritiesPurchaseAgreementMember 2023-02-23 0001460602 2023-02-23 0001460602 us-gaap:PrivatePlacementMember ORGS:SecuritiesPurchaseAgreementMember 2023-08-31 2023-08-31 0001460602 us-gaap:PrivatePlacementMember ORGS:SecuritiesPurchaseAgreementMember 2023-08-31 0001460602 ORGS:SecuritiesPurchaseAgreementMember 2023-11-08 0001460602 2023-11-08 0001460602 2023-11-08 2023-11-08 0001460602 us-gaap:InvestorMember 2024-03-08 0001460602 us-gaap:InvestorMember 2024-08-14 0001460602 us-gaap:PrivatePlacementMember ORGS:SecuritiesPurchaseAgreementMember 2024-03-03 2024-03-03 0001460602 us-gaap:PrivatePlacementMember ORGS:SecuritiesPurchaseAgreementMember 2024-03-03 0001460602 us-gaap:WarrantMember us-gaap:PrivatePlacementMember ORGS:SecuritiesPurchaseAgreementMember 2024-03-03 0001460602 ORGS:WarrantOneMember us-gaap:PrivatePlacementMember ORGS:SecuritiesPurchaseAgreementMember 2024-03-03 0001460602 2024-03-03 0001460602 us-gaap:PrivatePlacementMember ORGS:SecuritiesPurchaseAgreementMember 2024-05-10 2024-05-10 0001460602 us-gaap:PrivatePlacementMember ORGS:SecuritiesPurchaseAgreementMember 2024-05-10 0001460602 us-gaap:WarrantMember ORGS:SecuritiesPurchaseAgreementMember 2024-05-10 0001460602 ORGS:WarrantOneMember ORGS:SecuritiesPurchaseAgreementMember 2024-05-10 0001460602 ORGS:SecuritiesPurchaseAgreementMember 2024-05-10 2024-05-10 0001460602 ORGS:ProductionFacilityMember 2024-12-31 0001460602 ORGS:ProductionFacilityMember 2023-12-31 0001460602 ORGS:OfficeFurnitureAndComputersMember 2024-12-31 0001460602 ORGS:OfficeFurnitureAndComputersMember 2023-12-31 0001460602 ORGS:LabEquipmentMember 2024-12-31 0001460602 ORGS:LabEquipmentMember 2023-12-31 0001460602 ORGS:AdvancePaymentMember 2024-12-31 0001460602 ORGS:AdvancePaymentMember 2023-12-31 0001460602 country:BE 2024-12-31 0001460602 country:BE 2023-12-31 0001460602 country:GR 2024-12-31 0001460602 country:GR 2023-12-31 0001460602 country:NL 2024-12-31 0001460602 country:NL 2023-12-31 0001460602 country:IL 2024-12-31 0001460602 country:IL 2023-12-31 0001460602 country:US 2024-12-31 0001460602 country:US 2023-12-31 0001460602 ORGS:KnowHowMember 2023-12-31 0001460602 ORGS:TechnologyMember 2023-12-31 0001460602 us-gaap:LongTermDebtMember 2024-12-31 0001460602 us-gaap:LongTermDebtMember 2024-01-01 2024-12-31 0001460602 us-gaap:LongTermDebtMember 2023-12-31 0001460602 us-gaap:ShortTermDebtMember 2024-12-31 0001460602 us-gaap:ShortTermDebtMember 2023-12-31 0001460602 ORGS:ShortTermDebtOneMember 2024-12-31 0001460602 ORGS:ShortTermDebtOneMember 2023-12-31 0001460602 ORGS:ShortTermDebtTwoMember 2024-12-31 0001460602 ORGS:ShortTermDebtTwoMember 2023-12-31 0001460602 ORGS:ShortTermDebtThreeMember 2024-12-31 0001460602 ORGS:ShortTermDebtThreeMember 2023-12-31 0001460602 ORGS:DebtExchangeAgreementsMember 2024-01-01 2024-01-01 0001460602 ORGS:DebtExchangeAgreementsMember 2024-01-01 0001460602 ORGS:April072024Member us-gaap:WarrantMember 2024-01-01 2024-12-31 0001460602 ORGS:April072024Member us-gaap:WarrantMember 2024-12-31 0001460602 ORGS:April052024Member us-gaap:WarrantMember 2024-01-01 2024-12-31 0001460602 ORGS:April052024Member us-gaap:WarrantMember 2024-12-31 0001460602 ORGS:August212024Member us-gaap:WarrantMember 2024-01-01 2024-12-31 0001460602 ORGS:August212024Member us-gaap:WarrantMember 2024-12-31 0001460602 ORGS:August212024OneMember us-gaap:WarrantMember 2024-01-01 2024-12-31 0001460602 ORGS:August212024OneMember us-gaap:WarrantMember 2024-12-31 0001460602 ORGS:September062024Member us-gaap:WarrantMember 2024-01-01 2024-12-31 0001460602 ORGS:September062024Member us-gaap:WarrantMember 2024-12-31 0001460602 ORGS:September102024Member us-gaap:WarrantMember 2024-01-01 2024-12-31 0001460602 ORGS:September102024Member us-gaap:WarrantMember 2024-12-31 0001460602 ORGS:September092024Member us-gaap:WarrantMember 2024-01-01 2024-12-31 0001460602 ORGS:September092024Member us-gaap:WarrantMember 2024-12-31 0001460602 ORGS:September172024Member us-gaap:WarrantMember 2024-01-01 2024-12-31 0001460602 ORGS:September172024Member us-gaap:WarrantMember 2024-12-31 0001460602 ORGS:September302024Member us-gaap:WarrantMember 2024-01-01 2024-12-31 0001460602 ORGS:September302024Member us-gaap:WarrantMember 2024-12-31 0001460602 ORGS:October032024Member us-gaap:WarrantMember 2024-01-01 2024-12-31 0001460602 ORGS:October032024Member us-gaap:WarrantMember 2024-12-31 0001460602 ORGS:October222024Member us-gaap:WarrantMember 2024-01-01 2024-12-31 0001460602 ORGS:October222024Member us-gaap:WarrantMember 2024-12-31 0001460602 ORGS:October302024Member us-gaap:WarrantMember 2024-01-01 2024-12-31 0001460602 ORGS:October302024Member us-gaap:WarrantMember 2024-12-31 0001460602 ORGS:November042024Member us-gaap:WarrantMember 2024-01-01 2024-12-31 0001460602 ORGS:November042024Member us-gaap:WarrantMember 2024-12-31 0001460602 ORGS:November142024Member us-gaap:WarrantMember 2024-01-01 2024-12-31 0001460602 ORGS:November142024Member us-gaap:WarrantMember 2024-12-31 0001460602 ORGS:November152024Member us-gaap:WarrantMember 2024-01-01 2024-12-31 0001460602 ORGS:November152024Member us-gaap:WarrantMember 2024-12-31 0001460602 ORGS:November292024Member us-gaap:WarrantMember 2024-01-01 2024-12-31 0001460602 ORGS:November292024Member us-gaap:WarrantMember 2024-12-31 0001460602 ORGS:December132024Member us-gaap:WarrantMember 2024-01-01 2024-12-31 0001460602 ORGS:December132024Member us-gaap:WarrantMember 2024-12-31 0001460602 ORGS:December192024Member us-gaap:WarrantMember 2024-01-01 2024-12-31 0001460602 ORGS:December192024Member us-gaap:WarrantMember 2024-12-31 0001460602 ORGS:November302024Member us-gaap:WarrantMember 2024-01-01 2024-12-31 0001460602 ORGS:November302024Member us-gaap:WarrantMember 2024-12-31 0001460602 ORGS:December312024Member us-gaap:WarrantMember 2024-01-01 2024-12-31 0001460602 ORGS:December312024Member us-gaap:WarrantMember 2024-12-31 0001460602 ORGS:December312024OneMember us-gaap:WarrantMember 2024-01-01 2024-12-31 0001460602 ORGS:December312024OneMember us-gaap:WarrantMember 2024-12-31 0001460602 ORGS:December312024TwoMember us-gaap:WarrantMember 2024-01-01 2024-12-31 0001460602 ORGS:December312024TwoMember us-gaap:WarrantMember 2024-12-31 0001460602 ORGS:December312024ThreeMember us-gaap:WarrantMember 2024-01-01 2024-12-31 0001460602 ORGS:December312024ThreeMember us-gaap:WarrantMember 2024-12-31 0001460602 ORGS:December312024FourMember us-gaap:WarrantMember 2024-01-01 2024-12-31 0001460602 ORGS:December312024FourMember us-gaap:WarrantMember 2024-12-31 0001460602 ORGS:December312024FiveMember us-gaap:WarrantMember 2024-01-01 2024-12-31 0001460602 ORGS:December312024FiveMember us-gaap:WarrantMember 2024-12-31 0001460602 ORGS:December312024SixMember us-gaap:WarrantMember 2024-01-01 2024-12-31 0001460602 ORGS:December312024SixMember us-gaap:WarrantMember 2024-12-31 0001460602 ORGS:December312024SevenMember us-gaap:WarrantMember 2024-01-01 2024-12-31 0001460602 ORGS:December312024SevenMember us-gaap:WarrantMember 2024-12-31 0001460602 ORGS:December312024EightMember us-gaap:WarrantMember 2024-01-01 2024-12-31 0001460602 ORGS:December312024EightMember us-gaap:WarrantMember 2024-12-31 0001460602 us-gaap:WarrantMember 2024-01-01 2024-12-31 0001460602 us-gaap:WarrantMember 2024-12-31 0001460602 us-gaap:CommonStockMember ORGS:LoanAgreementMember 2024-10-31 0001460602 ORGS:LoanAgreementMember 2024-10-01 2024-10-31 0001460602 ORGS:ConvertibleLoansOneMember 2024-12-31 0001460602 ORGS:ConvertibleLoansOneMember 2024-01-01 2024-12-31 0001460602 ORGS:ConvertibleLoansTwoMember 2024-12-31 0001460602 ORGS:ConvertibleLoansTwoMember 2024-01-01 2024-12-31 0001460602 ORGS:ConvertibleLoansThreeMember 2024-12-31 0001460602 ORGS:ConvertibleLoansThreeMember 2024-01-01 2024-12-31 0001460602 ORGS:ConvertibleLoansFourMember 2024-12-31 0001460602 ORGS:ConvertibleLoansFourMember 2024-01-01 2024-12-31 0001460602 ORGS:ConvertibleLoansMember 2024-12-31 0001460602 ORGS:ConvertibleLoansOneMember 2023-12-31 0001460602 ORGS:ConvertibleLoansOneMember 2023-01-01 2023-12-31 0001460602 ORGS:ConvertibleLoansTwoMember 2023-12-31 0001460602 ORGS:ConvertibleLoansTwoMember 2023-01-01 2023-12-31 0001460602 ORGS:ConvertibleLoansThreeMember 2023-12-31 0001460602 ORGS:ConvertibleLoansThreeMember 2023-01-01 2023-12-31 0001460602 ORGS:ConvertibleLoansFourMember 2023-12-31 0001460602 ORGS:ConvertibleLoansFourMember 2023-01-01 2023-12-31 0001460602 ORGS:ConvertibleLoansFiveMember 2023-12-31 0001460602 ORGS:ConvertibleLoansFiveMember 2023-01-01 2023-12-31 0001460602 ORGS:ConvertibleLoansSixMember 2023-12-31 0001460602 ORGS:ConvertibleLoansSixMember 2023-01-01 2023-12-31 0001460602 ORGS:ConvertibleLoansSevenMember 2023-12-31 0001460602 ORGS:ConvertibleLoansSevenMember 2023-01-01 2023-12-31 0001460602 ORGS:ConvertibleLoansEightMember 2023-12-31 0001460602 ORGS:ConvertibleLoansEightMember 2023-01-01 2023-12-31 0001460602 ORGS:ConvertibleLoansNineMember 2023-12-31 0001460602 ORGS:ConvertibleLoansNineMember 2023-01-01 2023-12-31 0001460602 ORGS:ConvertibleLoansMember 2023-12-31 0001460602 ORGS:ConvertibleLoansRepaidOneMember 2023-01-01 2023-12-31 0001460602 ORGS:ConvertibleLoansRepaidOneMember 2023-12-31 0001460602 ORGS:ThreeConvertibleDebtHoldersMember ORGS:DebtExchangeAgreementsMember 2024-05-21 0001460602 ORGS:ThreeConvertibleDebtHoldersMember ORGS:DebtExchangeAgreementsMember 2024-05-21 2024-05-21 0001460602 ORGS:ThreeConvertibleDebtHoldersMember ORGS:DebtExchangeAgreementsMember 2024-12-31 0001460602 ORGS:ThreeConvertibleDebtHoldersMember srt:MaximumMember ORGS:DebtExchangeAgreementsMember 2024-12-31 0001460602 ORGS:ThreeConvertibleDebtHoldersMember srt:MinimumMember ORGS:DebtExchangeAgreementsMember 2024-12-31 0001460602 ORGS:ThreeConvertibleDebtHoldersMember ORGS:DebtExchangeAgreementsMember 2024-01-01 2024-12-31 0001460602 ORGS:DebtExchangeAgreementsMember 2024-01-01 2024-01-31 0001460602 ORGS:DebtExchangeAgreementsMember 2024-01-31 0001460602 ORGS:LoanAgreementMember 2024-01-01 2024-01-31 0001460602 ORGS:LenderMember ORGS:KoligoTherapeuticsIncMember 2023-03-27 0001460602 ORGS:LenderMember ORGS:KoligoTherapeuticsIncMember 2023-03-26 2023-03-27 0001460602 ORGS:BorrowerMember ORGS:KoligoTherapeuticsIncMember 2023-03-26 2023-03-27 0001460602 ORGS:LenderMember ORGS:ConvertibleLoanAgreementsMember 2023-03-27 0001460602 ORGS:LenderMember ORGS:ConvertibleLoanAgreementsMember 2023-03-26 2023-03-27 0001460602 ORGS:ConvertibleLoanAgreementsMember 2024-12-31 0001460602 ORGS:OffshoreInvestorMember 2024-01-01 2024-01-31 0001460602 ORGS:OffshoreInvestorMember 2024-01-31 0001460602 srt:MinimumMember us-gaap:ManufacturingFacilityMember 2024-12-31 0001460602 srt:MaximumMember us-gaap:ManufacturingFacilityMember 2024-12-31 0001460602 ORGS:OfficesMember 2024-12-31 0001460602 ORGS:TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember 2012-02-01 2012-02-02 0001460602 ORGS:PhaseIClinicalTrialsMember ORGS:TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember 2012-02-01 2012-02-02 0001460602 ORGS:PhaseIIClinicalTrialsMember ORGS:TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember 2012-02-01 2012-02-02 0001460602 ORGS:PhaseIIIClinicalTrialsMember ORGS:TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember 2012-02-01 2012-02-02 0001460602 ORGS:FirstProductByTheFDAMember ORGS:TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember 2012-02-01 2012-02-02 0001460602 ORGS:WorldwideNetSalesOfProductsMember ORGS:TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember 2012-02-01 2012-02-02 0001460602 ORGS:SalesMilestoneMember ORGS:TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember 2012-02-01 2012-02-02 0001460602 ORGS:TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember 2012-02-02 0001460602 ORGS:IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember 2015-09-09 0001460602 ORGS:IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember 2015-09-08 2015-09-09 0001460602 ORGS:ColumbiaLicenseAgreementMember 2019-03-29 2019-04-02 0001460602 srt:MaximumMember ORGS:CaliforniaUniversityJointResearchAgreementMember 2019-12-01 2019-12-31 0001460602 ORGS:CaerusTherapeuticsIncMember srt:MaximumMember 2019-10-01 2019-10-31 0001460602 srt:MaximumMember ORGS:TissueGenesisLLCMember 2024-12-31 0001460602 srt:MaximumMember ORGS:TissueGenesisLLCMember 2024-01-01 2024-12-31 0001460602 ORGS:SavicellAgreementMember 2021-01-01 2021-12-31 0001460602 srt:MaximumMember ORGS:StromatisAgreementMember 2021-01-01 2021-12-31 0001460602 ORGS:StromatisAgreementMember 2021-01-01 2021-12-31 0001460602 srt:MinimumMember ORGS:HMGUMember 2021-01-01 2021-12-31 0001460602 ORGS:HMGUMember 2021-01-01 2021-12-31 0001460602 srt:MaximumMember ORGS:HMGUMember 2021-01-01 2021-12-31 0001460602 ORGS:EuropeanInnovationCouncilAndSMEsExecutiveAgencyMember 2022-12-31 0001460602 srt:MaximumMember ORGS:EuropeanInnovationCouncilAndSMEsExecutiveAgencyMember ORGS:GrantFundingAgreementMember 2022-01-01 2022-12-31 0001460602 ORGS:EuropeanInnovationCouncilAndSMEsExecutiveAgencyMember ORGS:GrantFundingAgreementMember 2022-12-31 0001460602 ORGS:GrantsFromOtherMember ORGS:EuropeanInnovationCouncilAndSMEsExecutiveAgencyMember ORGS:GrantFundingAgreementMember 2022-12-31 0001460602 srt:SubsidiariesMember ORGS:EuropeanInnovationCouncilAndSMEsExecutiveAgencyMember ORGS:GrantFundingAgreementMember 2022-12-31 0001460602 us-gaap:GrantMember 2024-01-01 2024-12-31 0001460602 ORGS:MircodLLCMember 2023-07-25 2023-07-25 0001460602 ORGS:MircodLLCMember 2024-01-01 2024-12-31 0001460602 srt:MaximumMember ORGS:SubLicenseAgreementsMember 2023-07-25 0001460602 ORGS:SubLicenseAgreementsMember 2023-07-25 0001460602 ORGS:JointVentureAgreementMember ORGS:DeepMedIOLtdMember 2021-11-30 0001460602 ORGS:JointVentureAgreementMember ORGS:DeepMedIOLtdMember 2021-11-01 2021-11-30 0001460602 ORGS:JointVentureAgreementMember ORGS:DeepMedIOLtdMember 2022-01-01 2022-12-31 0001460602 ORGS:AssetPurchaseAgreementMember 2024-04-05 2024-04-05 0001460602 ORGS:AssetPurchaseAgreementMember 2024-12-31 2024-12-31 0001460602 us-gaap:WarrantMember 2024-04-05 2024-04-05 0001460602 ORGS:OptionsRSUAndWarrantsMember 2024-01-01 2024-12-31 0001460602 ORGS:SharesUponConversionOfConvertibleLoansMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsRSUAndWarrantsMember 2023-01-01 2023-12-31 0001460602 ORGS:SharesUponConversionOfConvertibleLoansMember 2023-01-01 2023-12-31 0001460602 ORGS:TwoZeroOneSevenEquityIncentivePlanMember 2024-12-31 0001460602 srt:MaximumMember ORGS:TwoZeroOneSevenEquityIncentivePlanMember 2024-01-01 2024-12-31 0001460602 ORGS:GlobalShareIncentivePlanTwoZeroOneTwoMember 2012-05-23 0001460602 srt:MaximumMember ORGS:GlobalShareIncentivePlanTwoZeroOneTwoMember 2012-05-21 2012-05-23 0001460602 ORGS:GlobalShareIncentivePlanTwoZeroOneTwoMember 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesAndDirectorsMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesAndDirectorsMember 2023-01-01 2023-12-31 0001460602 ORGS:MasthercellGlobalMember 2024-12-31 0001460602 ORGS:MasthercellGlobalMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToNonEmployeesMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToNonEmployeesMember 2023-01-01 2023-12-31 0001460602 ORGS:OptionsGrantedToNonEmployeesMember 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember 2024-01-01 2024-12-31 0001460602 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-12-31 0001460602 ORGS:EmployeesMember ORGS:OptionsGrantedToEmployeesMember 2024-01-01 2024-12-31 0001460602 srt:MinimumMember ORGS:EmployeesMember ORGS:OptionsGrantedToEmployeesMember 2024-01-01 2024-12-31 0001460602 srt:MaximumMember ORGS:EmployeesMember ORGS:OptionsGrantedToEmployeesMember 2024-01-01 2024-12-31 0001460602 srt:DirectorMember ORGS:OptionsGrantedToEmployeesMember 2024-01-01 2024-12-31 0001460602 srt:MinimumMember srt:DirectorMember ORGS:OptionsGrantedToEmployeesMember 2024-01-01 2024-12-31 0001460602 srt:MaximumMember srt:DirectorMember ORGS:OptionsGrantedToEmployeesMember 2024-01-01 2024-12-31 0001460602 ORGS:EmployeesMember ORGS:OptionsGrantedToEmployeesMember 2023-01-01 2023-12-31 0001460602 srt:MinimumMember ORGS:EmployeesMember ORGS:OptionsGrantedToEmployeesMember 2023-01-01 2023-12-31 0001460602 srt:MaximumMember ORGS:EmployeesMember ORGS:OptionsGrantedToEmployeesMember 2023-01-01 2023-12-31 0001460602 srt:DirectorMember ORGS:OptionsGrantedToEmployeesMember 2023-01-01 2023-12-31 0001460602 srt:MinimumMember ORGS:OptionsGrantedToEmployeesMember 2024-12-31 0001460602 srt:MaximumMember ORGS:OptionsGrantedToEmployeesMember 2024-12-31 0001460602 srt:MinimumMember ORGS:OptionsGrantedToEmployeesMember 2023-12-31 0001460602 srt:MaximumMember ORGS:OptionsGrantedToEmployeesMember 2023-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember 2023-01-01 2023-12-31 0001460602 srt:MinimumMember ORGS:OptionsGrantedToEmployeesMember 2024-01-01 2024-12-31 0001460602 srt:MaximumMember ORGS:OptionsGrantedToEmployeesMember 2024-01-01 2024-12-31 0001460602 srt:MinimumMember ORGS:OptionsGrantedToEmployeesMember 2023-01-01 2023-12-31 0001460602 srt:MaximumMember ORGS:OptionsGrantedToEmployeesMember 2023-01-01 2023-12-31 0001460602 ORGS:OptionsGrantedToNonEmployeesMember 2023-12-31 0001460602 srt:MinimumMember ORGS:OptionsGrantedToNonEmployeesMember 2024-01-01 2024-12-31 0001460602 srt:MaximumMember ORGS:OptionsGrantedToNonEmployeesMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember 2023-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember 2022-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember 2024-12-31 0001460602 ORGS:OptionsGrantedToNonEmployeesMember 2022-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceOneMember 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceOneMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceTwoMember 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceTwoMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceThreeMember 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceThreeMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceFourMember 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceFourMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceFiveMember 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceFiveMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceSixMember 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceSixMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceSevenMember 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceSevenMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceEightMember 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceEightMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceNineMember 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceNineMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceTenMember 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceTenMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceElevenMember 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceElevenMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceTwelveMember 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceTwelveMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceThirteenMember 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceThirteenMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceFourteenMember 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceFourteenMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceFifteenMember 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceFifteenMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceSixteenMember 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceSixteenMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceSeventeenMember 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceSeventeenMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceEighteenMember 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceEighteenMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceNineteenMember 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceNineteenMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceTwentyMember 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceTwentyMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceTwentyOneMember 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceTwentyOneMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceTwentyTwoMember 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceTwentyTwoMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceTwentyThreeMember 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceTwentyThreeMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceTwentyFourMember 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceTwentyFourMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceTwentyFiveMember 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceTwentyFiveMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceTwentySixMember 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceTwentySixMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceTwentySevenMember 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceTwentySevenMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceTwentyEightMember 2024-12-31 0001460602 ORGS:OptionsGrantedToEmployeesMember ORGS:ExercisePriceTwentyEightMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToNonEmployeesMember ORGS:ExercisePriceOneMember 2024-12-31 0001460602 ORGS:OptionsGrantedToNonEmployeesMember ORGS:ExercisePriceOneMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToNonEmployeesMember ORGS:ExercisePriceTwoMember 2024-12-31 0001460602 ORGS:OptionsGrantedToNonEmployeesMember ORGS:ExercisePriceTwoMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToNonEmployeesMember ORGS:ExercisePriceThreeMember 2024-12-31 0001460602 ORGS:OptionsGrantedToNonEmployeesMember ORGS:ExercisePriceThreeMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToNonEmployeesMember ORGS:ExercisePriceFourMember 2024-12-31 0001460602 ORGS:OptionsGrantedToNonEmployeesMember ORGS:ExercisePriceFourMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToNonEmployeesMember ORGS:ExercisePriceFiveMember 2024-12-31 0001460602 ORGS:OptionsGrantedToNonEmployeesMember ORGS:ExercisePriceFiveMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToNonEmployeesMember ORGS:ExercisePriceSixMember 2024-12-31 0001460602 ORGS:OptionsGrantedToNonEmployeesMember ORGS:ExercisePriceSixMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToNonEmployeesMember ORGS:ExercisePriceSevenMember 2024-12-31 0001460602 ORGS:OptionsGrantedToNonEmployeesMember ORGS:ExercisePriceSevenMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToNonEmployeesMember ORGS:ExercisePriceEightMember 2024-12-31 0001460602 ORGS:OptionsGrantedToNonEmployeesMember ORGS:ExercisePriceEightMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToNonEmployeesMember ORGS:ExercisePriceNineMember 2024-12-31 0001460602 ORGS:OptionsGrantedToNonEmployeesMember ORGS:ExercisePriceNineMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToNonEmployeesMember ORGS:ExercisePriceTenMember 2024-12-31 0001460602 ORGS:OptionsGrantedToNonEmployeesMember ORGS:ExercisePriceTenMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToNonEmployeesMember ORGS:ExercisePriceElevenMember 2024-12-31 0001460602 ORGS:OptionsGrantedToNonEmployeesMember ORGS:ExercisePriceElevenMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToNonEmployeesMember ORGS:ExercisePriceTwelveMember 2024-12-31 0001460602 ORGS:OptionsGrantedToNonEmployeesMember ORGS:ExercisePriceTwelveMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToNonEmployeesMember ORGS:ExercisePriceThirteenMember 2024-12-31 0001460602 ORGS:OptionsGrantedToNonEmployeesMember ORGS:ExercisePriceThirteenMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToNonEmployeesMember ORGS:ExercisePriceFourteenMember 2024-12-31 0001460602 ORGS:OptionsGrantedToNonEmployeesMember ORGS:ExercisePriceFourteenMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToNonEmployeesMember ORGS:ExercisePriceFifteenMember 2024-12-31 0001460602 ORGS:OptionsGrantedToNonEmployeesMember ORGS:ExercisePriceFifteenMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToNonEmployeesMember ORGS:ExercisePriceSixteenMember 2024-12-31 0001460602 ORGS:OptionsGrantedToNonEmployeesMember ORGS:ExercisePriceSixteenMember 2024-01-01 2024-12-31 0001460602 us-gaap:RestrictedStockUnitsRSUMember 2024-12-31 0001460602 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001460602 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001460602 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001460602 2024-03-07 2024-03-07 0001460602 2024-03-07 0001460602 2024-04-18 2024-04-18 0001460602 2024-04-18 0001460602 2024-04-23 2024-04-23 0001460602 2024-04-23 0001460602 2024-05-22 2024-05-22 0001460602 2024-05-22 0001460602 2024-07-14 2024-07-14 0001460602 2024-07-14 0001460602 2024-09-05 2024-09-05 0001460602 2024-09-05 0001460602 srt:MinimumMember us-gaap:WarrantMember 2024-12-31 0001460602 srt:MaximumMember us-gaap:WarrantMember 2024-12-31 0001460602 srt:MinimumMember us-gaap:WarrantMember 2024-01-01 2024-12-31 0001460602 srt:MaximumMember us-gaap:WarrantMember 2024-01-01 2024-12-31 0001460602 ORGS:OptionsGrantedToNonEmployeesMember us-gaap:WarrantMember 2024-01-01 2024-12-31 0001460602 country:US 2024-01-01 2024-12-31 0001460602 country:IL 2024-01-01 2024-12-31 0001460602 country:IL 2023-01-01 2023-12-31 0001460602 ORGS:CellProcessDevelopmentServicesAndHospitalServicesMember 2024-01-01 2024-12-31 0001460602 ORGS:CellProcessDevelopmentServicesAndHospitalServicesMember 2023-01-01 2023-12-31 0001460602 ORGS:LicenseFeesMember 2024-01-01 2024-12-31 0001460602 ORGS:LicenseFeesMember 2023-01-01 2023-12-31 0001460602 ORGS:CustomerAMember country:US 2024-01-01 2024-12-31 0001460602 ORGS:CustomerAMember country:US 2023-01-01 2023-12-31 0001460602 ORGS:CustomerBMember country:US 2024-01-01 2024-12-31 0001460602 ORGS:CustomerBMember country:US 2023-01-01 2023-12-31 0001460602 ORGS:CustomerCMember country:US 2024-01-01 2024-12-31 0001460602 ORGS:CustomerCMember country:US 2023-01-01 2023-12-31 0001460602 ORGS:CustomerDMember country:US 2024-01-01 2024-12-31 0001460602 ORGS:CustomerDMember country:US 2023-01-01 2023-12-31 0001460602 ORGS:ResearchAndDevelopmentExpensesMember 2024-01-01 2024-12-31 0001460602 ORGS:ResearchAndDevelopmentExpensesMember 2023-01-01 2023-12-31 0001460602 ORGS:BroadenMember 2024-07-10 0001460602 ORGS:TheracellMember 2024-07-12 2024-07-12 0001460602 ORGS:TheracellMember 2024-07-12 0001460602 ORGS:OrgenesisBiotechIsraelLimitedMember 2024-01-01 2024-12-31 0001460602 ORGS:OrgenesisBiotechIsraelLimitedMember us-gaap:RelatedPartyMember 2024-12-31 0001460602 ORGS:OrgenesisKoreaMember 2024-01-01 2024-12-31 0001460602 ORGS:OrgenesisBelgiumSRLAndOrgenesisSRLMember 2024-01-01 2024-12-31 0001460602 ORGS:OrgenesisBiotechIsraelLimitedMember 2024-02-14 0001460602 ORGS:OrgenesisKoreaMember 2024-10-01 0001460602 ORGS:OrgenesisBelgiumSRLMember 2024-12-20 0001460602 ORGS:OrgenesisServicesSRLMember 2024-12-20 0001460602 srt:ExecutiveOfficerMember us-gaap:SegmentContinuingOperationsMember 2024-01-01 2024-12-31 0001460602 srt:ExecutiveOfficerMember us-gaap:SegmentContinuingOperationsMember 2023-01-01 2023-12-31 0001460602 ORGS:BoardMembersMember us-gaap:SegmentContinuingOperationsMember 2024-01-01 2024-12-31 0001460602 ORGS:BoardMembersMember us-gaap:SegmentContinuingOperationsMember 2023-01-01 2023-12-31 0001460602 srt:ExecutiveOfficerMember 2024-12-31 0001460602 srt:ExecutiveOfficerMember 2023-12-31 0001460602 ORGS:NonexecutiveDirectorsMember 2024-12-31 0001460602 ORGS:NonexecutiveDirectorsMember 2023-12-31 0001460602 ORGS:OrgenesisBiotechIsraelLimitedMember us-gaap:RelatedPartyMember 2024-12-31 0001460602 ORGS:OrgenesisBiotechIsraelLimitedMember us-gaap:RelatedPartyMember 2023-12-31 0001460602 2022-01-17 2022-01-18 0001460602 2023-09-06 0001460602 ORGS:MrAmirHasidimMember ORGS:SouthernIsraelBridgingFundTwoLPMember 2023-10-25 2023-10-26 0001460602 ORGS:MrAmirHasidimMember 2023-10-26 0001460602 ORGS:UnsecuredConvertibleNoteAgreementsMember 2023-11-01 0001460602 ORGS:ConsultationAgreementMember 2023-11-01 0001460602 us-gaap:CommonStockMember 2018-03-31 2018-03-31 0001460602 2018-04-30 0001460602 2023-11-01 2023-11-01 0001460602 2023-11-01 0001460602 ORGS:UnsecuredConvertibleNoteAgreementsMember 2024-07-11 2024-07-11 0001460602 ORGS:UnsecuredConvertibleNoteAgreementsMember 2024-11-01 2024-11-30 0001460602 ORGS:UnsecuredConvertibleNoteTwoAgreementsMember 2024-07-11 2024-07-11 0001460602 us-gaap:SubsequentEventMember 2025-06-08 2025-06-08 0001460602 us-gaap:SubsequentEventMember ORGS:EquityPurchaseAgreementMember 2025-01-22 0001460602 us-gaap:SubsequentEventMember ORGS:RegistrationRightsAgreementMember 2025-01-22 0001460602 ORGS:WilliamsburgVentureHoldingsLLCMember us-gaap:SubsequentEventMember ORGS:EquityPurchaseAgreementMember 2025-01-22 0001460602 us-gaap:SubsequentEventMember ORGS:AssetPurchaseAgreementMember 2025-02-28 0001460602 us-gaap:SubsequentEventMember ORGS:ConvertibleLoanAgreementMember 2025-09-10 0001460602 us-gaap:SubsequentEventMember ORGS:ConvertibleLoanAgreementMember 2025-09-10 2025-09-10 0001460602 us-gaap:SubsequentEventMember 2026-01-09 iso4217:USD shares iso4217:USD shares pure iso4217:ILS ORGS:Segment iso4217:EUR false FY 0001460602

10-K true 2024-12-31 --12-31 2024 false 001-38416 ORGENESIS INC. NV 98-0583166 20271 Goldenrod Lane Germantown MD 20876 (480) 659-6404 Common Stock, par value $0.0001 per share ORGS No No No Yes Non-accelerated Filer true false false false false 7649760 9799538 None Cybersecurity Risk Management and Strategy; Effect of Risk We face risks related to cybersecurity such as unauthorized access, cybersecurity attacks and other security incidents, including those perpetrated by hackers and unintentional disruptions to hardware and software systems, loss of data, and misappropriation of confidential information. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90A_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20240101__20241231_zG967BKDCyy7">To identify and assess material risks from cybersecurity threats, we maintain a comprehensive cybersecurity program to ensure our systems are effective and prepared for information security risks, including regular oversight of our programs for security monitoring for internal and external threats to ensure the confidentiality and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90F_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_z6K6XsC0foUg">integrity of our information assets. We consider risks from cybersecurity threats alongside other company risks as part of our overall risk assessment process. We employ a range of tools and services, including regular network and endpoint monitoring, audits, vulnerability assessments, penetration testing, threat modelling and tabletop exercises to inform our risk identification and assessment. As discussed in more detail under “Cybersecurity Governance” below, our board of directors provides oversight of our cybersecurity risk management and strategy processes, which are led by our Chief Executive Officer. We also identify our cybersecurity threat risks by comparing our processes to standards set by the Center for Internet Security (CIS) as well as by engaging experts to attempt to infiltrate our information systems. To provide for the availability of critical data and systems, maintain regulatory compliance, manage our material risks from cybersecurity threats, and protect against and respond to cybersecurity incidents, we undertake the following activities: We also identify our cybersecurity threat risks by comparing our processes to standards set by the Center for Internet Security (CIS) as well as by engaging experts to attempt to infiltrate our information systems. We utilize Microsoft Security tools to facilitate our CIS assessments, ensuring alignment with industry best practices and enhancing our security posture. To provide for the availability of critical data and systems, maintain regulatory compliance, manage our material risks from cybersecurity threats, and protect against and respond to cybersecurity incidents, we undertake the following activities: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Monitor emerging data protection laws and implement changes to our processes designed to comply with such laws and implement the latest Center for Internet Security benchmarks to comply with up-to-date requirements using Microsoft Compliance Manager and Azure Security Center.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Through our policies, practices, and contracts (as applicable), require employees, as well as third parties that provide services on our behalf, to treat confidential information and data with care, including using policies such as “right to know” and “right to access” with granular access to confidential information, managed via Microsoft Azure Active Directory’s Role-Based Access Control (RBAC).</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Employ technical safeguards designed to protect our information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti-malware functionality, and access controls, which are evaluated and improved through vulnerability assessments and cybersecurity threat intelligence using Microsoft Defender for Endpoint and Microsoft Sentinel for active threat hunting and alerts monitoring by cybersecurity operators, threat analytics, endpoint management, and application evaluations.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Provide regular, mandatory training for our employees and contractors regarding cybersecurity threats as a means to equip them with effective tools to address cybersecurity threats, and to communicate our evolving information security policies, standards, processes and practices.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Conduct regular phishing email simulations for all employees and contractors with access to our email systems to enhance awareness and responsiveness to possible threats, including built-in tools for phishing campaigns and attack simulators, and usage of sandbox environments to evaluate threats.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Conduct annual cybersecurity management and incident training for employees involved in our systems and processes that handle sensitive data.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Run tabletop exercises to simulate responses to cybersecurity incidents and use the findings to improve our processes and technologies.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Leverage the NIST incident handling framework to help us identify, protect, detect, respond and recover when there is an actual or potential cybersecurity incident.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Carry information security risk insurance that provides protection against potential losses arising from a cybersecurity incident.</td></tr> </table> <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_908_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_zm0xXGxyoMla">Our processes also address cybersecurity threat risks associated with our use of third-party service providers, including our suppliers and manufacturers who have access to patient and employee data or our systems. In addition, cybersecurity considerations affect the selection and oversight of our third-party service providers. We perform diligence on third parties that have access to our systems, data, or facilities that house such systems or data, and continually monitor cybersecurity threat risks identified through such diligence. Additionally, we generally require those third parties that could introduce significant cybersecurity risk to us to agree by contract to manage their cybersecurity risks in specified ways, and to agree to be subject to cybersecurity audits, which we conduct as appropriate. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_905_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_c20240101__20241231_zNzWasUhbJud">We describe whether and how risks from identified cybersecurity threats, including as a result of any previous cybersecurity incidents, have materially affected or are reasonably likely to <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_903_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240101__20241231_zo514ntKDnvc">materially affect us, including our business strategy, results of operations, or financial condition, under the heading “We are increasingly dependent on information technology and our systems and infrastructure face certain risks, including cybersecurity and data storage risks.” Such disclosures are incorporated by reference herein. In the last three fiscal years, we have not experienced any material cybersecurity incidents and the expenses we have incurred from cybersecurity incidents were immaterial. This includes penalties and settlements, of which there were none. To identify and assess material risks from cybersecurity threats, we maintain a comprehensive cybersecurity program to ensure our systems are effective and prepared for information security risks, including regular oversight of our programs for security monitoring for internal and external threats to ensure the confidentiality and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90F_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_z6K6XsC0foUg">integrity of our information assets. true true We describe whether and how risks from identified cybersecurity threats, including as a result of any previous cybersecurity incidents, have materially affected or are reasonably likely to <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_903_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240101__20241231_zo514ntKDnvc">materially affect us, including our business strategy, results of operations, or financial condition, under the heading “We are increasingly dependent on information technology and our systems and infrastructure face certain risks, including cybersecurity and data storage risks.” false Cybersecurity is an important part of our risk management processes and an area of focus for our board of directors and management. In general, our board of directors oversees risk management activities designed and implemented by our management, and considers specific risks, including, for example, risks associated with our strategic plan, business operations, and capital structure. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240101__20241231_zotjN50w1x2c">Our board of directors executes its oversight responsibility for risk management both directly and through delegating oversight of certain of these risks to its committees, and our board of directors has authorized our audit committee to oversee risks from cybersecurity threats. Our board of directors receives an annual update, and more often if required, from management of our cybersecurity threat risk management and strategy processes. These updates cover topics such as our data security posture, results from third-party assessments, progress toward pre-determined risk-mitigation-related goals, our incident response plan, and material cybersecurity threat risks or incidents and developments, as well as the steps management has taken to respond to such risks. In these sessions, our board of directors generally receives a report that includes cybersecurity details and other materials discussing current and emerging material cybersecurity threat risks, and describing our ability to mitigate those risks, as well as recent developments, evolving standards, technological developments and information security considerations arising with respect to our peers and third parties. Management also discusses such matters with our Chief Executive Officer. Our board of directors also receives prompt and timely information regarding any cybersecurity incident that meets established reporting thresholds, as well as ongoing updates regarding any such incident until it has been addressed. Members of the board of directors are also encouraged to regularly engage in conversations with management on cybersecurity-related news events and discuss any updates to our cybersecurity risk management and strategy programs. Material cybersecurity threat risks are also considered during separate board meeting discussions of important matters like enterprise risk management, operational budgeting, business continuity planning, mergers and acquisitions, brand management, and other relevant matters. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_905_ecyd--CybersecurityRiskRoleOfManagementTextBlock_c20240101__20241231_zX4onzLbCVU2">Our cybersecurity risk management and strategy processes, which are discussed in greater detail above, are led by our Chief Executive Officer and our external cybersecurity consultants. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_907_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_c20240101__20241231_z9PfDITGfze5">These consultants are informed about, and monitor, the prevention, mitigation, detection, and remediation of cybersecurity incidents through their management of and participation in the cybersecurity risk management and strategy processes described above, including the operation of our incident response plan. As discussed above, these consultants report to management about cybersecurity threat risks, among other cybersecurity-related matters, at least annually. Our board of directors executes its oversight responsibility for risk management both directly and through delegating oversight of certain of these risks to its committees, and our board of directors has authorized our audit committee to oversee risks from cybersecurity threats. Our cybersecurity risk management and strategy processes, which are discussed in greater detail above, are led by our Chief Executive Officer and our external cybersecurity consultants. These consultants are informed about, and monitor, the prevention, mitigation, detection, and remediation of cybersecurity incidents through their management of and participation in the cybersecurity risk management and strategy processes described above, including the operation of our incident response plan. true true 1309 We have audited the accompanying consolidated balance sheets of Orgenesis Inc and its subsidiaries (the “Company”) as of December 31, 2024 and 2023, and the related consolidated statements of comprehensive loss (income), changes in equity and cash flows for the years then ended, including the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the years then ended in conformity with accounting principles generally accepted in the United States of America. Kesselman & Kesselman Haifa, Israel

78000

837000

609000

642000

14281000

40000

88000

34000

2017000

458000

34000

761000

4076000

12000

38000

8000

578000

1475000

7375000

351000

1211000

18000

590000

10476000

1351000

14552000

40000

10428000

6451000

2695000

133000

2695000

133000

2345000

2218000

781000

740000

2122000

1079000

52000

72000 2180000

6183000

650000

25000

18000

234000

216000

1995000

2670000

26920000

16407000

1308000

96000

2895000

5578000

18967000

1000

4000

2182000

61000

11964000

19128000

38884000

35535000

0.0001

14583333

5199963

3216363

5171306

3187706

5000

3000

5000

3000

188163000

156837000

384000

65000

286567

1266000

-224787000

-176622000

-37501000

-20983000

-32000

-37533000

-20983000

1351000

14552000

1035000

530000

1928000

6255000

-893000

-5725000

9622000

10623000

728000

721000

-4643000

2724000

24367000

14822000

35134000

-8000

-734000

699000

18338000

-39768000

-53636000

4480000

-5343000

606000

4000

-5422000

-283000

2688000

-4508000

-2499000

4304000

-48916000

-64445000

97000

473000

-49013000

-64918000

-848000

-9557000

-48165000

-55361000

11.44

19.08

4210839

2900787

-49013000

-64918000

-853000

49000

534000 -384000

-48694000

-64583000

-848000

-9557000

-47846000

-55026000

3187489

3000

156837000

65000

-1266000

-176622000

-20983000

359000

12410

25519

13000

119896

1629000

1577694

1000

20310000

20311000

1459000

5421000

242272

2496000

408000

-408000 -408000 408000 6026 1000 47000 48000 48000

319000

-48165000

-47846000

-848000

-48694000

5171306

5000

188163000

384000

-1266000

-224787000

-37501000

-32000

-37533000

2554356

3000

150355000

-270000

-1266000

-121261000

27561000

1510000

29071000

415000

48000

535764

5283000

97369

449000

287000

9406000 384000 9790000 -1360000 8430000 -9406000 -9406000 -9406000

-49000

-55361000

-55410000

-150000

-55560000

3187489

3000

156837000

65000

-1266000

-176622000

-20983000

-49013000

-64918000

3194000

463000

4304000 1580000

4480000

-5343000

-8000

-734000

2086000

1560000

2688000 2049000

699000

18338000

2447000 227000 -1588000 50000 -4643000 -1538000 -1508000

-5422000

-283000

-130000

-30060000

-2262000

-432000

-34000

389000

-43000

-13000

2000 439000

-1279000

5516000

-820000

1013000

1300000

411000

2000

-9000

-17076000

-14837000

55000

263000

2096000

660000

139000

11000 973000

-500000

33000

365000

-3707000

2556000

5283000

75000

5735000

5000000

3000000

226000

35000

6060000

635000

774000

6720000

15959000

13618000

-752000

-4926000

-40000

36000

1479000

6369000

687000

1479000

16007000

405000

752000

14000 5281000 287000

4000

785000

NOTE 1 – DESCRIPTION OF BUSINESS <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in">a.</td> <td style="text-align: justify">General</td></tr> </table> Orgenesis Inc. (the “Company”) is a global biotech company working to unlock the promise of cell and gene therapies (“CGTs”) in an affordable and accessible offering. CGTs can use the patient’s own cells (autologous), or use donor cells (allogenic), and for regulatory purposes, are classified as Advanced Therapy Medicinal Products (“ATMPs”). We are primarily focused on pioneering a paradigm-shifting decentralized approach to CGT therapies utilizing an automated and/or closed approach validated for compliant production at or near the patient care site (“Decentralized Cell Processing or DCP Platform”). This approach has the potential to overcome the limitations of traditional centralized processing methods due to their complex logistics and inefficient unscalable processing methods leading to cost prohibitive products that currently limit the number of patients that can have access to these therapies. To overcome the challenges posed by traditional centralized processing methods, the Company has designed and implemented its DCP Platform - a scalable hub and spoke infrastructure of analytical centers overseeing standardized production platforms, technology and services governed by a central quality system, focusing on replicability and standardization of infrastructure and equipment with centralized monitoring and data management. Features of the DCP Platform include a locally implemented quality system, Standard Operating Procedures (SOPs), Good Manufacturing Practices (“GMP”), training procedures, quality-control testing and hub oversight of the actual production. The Company is leveraging its unique approach to therapy production using its DCP Platform and various manufacturing platforms to address some of the quality, supply chain, scale-up and production challenges, adapting these therapies to validated manufacturing platforms that are adapted to standardized production units that can be placed quickly and a low cost throughout its DCP network. To achieve these goals, the Company is developing a pipeline of POCare advanced therapies that can be processed and produced under such closed and automated processes and systems (“POCare Therapies”) as well as developing a collaborative worldwide network of academia, hospitals, and industry partners (POCare Network”) who are collaborating with the Company to build its DCP Platform. On January 29, 2024 (“date of reconsolidation”), the Company and an affiliate of Metalmark Capital Partners (“Metalmark” or “MM”) entered into a Unit Purchase Agreement (the “UPA”), pursuant to which the Company acquired all of the preferred units of Octomera owned by MM (the “Acquisition”). Accordingly, the Company currently owns <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20240129__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OctomeraLLCMember_zJLBb80spzka" title="Equity method investment, ownership percentage">100% of the equity interests of Octomera. The Company had previously deconsolidated Octomera from its consolidated financial statements (See note 3). These consolidated financial statements include the accounts of Orgenesis Inc. and its subsidiaries. During 2024, the Company acquired Octomera (see note 3) and deconsolidated its OBI, Korea and Belgium subsidiaries (see note 20). On September 20, 2024, the Company implemented a 1-for-10 reverse stock split (the “Reverse Split”) of its authorized and outstanding shares of Common Stock. All share and per share amounts in these financial statements have been retroactively adjusted to reflect the reverse split as if it had been effected prior to the earliest financial statement period included herein. Following the Reverse Split, the number of authorized shares of common stock that the Company is authorized to issue from time to time is 14,583,333 shares. The Company’s common stock, par value $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ORGSMember_z3L9fWUrJzFk" title="Commons stock, par value">0.0001 per share (the “Common Stock”), is traded on the OTCQX under the symbol “ORGS.” On September 27, 2023, the Company received a notice from the Listing Qualifications Staff (“Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the bid price of the Common Stock had closed at less than $1.00 per share over the previous 30 consecutive business days, and, as a result, did not comply with Listing Rule 5550(a)(2) (the “Bid Price Rule”). On April 17, 2024, the Company received a notice (the “Notice”) from the Staff in which it determined that in accordance with Listing Rule 5810(c)(2)(A), the Staff stated that it could not accept a plan to regain compliance and the Staff stated that the Company’s securities would be delisted from The Nasdaq Capital Market unless the Company timely requested a hearing before a Nasdaq Hearings Panel (the “Panel”) to address the deficiencies and present a plan to regain compliance. As permitted by the Notice, the Company timely requested a hearing before the Panel, which request stayed any further delisting action by the Staff pending the ultimate outcome of the hearing and the expiration of any extension that may be granted by the Panel. On June 6, 2024, the Company met with the Panel regarding the Company’s potential delisting from The Nasdaq Stock Market as a result of its violation of the Bid Price Rule and non-compliance with the equity requirement in Listing Rule 5550(b)(1) (the “Equity Rule”) or any of the alternative requirements in Listing Rule 5550(b). On June 8, 2024, the Company received the Panel’s decision which granted the Company until October 14, 2024 to regain compliance with the Bid Price and Equity Rules. On October 17, 2024, Nasdaq notified the Company that the Panel had determined to delist the Company’s Common Stock and that trading of the Company’s Common Stock will be suspended at the open of trading on October 21, 2024. In connection with the Nasdaq delisting notice, Nasdaq will complete the delisting by filing a Form 25 Notification of Delisting with the U.S. Securities and Exchange Commission (the “SEC”) after applicable appeal periods have lapsed. The Company’s Common Stock began trading under “ORGS” on the OTCQX with the open of the markets on October 21, 2024. As used in this report and unless otherwise indicated, the term “Company” refers to Orgenesis Inc. and its Subsidiaries. Unless otherwise specified, all amounts are expressed in United States Dollars. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">b.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Liquidity</td></tr></table> Through December 31, 2024, the Company had an accumulated deficit of $224,787. For the year ended December 31, 2024, the Company incurred negative cash flows from operating activities of $17,076. The Company’s activities have been funded primarily by offerings of its equity securities, loans, and convertible loans. There is no assurance that the Company’s business will generate sustainable positive cash flows to fund its business operations. Further reductions in revenues or increases in operating costs, including cost to invest in and expand facilities, research and development, and commercial and clinical activities would require the Company to take mitigating actions such as seeking additional financing and/or postponing expenditures that are not based on firm commitments. In addition, to fund the Company’s operations until it can generate sustainable positive cash flows, the Company will need to raise additional funds. During the year ended December 31, 2024, management identified impairment indicators and performed an impairment assessment for the Therapies reporting unit. Based on the quantitative analysis, management concluded that the reporting unit’s fair value was below its carrying amount and therefore recorded a full impairment of goodwill of $1,211, property, plant and equipment of $8,752, and intangible assets of $8,375 (total impairment of approximately $18,338 million). This impairment conclusion was based on our potential delay of payments to suppliers because of lack of funds, the dissolution of our subsidiaries in Belgium and Israel, our lack of revenue and the low market value of our common stock. In addition, as part of the Company’s annual assessment of its lease agreements, the Company recognized total lease charges of $1,541 that were recorded in rent expense. The Company expects its current and projected cash resources and commitments will not be sufficient to meet the Company’s obligations for the next 12 months from the issuance of these financial statements,, raising a substantial doubt about the Company’s ability to continue as a going concern. Management plans include raising additional capital to fund the Company’s operations and to repay the Company’s outstanding loans when they become due, as well as exploring additional avenues to increase revenue and reduce capital expenditures. The Company’s ability to fund the completion of its ongoing and planned activities may be substantially dependent upon whether the Company can obtain sufficient funding at acceptable terms. If the Company is unable to raise sufficient additional capital or meet revenue targets, it may have to reduce or eliminate certain activities and reduce its headcount.

1-for-10 reverse stock split

14583333

0.0001

-224787000

-17076000

1211000

8752000

8375000

18338000

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES The consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in">a.</td> <td style="text-align: justify">Use of Estimates in the Preparation of Financial Statements</td></tr> </table> The preparation of the Company’s consolidated financial statements in conformity with U.S. GAAP requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates, judgments and methodologies. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity, the amount of revenues and expenses, determination of loss on deconsolidation, valuation of investments, goodwill impairment, and assessment of credit losses. Actual results could differ from those estimates. <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in">b.</td> <td style="text-align: justify">Business Combination</td></tr> </table> The Company allocates the fair value of consideration transferred in a business combination to the assets acquired, liabilities assumed, and non-controlling interests in the acquired business based on their fair values at the acquisition date. All assets and liabilities are recognized in fair value. The purchase price allocation process requires management to make significant estimates and assumptions, especially at the acquisition date with respect to intangible assets. Direct transaction costs associated with the business combination are expensed as incurred. The excess of the fair value of the consideration transferred plus the fair value of any non-controlling interest in the acquiree over the fair value of the assets acquired, liabilities assumed in the acquired business is recorded as goodwill. The allocation of the consideration transferred in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date. The cumulative impact of revisions during the measurement period is recognized in the reporting period in which the revisions are identified. The Company includes the results of operations of the business that it has acquired in its consolidated results prospectively from the date of acquisition. If the business combination is achieved in stages, the acquisition date carrying value of the acquirer’s previously held equity interest in the acquire is re-measured to fair value at the acquisition date; any gains or losses arising from such re-measurement are recognized in profit or loss. <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in">c.</td> <td style="text-align: justify">Cash Equivalents</td></tr> </table> The Company considers cash equivalents to be all short-term, highly liquid investments, which include money market instruments, that are not restricted as to withdrawal or use, and short-term bank deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash. <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in">d.</td> <td style="text-align: justify">Cost of development services and research and development expenses</td></tr> </table> Cost of development services and research and development expenses include costs directly attributable to the conduct of research and development activities, including the cost of salaries, stock-based compensation expenses, payroll taxes and other employees’ benefits, lab expenses, consumable equipment, courier fees, travel expenses, professional fees and consulting fees. All costs associated with research and developments are expensed as incurred. Participation from government departments and from research foundations for development of approved projects is recognized as a reduction of expense as the related costs are incurred. Research and development in-process acquired as part of an asset purchase, which has not reached technological feasibility and has no alternative future use, is expensed as incurred. <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in">e.</td> <td style="text-align: justify">Principles of Consolidation</td></tr> </table> The consolidated financial statements include the accounts of the Company and its Subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in">f.</td> <td style="text-align: justify">Non-Marketable Equity Investments</td></tr> </table> The Company’s investments in certain non-marketable equity securities in which it has the ability to exercise significant influence, but it does not control through variable interests or voting interests. These are accounted for under the equity method of accounting and presented as Investment in associates, net, in the Company’s consolidated balance sheets. Under the equity method, the Company recognizes its proportionate share of the comprehensive income or loss of the investee. The Company’s share of income and losses from equity method investments is included in share in losses of associated company. The Company periodically reviews equity method investments for impairment in value whenever events or changes in circumstances indicate that the carrying amount of such investments may not be recoverable. The Company will record an impairment charge to the extent that the estimated fair value of an investment is less than its carrying value and the Company determines the impairment is other-than-temporary. Impairment charges, if applicable, are recorded in “Share in net (losses) profits of associated companies”. <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in">g.</td> <td style="text-align: justify">Fair value measurement</td></tr> </table> The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable inputs that are based on inputs not quoted on active markets, but corroborated by market data. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value. <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in">h.</td> <td style="text-align: justify">Functional Currency</td></tr> </table> The currency of the primary economic environment in which the operations of the Company and part of its Subsidiaries are conducted is the U.S. dollar (“$” or “dollar”). The functional currency of the Belgian Subsidiary is the Euro (“€” or “Euro”). Most of the Company’s expenses are incurred in dollars, and the source of the Company’s financing has been provided in dollars. Thus, the functional currency of the Company and its other subsidiaries is the dollar. Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in foreign currencies are translated into dollars using historical and current exchange rates for nonmonetary and monetary balances, respectively. For foreign transactions and other items reflected in the statements of operations, the following exchange rates are used: (1) for transactions – exchange rates at transaction dates or average rates and (2) for other items (derived from nonmonetary balance sheet items such as depreciation) – historical exchange rates. The resulting transaction gains or losses are recorded as financial income or expenses. The financial statements of the Belgian Subsidiary is included in the consolidated financial statements, translated into U.S. dollars. Assets and liabilities are translated at year-end exchange rates, while revenues and expenses are translated at yearly average exchange rates during the year. Differences resulting from translation of assets and liabilities are presented as other comprehensive income. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">i.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inventory</td></tr></table> The Company’s inventory consists of raw material for use for the services provided. The Company periodically evaluates the quantities on hand. Cost of the raw materials is determined using the weighted average cost method. The inventory is recorded at the lower of cost or net realizable value. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">j.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Property, Plants and Equipment</td></tr></table> Property, plants and equipment are recorded at cost and depreciated by the straight-line method over the estimated useful lives of the related assets. <p id="xdx_896_ecustom--ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentTableTextBlock_z1KFDmEIx6ok" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Annual rates of depreciation are presented in the table below: SCHEDULE OF ANNUAL DEPRECIATION RATES, PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Useful Life (Years)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 72%; text-align: left">Production facility</td><td style="width: 2%"> </td> <td style="width: 26%; text-align: center"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionFacilityMember__srt--RangeAxis__srt--MinimumMember_ziMhD9Qv2Grl" title="Weighted average useful life">3 - <span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionFacilityMember__srt--RangeAxis__srt--MaximumMember_zkIXhi0rmaS5" title="Weighted average useful life">10</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Laboratory equipment</td><td> </td> <td style="text-align: center"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MinimumMember_zRjO4Y5NZvaa" title="Weighted average useful life">1 - <span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MaximumMember_zpC2Tn7HMvK3" title="Weighted average useful life">7</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Office equipment and computers</td><td> </td> <td style="text-align: center"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_z4jp32E5DcTe" title="Weighted average useful life">3 - <span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zcrPUM3qYjOi" title="Weighted average useful life">17</td></tr> </table> Impairment charges of property, Plants and Equipment during the year ended December 31, 2024 were $8,752, see note 1. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">k.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Intangible assets</td></tr></table> Intangible assets and their useful lives are as follows: SCHEDULE OF INTANGIBLE ASSETS AND THEIR USEFUL LIVE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 26%"> </td> <td style="width: 2%"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 18%; text-align: center">Useful Life (Years)</td> <td style="width: 2%"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 52%; text-align: center">Amortization Recorded at Comprehensive Loss Line Item</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Know-How</td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KnowHowMember_zQCIaOhImzd5" title="Intangible assets and useful lives (Years)">10</td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Amortization of intangible assets</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Technology</td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TechnologyMember_zKpjQgRxrVPg" title="Intangible assets and useful lives (Years)">15</td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Amortization of intangible assets</td></tr> </table> Intangible assets are recorded at acquisition less accumulated amortization and impairment. Definite lived intangible assets are amortized over their estimated useful life using the straight-line method, which is determined by identifying the period over which the cash flows from the asset are expected to be generated. The Company capitalizes IPR&D projects acquired as part of a business combination. On successful completion of each project, IPR&D assets are reclassified to developed technology and amortized over their estimated useful lives. Impairment charges of intangible assets during the year ended December 31, 2024 were $8,375, see note 1. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">l.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Goodwill</td></tr></table> Goodwill represents the excess of consideration transferred over the value assigned to the net tangible and identifiable intangible assets of businesses acquired. Goodwill is allocated to reporting units expected to benefit from the business combination. Goodwill is not amortized but rather tested for impairment at least annually in the fourth quarter, or more frequently if events or changes in circumstances indicate that goodwill may be impaired. Before the Octomera deconsolidation (see note 3), the Company reallocated its goodwill into two identified operating units: Octomera and Therapies. Subsequent to the Octomera deconsolidation, the goodwill allocated to Octomera was derecognized. During the year ended December 31, 2024, the Company recorded goodwill impairment charges of $1,211 (see note 1). As a result of the derecognition and impairment recorded during 2024, the Company had no goodwill recorded as of December 31, 2024. Goodwill impairment is recognized when the quantitative assessment results in the carrying value exceeding the fair value, in which case an impairment charge is recorded to the extent the carrying value exceeds the fair value. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">m.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Impairment of Long-lived Assets</td></tr></table> The Company reviews its property, plants and equipment, intangible assets subject to amortization and other long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset class may not be recoverable. Indicators of potential impairment include: an adverse change in legal factors or in the business climate that could affect the value of the asset; an adverse change in the extent or manner in which the asset is used or is expected to be used, or in its physical condition; and current or forecasted operating or cash flow losses that demonstrate continuing losses associated with the use of the asset. If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset. If the expected cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted cash flows. For indefinite life intangible assets, the Company performs an impairment test annually in the fourth quarter and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. The Company determines the fair value of the asset based on discounted cash flows and records an impairment loss if its book value exceeds fair value. Impairment charges of other investment during the year ended December 31, 2023 were $699. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">n.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Income Taxes</td></tr></table> 1) With respect to deferred taxes, income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is recognized to the extent that it is more likely than not that the deferred taxes will not be realized in the foreseeable future. 2) The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the available evidence indicates that it is more likely than not that the position will be sustained on examination. If this threshold is met, the second step is to measure the tax position as the largest amount that is greater than 50% likely of being realized upon ultimate settlement. 3) Taxes that would apply in the event of disposal of investment in Subsidiaries and associated companies have not been taken into account in computing the deferred income taxes, as it is the Company’s intention to hold these investments and not realize them. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">o.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Stock-based Compensation</td></tr></table> The Company recognizes stock-based compensation for the estimated fair value of share-based awards. The Company measures compensation expense for share-based awards based on estimated fair values on the date of grant using the Black-Scholes option-pricing model. This option pricing model requires estimates as to the option’s expected term and the price volatility of the underlying stock. The Company amortizes the value of share-based awards to expense over the vesting period on a straight-line basis. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">p.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Loss per Share of Common Stock</td></tr></table> Basic net loss (income) per share is computed by dividing the net loss (income) for the period by the weighted average number of shares of common stock outstanding for each period. Diluted net income per share is based upon the weighted average number of common shares and of common shares equivalents outstanding when dilutive. Common share equivalents include: (i) outstanding stock options, RSUs and warrants which are included under the treasury share method when dilutive, and (ii) common shares to be issued under the assumed conversion of the Company’s outstanding convertible loans and debt, which are included under the if-converted method when dilutive (See Note 14). <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">q.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Concentration of Credit Risk</td></tr></table> Financial instruments that potentially subject the Company to concentration of credit risk consist of principally cash and cash equivalents, bank deposits and certain receivables. The Company held these instruments with highly rated financial institutions and the Company has not experienced any significant credit losses in these accounts and does not believe the Company is exposed to any significant credit risk on these instruments apart of accounts receivable. The Company performs ongoing credit evaluations of its customers for the purpose of determining the appropriate allowance for doubtful accounts. The Company maintains the allowance for estimated losses resulting from the inability of the Company’s customers to make required payments. The Company considers historical collection experience for each of its customers and when revenue and accounts receivable are recorded. The Company also recognizes estimated expected credit losses over the life of the accounts receivables. The estimate of expected credit losses considers not only historical information, but also current and future economic conditions and events. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">r.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Treasury shares</td></tr></table> The Company repurchases its common stock from time to time on the open market and holds such shares as treasury stock. The Company presents the cost to repurchase treasury stock as a reduction of shareholders’ equity. The Company did not reissue nor cancel treasury shares during the year ended December 31, 2024 and December 31, 2023. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">s.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Other Comprehensive Loss</td></tr></table> Other comprehensive loss represents adjustments of foreign currency translation. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">t.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Revenue from Contracts with Customers</td></tr></table> The Company’s agreements are primarily service and processing contracts, the performance obligations of which range in duration from a few months to one year. The Company applies the revenue guidance to contracts when control of the services is transferred to the customer for an amount, referred to as the transaction price, which reflects the consideration to which the Company is expected to be entitled in exchange for those goods or services and when it is probable that the Company will collect substantially all of the consideration to which it is entitled in exchange for the goods and services it transfers to the customer. The Company does not adjust the promised amount of consideration for the effects of a significant financing component since the Company expects, at contract inception, that the period between the time of transfer of the promised goods or services to the customer and the time the customer pays for these goods or services to be generally one year or less. The Company’s credit terms to customers are in average between thirty and one hundred and fifty days. Nature of Revenue Streams The Company has four main revenue streams, which are License fees, POCare development services, cell process development services, including hospital supplies, and POCare cell processing. License fees Revenue recognized under license fees are recognized upon the confirmation of licensee of milestones completed and certainty of payment of the license fee. Significant Judgement and Estimates Significant judgment is required to identifying the distinct performance obligations and estimating the standalone selling price of each distinct performance obligation and identifying which performance obligations create assets with alternative use to the Company, which results in revenue recognized upon completion, and which performance obligations are transferred to the customer over time, and the estimate of credit losses. Cell Process Development Services Revenue recognized under contracts for cell process development services may, in some contracts, represent multiple performance obligations (where promises to the customers are distinct) in circumstances in which the work packages and milestones are not interrelated or the customer is able to complete the services performed independently or by using competitors of the Company. In other contracts when the above circumstances are not met, the promises are not considered distinct, and the contract represents one performance obligation. All performance obligations are satisfied over time, as there is no alternative use to the services it performs, since, in nature, those services are unique to the customer, which retain the ownership of the intellectual property created through the process. For arrangements that include multiple performance obligations, the transaction price is allocated to the identified performance obligations based on their relative standalone selling prices. For these contracts, the standalone selling prices are based on the Company’s normal pricing practices when sold separately with consideration of market conditions and other factors, including customer demographics and geographic location. The Company measures the revenue to be recognized over time on a contract-by-contract basis, determining the use of either a cost-based input method or output method, depending on whichever best depicts the transfer of control over the life of the performance obligation. Included in cell process development services is hospital supplies revenue, which is derived principally from the performance of services to hospitals or other medical providers. Revenue is earned and recognized when product and services are received by the customer. Change Orders Changes in the scope of work are common and can result in a change in transaction price, equipment used and payment terms. Change orders are evaluated on a contract-by-contract basis to determine if they should be accounted for as a new contract or as part of the existing contract. Generally, services from change orders are not distinct from the original performance obligation. As a result, the effect that the contract modification has on the contract revenue, and measure of progress, is recognized as an adjustment to revenue when they occur. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">u.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Leases</td></tr></table> The Company determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC 842-10-25-2. If any of these five criteria is met, The Company classifies the lease as a finance lease; otherwise, the Company classifies the lease as an operating lease. When determining lease classification, the Company’s approach in assessing two of the mentioned criteria is: (i) generally 75% or more of the remaining economic life of the underlying asset is a major part of the remaining economic life of that underlying asset; and (ii) generally 90% or more of the fair value of the underlying asset comprises substantially all of the fair value of the underlying asset. Operating leases are included in operating lease right-of-use (“ROU”) assets and operating lease liabilities in the consolidated balance sheet. Finance leases are included in property, plants and equipment, net and finance lease liabilities in the consolidated balance sheet. ROU assets represent Orgenesis’ right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date to determine the present value of the lease payments. The standard also provides practical expedients for an entity’s ongoing accounting. The Company elected the short-term lease recognition exemption for all leases with a term shorter than 12 months. This means that for those leases, the Company does not recognize ROU assets or lease liabilities but recognizes lease expenses over the lease term on a straight-line basis. Lease terms will include options to extend or terminate the lease when it is reasonably certain that Orgenesis will exercise or not exercise the option to renew or terminate the lease. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">v.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Segment reporting</td></tr></table> The Company’s business includes two reporting segments: Octomera and Therapies. See note 5. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">w.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Recently issued accounting pronouncements, not yet adopted</td></tr></table> On August 23, 2023, the FASB issued guidance requiring a joint venture to initially measure all contributions received upon its formation at fair value. This accounting will largely be consistent with ASC 805, Business Combinations, although there are some specific exceptions. Before the ASU, there was no authoritative guidance in US GAAP that addressed how a joint venture should recognize contributions received. As a result, there has been diversity in practice, with some joint ventures accounting for contributions received at carry over basis and others at fair value. This new guidance is intended to reduce diversity in practice and provide users of the joint venture’s financial statements with more decision-useful information. It may also reduce the amount of basis differences that an investor in a joint venture needs to track. The new guidance should be applied prospectively and is effective for all newly-formed joint venture entities with a formation date on or after January 1, 2025, with early adoption permitted. The adoption of this guidance will not have a material impact on the Company’s consolidated financial statements. In December 2023, the FASB issued ASU 2023-09 “Income Taxes (Topic 740): Improvements to Income Tax Disclosures”. This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures. In November 2024, the FASB issued ASU No. 2024-03 Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40). The ASU improves the disclosures about a public business entity’s expenses and provides more detailed information about the types of expenses in commonly presented expense captions. The amendments require that at each interim and annual reporting period an entity will, inter alia, disclose amounts of purchases of inventory, employee compensation, depreciation and amortization included in each relevant expense caption (such as cost of sales, SG&A and research and development). The ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating this ASU to determine its impact on the Company’s disclosures. In July 2025, the FASB issued ASU 2025-05 “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets”. The ASU introduces a practical expedient for all entities when estimating expected credit losses for current accounts receivable and current contract assets arising from transactions accounted for under ASC 606. Under the practical expedient, when developing reasonable and supportable forecast as part of estimating expected credit losses, an entity may assume that current conditions as of the balance sheet date do not change for the remaining life of the asset. The ASU is effective for annual reporting period beginning after December 15, 2025 and interim reporting within those annual reporting periods. Early adoption is permitted in both interim and annual reporting periods. The Company is evaluating the impact of ASU 2025-05 on its consolidated financial statements if it elects to apply the practical expedient. In September 2025, the FASB issued ASU 2025-07 “Derivatives Scope Refinements and Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract”. The ASU excludes from the derivative accounting certain non-exchange-traded contracts with contracts with underlying that are based on operations or activities specific to one of the parties to the contract. Further, the ASU clarifies that an entity should apply the guidance in ASC 606 to a contract with share-based noncash consideration. The guidance in other Topics (such as ASC 815 or ASC 312) does not apply to such consideration unless and until the entity’s right to receive or retain the consideration is unconditional. The ASU is effective for annual periods beginning after December 15, 2026 and interim periods within those annual periods. Early adoption is permitted. The amendment can be applied either prospectively to new contracts entered into on or after the date of adoption or on a modified retrospective basis through cumulative effect adjustment to the opening balance of retained earnings as of the beginning of the annual reporting period of adoption. The Company is in the process of evaluating the effects of the ASU on its contracts.

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in">a.</td> <td style="text-align: justify">Use of Estimates in the Preparation of Financial Statements</td></tr> </table> The preparation of the Company’s consolidated financial statements in conformity with U.S. GAAP requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates, judgments and methodologies. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity, the amount of revenues and expenses, determination of loss on deconsolidation, valuation of investments, goodwill impairment, and assessment of credit losses. Actual results could differ from those estimates.

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in">b.</td> <td style="text-align: justify">Business Combination</td></tr> </table> The Company allocates the fair value of consideration transferred in a business combination to the assets acquired, liabilities assumed, and non-controlling interests in the acquired business based on their fair values at the acquisition date. All assets and liabilities are recognized in fair value. The purchase price allocation process requires management to make significant estimates and assumptions, especially at the acquisition date with respect to intangible assets. Direct transaction costs associated with the business combination are expensed as incurred. The excess of the fair value of the consideration transferred plus the fair value of any non-controlling interest in the acquiree over the fair value of the assets acquired, liabilities assumed in the acquired business is recorded as goodwill. The allocation of the consideration transferred in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date. The cumulative impact of revisions during the measurement period is recognized in the reporting period in which the revisions are identified. The Company includes the results of operations of the business that it has acquired in its consolidated results prospectively from the date of acquisition. If the business combination is achieved in stages, the acquisition date carrying value of the acquirer’s previously held equity interest in the acquire is re-measured to fair value at the acquisition date; any gains or losses arising from such re-measurement are recognized in profit or loss.

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in">c.</td> <td style="text-align: justify">Cash Equivalents</td></tr> </table> The Company considers cash equivalents to be all short-term, highly liquid investments, which include money market instruments, that are not restricted as to withdrawal or use, and short-term bank deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash.

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in">d.</td> <td style="text-align: justify">Cost of development services and research and development expenses</td></tr> </table> Cost of development services and research and development expenses include costs directly attributable to the conduct of research and development activities, including the cost of salaries, stock-based compensation expenses, payroll taxes and other employees’ benefits, lab expenses, consumable equipment, courier fees, travel expenses, professional fees and consulting fees. All costs associated with research and developments are expensed as incurred. Participation from government departments and from research foundations for development of approved projects is recognized as a reduction of expense as the related costs are incurred. Research and development in-process acquired as part of an asset purchase, which has not reached technological feasibility and has no alternative future use, is expensed as incurred.

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in">e.</td> <td style="text-align: justify">Principles of Consolidation</td></tr> </table> The consolidated financial statements include the accounts of the Company and its Subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in">f.</td> <td style="text-align: justify">Non-Marketable Equity Investments</td></tr> </table> The Company’s investments in certain non-marketable equity securities in which it has the ability to exercise significant influence, but it does not control through variable interests or voting interests. These are accounted for under the equity method of accounting and presented as Investment in associates, net, in the Company’s consolidated balance sheets. Under the equity method, the Company recognizes its proportionate share of the comprehensive income or loss of the investee. The Company’s share of income and losses from equity method investments is included in share in losses of associated company. The Company periodically reviews equity method investments for impairment in value whenever events or changes in circumstances indicate that the carrying amount of such investments may not be recoverable. The Company will record an impairment charge to the extent that the estimated fair value of an investment is less than its carrying value and the Company determines the impairment is other-than-temporary. Impairment charges, if applicable, are recorded in “Share in net (losses) profits of associated companies”.

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in">g.</td> <td style="text-align: justify">Fair value measurement</td></tr> </table> The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable inputs that are based on inputs not quoted on active markets, but corroborated by market data. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in">h.</td> <td style="text-align: justify">Functional Currency</td></tr> </table> The currency of the primary economic environment in which the operations of the Company and part of its Subsidiaries are conducted is the U.S. dollar (“$” or “dollar”). The functional currency of the Belgian Subsidiary is the Euro (“€” or “Euro”). Most of the Company’s expenses are incurred in dollars, and the source of the Company’s financing has been provided in dollars. Thus, the functional currency of the Company and its other subsidiaries is the dollar. Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in foreign currencies are translated into dollars using historical and current exchange rates for nonmonetary and monetary balances, respectively. For foreign transactions and other items reflected in the statements of operations, the following exchange rates are used: (1) for transactions – exchange rates at transaction dates or average rates and (2) for other items (derived from nonmonetary balance sheet items such as depreciation) – historical exchange rates. The resulting transaction gains or losses are recorded as financial income or expenses. The financial statements of the Belgian Subsidiary is included in the consolidated financial statements, translated into U.S. dollars. Assets and liabilities are translated at year-end exchange rates, while revenues and expenses are translated at yearly average exchange rates during the year. Differences resulting from translation of assets and liabilities are presented as other comprehensive income.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">i.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inventory</td></tr></table> The Company’s inventory consists of raw material for use for the services provided. The Company periodically evaluates the quantities on hand. Cost of the raw materials is determined using the weighted average cost method. The inventory is recorded at the lower of cost or net realizable value.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">j.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Property, Plants and Equipment</td></tr></table> Property, plants and equipment are recorded at cost and depreciated by the straight-line method over the estimated useful lives of the related assets. <p id="xdx_896_ecustom--ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentTableTextBlock_z1KFDmEIx6ok" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Annual rates of depreciation are presented in the table below: SCHEDULE OF ANNUAL DEPRECIATION RATES, PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Useful Life (Years)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 72%; text-align: left">Production facility</td><td style="width: 2%"> </td> <td style="width: 26%; text-align: center"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionFacilityMember__srt--RangeAxis__srt--MinimumMember_ziMhD9Qv2Grl" title="Weighted average useful life">3 - <span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionFacilityMember__srt--RangeAxis__srt--MaximumMember_zkIXhi0rmaS5" title="Weighted average useful life">10</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Laboratory equipment</td><td> </td> <td style="text-align: center"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MinimumMember_zRjO4Y5NZvaa" title="Weighted average useful life">1 - <span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MaximumMember_zpC2Tn7HMvK3" title="Weighted average useful life">7</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Office equipment and computers</td><td> </td> <td style="text-align: center"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_z4jp32E5DcTe" title="Weighted average useful life">3 - <span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zcrPUM3qYjOi" title="Weighted average useful life">17</td></tr> </table> Impairment charges of property, Plants and Equipment during the year ended December 31, 2024 were $8,752, see note 1.

<p id="xdx_896_ecustom--ScheduleOfAnnualDepreciationRatesPropertyAndEquipmentTableTextBlock_z1KFDmEIx6ok" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Annual rates of depreciation are presented in the table below: SCHEDULE OF ANNUAL DEPRECIATION RATES, PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Useful Life (Years)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 72%; text-align: left">Production facility</td><td style="width: 2%"> </td> <td style="width: 26%; text-align: center"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionFacilityMember__srt--RangeAxis__srt--MinimumMember_ziMhD9Qv2Grl" title="Weighted average useful life">3 - <span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionFacilityMember__srt--RangeAxis__srt--MaximumMember_zkIXhi0rmaS5" title="Weighted average useful life">10</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Laboratory equipment</td><td> </td> <td style="text-align: center"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MinimumMember_zRjO4Y5NZvaa" title="Weighted average useful life">1 - <span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MaximumMember_zpC2Tn7HMvK3" title="Weighted average useful life">7</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Office equipment and computers</td><td> </td> <td style="text-align: center"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_z4jp32E5DcTe" title="Weighted average useful life">3 - <span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zcrPUM3qYjOi" title="Weighted average useful life">17</td></tr> </table>

P3Y

P10Y

P1Y

P7Y

P3Y

P17Y

8752000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">k.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Intangible assets</td></tr></table> Intangible assets and their useful lives are as follows: SCHEDULE OF INTANGIBLE ASSETS AND THEIR USEFUL LIVE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 26%"> </td> <td style="width: 2%"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 18%; text-align: center">Useful Life (Years)</td> <td style="width: 2%"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 52%; text-align: center">Amortization Recorded at Comprehensive Loss Line Item</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Know-How</td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KnowHowMember_zQCIaOhImzd5" title="Intangible assets and useful lives (Years)">10</td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Amortization of intangible assets</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Technology</td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TechnologyMember_zKpjQgRxrVPg" title="Intangible assets and useful lives (Years)">15</td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Amortization of intangible assets</td></tr> </table> Intangible assets are recorded at acquisition less accumulated amortization and impairment. Definite lived intangible assets are amortized over their estimated useful life using the straight-line method, which is determined by identifying the period over which the cash flows from the asset are expected to be generated. The Company capitalizes IPR&D projects acquired as part of a business combination. On successful completion of each project, IPR&D assets are reclassified to developed technology and amortized over their estimated useful lives. Impairment charges of intangible assets during the year ended December 31, 2024 were $8,375, see note 1.

Intangible assets and their useful lives are as follows: SCHEDULE OF INTANGIBLE ASSETS AND THEIR USEFUL LIVE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 26%"> </td> <td style="width: 2%"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 18%; text-align: center">Useful Life (Years)</td> <td style="width: 2%"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 52%; text-align: center">Amortization Recorded at Comprehensive Loss Line Item</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Know-How</td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KnowHowMember_zQCIaOhImzd5" title="Intangible assets and useful lives (Years)">10</td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Amortization of intangible assets</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Technology</td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TechnologyMember_zKpjQgRxrVPg" title="Intangible assets and useful lives (Years)">15</td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Amortization of intangible assets</td></tr> </table>

P10Y

P15Y

8375000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">l.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Goodwill</td></tr></table> Goodwill represents the excess of consideration transferred over the value assigned to the net tangible and identifiable intangible assets of businesses acquired. Goodwill is allocated to reporting units expected to benefit from the business combination. Goodwill is not amortized but rather tested for impairment at least annually in the fourth quarter, or more frequently if events or changes in circumstances indicate that goodwill may be impaired. Before the Octomera deconsolidation (see note 3), the Company reallocated its goodwill into two identified operating units: Octomera and Therapies. Subsequent to the Octomera deconsolidation, the goodwill allocated to Octomera was derecognized. During the year ended December 31, 2024, the Company recorded goodwill impairment charges of $1,211 (see note 1). As a result of the derecognition and impairment recorded during 2024, the Company had no goodwill recorded as of December 31, 2024. Goodwill impairment is recognized when the quantitative assessment results in the carrying value exceeding the fair value, in which case an impairment charge is recorded to the extent the carrying value exceeds the fair value.

1211000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">m.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Impairment of Long-lived Assets</td></tr></table> The Company reviews its property, plants and equipment, intangible assets subject to amortization and other long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset class may not be recoverable. Indicators of potential impairment include: an adverse change in legal factors or in the business climate that could affect the value of the asset; an adverse change in the extent or manner in which the asset is used or is expected to be used, or in its physical condition; and current or forecasted operating or cash flow losses that demonstrate continuing losses associated with the use of the asset. If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset. If the expected cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted cash flows. For indefinite life intangible assets, the Company performs an impairment test annually in the fourth quarter and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. The Company determines the fair value of the asset based on discounted cash flows and records an impairment loss if its book value exceeds fair value. Impairment charges of other investment during the year ended December 31, 2023 were $699.

699000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">n.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Income Taxes</td></tr></table> 1) With respect to deferred taxes, income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is recognized to the extent that it is more likely than not that the deferred taxes will not be realized in the foreseeable future. 2) The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the available evidence indicates that it is more likely than not that the position will be sustained on examination. If this threshold is met, the second step is to measure the tax position as the largest amount that is greater than 50% likely of being realized upon ultimate settlement. 3) Taxes that would apply in the event of disposal of investment in Subsidiaries and associated companies have not been taken into account in computing the deferred income taxes, as it is the Company’s intention to hold these investments and not realize them.

greater than 50% likely of being realized upon ultimate settlement.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">o.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Stock-based Compensation</td></tr></table> The Company recognizes stock-based compensation for the estimated fair value of share-based awards. The Company measures compensation expense for share-based awards based on estimated fair values on the date of grant using the Black-Scholes option-pricing model. This option pricing model requires estimates as to the option’s expected term and the price volatility of the underlying stock. The Company amortizes the value of share-based awards to expense over the vesting period on a straight-line basis.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">p.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Loss per Share of Common Stock</td></tr></table> Basic net loss (income) per share is computed by dividing the net loss (income) for the period by the weighted average number of shares of common stock outstanding for each period. Diluted net income per share is based upon the weighted average number of common shares and of common shares equivalents outstanding when dilutive. Common share equivalents include: (i) outstanding stock options, RSUs and warrants which are included under the treasury share method when dilutive, and (ii) common shares to be issued under the assumed conversion of the Company’s outstanding convertible loans and debt, which are included under the if-converted method when dilutive (See Note 14).

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">q.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Concentration of Credit Risk</td></tr></table> Financial instruments that potentially subject the Company to concentration of credit risk consist of principally cash and cash equivalents, bank deposits and certain receivables. The Company held these instruments with highly rated financial institutions and the Company has not experienced any significant credit losses in these accounts and does not believe the Company is exposed to any significant credit risk on these instruments apart of accounts receivable. The Company performs ongoing credit evaluations of its customers for the purpose of determining the appropriate allowance for doubtful accounts. The Company maintains the allowance for estimated losses resulting from the inability of the Company’s customers to make required payments. The Company considers historical collection experience for each of its customers and when revenue and accounts receivable are recorded. The Company also recognizes estimated expected credit losses over the life of the accounts receivables. The estimate of expected credit losses considers not only historical information, but also current and future economic conditions and events.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">r.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Treasury shares</td></tr></table> The Company repurchases its common stock from time to time on the open market and holds such shares as treasury stock. The Company presents the cost to repurchase treasury stock as a reduction of shareholders’ equity. The Company did not reissue nor cancel treasury shares during the year ended December 31, 2024 and December 31, 2023.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">s.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Other Comprehensive Loss</td></tr></table> Other comprehensive loss represents adjustments of foreign currency translation.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">t.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Revenue from Contracts with Customers</td></tr></table> The Company’s agreements are primarily service and processing contracts, the performance obligations of which range in duration from a few months to one year. The Company applies the revenue guidance to contracts when control of the services is transferred to the customer for an amount, referred to as the transaction price, which reflects the consideration to which the Company is expected to be entitled in exchange for those goods or services and when it is probable that the Company will collect substantially all of the consideration to which it is entitled in exchange for the goods and services it transfers to the customer. The Company does not adjust the promised amount of consideration for the effects of a significant financing component since the Company expects, at contract inception, that the period between the time of transfer of the promised goods or services to the customer and the time the customer pays for these goods or services to be generally one year or less. The Company’s credit terms to customers are in average between thirty and one hundred and fifty days. Nature of Revenue Streams The Company has four main revenue streams, which are License fees, POCare development services, cell process development services, including hospital supplies, and POCare cell processing. License fees Revenue recognized under license fees are recognized upon the confirmation of licensee of milestones completed and certainty of payment of the license fee. Significant Judgement and Estimates Significant judgment is required to identifying the distinct performance obligations and estimating the standalone selling price of each distinct performance obligation and identifying which performance obligations create assets with alternative use to the Company, which results in revenue recognized upon completion, and which performance obligations are transferred to the customer over time, and the estimate of credit losses. Cell Process Development Services Revenue recognized under contracts for cell process development services may, in some contracts, represent multiple performance obligations (where promises to the customers are distinct) in circumstances in which the work packages and milestones are not interrelated or the customer is able to complete the services performed independently or by using competitors of the Company. In other contracts when the above circumstances are not met, the promises are not considered distinct, and the contract represents one performance obligation. All performance obligations are satisfied over time, as there is no alternative use to the services it performs, since, in nature, those services are unique to the customer, which retain the ownership of the intellectual property created through the process. For arrangements that include multiple performance obligations, the transaction price is allocated to the identified performance obligations based on their relative standalone selling prices. For these contracts, the standalone selling prices are based on the Company’s normal pricing practices when sold separately with consideration of market conditions and other factors, including customer demographics and geographic location. The Company measures the revenue to be recognized over time on a contract-by-contract basis, determining the use of either a cost-based input method or output method, depending on whichever best depicts the transfer of control over the life of the performance obligation. Included in cell process development services is hospital supplies revenue, which is derived principally from the performance of services to hospitals or other medical providers. Revenue is earned and recognized when product and services are received by the customer. Change Orders Changes in the scope of work are common and can result in a change in transaction price, equipment used and payment terms. Change orders are evaluated on a contract-by-contract basis to determine if they should be accounted for as a new contract or as part of the existing contract. Generally, services from change orders are not distinct from the original performance obligation. As a result, the effect that the contract modification has on the contract revenue, and measure of progress, is recognized as an adjustment to revenue when they occur.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">u.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Leases</td></tr></table> The Company determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC 842-10-25-2. If any of these five criteria is met, The Company classifies the lease as a finance lease; otherwise, the Company classifies the lease as an operating lease. When determining lease classification, the Company’s approach in assessing two of the mentioned criteria is: (i) generally 75% or more of the remaining economic life of the underlying asset is a major part of the remaining economic life of that underlying asset; and (ii) generally 90% or more of the fair value of the underlying asset comprises substantially all of the fair value of the underlying asset. Operating leases are included in operating lease right-of-use (“ROU”) assets and operating lease liabilities in the consolidated balance sheet. Finance leases are included in property, plants and equipment, net and finance lease liabilities in the consolidated balance sheet. ROU assets represent Orgenesis’ right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date to determine the present value of the lease payments. The standard also provides practical expedients for an entity’s ongoing accounting. The Company elected the short-term lease recognition exemption for all leases with a term shorter than 12 months. This means that for those leases, the Company does not recognize ROU assets or lease liabilities but recognizes lease expenses over the lease term on a straight-line basis. Lease terms will include options to extend or terminate the lease when it is reasonably certain that Orgenesis will exercise or not exercise the option to renew or terminate the lease.

When determining lease classification, the Company’s approach in assessing two of the mentioned criteria is: (i) generally 75% or more of the remaining economic life of the underlying asset is a major part of the remaining economic life of that underlying asset; and (ii) generally 90% or more of the fair value of the underlying asset comprises substantially all of the fair value of the underlying asset.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">v.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Segment reporting</td></tr></table> The Company’s business includes two reporting segments: Octomera and Therapies. See note 5.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">w.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Recently issued accounting pronouncements, not yet adopted</td></tr></table> On August 23, 2023, the FASB issued guidance requiring a joint venture to initially measure all contributions received upon its formation at fair value. This accounting will largely be consistent with ASC 805, Business Combinations, although there are some specific exceptions. Before the ASU, there was no authoritative guidance in US GAAP that addressed how a joint venture should recognize contributions received. As a result, there has been diversity in practice, with some joint ventures accounting for contributions received at carry over basis and others at fair value. This new guidance is intended to reduce diversity in practice and provide users of the joint venture’s financial statements with more decision-useful information. It may also reduce the amount of basis differences that an investor in a joint venture needs to track. The new guidance should be applied prospectively and is effective for all newly-formed joint venture entities with a formation date on or after January 1, 2025, with early adoption permitted. The adoption of this guidance will not have a material impact on the Company’s consolidated financial statements. In December 2023, the FASB issued ASU 2023-09 “Income Taxes (Topic 740): Improvements to Income Tax Disclosures”. This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures. In November 2024, the FASB issued ASU No. 2024-03 Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40). The ASU improves the disclosures about a public business entity’s expenses and provides more detailed information about the types of expenses in commonly presented expense captions. The amendments require that at each interim and annual reporting period an entity will, inter alia, disclose amounts of purchases of inventory, employee compensation, depreciation and amortization included in each relevant expense caption (such as cost of sales, SG&A and research and development). The ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating this ASU to determine its impact on the Company’s disclosures. In July 2025, the FASB issued ASU 2025-05 “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets”. The ASU introduces a practical expedient for all entities when estimating expected credit losses for current accounts receivable and current contract assets arising from transactions accounted for under ASC 606. Under the practical expedient, when developing reasonable and supportable forecast as part of estimating expected credit losses, an entity may assume that current conditions as of the balance sheet date do not change for the remaining life of the asset. The ASU is effective for annual reporting period beginning after December 15, 2025 and interim reporting within those annual reporting periods. Early adoption is permitted in both interim and annual reporting periods. The Company is evaluating the impact of ASU 2025-05 on its consolidated financial statements if it elects to apply the practical expedient. In September 2025, the FASB issued ASU 2025-07 “Derivatives Scope Refinements and Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract”. The ASU excludes from the derivative accounting certain non-exchange-traded contracts with contracts with underlying that are based on operations or activities specific to one of the parties to the contract. Further, the ASU clarifies that an entity should apply the guidance in ASC 606 to a contract with share-based noncash consideration. The guidance in other Topics (such as ASC 815 or ASC 312) does not apply to such consideration unless and until the entity’s right to receive or retain the consideration is unconditional. The ASU is effective for annual periods beginning after December 15, 2026 and interim periods within those annual periods. Early adoption is permitted. The amendment can be applied either prospectively to new contracts entered into on or after the date of adoption or on a modified retrospective basis through cumulative effect adjustment to the opening balance of retained earnings as of the beginning of the annual reporting period of adoption. The Company is in the process of evaluating the effects of the ASU on its contracts.

NOTE 3 – RECONSOLIDATION OF OCTOMERA LLC On June 30, 2023, the Company and MM entered into Amendment No. 1 to the Second Amended and Restated Limited Liability Company Agreement (the “LLC Agreement Amendment”) to amend Octomera’s board composition. Pursuant to the LLC Agreement Amendment, the board of managers of Octomera (the “Octomera Board”) will be comprised of five managers, two of which will be appointed by the Company, one of which will be an industry expert appointed by MM, and two of which will be appointed by MM. The change was effective immediately. As a result of the amendment to the composition of the Octomera Board pursuant to the LLC Agreement Amendment described above, the Company deconsolidated Octomera from its consolidated financial statements as of June 30, 2023 (“date of deconsolidation”) and recorded its equity interest in Octomera as an equity method investment Prior to the date of deconsolidation the MM investment in Octomera was presented as a redeemable non-controlling interest on the Company’s balance sheet, and outside of permanent equity. On January 29, 2024, the Company and MM entered into a UPA pursuant to which the Company acquired all of the preferred units of Octomera owned by MM and the Company and MM agreed to the following: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">3.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Consideration:</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Royalty Payments: If Octomera and its subsidiaries generate Net Revenue during the three-year period 2025-2027, then the Company will pay <span id="xdx_90C_ecustom--RoyaltyPercentageToBeReceivedOnGenerateNetRevenues_pid_dp_uPure_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MetalmarkMember__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember_zwkZj6QXSvo8" title="Royalty percentage to be received">5% of Net Revenues to MM pursuant to the MM UPA.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Milestone Payments: If the Company sells Octomera within ten years from the date of the Closing at a price that is more than $40 million excluding consideration for certain Excluded Assets as per the UPA, the Company shall pay MM <span id="xdx_90D_ecustom--MaximumAmountOfSalesMilestonePaymentsIfTotalSalesAchieveSpecificLevels_pid_dp_uPure_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--UnitPurchaseAgreementMember_zLSV1ONusr4i" title="Milestone sales percentage">5% of the net proceeds.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">4.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">MM’s designated members of the Board of Managers of Octomera resigned and the Company amended the Second Amended and Restated Limited Liability Company Agreement of Octomera (the “Octomera LLC Agreement”) to be a single member agreement reflecting the transactions consummated under the UPA, such that MM no longer (i) is a member of Octomera or a party to the Octomera LLC Agreement, or (ii) has a right to appoint members of the board of managers of Octomera.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">5.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">10 secured promissory notes between Orgenesis Maryland LLC and MM, reflecting an aggregate outstanding principal amount of $2,600 (the “Notes”), were amended to, among other things, extend the maturity thereof to January 29, 2034 and to terminate the security interest granted by Orgenesis Maryland LLC in favor of MM that secured the obligations under the Notes.</td></tr></table> Fair Value of Consideration Transferred Accounting guidance provides that the allocation of the purchase price may be adjusted for up to one year from the date of the acquisition to the extent that additional information is obtained about the facts and circumstances that existed as of the acquisition date. The primary area of the purchase price allocation that is not yet finalized is related to intangible assets, property, plant and equipment, and certain other assets and tax matters and the related impact on goodwill. In evaluating the fair value of the Octomera Equity Investment under the income approach, the Company used a discounted cash flow model of the business, adjusted to the Company’s share in the investment. Key assumptions used to determine the estimated fair value included: (a) internal cash flows forecasts for 5 years following the assessment date, including expected revenue growth, costs to produce, operating profit margins and estimated capital needs; (b) an estimated terminal value using a terminal year long-term future growth determined based on the growth prospects of the reporting units; and (c) a discount rate which reflects the weighted average cost of capital adjusted for the relevant risk associated with the Company’s reporting unit operations and the uncertainty inherent in the Company’s internally developed forecasts. The allocation of the purchase price to the net assets acquired and liabilities assumed resulted in the recognition of other intangible assets, net, which comprised of technology. The useful life of the technology for amortization purposes was determined by considering the period of expected cash flows generated by the assets used to measure the fair value of the intangible assets, adjusted as appropriate for the entity-specific factors including legal, regulatory, contractual, competitive, economic, or other factors that may limit the useful life of intangible assets. The following table summarizes the allocation of purchase price to the fair values of the assets acquired and liabilities assumed as of the Transaction date: SCHEDULE OF PURCHASE PRICE TO THE FAIR VALUES OF THE ASSETS ACQUIRED AND LIABILITIES ASSUMED <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20241231__us-gaap--BusinessAcquisitionAxis__custom--OctomeraMember_z2n6XwDY5K9" style="border-bottom: Black 1pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40F_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNet_iNI_pn3n3_di_maLFVDzs4H_zYT2UCxgylaf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify; padding-bottom: 1pt">Total Contingent consideration to MM for royalty and milestone payments</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 20%; text-align: right">4,643</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_iB_zMcgar2KRsSi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify">Total assets acquired:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_pn3n3_maAFVDzmwR_maBCRIAzwYC_zjySvWYaDw13" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Cash and cash equivalents</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">139</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_iI_pn3n3_maAFVDzmwR_maBCRIAzwYC_zOc7r1x121q9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Property, plants and equipment, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,852</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_iI_pn3n3_maAFVDzmwR_maBCRIAzwYC_zOsnJlxnSnJ3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Other Assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,478</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iTI_pn3n3_mtBCRIAzwYC_maBCRIAzjZ1_zsDaKP6YVUk9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Total assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">21,469</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_iB_z7iCdwMZKOnd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify">Total liabilities assumed:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_i01NI_di_maBCRIAz3PH_zq3UAg3eBhF6" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Total current liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(12,518</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities_iNI_di_maBCRIAz3PH_zzuNeXAmjIQe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Total long-term liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(5,628</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iNTI_pn3n3_di_mtBCRIAz3PH_msBCRIAzjZ1_z46Ie9BrCgr6" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; font-style: italic; text-align: justify">Total liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(18,146</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_pn3n3_maBCRIAzjZ1_zWj6Jun8Dll2" style="vertical-align: bottom; background-color: White"> <td style="font-style: italic; text-align: justify">Know how Technology</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,728</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iTI_pn3n3_mtBCRIAzjZ1_maBCRIAzcp3_zY4XWKkR48Nj" style="vertical-align: bottom; background-color: White"> <td style="font-style: italic; text-align: justify">Total Net Assets</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5,051</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_iNI_pn3n3_di_maLFVDzs4H_msBCRIAzcp3_zeiDtMiq7Xq6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify">Fair-Value of Non-controlling interests</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(408</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_iTI_pn3n3_mtBCRIAzcp3_zPgMlnjzVOa" style="vertical-align: bottom; background-color: White"> <td style="font-style: italic; text-align: justify">Total liability to MM</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4,643</td><td style="text-align: left"> </td></tr> </table> The allocation of the purchase price to the net assets acquired and liabilities assumed resulted in the recognition of an intangible asset know-how of $<span id="xdx_900_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_pn3n3_c20241231__us-gaap--BusinessAcquisitionAxis__custom--OctomeraMember_zfyi4G6pfLy2" title="Recognition of intangible asset">1,728 and a liability to MM in the amount of $<span id="xdx_90C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_iI_pn3n3_c20241231__us-gaap--BusinessAcquisitionAxis__custom--OctomeraMember_zMuTmpCoHUK6" title="Liability to MM">4,643. The know-how has a useful life of <span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KnowHowTechnologyMember_z1w4yaYKlJFd" title="Intangible assets useful life">10 years. The useful life of the intangible asset for amortization purposes was determined considering the period of expected cash flows generated by the assets used to measure the fair value of the intangible asset adjusted as appropriate for the entity-specific factors, including legal, regulatory, contractual, competitive, economic or other factors that may limit the useful life of intangible assets. <p id="xdx_89D_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_z9bpJj77Dq9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Key inputs for the fair values valuation are summarized below. SCHEDULE OF KEY INPUTS FOR THE FAIR VALUES VALUATION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Key Valuation Inputs</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20240129__us-gaap--BusinessAcquisitionAxis__custom--OctomeraMember_zcNiszUKP03e" style="border-bottom: Black 1pt solid; text-align: center">Jan 29, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_402_eus-gaap--BusinessCombinationContingentConsiderationLiabilityMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_zNrdZYzIMixc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Discount rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right">40</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_40F_eus-gaap--BusinessCombinationContingentConsiderationLiabilityMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zdBI4TvBFvQ5" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.4</td><td style="text-align: left">%</td></tr> <tr id="xdx_400_eus-gaap--BusinessCombinationContingentConsiderationLiabilityMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputLongTermRevenueGrowthRateMember_zrEr4LP8Cxne" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Average 5 years revenue growth</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50</td><td style="text-align: left">%</td></tr> <tr id="xdx_40A_eus-gaap--BusinessCombinationContingentConsiderationLiabilityMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputLongTermRevenueGrowthRateMember_zxOkLfgaA56b" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Measurement input</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50</td><td style="text-align: left">%</td></tr> </table> The Company incurred transaction costs of approximately $50 and $0 during the year ended December 31, 2024 respectively, which were included in general and administrative expenses in the condensed consolidated statements of operations. The revenues and net loss of Octomera from January 1, 2024 until the reconsolidation date were $23 and $1,244 respectively. Fair value assumptions used in accounting for contingent consideration On January 29, 2024, in connection with the PPA study of Octomera LLC, the Company recognized a contingent consideration to pay MM based on two components: 1. Royalties based on revenues in 2025, 2026 and 2027, and; 2. An earnout amount, which is dependent on a future triggering event being either an IPO or exit. The estimated fair value of the contingent consideration is based on management’s assessment of whether, and at what level, the financial metrics will be achieved, and the present value factors associated with the timing of the payments. This fair value measurement is based on significant unobservable inputs in the market and thus represents a Level 3 fair value measurement and used the Monte Carlo pricing model to calculate the fair value, which was $<span id="xdx_90C_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_pn3n3_c20240129__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zbLRv5g7VHi5" title="Fair value of derivative asset">4,643 as of January 29, 2024. As of December 31, 2024, the fair value was $0, primarily as the Company does not expect significant revenue (see note 1). Changes in the fair value of contingent consideration are recorded in operating expenses. The total revaluation income for the period ended December 31, 2024 was $4,643. Key inputs for the simulation are summarized below. SCHEDULE OF KEY INPUTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Key Valuation Inputs</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Jan 29, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Standard Deviation</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right"><span id="xdx_905_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240129__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputStandardDeviationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zRLqGEVb2e06" title="Measurement input">13.5</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240129__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zij64wdTniZj" title="Measurement input">4.4</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Possible trigger event examination</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">Year <span id="xdx_909_ecustom--PossibleTriggerEventExamination_dtY_c20240129__20240129__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputTriggerEventMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zLY5Ej2INyi8" title="Possible trigger event examination">10</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Average 5 years revenue growth</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240129__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputLongTermRevenueGrowthRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXni9RjJKWHe" title="Measurement input">50</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Trigger events</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240129__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputTriggerEventsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmq4D6Em5OGb" title="Measurement input">30</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">EV/EBIT Multiple</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240129__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRevenueMultipleMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zOLKlrbSrMO4" title="Measurement input">11.1</td><td style="text-align: left"> </td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in">*</td> <td style="text-align: justify">Based on a Monte Carlo simulation analysis of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEtFWSBJTlBVVFMgRk9SIFRIRSBGQUlSIFZBTFVFUyBWQUxVQVRJT04gKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--SharesIssued_iI_c20240129_z1xO9Ra1z9Q8" title="Shares issued">30,000 iterations</td></tr> </table> 0.05 40000000 0.05

2600000

The following table summarizes the allocation of purchase price to the fair values of the assets acquired and liabilities assumed as of the Transaction date: SCHEDULE OF PURCHASE PRICE TO THE FAIR VALUES OF THE ASSETS ACQUIRED AND LIABILITIES ASSUMED <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20241231__us-gaap--BusinessAcquisitionAxis__custom--OctomeraMember_z2n6XwDY5K9" style="border-bottom: Black 1pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40F_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesNet_iNI_pn3n3_di_maLFVDzs4H_zYT2UCxgylaf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify; padding-bottom: 1pt">Total Contingent consideration to MM for royalty and milestone payments</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 20%; text-align: right">4,643</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_iB_zMcgar2KRsSi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify">Total assets acquired:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_pn3n3_maAFVDzmwR_maBCRIAzwYC_zjySvWYaDw13" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Cash and cash equivalents</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">139</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_iI_pn3n3_maAFVDzmwR_maBCRIAzwYC_zOc7r1x121q9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Property, plants and equipment, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,852</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_iI_pn3n3_maAFVDzmwR_maBCRIAzwYC_zOsnJlxnSnJ3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Other Assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,478</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iTI_pn3n3_mtBCRIAzwYC_maBCRIAzjZ1_zsDaKP6YVUk9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Total assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">21,469</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_iB_z7iCdwMZKOnd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify">Total liabilities assumed:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_i01NI_di_maBCRIAz3PH_zq3UAg3eBhF6" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Total current liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(12,518</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities_iNI_di_maBCRIAz3PH_zzuNeXAmjIQe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Total long-term liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(5,628</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iNTI_pn3n3_di_mtBCRIAz3PH_msBCRIAzjZ1_z46Ie9BrCgr6" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; font-style: italic; text-align: justify">Total liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(18,146</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_pn3n3_maBCRIAzjZ1_zWj6Jun8Dll2" style="vertical-align: bottom; background-color: White"> <td style="font-style: italic; text-align: justify">Know how Technology</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,728</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iTI_pn3n3_mtBCRIAzjZ1_maBCRIAzcp3_zY4XWKkR48Nj" style="vertical-align: bottom; background-color: White"> <td style="font-style: italic; text-align: justify">Total Net Assets</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5,051</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_iNI_pn3n3_di_maLFVDzs4H_msBCRIAzcp3_zeiDtMiq7Xq6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify">Fair-Value of Non-controlling interests</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(408</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_iTI_pn3n3_mtBCRIAzcp3_zPgMlnjzVOa" style="vertical-align: bottom; background-color: White"> <td style="font-style: italic; text-align: justify">Total liability to MM</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4,643</td><td style="text-align: left"> </td></tr> </table>

-4643000

139000

17852000

3478000

21469000

12518000

5628000

18146000

1728000

5051000

408000

4643000

1728000

4643000

P10Y

<p id="xdx_89D_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_z9bpJj77Dq9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Key inputs for the fair values valuation are summarized below. SCHEDULE OF KEY INPUTS FOR THE FAIR VALUES VALUATION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Key Valuation Inputs</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20240129__us-gaap--BusinessAcquisitionAxis__custom--OctomeraMember_zcNiszUKP03e" style="border-bottom: Black 1pt solid; text-align: center">Jan 29, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_402_eus-gaap--BusinessCombinationContingentConsiderationLiabilityMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_zNrdZYzIMixc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Discount rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right">40</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_40F_eus-gaap--BusinessCombinationContingentConsiderationLiabilityMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zdBI4TvBFvQ5" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.4</td><td style="text-align: left">%</td></tr> <tr id="xdx_400_eus-gaap--BusinessCombinationContingentConsiderationLiabilityMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputLongTermRevenueGrowthRateMember_zrEr4LP8Cxne" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Average 5 years revenue growth</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50</td><td style="text-align: left">%</td></tr> <tr id="xdx_40A_eus-gaap--BusinessCombinationContingentConsiderationLiabilityMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputLongTermRevenueGrowthRateMember_zxOkLfgaA56b" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Measurement input</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50</td><td style="text-align: left">%</td></tr> </table>

4.4

50000 0

23000

1244000

4643000

4643000 Key inputs for the simulation are summarized below. SCHEDULE OF KEY INPUTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Key Valuation Inputs</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Jan 29, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Standard Deviation</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right"><span id="xdx_905_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240129__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputStandardDeviationMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zRLqGEVb2e06" title="Measurement input">13.5</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240129__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zij64wdTniZj" title="Measurement input">4.4</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Possible trigger event examination</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">Year <span id="xdx_909_ecustom--PossibleTriggerEventExamination_dtY_c20240129__20240129__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputTriggerEventMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zLY5Ej2INyi8" title="Possible trigger event examination">10</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Average 5 years revenue growth</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240129__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputLongTermRevenueGrowthRateMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXni9RjJKWHe" title="Measurement input">50</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Trigger events</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240129__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputTriggerEventsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmq4D6Em5OGb" title="Measurement input">30</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">EV/EBIT Multiple</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240129__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRevenueMultipleMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zOLKlrbSrMO4" title="Measurement input">11.1</td><td style="text-align: left"> </td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in">*</td> <td style="text-align: justify">Based on a Monte Carlo simulation analysis of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEtFWSBJTlBVVFMgRk9SIFRIRSBGQUlSIFZBTFVFUyBWQUxVQVRJT04gKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--SharesIssued_iI_c20240129_z1xO9Ra1z9Q8" title="Shares issued">30,000 iterations</td></tr> </table>

13.5

4.4

P10Y

11.1

30000000

NOTE 4 – EQUITY INVESTMENTS AND LOANS TO ASSOCIATES As of December 31, 2024, and December 31, 2023, the balances of our equity-method investments were $- and $8, respectively, and are as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">a.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Octomera LLC</td></tr></table> Since the date of deconsolidation, until the date of reconsolidation, the Company recorded its equity interest in Octomera as an equity method investment. As of January 31, 2024, the balance of our equity-method investment related to Octomera was approximately $<span id="xdx_909_eus-gaap--EquityMethodInvestments_iI_pn3n3_c20240131__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OctomeraLLCMember_z7EvYt2rvJk1" title="Equity method investments">0. The Company therefore did not provide for additional losses once the investment was reduced to zero since the Company did not guarantee obligations of Octomera and is not otherwise committed to provide further financial support to Octomera. The following table presents summarized results of operations for the period that the investment in Octomera was recorded under the equity method: SUMMARY OF RESULTS OF OPERATIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20240101__20240131__us-gaap--EquityMethodInvestmentNonconsolidatedInvesteeAxis__custom--OctomeraLLCMember_zmNZqiaXIMW2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">One-Months Ended</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20230701__20231231__us-gaap--EquityMethodInvestmentNonconsolidatedInvesteeAxis__custom--OctomeraLLCMember_zlFQIXLRnM6f" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six-Months Ended</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">January 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--Revenues_pn3n3_zSt4qg69QzM" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Total revenue</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">23</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">53</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--GrossProfit_pn3n3_zKY9UWWaH11d" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Gross loss</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">771</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5,010</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--NetIncomeLoss_pn3n3_zDJWvlUMR6ge" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net loss</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,648</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">20,145</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">b.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Butterfly Biosciences Sarl</td></tr></table> There were no significant transactions in Butterfly Biosciences Sarl (“BB”), a Swiss corporation in which the Company holds a <span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ButterflyBiosciencesSarlMember_zqZbJpljIijd" title="Ownership percentage"><span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20241231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ButterflyBiosciencesSarlMember_zZVZyGRgwEr8" title="Ownership percentage">49% participating interest incorporated pursuant to a joint venture agreement (“KC JVA”) with Kidney Cure Ltd (“KC”) in both of the years ending December 31, 2023 and 2024. In 2023, the Company and KC decided to terminate the KC JVA and liquidate BB. As of December 31, 2024, BB was not yet liquidated. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">c.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">RevaCel</td></tr></table> During 2021, the Company and Revatis S.A (“Revatis”), pursuant to the Revatis JVA incorporated the Revatis JV Entity known as RevaCel Srl (“RevaCel”) in Belgium. RevaCel will develop products in the field of muscle-derived mesenchymal stem/progenitor cells. The Company holds a <span id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20211231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RevacelSrlMember_zWQsgNywAKNa" title="Ownership percentage">51% participating interest in RevaCel and Revatis holds the remaining <span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20211231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RevacelSrlMember__dei--LegalEntityAxis__custom--RevatisMember_zq4xF3lGhAI8" title="Ownership percentage">49% and is entitled to appoint 2 of the 5 members of RevaCel’s board. Due to the Company’s significant influence over the JVE, the Company applies the equity method of accounting and is treated as an associated company. <p id="xdx_89F_eus-gaap--InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_zsSe8sRc02z1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The table below sets forth a summary of the changes in the investments and loans for the years ended December 31, 2024 and December 31, 2023 SCHEDULE OF CHANGES IN INVESTMENTS AND LOAN <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20240101__20241231_zitN1emxlW3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20230101__20231231_zdRXtdqKqEO8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40D_ecustom--EquityMethodInvestmentsAndLoansToAssociates_iS_pn3n3_z2fGdigxLQ62" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Opening balance</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">8</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">135</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--PaymentsToAcquireEquityMethodInvestments_pn3n3_zVHLipSNUCr5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Investments during the period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">660</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--RepaymentOfLoan_pn3n3_zH3DaD4VUw55" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Repayment of loan</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(55</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--IncomeLossFromEquityMethodInvestments_pn3n3_zcCwEOW0sy14" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Share in net loss of associated companies</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(8</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(734</td><td style="text-align: left">)</td></tr> <tr id="xdx_403_ecustom--EquityMethodInvestmentExchangeRateDifference_pn3n3_zSyZK2ysJgYk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Exchange rate differences</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_ecustom--EquityMethodInvestmentsAndLoansToAssociates_iE_pn3n3_zxbD86s25ahk" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

8000

The following table presents summarized results of operations for the period that the investment in Octomera was recorded under the equity method: SUMMARY OF RESULTS OF OPERATIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20240101__20240131__us-gaap--EquityMethodInvestmentNonconsolidatedInvesteeAxis__custom--OctomeraLLCMember_zmNZqiaXIMW2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">One-Months Ended</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20230701__20231231__us-gaap--EquityMethodInvestmentNonconsolidatedInvesteeAxis__custom--OctomeraLLCMember_zlFQIXLRnM6f" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six-Months Ended</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">January 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--Revenues_pn3n3_zSt4qg69QzM" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Total revenue</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">23</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">53</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--GrossProfit_pn3n3_zKY9UWWaH11d" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Gross loss</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">771</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5,010</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--NetIncomeLoss_pn3n3_zDJWvlUMR6ge" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net loss</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,648</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">20,145</td><td style="text-align: left"> </td></tr> </table>

23000

53000

771000

5010000

8648000

20145000

0.49

0.51

0.49

<p id="xdx_89F_eus-gaap--InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_zsSe8sRc02z1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The table below sets forth a summary of the changes in the investments and loans for the years ended December 31, 2024 and December 31, 2023 SCHEDULE OF CHANGES IN INVESTMENTS AND LOAN <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20240101__20241231_zitN1emxlW3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20230101__20231231_zdRXtdqKqEO8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40D_ecustom--EquityMethodInvestmentsAndLoansToAssociates_iS_pn3n3_z2fGdigxLQ62" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Opening balance</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">8</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">135</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--PaymentsToAcquireEquityMethodInvestments_pn3n3_zVHLipSNUCr5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Investments during the period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">660</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--RepaymentOfLoan_pn3n3_zH3DaD4VUw55" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Repayment of loan</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(55</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--IncomeLossFromEquityMethodInvestments_pn3n3_zcCwEOW0sy14" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Share in net loss of associated companies</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(8</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(734</td><td style="text-align: left">)</td></tr> <tr id="xdx_403_ecustom--EquityMethodInvestmentExchangeRateDifference_pn3n3_zSyZK2ysJgYk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Exchange rate differences</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_ecustom--EquityMethodInvestmentsAndLoansToAssociates_iE_pn3n3_zxbD86s25ahk" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

8000 135000

660000

-55000

-8000

-734000

2000 8000

NOTE 5 – SEGMENT INFORMATION The Company’s Chief Executive Officer (“CEO”), was identified as the chief operating decision maker (“CODM”). The CODM reviews financial information prepared on a consolidated basis, together with disaggregated information about revenues and contributed profit for the Company’s two reportable segments, Octomera and Therapies, in order to make decisions about resources to be allocated to the segments and to assess their performance. The Octomera segment reports the results of Octomera LLC and its subsidiaries, which specialize in providing processing services within the Orgenesis group and to third party customers. The Therapies segment includes all other group activities. Segment revenues, expenses and contributed profit exclude intersegment transactions.one The CDMO does not make operating and investing decisions based on assets and, accordingly, does not review asset information by segment. Therefore, a measure of segment assets is not disclosed. <p id="xdx_89A_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z2HNdOFNXhqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Segment data for the year ended December 31, 2024 is as follows: SCHEDULE OF SEGMENT REPORTING <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--OctomeraMember_zsOX38vpacW7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Octomera</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TherapiesMember_zfn1el4bYZSk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Therapies</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--EliminationsMember_zsVr7zJUUZvj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Eliminations</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20240101__20241231_zxy3aVaeHcDc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Consolidated</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zmImY5EQY0O6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: justify">Revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">533</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">525</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(23</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,035</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--CostOfRevenueExcludingDepreciationAndAmortizationExpenses_iN_pn3n3_di_zw2oxXumgIOf" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Cost of revenues*</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,351</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(633</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">710</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,274</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_403_ecustom--GrossProfitExcludingDepreciationAndAmortizationExpenses_pn3n3_zGbQVHVoYN6i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Gross profit (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(818</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(108</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">687</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(239</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_ecustom--ResearchAndDevelopmentExpenseExcludingDepreciationAndAmortizationExpenses_iN_pn3n3_di_zgA9JjpmvVy4" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Cost of development services and research and development expenses*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,530</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,169</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">697</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(9,002</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_ecustom--OperatingExpensesExcludingDepreciationAndAmortizationExpenses_pn3n3_zhblZ51VkEjf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Operating expenses*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,557</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(10,716</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,178</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(10,095</td><td style="text-align: left">)</td></tr> <tr id="xdx_40B_ecustom--ImpairmentOfInvestment_iN_pn3n3_di_z6Rumrz1DYdj" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Impairment of investment**</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6,509</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11,829</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(18,338</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--IncomeLossFromEquityMethodInvestments_pn3n3_zTP10Nc20BG" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Share in net income of associated companies</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(8</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(8</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--DeconsolidationGainOrLossAmount_pn3n3_zsbB4zGHCuN9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Profit from deconsolidation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,480</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,480</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OtherOperatingIncomeExpenseNet_pn3n3_z6X1naqiLYU8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Other income, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,022</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(416</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">606</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DepreciationDepletionAndAmortization_iN_pn3n3_di_zl8ZtevLFBjc" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Depreciation and amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,558</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(771</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">243</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,086</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn3n3_zahehgzEk1E4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Loss from extinguishment in connection with convertible loan</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,422</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,422</td><td style="text-align: left">)</td></tr> <tr id="xdx_403_ecustom--CreditLossOnConvertibleLoanReceivable_iN_pn3n3_di_zwirofdzlso7" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Credit loss on convertible loan receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_z2BmId0mZlb9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Financial Expenses, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,682</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">125</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,508</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_ecustom--FinanceFeesRelatedToConvertibleLoansToEquity_pn3n3_zu4ApalV49Y1" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Finance fees related to convertible loans to equity</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,304</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,304</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_zXJ4RhZngT5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Income (loss) before income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(20,632</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(38,694</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,410</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(48,916</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">*</td><td style="width: 5pt"></td><td style="text-align: justify">Excluding Depreciation, amortization and impairment expenses</td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">**</td><td style="width: 5pt"></td><td style="text-align: justify">Relates to impairment expenses on certain property, plant and equipment.</td> </tr></table> Segment data for the year ended December 31, 2023 is as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--OctomeraMember_zKF6gZesItQc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Octomera</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--TherapiesMember_zZnp1lVmgmoc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Therapies</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--EliminationsMember_zcsPVy85Wxba" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Eliminations</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20230101__20231231_zlCtQNKkny42" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Consolidated</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zOR6EtEASsrh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: justify">Revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">68</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">515</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(53</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">530</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--CostOfRevenueExcludingDepreciationAndAmortizationExpenses_iN_pn3n3_di_zueYIXiCM6O" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Cost of revenues*</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(9,505</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(690</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,421</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(5,774</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_403_ecustom--GrossProfitExcludingDepreciationAndAmortizationExpenses_pn3n3_z0paiMjdxgb4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Gross profit (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(9,437</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(175</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,368</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,244</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_ecustom--ResearchAndDevelopmentExpenseExcludingDepreciationAndAmortizationExpenses_iN_pn3n3_di_znnVOLBpAfe1" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Cost of development services and research and development expenses*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(9,211</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,811</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,711</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(10,311</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_ecustom--OperatingExpensesExcludingDepreciationAndAmortizationExpenses_pn3n3_z5ffHWzAbS0l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Operating expenses*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(37,878</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(7,102</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,892</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(35,088</td><td style="text-align: left">)</td></tr> <tr id="xdx_40B_ecustom--ImpairmentOfInvestment_iN_pn3n3_di_zBNFU2ieGvP9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Impairment of investment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(699</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(699</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--IncomeLossFromEquityMethodInvestments_pn3n3_zfiUNufPDtC3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Share in net income of associated companies</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(74</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(660</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(734</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--DeconsolidationGainOrLossAmount_pn3n3_zLtn5WsevI5j" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Profit from deconsolidation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,343</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,343</td><td style="text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--OtherOperatingIncomeExpenseNet_pn3n3_zguLXYcIzm9a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Other income, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DepreciationDepletionAndAmortization_iN_pn3n3_di_zFhd8B1TxCU7" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Depreciation and amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,765</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(782</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">987</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,560</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_ecustom--CreditLossOnConvertibleLoanReceivable_iN_pn3n3_di_zmqfzPZKqM3k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Credit loss on convertible loan receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,688</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,688</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn3n3_zQl0uc7YdY26" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Loss from extinguishment in connection with convertible loan</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(283</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(283</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_zPtB9gaqHQv" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Financial Expenses, net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(573</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,004</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">78</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,499</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_zFKBzAZmCnO1" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Income (loss) before income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(58,863</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(19,615</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">14,033</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(64,445</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td id="xdx_F00_zNUIp7zh2qV7" style="width: 15pt; text-align: right">*</td><td style="width: 5pt"></td><td style="text-align: justify">Excluding Depreciation, amortization and impairment expenses</td> </tr></table>

<p id="xdx_89A_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z2HNdOFNXhqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Segment data for the year ended December 31, 2024 is as follows: SCHEDULE OF SEGMENT REPORTING <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--OctomeraMember_zsOX38vpacW7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Octomera</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--TherapiesMember_zfn1el4bYZSk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Therapies</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--EliminationsMember_zsVr7zJUUZvj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Eliminations</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20240101__20241231_zxy3aVaeHcDc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Consolidated</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zmImY5EQY0O6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: justify">Revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">533</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">525</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(23</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,035</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--CostOfRevenueExcludingDepreciationAndAmortizationExpenses_iN_pn3n3_di_zw2oxXumgIOf" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Cost of revenues*</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,351</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(633</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">710</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,274</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_403_ecustom--GrossProfitExcludingDepreciationAndAmortizationExpenses_pn3n3_zGbQVHVoYN6i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Gross profit (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(818</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(108</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">687</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(239</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_ecustom--ResearchAndDevelopmentExpenseExcludingDepreciationAndAmortizationExpenses_iN_pn3n3_di_zgA9JjpmvVy4" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Cost of development services and research and development expenses*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,530</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,169</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">697</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(9,002</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_ecustom--OperatingExpensesExcludingDepreciationAndAmortizationExpenses_pn3n3_zhblZ51VkEjf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Operating expenses*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,557</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(10,716</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,178</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(10,095</td><td style="text-align: left">)</td></tr> <tr id="xdx_40B_ecustom--ImpairmentOfInvestment_iN_pn3n3_di_z6Rumrz1DYdj" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Impairment of investment**</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6,509</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11,829</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(18,338</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--IncomeLossFromEquityMethodInvestments_pn3n3_zTP10Nc20BG" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Share in net income of associated companies</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(8</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(8</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--DeconsolidationGainOrLossAmount_pn3n3_zsbB4zGHCuN9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Profit from deconsolidation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,480</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,480</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OtherOperatingIncomeExpenseNet_pn3n3_z6X1naqiLYU8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Other income, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,022</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(416</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">606</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DepreciationDepletionAndAmortization_iN_pn3n3_di_zl8ZtevLFBjc" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Depreciation and amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,558</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(771</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">243</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,086</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn3n3_zahehgzEk1E4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Loss from extinguishment in connection with convertible loan</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,422</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,422</td><td style="text-align: left">)</td></tr> <tr id="xdx_403_ecustom--CreditLossOnConvertibleLoanReceivable_iN_pn3n3_di_zwirofdzlso7" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Credit loss on convertible loan receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_z2BmId0mZlb9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Financial Expenses, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,682</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">125</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,508</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_ecustom--FinanceFeesRelatedToConvertibleLoansToEquity_pn3n3_zu4ApalV49Y1" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Finance fees related to convertible loans to equity</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,304</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,304</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_zXJ4RhZngT5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Income (loss) before income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(20,632</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(38,694</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,410</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(48,916</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">*</td><td style="width: 5pt"></td><td style="text-align: justify">Excluding Depreciation, amortization and impairment expenses</td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">**</td><td style="width: 5pt"></td><td style="text-align: justify">Relates to impairment expenses on certain property, plant and equipment.</td> </tr></table> Segment data for the year ended December 31, 2023 is as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--OctomeraMember_zKF6gZesItQc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Octomera</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--TherapiesMember_zZnp1lVmgmoc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Therapies</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--EliminationsMember_zcsPVy85Wxba" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Eliminations</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20230101__20231231_zlCtQNKkny42" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Consolidated</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zOR6EtEASsrh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: justify">Revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">68</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">515</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(53</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">530</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--CostOfRevenueExcludingDepreciationAndAmortizationExpenses_iN_pn3n3_di_zueYIXiCM6O" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Cost of revenues*</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(9,505</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(690</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,421</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(5,774</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_403_ecustom--GrossProfitExcludingDepreciationAndAmortizationExpenses_pn3n3_z0paiMjdxgb4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Gross profit (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(9,437</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(175</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,368</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,244</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_ecustom--ResearchAndDevelopmentExpenseExcludingDepreciationAndAmortizationExpenses_iN_pn3n3_di_znnVOLBpAfe1" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Cost of development services and research and development expenses*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(9,211</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,811</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,711</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(10,311</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_ecustom--OperatingExpensesExcludingDepreciationAndAmortizationExpenses_pn3n3_z5ffHWzAbS0l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Operating expenses*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(37,878</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(7,102</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,892</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(35,088</td><td style="text-align: left">)</td></tr> <tr id="xdx_40B_ecustom--ImpairmentOfInvestment_iN_pn3n3_di_zBNFU2ieGvP9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Impairment of investment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(699</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(699</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--IncomeLossFromEquityMethodInvestments_pn3n3_zfiUNufPDtC3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Share in net income of associated companies</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(74</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(660</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(734</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--DeconsolidationGainOrLossAmount_pn3n3_zLtn5WsevI5j" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Profit from deconsolidation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,343</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,343</td><td style="text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--OtherOperatingIncomeExpenseNet_pn3n3_zguLXYcIzm9a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Other income, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DepreciationDepletionAndAmortization_iN_pn3n3_di_zFhd8B1TxCU7" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Depreciation and amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,765</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(782</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">987</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,560</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_ecustom--CreditLossOnConvertibleLoanReceivable_iN_pn3n3_di_zmqfzPZKqM3k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Credit loss on convertible loan receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,688</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,688</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn3n3_zQl0uc7YdY26" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Loss from extinguishment in connection with convertible loan</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(283</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(283</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_zPtB9gaqHQv" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Financial Expenses, net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(573</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,004</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">78</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,499</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_zFKBzAZmCnO1" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Income (loss) before income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(58,863</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(19,615</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">14,033</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(64,445</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td id="xdx_F00_zNUIp7zh2qV7" style="width: 15pt; text-align: right">*</td><td style="width: 5pt"></td><td style="text-align: justify">Excluding Depreciation, amortization and impairment expenses</td> </tr></table>

533000

525000

-23000

1035000

1351000 633000 -710000 1274000 -818000 -108000 687000 -239000 4530000 5169000 -697000 9002000 -3557000 -10716000 4178000 -10095000 6509000 11829000 18338000

-8000

4480000

1022000

-416000

606000

1558000

771000

-243000

2086000

-5422000

-4682000

49000

125000

-4508000

-4304000 -4304000

-20632000

-38694000

10410000

-48916000

68000

515000

-53000

530000

9505000 690000 -4421000 5774000 -9437000 -175000 4368000 -5244000 9211000 5811000 -4711000 10311000 -37878000 -7102000 9892000 -35088000 699000 699000

-74000

-660000

-734000

-5343000

1000

3000

4000

1765000

782000

-987000

1560000

2688000 2688000

-283000

-573000

-2004000

78000

-2499000

-58863000

-19615000

14033000

-64445000

NOTE 6 – EQUITY a. Financings On February 23, 2023, the Company entered into a securities purchase agreement with certain institutional and accredited investors relating to the issuance and sale of <span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230222__20230223__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zUOJwDLbUVLi" title="Sale of stock, shares">194,736 shares of Common Stock and warrants to purchase up to <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230223__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zDzZ2H3vYaLf" title="Purchase of warrants">97,368 shares of Common Stock (the “Warrants”) at a purchase price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230223__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zhzJWzZCfCVc" title="Exercise price of warrants">19.0 per share of Common Stock and accompanying Warrants in a registered direct offering (the “February 2023 Offering”). The February 2023 Offering closed on February 27, 2023. <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20230222__20230223__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zYbd3SzmypK2" title="Warrant exercisable description">The Warrants had an exercise price of $10.90 per share, were exercisable immediately and were to expire five years following the date of issuance. <span id="xdx_904_ecustom--WarrantAlternatedCashlessExerciseDescription_c20230222__20230223__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zQLK3a3DQD0g" title="Warrant alternated cashless exercise description">The Warrants had an alternate cashless exercise option (beginning on or after the earlier of (a) the thirty-day anniversary of the date of the Purchase Agreement and (b) the date on which the aggregate composite trading volume of Common Stock following the public announcement of the pricing terms exceeds 13,600,000 shares), to receive an aggregate number of shares equal to the product of (x) the aggregate number of shares of Common Stock that would be issuable upon a cash exercise and (y) 1.0. The aggregate gross proceeds to the Company from the Offering were $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20230222__20230223__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z8Nv06HomLC1" title="Proceeds from private placemenrt">3,700, before deducting placement agent cash fees equal to 7.0% of the gross proceeds received and other expenses payable by the Company. All of the Warrants were exercised using the alternate cashless exercise option described above. On August 31, 2023, the Company entered into a Securities Purchase Agreement with a certain accredited investor, pursuant to which the Company agreed to issue and sell, in a private placement (the “August 2023 Offering”), <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230831__20230831__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zfVecflpWle8" title="Stock issued during period, shares, new issues">200,000 shares of the Company’s Common Stock at a purchase price of $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20230831__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zNAFXWDp6P9c" title="Shares issued, price per share">5.00 per share. The Company received proceeds of $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230831__20230831__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z7kK09MmRyw5" title="Proceeds from issuance of common stock">1,000. The August 2023 Offering closed on August 31, 2023. On November 8, 2023, the Company entered into a Securities Purchase Agreement with an institutional investor, pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the investor (the “November 2023 Offering”), (i) 141,025 shares of Common Stock, and (ii) warrants exercisable for <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231108__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zExK3F5XsUMc" title="Warrants exercisable">141,025 shares of Common Stock. The combined offering price for each share and accompanying warrant was $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231108__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zdG14G86xrde" title="Offering price">7.80. The warrants will be exercisable immediately following the date of issuance and may be exercised for a period of five years from the initial exercisability date at an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231108__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zpadAI5iqSRg" title="Offering price">7.80 per share. The exercise prices and numbers of shares of Common Stock issuable upon exercise of the warrants will be subject to adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting the Company’s Common Stock. The Company received net proceeds of $942 after deducting $158 related transaction fees. The November 2023 Offering closed on November 9, 2023. On March 8, 2024, the institutional investor exercised 2,500 warrants and on August 14, 2024 a further 3,526 warrants, at the $7.80 exercise price. On March 3, 2024, the Company entered into a Securities Purchase Agreement with certain accredited investors, pursuant to which the Company agreed to issue and sell, in a private placement, <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240303__20240303__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zWBoccA2eZoh" title="Common stock shares issued and sell">227,272 shares of Common Stock at a purchase price of $<span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20240303__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zwZupsrtzsQg" title="Sale of stock, price per share">10.3 per share, Warrants to purchase up to <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240303__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z15ogDgUDmN5" title="Purchase of warrants">227,272 shares of Common Stock at an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240303__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbR7vZk7G8a4" title="Exercise price of warrants">15.0 per share, and further Warrants to purchase up to <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240303__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_z2PDw8ZsEwIk" title="Purchase of warrants">227,272 shares of Common Stock at an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240303__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_z6F2BhmWpLn9" title="Exercise price of warrants">20.0 per share, all such Warrants exercisable immediately and expiring five years from their date of issuance. The Company received gross proceeds of approximately $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20240303__20240303__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zdPan28npw9i" title="Gross proceeds from offering">2.3 million before deducting related offering expenses. The Offering closed on March 5, 2024. On May 10, 2024, the Company entered into a Securities Purchase Agreement with certain accredited investors, pursuant to which the Company agreed to issue and sell, in a private placement, <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240510__20240510__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zlz8pYBfL3Pk" title="Common stock shares issued and sell">15,000 shares of the Company’s Common Stock at a purchase price of $<span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20240510__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zDbKtv6YUuA1" title="Sale of stock, price per share">10.3 per share, Warrants to purchase up to <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240510__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeLy2Ai0BPBa" title="Purchase of warrants">15,000 shares of Common Stock at an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240510__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zP4Hlwqy0Zzh" title="Exercise price of warrants">15.0 per share, and further Warrants to purchase up to <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240510__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zrTYnnb1r9z" title="Purchase of warrants">15,000 shares of Common Stock at an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240510__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zorWJMb0CaMf" title="Exercise price of warrants">20.0 per share, all such Warrants exercisable immediately and expiring five years from their date of issuance. The Company received gross proceeds of approximately $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn3n3_c20240510__20240510__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zZj2PoVVAaW" title="Gross proceeds from offering">154 before deducting related offering expenses. The Offering closed on May 10, 2024. b. Warrants <p id="xdx_899_ecustom--ScheduleOfStockholdersEquityNoteWarrantOrRightsTextBlock_zEn7dLwYktwa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">A summary of the Company’s warrants granted to investors and as finder’s fees as of December 31, 2024, and December 31, 2023 and changes for the periods then ended is presented below: SCHEDULE OF WARRANTS ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Number of Warrants </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average Exercise Price $</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Number of Warrants </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average Exercise Price $</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify">Warrants outstanding at the beginning of the period</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231_zs0WFirb5jI" style="width: 11%; text-align: right" title="Number of warrants - warrants outstanding at the beginning of the period">584,216</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231_zHQG7S8oFbG4" style="width: 11%; text-align: right" title="Weighted average exercise price - warrants outstanding at the beginning of the period">30.64</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231_zbF02QnFACj2" style="width: 11%; text-align: right" title="Number of warrants - warrants outstanding at the beginning of the period">538,158</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_z3h6SlanU1w3" style="width: 11%; text-align: right" title="Weighted average exercise price - warrants outstanding at the beginning of the period">44.10</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Changes during the period:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231_zAJwVosZ2oj" style="text-align: right" title="Number of warrants - issued">7,015,288</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_pid_c20240101__20241231_zhLjcqEQIoua" style="text-align: right" title="Weighted average exercise price - issued">2.52</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231_zs0xFVZHR1Kl" style="text-align: right" title="Number of warrants - issued">289,124</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_pid_c20230101__20231231_z4jWK4QEMU9d" style="text-align: right" title="Weighted average exercise price - issued">14.60</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20240101__20241231_zKrsTZKTA8h1" style="text-align: right" title="Number of warrants - exercised">(6,026</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_pid_c20240101__20241231_zWzl7JBHULb2" style="text-align: right" title="Weighted average exercise price - exercised">7.80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20230101__20231231_zZKrMoZo2U99" style="text-align: right" title="Number of warrants - exercised">(97,368</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_pid_c20230101__20231231_z4d6orPAooJa" style="text-align: right" title="Weighted average exercise price - exercised">19.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20240101__20241231_zWMsBV75WM84" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants - expired">(2,286</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice_pid_c20240101__20241231_zhS8bWWvd0Yb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price - expired">70.00</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20230101__20231231_zGkHabmZsPjb" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants - expired">(145,698</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice_pid_c20230101__20231231_zPvxS9Eet15e" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price - expired">56.30</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Warrants outstanding and exercisable at end of the period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20241231_zMOMc5yGzjij" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants - warrants outstanding at the end of the period">7,591,192</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231_z0IJWLHtjEpa" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price - warrants outstanding at the end of the period">3.58</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231_z3a5sOslvwK2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants - warrants outstanding at the end of the period">584,216</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231_zorbXYqu5KS7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price - warrants outstanding at the end of the period">30.64</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

194736

97368

19.0

The Warrants had an exercise price of $10.90 per share, were exercisable immediately and were to expire five years following the date of issuance.

10.90

The Warrants had an alternate cashless exercise option (beginning on or after the earlier of (a) the thirty-day anniversary of the date of the Purchase Agreement and (b) the date on which the aggregate composite trading volume of Common Stock following the public announcement of the pricing terms exceeds 13,600,000 shares), to receive an aggregate number of shares equal to the product of (x) the aggregate number of shares of Common Stock that would be issuable upon a cash exercise and (y) 1.0. The aggregate gross proceeds to the Company from the Offering were $3,700, before deducting placement agent cash fees equal to 7.0% of the gross proceeds received and other expenses payable by the Company.

3700000

200000

5.00

1000

141025

7.80

P5Y

7.80

942000

158000

2500

3526

7.80

227272

10.3

227272

15.0

227272

20.0

P5Y

2300000

15000

10.3

15000

15.0

15000

20.0

154000

<p id="xdx_899_ecustom--ScheduleOfStockholdersEquityNoteWarrantOrRightsTextBlock_zEn7dLwYktwa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">A summary of the Company’s warrants granted to investors and as finder’s fees as of December 31, 2024, and December 31, 2023 and changes for the periods then ended is presented below: SCHEDULE OF WARRANTS ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Number of Warrants </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average Exercise Price $</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Number of Warrants </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average Exercise Price $</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify">Warrants outstanding at the beginning of the period</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231_zs0WFirb5jI" style="width: 11%; text-align: right" title="Number of warrants - warrants outstanding at the beginning of the period">584,216</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231_zHQG7S8oFbG4" style="width: 11%; text-align: right" title="Weighted average exercise price - warrants outstanding at the beginning of the period">30.64</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231_zbF02QnFACj2" style="width: 11%; text-align: right" title="Number of warrants - warrants outstanding at the beginning of the period">538,158</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_z3h6SlanU1w3" style="width: 11%; text-align: right" title="Weighted average exercise price - warrants outstanding at the beginning of the period">44.10</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Changes during the period:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231_zAJwVosZ2oj" style="text-align: right" title="Number of warrants - issued">7,015,288</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_pid_c20240101__20241231_zhLjcqEQIoua" style="text-align: right" title="Weighted average exercise price - issued">2.52</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231_zs0xFVZHR1Kl" style="text-align: right" title="Number of warrants - issued">289,124</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice_pid_c20230101__20231231_z4jWK4QEMU9d" style="text-align: right" title="Weighted average exercise price - issued">14.60</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20240101__20241231_zKrsTZKTA8h1" style="text-align: right" title="Number of warrants - exercised">(6,026</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_pid_c20240101__20241231_zWzl7JBHULb2" style="text-align: right" title="Weighted average exercise price - exercised">7.80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20230101__20231231_zZKrMoZo2U99" style="text-align: right" title="Number of warrants - exercised">(97,368</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice_pid_c20230101__20231231_z4d6orPAooJa" style="text-align: right" title="Weighted average exercise price - exercised">19.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20240101__20241231_zWMsBV75WM84" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants - expired">(2,286</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice_pid_c20240101__20241231_zhS8bWWvd0Yb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price - expired">70.00</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20230101__20231231_zGkHabmZsPjb" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants - expired">(145,698</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice_pid_c20230101__20231231_zPvxS9Eet15e" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price - expired">56.30</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Warrants outstanding and exercisable at end of the period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20241231_zMOMc5yGzjij" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants - warrants outstanding at the end of the period">7,591,192</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231_z0IJWLHtjEpa" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price - warrants outstanding at the end of the period">3.58</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231_z3a5sOslvwK2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of warrants - warrants outstanding at the end of the period">584,216</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231_zorbXYqu5KS7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price - warrants outstanding at the end of the period">30.64</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

584216

30.64

538158

44.10

7015288

2.52

289124

14.60

6026

7.80

97368

19.00

2286

70.00

145698

56.30

7591192

3.58

584216

30.64

NOTE 7 – PROPERTY, PLANTS AND EQUIPMENT The following table represents the components of property, plants and equipment: SCHEDULE OF COMPONENTS OF PROPERTY, PLANT AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20241231_zuc7cKRWTZyb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20231231_zJyXXiFdNZIi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Cost:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionFacilityMember_zx7a5xN1nmD3" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Production facility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">341</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">55</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndComputersMember_ziKc6TQas2X3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Office furniture and computers</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">287</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">242</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zPmiCFjr22Jd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lab equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,010</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,061</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancePaymentMember_ziCRhKKAc3F2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Advance payment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,526</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">692</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzOGT_zb4UwaM5m6Ee" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Subtotal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,164</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,050</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzOGT_zzaAn1aJPMqb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less – accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(12,586</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(575</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzOGT_zQEKbIEriUh" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">578</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,475</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Depreciation expense for the years ended December 31, 2024 and December 31, 2023 were $1,360 thousand and $839 thousand, respectively. Impairment expense for the years ended December 31, 2024 and December 31, 2023 were $8,752 thousand and $0 thousand, respectively (see note 1). <p id="xdx_891_ecustom--ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationTableTextBlock_zrLQiiGn5OL2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Property, plants and equipment, net by geographical location were as follows: SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT BY GEOGRAPHICAL AXIS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20241231_zJLczROkYume" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20231231_z1McBayYn0n6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_hsrt--StatementGeographicalAxis__country--BE_zmHu454Bgu0j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Belgium</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">29</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_hsrt--StatementGeographicalAxis__country--GR_z54ppegoOB31" style="vertical-align: bottom; background-color: White"> <td>Greece</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">147</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_hsrt--StatementGeographicalAxis__country--NL_z7aP8doHBnqb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Netherlands</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">181</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">289</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_hsrt--StatementGeographicalAxis__country--IL_z8S67dMhvMA" style="vertical-align: bottom; background-color: White"> <td>Israel</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">56</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_hsrt--StatementGeographicalAxis__country--US_zJftWUK2mFxa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">U.S.</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">250</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,101</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_zNkP9UQTUJDi" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">578</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,475</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_zZMN5Od9Rjaj" style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Property, plants and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">578</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,475</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

The following table represents the components of property, plants and equipment: SCHEDULE OF COMPONENTS OF PROPERTY, PLANT AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20241231_zuc7cKRWTZyb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20231231_zJyXXiFdNZIi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Cost:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionFacilityMember_zx7a5xN1nmD3" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Production facility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">341</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">55</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndComputersMember_ziKc6TQas2X3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Office furniture and computers</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">287</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">242</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zPmiCFjr22Jd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lab equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,010</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,061</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AdvancePaymentMember_ziCRhKKAc3F2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Advance payment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,526</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">692</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzOGT_zb4UwaM5m6Ee" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Subtotal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,164</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,050</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzOGT_zzaAn1aJPMqb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less – accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(12,586</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(575</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzOGT_zQEKbIEriUh" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">578</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,475</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

341000

55000

287000

242000

10010000

1061000

2526000

692000

13164000

2050000

12586000

575000

578000

1475000

1360000

839000

8752000

<p id="xdx_891_ecustom--ScheduleOfPropertyPlantAndEquipmentByGeographicalLocationTableTextBlock_zrLQiiGn5OL2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Property, plants and equipment, net by geographical location were as follows: SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT BY GEOGRAPHICAL AXIS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20241231_zJLczROkYume" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20231231_z1McBayYn0n6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_hsrt--StatementGeographicalAxis__country--BE_zmHu454Bgu0j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Belgium</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">29</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_hsrt--StatementGeographicalAxis__country--GR_z54ppegoOB31" style="vertical-align: bottom; background-color: White"> <td>Greece</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">147</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_hsrt--StatementGeographicalAxis__country--NL_z7aP8doHBnqb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Netherlands</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">181</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">289</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_hsrt--StatementGeographicalAxis__country--IL_z8S67dMhvMA" style="vertical-align: bottom; background-color: White"> <td>Israel</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">56</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_hsrt--StatementGeographicalAxis__country--US_zJftWUK2mFxa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">U.S.</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">250</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,101</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_zNkP9UQTUJDi" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">578</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,475</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_zZMN5Od9Rjaj" style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Property, plants and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">578</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,475</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

29000

147000

181000

289000

56000

250000

1101000

578000

1475000

578000

1475000

NOTE 8 – INTANGIBLE ASSETS AND GOODWILL Changes in the carrying amount of the Company’s goodwill for the years ended December 31, 2024 and 2023 are as follows: SCHEDULE OF GOODWILL <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; padding-bottom: 1pt">Goodwill as of December 31, 2022</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--Goodwill_iS_pn3n3_c20230101__20231231_zvtfDqH8PJg5" style="border-bottom: Black 1pt solid; width: 18%; text-align: right" title="Goodwill, beginning balance">8,187</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Deconsolidation of Octomera</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--GoodwillDeconsolidation_pn3n3_c20230101__20231231_z5wyqqFRUZSe" style="text-align: right" title="Goodwill deconsolidation">(6,815</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Translation differences</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--GoodwillForeignCurrencyTranslationGainLoss_pn3n3_c20230101__20231231_zElqZcpOutNc" style="border-bottom: Black 1pt solid; text-align: right" title="Translation differences">(161</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Goodwill as of December 31, 2023</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--Goodwill_iS_pn3n3_c20240101__20241231_zCfRWpi4Vm53" style="text-align: right" title="Goodwill, beginning balance">1,211</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Impairment of Goodwill</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_ecustom--GoodwillImpairment_iN_pn3n3_di_c20240101__20241231_zjK6w0ci5gU9" style="border-bottom: Black 2.5pt double; text-align: right" title="Impairment of Goodwill">(1,211</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Goodwill as of December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--Goodwill_iE_pn3n3_c20240101__20241231_zn1iBQmq66F2" style="border-bottom: Black 2.5pt double; text-align: right" title="Goodwill, ending balance">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Goodwill impairment assessment for the year ended December 31, 2024 As of December 31, 2024, the Company performed an impairment analysis for its reporting units. Based on the Company’s assessment, it was concluded that the fair value of the Therapies reporting unit was below its carrying amounts and, accordingly, the Company recorded a full impairment of goodwill of $1,211 thousand (see note 1). In evaluating the fair value of reporting units under the income approach, the Company used a discounted cash flow model. Key assumptions used to determine the estimated fair value included: (a) internal cash flows forecasts for 5 years following the assessment date, including expected revenue growth, costs to produce, operating profit margins and estimated capital needs; (b) an estimated terminal value using a terminal year long-term future growth determined based on the growth prospects of the reporting units; and (c) a discount rate which reflects the weighted average cost of capital adjusted for the relevant risk associated with the Company’s reporting unit operations and the uncertainty inherent in the Company’s internally developed forecasts. Actual results may differ from those assumed in the Company’s valuation method. It is reasonably possible that the Company’s assumptions described above could change in future periods. If any of these were to vary materially from the Company’s plans, it may record impairment of goodwill allocated to any of these reporting units in the future. Other Intangible Assets Other intangible assets consisted of the following: SCHEDULE OF OTHER INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_49C_20241231_zGVH8I8hH7T5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_496_20231231_zkTqiJvmHv1k" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Gross Carrying Amount:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KnowhowMember_z3WNmGdFCnw1" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Know How</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,728</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TechnologyMember_z0DIm2nDxsxg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Technology</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9,340</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9,340</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_maFLIANzLoB_zmaEda7Uc855" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Subtotal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,068</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,340</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less – Accumulated amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">* (11,068</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,965</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzLoB_zCzHPcLOB6m6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net carrying amount of other intangible assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,375</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"> <tr style="display: none; vertical-align: top; text-align: justify"> <td style="text-align: right; width: 0.15in">*</td><td style="text-align: justify">Including impairment expense for the years ended December 31, 2024 and December 31, 2023 were $8,375 thousand and $0 thousand, respectively (see note 1).</td> </tr> </table> Intangible assets amortization expenses were approximately $728 thousand and $721 thousand for the years ended December 31, 2024 and December 31, 2023, respectively. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.15in; text-align: right">*</td><td style="text-align: justify">Including impairment expense for the years ended December 31, 2024 and December 31, 2023 were $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9USEVSIElOVEFOR0lCTEUgQVNTRVRTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--IntangibleAssetsCurrent_iI_pn3n3_c20241231_zyr0Zgy4vm5g" title="Intangible assets">8,375 thousand and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE9USEVSIElOVEFOR0lCTEUgQVNTRVRTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--IntangibleAssetsCurrent_iI_pn3n3_c20231231_z7PjkyfRJMh5" title="Intangible assets">0 thousand, respectively (see note 1).</td> </tr></table>

Changes in the carrying amount of the Company’s goodwill for the years ended December 31, 2024 and 2023 are as follows: SCHEDULE OF GOODWILL <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; padding-bottom: 1pt">Goodwill as of December 31, 2022</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--Goodwill_iS_pn3n3_c20230101__20231231_zvtfDqH8PJg5" style="border-bottom: Black 1pt solid; width: 18%; text-align: right" title="Goodwill, beginning balance">8,187</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Deconsolidation of Octomera</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--GoodwillDeconsolidation_pn3n3_c20230101__20231231_z5wyqqFRUZSe" style="text-align: right" title="Goodwill deconsolidation">(6,815</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Translation differences</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--GoodwillForeignCurrencyTranslationGainLoss_pn3n3_c20230101__20231231_zElqZcpOutNc" style="border-bottom: Black 1pt solid; text-align: right" title="Translation differences">(161</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Goodwill as of December 31, 2023</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--Goodwill_iS_pn3n3_c20240101__20241231_zCfRWpi4Vm53" style="text-align: right" title="Goodwill, beginning balance">1,211</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Impairment of Goodwill</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_ecustom--GoodwillImpairment_iN_pn3n3_di_c20240101__20241231_zjK6w0ci5gU9" style="border-bottom: Black 2.5pt double; text-align: right" title="Impairment of Goodwill">(1,211</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Goodwill as of December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--Goodwill_iE_pn3n3_c20240101__20241231_zn1iBQmq66F2" style="border-bottom: Black 2.5pt double; text-align: right" title="Goodwill, ending balance">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

8187000

-6815000

-161000

1211000

1211000 1211000

Other intangible assets consisted of the following: SCHEDULE OF OTHER INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_49C_20241231_zGVH8I8hH7T5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_496_20231231_zkTqiJvmHv1k" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Gross Carrying Amount:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KnowhowMember_z3WNmGdFCnw1" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Know How</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,728</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TechnologyMember_z0DIm2nDxsxg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Technology</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9,340</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9,340</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_maFLIANzLoB_zmaEda7Uc855" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Subtotal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,068</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,340</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less – Accumulated amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">* (11,068</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,965</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzLoB_zCzHPcLOB6m6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net carrying amount of other intangible assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,375</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"> <tr style="display: none; vertical-align: top; text-align: justify"> <td style="text-align: right; width: 0.15in">*</td><td style="text-align: justify">Including impairment expense for the years ended December 31, 2024 and December 31, 2023 were $8,375 thousand and $0 thousand, respectively (see note 1).</td> </tr> </table>

1728000

9340000

11068000

9340000

11068000

1965000

7375000

728000

721000

8375000

NOTE 9 –LOANS The table below summarizes the Company’s outstanding long-term loans as of December 31, 2024 and December 31, 2023, respectively: SCHEDULE OF LONG TERM LOANS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Principal Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Interest Rate</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year of Maturity</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">%</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__us-gaap--LongTermDebtMember_z1h2nQtXQqw4" style="width: 16%; text-align: right" title="Principal amount">2,600</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">10</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> 2034</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right"> 2,895</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right"> -</td><td style="width: 1%; text-align: left"> </td></tr> </table> See Note 3. The table below summarizes the Company’s outstanding short-term loans as of December 31, 2024 and December 31, 2023, respectively: SCHEDULE OF SHORT TERM LOANS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Currency</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Interest Rate</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">%</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: justify">USD</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: center">8</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">291</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">258</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">USD</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center">10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,877</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">61</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">USD</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center">(*)8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(**)331</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Euro</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: center">8</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">15</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,183</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">650</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">(*)</td><td style="width: 5pt"></td><td style="text-align: justify">Weighted average interest.</td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">(**)</td><td style="width: 5pt"></td><td style="text-align: justify">The terms of the loan were amended on January 1, 2024. Under the new terms, the loan became convertible into shares of Common Stock and the lender agreed to extend the maturity date to <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNIT1JUIFRFUk0gTE9BTlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_dd_c20240101__20240101__us-gaap--TypeOfArrangementAxis__custom--DebtExchangeAgreementsMember_zGSJoLiuIqa2" title="Debt instrument, maturity date">December 31, 2024. In consideration for such extension, the Company issued to the lender warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNIT1JUIFRFUk0gTE9BTlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240101__us-gaap--TypeOfArrangementAxis__custom--DebtExchangeAgreementsMember_zq4oo4idQ1Rf" title="Number of securities called by warrants or rights">36,000 shares of the Company’s Common Stock at a price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNIT1JUIFRFUk0gTE9BTlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240101__us-gaap--TypeOfArrangementAxis__custom--DebtExchangeAgreementsMember_zEMNXBv0i6m6" title="Exercise price of warrants">8.5 per share and granted lender the right to convert any part of the outstanding balance of the loan into Common Stock of the Company at the conversion rate of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNIT1JUIFRFUk0gTE9BTlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20240101__us-gaap--TypeOfArrangementAxis__custom--DebtExchangeAgreementsMember_zPfS2SwRN57e" title="Conversion price">8.5 per share. Based on its analysis, the Company concluded that this change in terms should be accounted for as a modification. This loan was converted as per the debt exchange agreement. See note 10.</td> </tr></table> The table below summarizes the Company’s warrants granted to loan holders for the period ended December 31, 2024. SCHEDULE OF WARRANTS GRANTED <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Date of issuance</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Expiration date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 30%; text-align: justify"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--April072024Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zh9wlhaF3BKk" title="Date of issuance">April 07, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--April072024Member_zqar4ElEYer7" style="width: 18%; text-align: right" title="Number of warrants">15,625</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--April072024Member_z7wcZPUKmpa" style="width: 18%; text-align: right" title="Exercise price">1.03</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 24%; text-align: justify"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--April072024Member_zTRD487eYrC4">December 31, 2025</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--April052024Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGOA0vDK5dNf" title="Date of issuance">April 05, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--April052024Member_zLV8N31mJte1" style="text-align: right" title="Number of warrants">24,272</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--April052024Member_zbrwamjhy9Fj" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: justify"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--April052024Member_zK4J4rpUonT5">December 31, 2025</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--August212024Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmUfCLL5yW93" title="Date of issuance">August 21, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--August212024Member_zJ919tvSrB1" style="text-align: right" title="Number of warrants">21,875</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--August212024Member_z8dH5JsxlJMg" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: justify"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--August212024Member_zidXyVKpLtG9">August 20, 2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--August212024OneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZUok5iYA02a" title="Date of issuance">August 21, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--August212024OneMember_zNPcUzZwGWJh" style="text-align: right" title="Number of warrants">97,088</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--August212024OneMember_zYc2tp0usdQb" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: justify"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--August212024OneMember_zZucB1q2I6m8">August 20, 2029</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--September062024Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxjOY1tfvv8f" title="Date of issuance">September 06, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--September062024Member_zJ91dmBA7EBk" style="text-align: right" title="Number of warrants">24,272</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--September062024Member_zSRlNDtiMDW8" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: justify"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--September062024Member_zvMFbHMsEsSl">September 05, 2025</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--September102024Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQdagGXoIet5" title="Date of issuance">September 10, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--September102024Member_zjGKk6QTgig7" style="text-align: right" title="Number of warrants">1,942</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--September102024Member_zNKCkU3eOfC5" style="text-align: right" title="Exercise price">10.3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: justify"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--September102024Member_z4rPsR5xfRB6">September 09, 2025</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--September092024Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5mrXGwcot3e" title="Date of issuance">September 09, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--September092024Member_zwmUrQfNCETj" style="text-align: right" title="Number of warrants">24,272</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--September092024Member_zwbu7lEDONT8" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: justify"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--September092024Member_zhWdOljTaWK5">September 08, 2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--September172024Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfjmdq7YR1Ii" title="Date of issuance">September 17, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--September172024Member_zYPuHbCpfed8" style="text-align: right" title="Number of warrants">24,272</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--September172024Member_z8UuYWUc5Gu9" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: justify"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--September172024Member_zc2x21Ua8hJe">September 15, 2029</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--September302024Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zamUNpyHiCNk" title="Date of issuance">September 30, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--September302024Member_zIzXPBYklu0j" style="text-align: right" title="Number of warrants">14,563</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--September302024Member_z387Qdh9sqXj" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: justify"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--September302024Member_zNj0z0nancwa">September 29, 2025</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--October032024Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVh8h1SKEyL" title="Date of issuance">October 03, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--October032024Member_zIFPEWm3i3ea" style="text-align: right" title="Number of warrants">200,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--October032024Member_z2NPN534ZVa4" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--October032024Member_zkF4Ead1x24l">November 29, 2025</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--October222024Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwv7PQYiCHIh" title="Date of issuance">October 22, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--October222024Member_zwXhr2ys0kM5" style="text-align: right" title="Number of warrants">485,437</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--October222024Member_zNEe2P3wn0D1" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--October222024Member_zsbTaIrzYala">October 21, 2025</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--October302024Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlyRWKzH0LOe" title="Date of issuance">October 30, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--October302024Member_zsKY1aXos2S7" style="text-align: right" title="Number of warrants">38,834</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--October302024Member_zSnTG6JHynUl" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--October302024Member_zx79RiyCRItd">October 28, 2025</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--November042024Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zusfYcvnmpwl" title="Date of issuance">November 04, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--November042024Member_z02wPrbA5aR" style="text-align: right" title="Number of warrants">242,718</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--November042024Member_zQ8s5FBKjci4" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--November042024Member_zvSdLmRKq0n1">November 03, 2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--November142024Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdIcqjRzRIMe" title="Date of issuance">November 14, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--November142024Member_zdSa1ymYcape" style="text-align: right" title="Number of warrants">194,175</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--November142024Member_zs3aspRQtPA5" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--November142024Member_zuv13tiM6tcj">November 13, 2025</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--November152024Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTAhp0skFS53" title="Date of issuance">November 15, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--November152024Member_zW9eXIK2VzA7" style="text-align: right" title="Number of warrants">242,718</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--November152024Member_ztRs12M8H7Gc" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--November152024Member_zR7f81RhaOcg">November 14, 2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--November292024Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQpo1gG21KR8" title="Date of issuance">November 29, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--November292024Member_zO03xITEQjg3" style="text-align: right" title="Number of warrants">48,544</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--November292024Member_z7GCRe8d2w4c" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--November292024Member_zzsrIApNzy3e">December 28, 2029</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--December132024Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zF9mMZZ4LKDl" title="Date of issuance">December 13, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December132024Member_zQZplgtKfQM1" style="text-align: right" title="Number of warrants">48,544</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December132024Member_z6L1YXuEw9g8" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December132024Member_zNQaG9NHoOzh">December 12, 2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--December192024Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zO3dQyHyWGLd" title="Date of issuance">December 19, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December192024Member_zmfhnCwYvjGd" style="text-align: right" title="Number of warrants">48,544</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December192024Member_zB07tOgPHuA3" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December192024Member_z3vt3yfvNUk6">December 18, 2029</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--November302024Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrV2fFZnJfOc" title="Date of issuance">November 30, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--November302024Member_zE8VJl3nA9Ni" style="text-align: right" title="Number of warrants">2,020,238</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--November302024Member_zRPqdWrwqzbi" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--November302024Member_zCiZaa5yy00b">March 31, 2026</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--December312024Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zibKxidQek5d" title="Date of issuance">December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024Member_zALnQDef7rnk" style="text-align: right" title="Number of warrants">250,432</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024Member_z6aua1WLkOHa" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024Member_zAthQ7bAPDK3">March 31, 2026</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--December312024OneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcocTR7ot1ee" title="Date of issuance">December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024OneMember_z0NrYIkE1Kp9" style="text-align: right" title="Number of warrants">249,701</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024OneMember_zDegv3oT0W58" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024OneMember_zVHE0593df0f">March 31, 2026</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--December312024TwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRhEC9uSFT5i" title="Date of issuance">December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024TwoMember_z3dyiKEu2Wd8" style="text-align: right" title="Number of warrants">149,302</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024TwoMember_zIZ6SeneA1l2" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024TwoMember_zMFwhb9WINY3">March 31, 2026</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--December312024ThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zv1B491IB4p9" title="Date of issuance">December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024ThreeMember_z9vo8xXOvMli" style="text-align: right" title="Number of warrants">1,012,037</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024ThreeMember_zAGn0hzlNR3" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024ThreeMember_zjjNLcCJ8yQe">December 30, 2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--December312024FourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIkgI6ds99qf" title="Date of issuance">December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024FourMember_z2zUHpXQ4qLe" style="text-align: right" title="Number of warrants">48,970</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024FourMember_z074MRjWvKIk" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024FourMember_zkNaINb6IEHi">December 30, 2029</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--December312024FiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvdetupa7Val" title="Date of issuance">December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024FiveMember_zcWmYD5lo9u3" style="text-align: right" title="Number of warrants">48,784</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024FiveMember_z7lSr4UuQuy3" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024FiveMember_zpD0dDKgD0fh">December 30, 2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--December312024SixMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXaQNlne4HKc" title="Date of issuance">December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024SixMember_znJWphXdsoT1" style="text-align: right" title="Number of warrants">48,704</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024SixMember_zOxbZGpF1XJ3" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024SixMember_zxNqZBUpslSd">December 30, 2029</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--December312024SevenMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRc7sgLICTpi" title="Date of issuance">December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024SevenMember_zBVpJs5ecLt" style="text-align: right" title="Number of warrants">246,909</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024SevenMember_zz0l8y1jK876" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024SevenMember_zZyjoR79xuUd">December 30, 2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--December312024EightMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBLH4NdC5gd6" title="Date of issuance">December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024EightMember_zKGcKqR6em09" style="text-align: right" title="Number of warrants">250,234</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024EightMember_zrGLBOa2anx2" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024EightMember_zHOCtdiesfFb" title="Expiration date">December 30, 2029</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Total</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEdwQAxltih3" style="text-align: right" title="Number of warrants">6,123,006</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zB4Qw5Bl9BQ" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: justify"> </td></tr> </table> In October 2024, the Company entered into agreements with its lenders to extend the maturity dates of certain loans to dates ranging from January through April 2025. In consideration for these extensions, the Company issued the lenders warrants to purchase an aggregate of <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241031__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeXT1zXPOOf6" title="Purchase of warrants">4,913,661 shares of the Company’s Common Stock at an exercise price of $<span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20241031__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z58UHXpiZV7g" title="Sale of stock, price per share">1.03 per share. Based on management’s evaluation of the modification terms, the Company concluded that the amendments should be accounted for as a debt extinguishment and recorded an extinguishment loss of $5,280. All warrants were fully vested upon issuance. The warrants remain exercisable only so long as the related service continues to be provided to the Company, in accordance with the applicable warrant agreements.

The table below summarizes the Company’s outstanding long-term loans as of December 31, 2024 and December 31, 2023, respectively: SCHEDULE OF LONG TERM LOANS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Principal Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Interest Rate</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year of Maturity</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">%</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__us-gaap--LongTermDebtMember_z1h2nQtXQqw4" style="width: 16%; text-align: right" title="Principal amount">2,600</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">10</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> 2034</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right"> 2,895</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right"> -</td><td style="width: 1%; text-align: left"> </td></tr> </table>

2600000

0.10

2034

2895000

The table below summarizes the Company’s outstanding short-term loans as of December 31, 2024 and December 31, 2023, respectively: SCHEDULE OF SHORT TERM LOANS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Currency</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Interest Rate</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">%</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: justify">USD</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: center">8</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">291</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">258</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">USD</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center">10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,877</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">61</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">USD</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center">(*)8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(**)331</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Euro</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: center">8</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">15</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,183</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">650</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">(*)</td><td style="width: 5pt"></td><td style="text-align: justify">Weighted average interest.</td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">(**)</td><td style="width: 5pt"></td><td style="text-align: justify">The terms of the loan were amended on January 1, 2024. Under the new terms, the loan became convertible into shares of Common Stock and the lender agreed to extend the maturity date to <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNIT1JUIFRFUk0gTE9BTlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_dd_c20240101__20240101__us-gaap--TypeOfArrangementAxis__custom--DebtExchangeAgreementsMember_zGSJoLiuIqa2" title="Debt instrument, maturity date">December 31, 2024. In consideration for such extension, the Company issued to the lender warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNIT1JUIFRFUk0gTE9BTlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240101__us-gaap--TypeOfArrangementAxis__custom--DebtExchangeAgreementsMember_zq4oo4idQ1Rf" title="Number of securities called by warrants or rights">36,000 shares of the Company’s Common Stock at a price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNIT1JUIFRFUk0gTE9BTlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240101__us-gaap--TypeOfArrangementAxis__custom--DebtExchangeAgreementsMember_zEMNXBv0i6m6" title="Exercise price of warrants">8.5 per share and granted lender the right to convert any part of the outstanding balance of the loan into Common Stock of the Company at the conversion rate of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNIT1JUIFRFUk0gTE9BTlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20240101__us-gaap--TypeOfArrangementAxis__custom--DebtExchangeAgreementsMember_zPfS2SwRN57e" title="Conversion price">8.5 per share. Based on its analysis, the Company concluded that this change in terms should be accounted for as a modification. This loan was converted as per the debt exchange agreement. See note 10.</td> </tr></table>

0.08

291000

258000

0.10

5877000

61000

0.08

331000

0.08

15000

6183000

650000

2024-12-31

36000

8.5

The table below summarizes the Company’s warrants granted to loan holders for the period ended December 31, 2024. SCHEDULE OF WARRANTS GRANTED <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Date of issuance</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Expiration date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 30%; text-align: justify"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--April072024Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zh9wlhaF3BKk" title="Date of issuance">April 07, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--April072024Member_zqar4ElEYer7" style="width: 18%; text-align: right" title="Number of warrants">15,625</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--April072024Member_z7wcZPUKmpa" style="width: 18%; text-align: right" title="Exercise price">1.03</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 24%; text-align: justify"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--April072024Member_zTRD487eYrC4">December 31, 2025</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--April052024Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGOA0vDK5dNf" title="Date of issuance">April 05, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--April052024Member_zLV8N31mJte1" style="text-align: right" title="Number of warrants">24,272</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--April052024Member_zbrwamjhy9Fj" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: justify"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--April052024Member_zK4J4rpUonT5">December 31, 2025</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--August212024Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmUfCLL5yW93" title="Date of issuance">August 21, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--August212024Member_zJ919tvSrB1" style="text-align: right" title="Number of warrants">21,875</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--August212024Member_z8dH5JsxlJMg" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: justify"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--August212024Member_zidXyVKpLtG9">August 20, 2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--August212024OneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZUok5iYA02a" title="Date of issuance">August 21, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--August212024OneMember_zNPcUzZwGWJh" style="text-align: right" title="Number of warrants">97,088</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--August212024OneMember_zYc2tp0usdQb" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: justify"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--August212024OneMember_zZucB1q2I6m8">August 20, 2029</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--September062024Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxjOY1tfvv8f" title="Date of issuance">September 06, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--September062024Member_zJ91dmBA7EBk" style="text-align: right" title="Number of warrants">24,272</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--September062024Member_zSRlNDtiMDW8" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: justify"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--September062024Member_zvMFbHMsEsSl">September 05, 2025</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--September102024Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQdagGXoIet5" title="Date of issuance">September 10, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--September102024Member_zjGKk6QTgig7" style="text-align: right" title="Number of warrants">1,942</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--September102024Member_zNKCkU3eOfC5" style="text-align: right" title="Exercise price">10.3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: justify"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--September102024Member_z4rPsR5xfRB6">September 09, 2025</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--September092024Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5mrXGwcot3e" title="Date of issuance">September 09, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--September092024Member_zwmUrQfNCETj" style="text-align: right" title="Number of warrants">24,272</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--September092024Member_zwbu7lEDONT8" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: justify"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--September092024Member_zhWdOljTaWK5">September 08, 2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--September172024Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfjmdq7YR1Ii" title="Date of issuance">September 17, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--September172024Member_zYPuHbCpfed8" style="text-align: right" title="Number of warrants">24,272</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--September172024Member_z8UuYWUc5Gu9" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: justify"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--September172024Member_zc2x21Ua8hJe">September 15, 2029</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--September302024Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zamUNpyHiCNk" title="Date of issuance">September 30, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--September302024Member_zIzXPBYklu0j" style="text-align: right" title="Number of warrants">14,563</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--September302024Member_z387Qdh9sqXj" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: justify"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--September302024Member_zNj0z0nancwa">September 29, 2025</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--October032024Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVh8h1SKEyL" title="Date of issuance">October 03, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--October032024Member_zIFPEWm3i3ea" style="text-align: right" title="Number of warrants">200,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--October032024Member_z2NPN534ZVa4" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--October032024Member_zkF4Ead1x24l">November 29, 2025</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--October222024Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwv7PQYiCHIh" title="Date of issuance">October 22, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--October222024Member_zwXhr2ys0kM5" style="text-align: right" title="Number of warrants">485,437</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--October222024Member_zNEe2P3wn0D1" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--October222024Member_zsbTaIrzYala">October 21, 2025</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--October302024Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlyRWKzH0LOe" title="Date of issuance">October 30, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--October302024Member_zsKY1aXos2S7" style="text-align: right" title="Number of warrants">38,834</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--October302024Member_zSnTG6JHynUl" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--October302024Member_zx79RiyCRItd">October 28, 2025</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--November042024Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zusfYcvnmpwl" title="Date of issuance">November 04, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--November042024Member_z02wPrbA5aR" style="text-align: right" title="Number of warrants">242,718</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--November042024Member_zQ8s5FBKjci4" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--November042024Member_zvSdLmRKq0n1">November 03, 2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--November142024Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdIcqjRzRIMe" title="Date of issuance">November 14, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--November142024Member_zdSa1ymYcape" style="text-align: right" title="Number of warrants">194,175</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--November142024Member_zs3aspRQtPA5" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--November142024Member_zuv13tiM6tcj">November 13, 2025</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--November152024Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTAhp0skFS53" title="Date of issuance">November 15, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--November152024Member_zW9eXIK2VzA7" style="text-align: right" title="Number of warrants">242,718</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--November152024Member_ztRs12M8H7Gc" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--November152024Member_zR7f81RhaOcg">November 14, 2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--November292024Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQpo1gG21KR8" title="Date of issuance">November 29, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--November292024Member_zO03xITEQjg3" style="text-align: right" title="Number of warrants">48,544</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--November292024Member_z7GCRe8d2w4c" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--November292024Member_zzsrIApNzy3e">December 28, 2029</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--December132024Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zF9mMZZ4LKDl" title="Date of issuance">December 13, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December132024Member_zQZplgtKfQM1" style="text-align: right" title="Number of warrants">48,544</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December132024Member_z6L1YXuEw9g8" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December132024Member_zNQaG9NHoOzh">December 12, 2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--December192024Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zO3dQyHyWGLd" title="Date of issuance">December 19, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December192024Member_zmfhnCwYvjGd" style="text-align: right" title="Number of warrants">48,544</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December192024Member_zB07tOgPHuA3" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December192024Member_z3vt3yfvNUk6">December 18, 2029</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--November302024Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrV2fFZnJfOc" title="Date of issuance">November 30, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--November302024Member_zE8VJl3nA9Ni" style="text-align: right" title="Number of warrants">2,020,238</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--November302024Member_zRPqdWrwqzbi" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--November302024Member_zCiZaa5yy00b">March 31, 2026</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--December312024Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zibKxidQek5d" title="Date of issuance">December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024Member_zALnQDef7rnk" style="text-align: right" title="Number of warrants">250,432</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024Member_z6aua1WLkOHa" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024Member_zAthQ7bAPDK3">March 31, 2026</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--December312024OneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcocTR7ot1ee" title="Date of issuance">December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024OneMember_z0NrYIkE1Kp9" style="text-align: right" title="Number of warrants">249,701</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024OneMember_zDegv3oT0W58" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024OneMember_zVHE0593df0f">March 31, 2026</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--December312024TwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRhEC9uSFT5i" title="Date of issuance">December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024TwoMember_z3dyiKEu2Wd8" style="text-align: right" title="Number of warrants">149,302</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024TwoMember_zIZ6SeneA1l2" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024TwoMember_zMFwhb9WINY3">March 31, 2026</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--December312024ThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zv1B491IB4p9" title="Date of issuance">December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024ThreeMember_z9vo8xXOvMli" style="text-align: right" title="Number of warrants">1,012,037</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024ThreeMember_zAGn0hzlNR3" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024ThreeMember_zjjNLcCJ8yQe">December 30, 2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--December312024FourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIkgI6ds99qf" title="Date of issuance">December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024FourMember_z2zUHpXQ4qLe" style="text-align: right" title="Number of warrants">48,970</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024FourMember_z074MRjWvKIk" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024FourMember_zkNaINb6IEHi">December 30, 2029</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--December312024FiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvdetupa7Val" title="Date of issuance">December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024FiveMember_zcWmYD5lo9u3" style="text-align: right" title="Number of warrants">48,784</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024FiveMember_z7lSr4UuQuy3" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024FiveMember_zpD0dDKgD0fh">December 30, 2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--December312024SixMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXaQNlne4HKc" title="Date of issuance">December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024SixMember_znJWphXdsoT1" style="text-align: right" title="Number of warrants">48,704</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024SixMember_zOxbZGpF1XJ3" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024SixMember_zxNqZBUpslSd">December 30, 2029</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--December312024SevenMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRc7sgLICTpi" title="Date of issuance">December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024SevenMember_zBVpJs5ecLt" style="text-align: right" title="Number of warrants">246,909</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024SevenMember_zz0l8y1jK876" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024SevenMember_zZyjoR79xuUd">December 30, 2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--December312024EightMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBLH4NdC5gd6" title="Date of issuance">December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024EightMember_zKGcKqR6em09" style="text-align: right" title="Number of warrants">250,234</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024EightMember_zrGLBOa2anx2" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--December312024EightMember_zHOCtdiesfFb" title="Expiration date">December 30, 2029</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Total</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEdwQAxltih3" style="text-align: right" title="Number of warrants">6,123,006</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zB4Qw5Bl9BQ" style="text-align: right" title="Exercise price">1.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: justify"> </td></tr> </table>

2024-04-07

15625

1.03

2025-12-31

2024-04-05

24272

1.03

2025-12-31

2024-08-21

21875

1.03

2029-08-20

2024-08-21

97088

1.03

2029-08-20

2024-09-06

24272

1.03

2025-09-05

2024-09-10

1942

10.3

2025-09-09

2024-09-09

24272

1.03

2029-09-08

2024-09-17

24272

1.03

2029-09-15

2024-09-30

14563

1.03

2025-09-29

2024-10-03

200000

1.03

2025-11-29

2024-10-22

485437

1.03

2025-10-21

2024-10-30

38834

1.03

2025-10-28

2024-11-04

242718

1.03

2029-11-03

2024-11-14

194175

1.03

2025-11-13

2024-11-15

242718

1.03

2029-11-14

2024-11-29

48544

1.03

2029-12-28

2024-12-13

48544

1.03

2029-12-12

2024-12-19

48544

1.03

2029-12-18

2024-11-30

2020238

1.03

2026-03-31

2024-12-31

250432

1.03

2026-03-31

2024-12-31

249701

1.03

2026-03-31

2024-12-31

149302

1.03

2026-03-31

2024-12-31

1012037

1.03

2029-12-30

2024-12-31

48970

1.03

2029-12-30

2024-12-31

48784

1.03

2029-12-30

2024-12-31

48704

1.03

2029-12-30

2024-12-31

246909

1.03

2029-12-30

2024-12-31

250234

1.03

2029-12-30

6123006

1.03

4913661

1.03

5280

NOTE 10 – CONVERTIBLE LOANS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">a.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Long-Term Convertible Loans</td></tr></table> The tables below summarize the Company’s outstanding convertible loans as of December 31, 2024 and December 31, 2023 respectively: SCHEDULE OF LONG TERM CONVERTIBLE NOTES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td colspan="2" style="padding-bottom: 1pt; text-align: center">Principal</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Issuance Date</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Current Interest Rate</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Current Maturity</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Current Conversion Price of loan into equity</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Year)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Year)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="14" style="font-weight: bold">Convertible Loans Outstanding as of December 31, 2024</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold"> </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20241231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zkv4gKoDkkCh" style="width: 16%; text-align: right" title="Principal Amount at Issuance">100</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">2019</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> 8</td><td style="width: 1%; text-align: left">%</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right">2024</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right"> <span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20241231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zaUkBd8j54Tc" title="Current Conversion Price of loan into equity">10.3</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20241231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_zhiB0C4Fzz3l" style="text-align: right" title="Principal Amount at Issuance">100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2020</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2024</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20241231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_zGNmKMsr0rP4" title="Current Conversion Price of loan into equity">10.3</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20241231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_z3sZcJBraqck" style="text-align: right" title="Principal Amount at Issuance">1,150</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentIssuanceDateYear_c20240101__20241231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_z119TmW8JePd" title="Issuance Date (Year)">2022</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20241231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_zC7TKx2qD9zf" title="Current Interest Rate">6</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">*<span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDateDescription_c20240101__20241231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_fKg_____z0JfouS93v2l" title="Current Maturity (Year)">2023</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20241231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_zE4v07JOqWO1" title="Current Conversion Price of loan into equity">45.0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20241231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansFourMember_zmbFVLb7fWng" style="border-bottom: Black 2.5pt double; text-align: right" title="Principal Amount at Issuance">5,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentIssuanceDateYear_c20240101__20241231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansFourMember_zFvQJd2pGb9k" title="Issuance Date (Year)">2023</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20241231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansFourMember_zhOjDcTbwUr9" title="Current Interest Rate">8</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right">2026</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20241231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansFourMember_zKF7bjVvAqQ3" title="Current Conversion Price of loan into equity">24.6</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20241231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansMember_zPASIvgAh1x9" style="border-bottom: Black 2.5pt double; text-align: right" title="Principal Amount at Issuance">6,350</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">*</td><td style="width: 5pt"></td><td style="text-align: justify">Following the balance sheet date, the maturities of the loans were extended to dates in 2025.</td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">**</td><td style="width: 5pt"></td><td style="text-align: justify">Was not yet paid by December 31, 2024.</td> </tr></table> Convertible Loans Outstanding as of December 31, 2023 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zekiZUUBdbF2" style="width: 16%; text-align: right" title="Principal Amount at Issuance">750</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">2018</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">10</td><td style="width: 1%; text-align: left">%</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right">2026</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right"><span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zRQag2cTU0eh" title="Current Conversion Price of loan into equity">2.50</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_zgSW0wtvuXA4" style="text-align: right" title="Principal Amount at Issuance">1,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2019</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2026</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_zQ0PWIYf0NB4" title="Current Conversion Price of loan into equity">2.50</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_zmv6KXYeHmpa" style="text-align: right" title="Principal Amount at Issuance">100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--DebtConversionConvertedInstrumentIssuanceDateYear_c20230101__20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_zyVrfkr1ohAj" title="Issuance Date (Year)">2019</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_zfMhBQvN0Ht" title="Current Interest Rate">8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2024</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_zRfAEcrbel2d" title="Current Conversion Price of loan into equity">2.50</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansFourMember_zWOcNBsCeJha" style="text-align: right" title="Principal Amount at Issuance">5,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentIssuanceDateYear_c20230101__20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansFourMember_zNKdwbFvMdvg" title="Issuance Date (Year)">2019</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansFourMember_zfNFneB77j3i" title="Current Interest Rate">10</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2026</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansFourMember_z0VmEjt7uU93" title="Current Conversion Price of loan into equity">2.50</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansFiveMember_z6QFirl2bwYh" style="text-align: right" title="Principal Amount at Issuance">100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--DebtConversionConvertedInstrumentIssuanceDateYear_c20230101__20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansFiveMember_zn2afrRohqkf" title="Issuance Date (Year)">2020</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansFiveMember_zYPutelzUcxi" title="Current Interest Rate">8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2024</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansFiveMember_zwDn8yoljkw" title="Current Conversion Price of loan into equity">7.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansSixMember_zqHS0S7jBiya" style="text-align: right" title="Principal Amount at Issuance">5,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2022</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2026</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansSixMember_z9mANwalEQh" title="Current Conversion Price of loan into equity">2.50</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansSevenMember_z4H1MFhj1kp6" style="text-align: right" title="Principal Amount at Issuance">1,150</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentIssuanceDateYear_c20230101__20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansSevenMember_zTfhHlufwCT1" title="Issuance Date (Year)">2022</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansSevenMember_zNFqSOILg8Ik" title="Current Interest Rate">6</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> **2023</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansSevenMember_zzqCFSM4On95" title="Current Conversion Price of loan into equity">4.50</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansEightMember_zulwoK6abiHh" style="text-align: right" title="Principal Amount at Issuance">5,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentIssuanceDateYear_c20230101__20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansEightMember_zevbDGNkfFu1" title="Issuance Date (Year)">2023</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansEightMember_znhKkEsYqOH" title="Current Interest Rate">8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2026</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansEightMember_z8E5dszLPcI3" title="Current Conversion Price of loan into equity">2.46</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansNineMember_zYrB9J2yQT6c" style="border-bottom: Black 2.5pt double; text-align: right" title="Principal Amount at Issuance">735</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentIssuanceDateYear_c20230101__20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansNineMember_z2qsKgQfbwY5" title="Issuance Date (Year)">2023</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansNineMember_zqz22hu8cVT3" title="Current Interest Rate">8</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right">2024</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansNineMember_fKg_____zaUSXdN0Mga5" style="display: none" title="Current Conversion Price of loan into equity">-*</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 2.5pt double; text-align: right">$</td><td id="xdx_987_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansMember_z09pkJ4w357c" style="border-bottom: Black 2.5pt double; text-align: right" title="Principal Amount at Issuance">19,335</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">*</td><td style="width: 5pt"></td><td style="text-align: justify">The conversion price is not fixed and is contingent on the terms under the loan agreement.</td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">**</td><td style="width: 5pt"></td><td style="text-align: justify">Was not yet paid by December 31, 2023.</td> </tr></table> Convertible Loans repaid during the year ended December 31, 2023 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; border-collapse: collapse; width: 70%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Principal Amount</td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Issuance Year</td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Interest Rate</td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Maturity Period</td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Exercise Price</td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--RepaymentsOfConvertibleDebt_pn3n3_c20230101__20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansRepaidOneMember_zWaqKw59UACi" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Repaid, principal amount">3,000</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--DebtConversionConvertedInstrumentIssuanceDateYear_c20230101__20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansRepaidOneMember_zZM7uhiMu8Rg" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Issuance Year">2022</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansRepaidOneMember_zMYo5QVzM9I4" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Interest Rate">10</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right">1</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td> <td id="xdx_981_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansRepaidOneMember_zzYhlNHzrp2j" style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right" title="Exercise price">2.5</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> </table> Debt Exchange Agreements On May 21, 2024, the Company entered into debt exchange agreements with three convertible debt holders pursuant to which a total of $<span id="xdx_903_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_c20240521__us-gaap--TypeOfArrangementAxis__custom--DebtExchangeAgreementsMember__srt--CounterpartyNameAxis__custom--ThreeConvertibleDebtHoldersMember_zAaak8uSVs7f" title="Outstanding principal and accrued interest">16,007 of outstanding principal and accrued interest was exchanged for the right to receive an aggregate of <span id="xdx_90D_eus-gaap--ConversionOfStockSharesIssued1_pid_c20240521__20240521__us-gaap--TypeOfArrangementAxis__custom--DebtExchangeAgreementsMember__srt--CounterpartyNameAxis__custom--ThreeConvertibleDebtHoldersMember_zH7U4bkn0fj7" title="Number of shares issued">1,577,695 shares of the Company’s Common Stock. During the year ended December 31, 2024, the Company issued an aggregate of <span id="xdx_90E_eus-gaap--CommonStockSharesIssued_iI_pid_c20241231__us-gaap--TypeOfArrangementAxis__custom--DebtExchangeAgreementsMember__srt--CounterpartyNameAxis__custom--ThreeConvertibleDebtHoldersMember_z4usWCXVpQBd" title="Common stock issued">1,577,694. The Company reduced the exchange price from $<span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20241231__us-gaap--TypeOfArrangementAxis__custom--DebtExchangeAgreementsMember__srt--CounterpartyNameAxis__custom--ThreeConvertibleDebtHoldersMember__srt--RangeAxis__srt--MaximumMember_ztjrytwNZTKg" title="Exchange price">25.0 to $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20241231__us-gaap--TypeOfArrangementAxis__custom--DebtExchangeAgreementsMember__srt--CounterpartyNameAxis__custom--ThreeConvertibleDebtHoldersMember__srt--RangeAxis__srt--MinimumMember_zAZgeU84Oyol" title="Exchange price">10.3 per share for a total of $<span id="xdx_909_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--DebtExchangeAgreementsMember__srt--CounterpartyNameAxis__custom--ThreeConvertibleDebtHoldersMember_zsmE7P3GMDod" title="Outstanding principal">14,784 of outstanding principal. As a result, the Company recorded an induced conversion expense equal to the fair value of the incremental consideration, amounting to $<span id="xdx_90C_eus-gaap--InducedConversionOfConvertibleDebtExpense_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--DebtExchangeAgreementsMember__srt--CounterpartyNameAxis__custom--ThreeConvertibleDebtHoldersMember_zJ3xKfGYvZe1" title="Debt conversion expense">4,304. Additional notes related to changes in convertible loans terms that occurred in 2024 In January 2024, the Company and lender agreed to extend the maturity date of the loan amount to December 31, 2026. Inconsideration for such extension, the Company issued to the lender warrants to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240131__us-gaap--TypeOfArrangementAxis__custom--DebtExchangeAgreementsMember_zaBXH6fmI9d4" title="Number of securities called by warrants or rights">84,000 shares of Common Stock at an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240131__us-gaap--TypeOfArrangementAxis__custom--DebtExchangeAgreementsMember_zxPE366PH3Ug" title="Exercise price of warrants">8.5 per share. Based on its analysis, the Company concluded that this change in terms should be accounted for as an extinguishment loss of $141. The loan amount was included in the debt exchange agreement. Koligo Convertible Loan On March 27, 2023, the Company’s subsidiary Koligo Therapeutics Inc. (“Borrower”), entered into a convertible loan agreement (the “Convertible Loan Agreement”) with Yehuda Nir (the “Lender,” and together with the Borrower, the “Parties”), pursuant to which the Lender agreed to loan the Borrower up to $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20230327__us-gaap--RelatedPartyTransactionAxis__custom--KoligoTherapeuticsIncMember__srt--TitleOfIndividualAxis__custom--LenderMember_zWUDv0frK04e" title="Principal loan amount">5,000 (the “Loan Amount”). Interest is calculated at <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20230327__us-gaap--RelatedPartyTransactionAxis__custom--KoligoTherapeuticsIncMember__srt--TitleOfIndividualAxis__custom--LenderMember_zSMuxKIhuMmc" title="Interest rate">8% per annum (based on a 365-day year) and is payable, along with the principal, on or before <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20230326__20230327__us-gaap--RelatedPartyTransactionAxis__custom--KoligoTherapeuticsIncMember__srt--TitleOfIndividualAxis__custom--LenderMember_zufiIRp1qhec" title="Debt instrument maturity date">January 1, 2024 (the “Maturity Date”). The Maturity Date may be extended by the Lender in the Lender’s sole and absolute discretion and any such extension(s) shall be in writing signed by the Parties. The Loan Amount may be prepaid by the Borrower in whole or in part at any time with the prior written approval of the Lender. <span id="xdx_909_eus-gaap--DebtConversionDescription_c20230326__20230327__us-gaap--RelatedPartyTransactionAxis__custom--KoligoTherapeuticsIncMember__srt--TitleOfIndividualAxis__custom--BorrowerMember_zLNLFt4Cdsqh" title="Debt instrument conversion">If prior to December 31, 2023, the Borrower issues equity securities (“Equity Securities”) in a transaction or series of related transactions resulting in aggregate gross proceeds to the Borrower of at least $5,000 (excluding conversion of the Loan Amount) (a “Qualified Financing”), then the outstanding principal amount of the Loan Amount, and any and all accrued but unpaid interest thereon (collectively, the “Outstanding Amount”), will automatically convert into such Equity Securities issued pursuant to the Qualified Financing at a price per share equal to fifty percent (50%) of the price per share paid for each share of the Equity Securities purchased for cash by the investors in the Qualified Financing (the “Mandatory Conversion”). The per share price for the Mandatory Conversion shall be calculated on a fully diluted basis (including equity underlying all outstanding options, warrants, and other convertible securities, but excluding the Equity Securities issuable upon the Mandatory Conversion). The Parties agreed that the Lender shall have the option to assign $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20230327__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementsMember__srt--TitleOfIndividualAxis__custom--LenderMember_z6I2KSB70x0k" title="Principal loan amount">1,500 of the Loan Amount due to the Lender under that certain convertible loan agreement between the Lender and the Company dated April 21, 2022, as amended, (collectively the “Original Loan”), to the Borrower (the “Loan Assignment”). The terms of the Loan Assignment will be the same as under the Original Loan, including a maturity date of <span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20230326__20230327__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementsMember__srt--TitleOfIndividualAxis__custom--LenderMember_zUqXw07RDM73" title="Debt instrument maturity date">January 31, 2026 and an annual interest rate of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20230327__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementsMember__srt--TitleOfIndividualAxis__custom--LenderMember_z6b9gO9rZGe1" title="Interest rate">10%. The Loan Assignment will be subject to the Mandatory Conversion as described above. As of the date of the issue of these financial statements, said assignment has not occurred. Under the terms of the Koligo Convertible Loan Agreement, the Borrower agreed to use the Loan Amount to fund working capital and ongoing operations and for no other purposes unless the Lender agrees in writing. As of December 31, 2024, Koligo received $773 under the Koligo Convertible Loan Agreement, which was converted into shares in May 2024. In January 2024, the Company and Lender agreed to extend the maturity date of the loan amount to December 31, 2026. The Company awarded warrants to purchase <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240101__20240131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OffshoreInvestorMember_zDDgvXyFrnH2" title="Proceeds from issuance of warrants">840,000 of the Company’s Common Stock at a price of $0.85 per share, and granted Lender the right to convert any part of the Outstanding amount into Common Stock of the Company at the conversion rate of $<span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20240131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OffshoreInvestorMember_zIwQXbqYYxe4" title="Conversion rate">0.85 per share.

The tables below summarize the Company’s outstanding convertible loans as of December 31, 2024 and December 31, 2023 respectively: SCHEDULE OF LONG TERM CONVERTIBLE NOTES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td colspan="2" style="padding-bottom: 1pt; text-align: center">Principal</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Issuance Date</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Current Interest Rate</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Current Maturity</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Current Conversion Price of loan into equity</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Year)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Year)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="14" style="font-weight: bold">Convertible Loans Outstanding as of December 31, 2024</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold"> </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20241231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zkv4gKoDkkCh" style="width: 16%; text-align: right" title="Principal Amount at Issuance">100</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">2019</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> 8</td><td style="width: 1%; text-align: left">%</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right">2024</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right"> <span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20241231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zaUkBd8j54Tc" title="Current Conversion Price of loan into equity">10.3</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20241231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_zhiB0C4Fzz3l" style="text-align: right" title="Principal Amount at Issuance">100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2020</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2024</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20241231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_zGNmKMsr0rP4" title="Current Conversion Price of loan into equity">10.3</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20241231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_z3sZcJBraqck" style="text-align: right" title="Principal Amount at Issuance">1,150</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentIssuanceDateYear_c20240101__20241231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_z119TmW8JePd" title="Issuance Date (Year)">2022</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20241231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_zC7TKx2qD9zf" title="Current Interest Rate">6</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">*<span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDateDescription_c20240101__20241231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_fKg_____z0JfouS93v2l" title="Current Maturity (Year)">2023</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20241231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_zE4v07JOqWO1" title="Current Conversion Price of loan into equity">45.0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20241231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansFourMember_zmbFVLb7fWng" style="border-bottom: Black 2.5pt double; text-align: right" title="Principal Amount at Issuance">5,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentIssuanceDateYear_c20240101__20241231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansFourMember_zFvQJd2pGb9k" title="Issuance Date (Year)">2023</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20241231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansFourMember_zhOjDcTbwUr9" title="Current Interest Rate">8</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right">2026</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20241231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansFourMember_zKF7bjVvAqQ3" title="Current Conversion Price of loan into equity">24.6</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20241231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansMember_zPASIvgAh1x9" style="border-bottom: Black 2.5pt double; text-align: right" title="Principal Amount at Issuance">6,350</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">*</td><td style="width: 5pt"></td><td style="text-align: justify">Following the balance sheet date, the maturities of the loans were extended to dates in 2025.</td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">**</td><td style="width: 5pt"></td><td style="text-align: justify">Was not yet paid by December 31, 2024.</td> </tr></table> Convertible Loans Outstanding as of December 31, 2023 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zekiZUUBdbF2" style="width: 16%; text-align: right" title="Principal Amount at Issuance">750</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">2018</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">10</td><td style="width: 1%; text-align: left">%</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right">2026</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right"><span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansOneMember_zRQag2cTU0eh" title="Current Conversion Price of loan into equity">2.50</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_zgSW0wtvuXA4" style="text-align: right" title="Principal Amount at Issuance">1,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2019</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2026</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansTwoMember_zQ0PWIYf0NB4" title="Current Conversion Price of loan into equity">2.50</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_zmv6KXYeHmpa" style="text-align: right" title="Principal Amount at Issuance">100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--DebtConversionConvertedInstrumentIssuanceDateYear_c20230101__20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_zyVrfkr1ohAj" title="Issuance Date (Year)">2019</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_zfMhBQvN0Ht" title="Current Interest Rate">8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2024</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansThreeMember_zRfAEcrbel2d" title="Current Conversion Price of loan into equity">2.50</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansFourMember_zWOcNBsCeJha" style="text-align: right" title="Principal Amount at Issuance">5,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentIssuanceDateYear_c20230101__20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansFourMember_zNKdwbFvMdvg" title="Issuance Date (Year)">2019</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansFourMember_zfNFneB77j3i" title="Current Interest Rate">10</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2026</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansFourMember_z0VmEjt7uU93" title="Current Conversion Price of loan into equity">2.50</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansFiveMember_z6QFirl2bwYh" style="text-align: right" title="Principal Amount at Issuance">100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--DebtConversionConvertedInstrumentIssuanceDateYear_c20230101__20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansFiveMember_zn2afrRohqkf" title="Issuance Date (Year)">2020</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansFiveMember_zYPutelzUcxi" title="Current Interest Rate">8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2024</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansFiveMember_zwDn8yoljkw" title="Current Conversion Price of loan into equity">7.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansSixMember_zqHS0S7jBiya" style="text-align: right" title="Principal Amount at Issuance">5,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2022</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2026</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansSixMember_z9mANwalEQh" title="Current Conversion Price of loan into equity">2.50</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansSevenMember_z4H1MFhj1kp6" style="text-align: right" title="Principal Amount at Issuance">1,150</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentIssuanceDateYear_c20230101__20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansSevenMember_zTfhHlufwCT1" title="Issuance Date (Year)">2022</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansSevenMember_zNFqSOILg8Ik" title="Current Interest Rate">6</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> **2023</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansSevenMember_zzqCFSM4On95" title="Current Conversion Price of loan into equity">4.50</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansEightMember_zulwoK6abiHh" style="text-align: right" title="Principal Amount at Issuance">5,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentIssuanceDateYear_c20230101__20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansEightMember_zevbDGNkfFu1" title="Issuance Date (Year)">2023</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansEightMember_znhKkEsYqOH" title="Current Interest Rate">8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2026</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansEightMember_z8E5dszLPcI3" title="Current Conversion Price of loan into equity">2.46</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansNineMember_zYrB9J2yQT6c" style="border-bottom: Black 2.5pt double; text-align: right" title="Principal Amount at Issuance">735</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentIssuanceDateYear_c20230101__20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansNineMember_z2qsKgQfbwY5" title="Issuance Date (Year)">2023</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansNineMember_zqz22hu8cVT3" title="Current Interest Rate">8</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right">2024</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansNineMember_fKg_____zaUSXdN0Mga5" style="display: none" title="Current Conversion Price of loan into equity">-*</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 2.5pt double; text-align: right">$</td><td id="xdx_987_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansMember_z09pkJ4w357c" style="border-bottom: Black 2.5pt double; text-align: right" title="Principal Amount at Issuance">19,335</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">*</td><td style="width: 5pt"></td><td style="text-align: justify">The conversion price is not fixed and is contingent on the terms under the loan agreement.</td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">**</td><td style="width: 5pt"></td><td style="text-align: justify">Was not yet paid by December 31, 2023.</td> </tr></table> Convertible Loans repaid during the year ended December 31, 2023 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; border-collapse: collapse; width: 70%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Principal Amount</td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Issuance Year</td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Interest Rate</td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Maturity Period</td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Exercise Price</td> <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td> <td id="xdx_98A_eus-gaap--RepaymentsOfConvertibleDebt_pn3n3_c20230101__20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansRepaidOneMember_zWaqKw59UACi" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Repaid, principal amount">3,000</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td> <td id="xdx_980_eus-gaap--DebtConversionConvertedInstrumentIssuanceDateYear_c20230101__20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansRepaidOneMember_zZM7uhiMu8Rg" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Issuance Year">2022</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td> <td id="xdx_985_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansRepaidOneMember_zMYo5QVzM9I4" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Interest Rate">10</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right">1</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td> <td id="xdx_981_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleLoansRepaidOneMember_zzYhlNHzrp2j" style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right" title="Exercise price">2.5</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> </table>

100000

2019

0.08

2024

10.3

100000

2020

0.08

2024

10.3

1150000

2022

0.06

2023

45.0

5000000

2023

0.08

2026

24.6

6350000

750000

2018

0.10

2026

2.50

1500000

2019

0.10

2026

2.50

100000

2019

0.08

2024

2.50

5000000

2019

0.10

2026

2.50

100000

2020

0.08

2024

7.00

5000000

2022

0.10

2026

2.50

1150000

2022

0.06

2023

4.50

5000000

2023

0.08

2026

2.46

735000

2023

0.08

2024

19335000

3000000

2022

0.10

P1Y

2.5

16007000

1577695

1577694

25.0

10.3

14784000

4304000

2026-12-31

84000

8.5

141000

5000000

0.08

2024-01-01

If prior to December 31, 2023, the Borrower issues equity securities (“Equity Securities”) in a transaction or series of related transactions resulting in aggregate gross proceeds to the Borrower of at least $5,000 (excluding conversion of the Loan Amount) (a “Qualified Financing”), then the outstanding principal amount of the Loan Amount, and any and all accrued but unpaid interest thereon (collectively, the “Outstanding Amount”), will automatically convert into such Equity Securities issued pursuant to the Qualified Financing at a price per share equal to fifty percent (50%) of the price per share paid for each share of the Equity Securities purchased for cash by the investors in the Qualified Financing (the “Mandatory Conversion”). The per share price for the Mandatory Conversion shall be calculated on a fully diluted basis (including equity underlying all outstanding options, warrants, and other convertible securities, but excluding the Equity Securities issuable upon the Mandatory Conversion).

1500000

2026-01-31

0.10

773000

840000

0.85

NOTE 11 – LEASES The Company leases research and development facilities, equipment and offices under finance and operating leases. For leases with terms greater than 12 months, the Company records the related asset and obligation at the present value of lease payments over the term. Many of the leases include rental escalation clauses, renewal options and/or termination options that are factored into the determination of lease payments when appropriate. The Company’s leases do not provide a readily determinable implicit rate. Therefore, the Company estimated the incremental borrowing rate to discount the lease payments based on information available at lease commencement. Manufacturing facilities The Company leases space for its manufacturing facilities under operating lease agreements. The leasing contracts are for a period of <span id="xdx_900_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ManufacturingFacilityMember__srt--RangeAxis__srt--MinimumMember_zaR7ScH1y6j4" title="Leasing contracts period">3-<span id="xdx_900_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ManufacturingFacilityMember__srt--RangeAxis__srt--MaximumMember_zKcFT7RUSE6a" title="Leasing contracts period">10 years. Offices The Company leases space for offices under operating leases. The leasing contracts are valid for terms of 4 years. Lease Position <p id="xdx_896_ecustom--LeasesOfLesseeBalanceSheetDisclosuresTableTextBlock_zYzwtWIvwEQc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The table below presents the lease-related assets and liabilities recorded on the balance sheet: SCHEDULE OF LEASE-RELATED ASSETS AND LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.75in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20241231_z0lg654iLMy7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20231231_z3NdeRoSJOX8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Operating Leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Operating lease right-of-use assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">351</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Finance Leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_iI_pn3n3_z7ZPS1qxB78d" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Property, plants and equipment, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">136</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">89</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_iNI_pn3n3_di_zaPYU1a9nKb3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(136</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(65</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_iI_pn3n3_zOFwHgs5O205" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Property and equipment, net</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">24</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Current liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Current maturities of operating leases</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">234</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">216</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FinanceLeaseLiabilityCurrent_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current maturities of long-term finance leases</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">18</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Long-term liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Non-current operating leases</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,308</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">96</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Long-term finance leases</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Weighted Average Remaining Lease Term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 6.5 years</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 1.1 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Finance leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 0.6 years</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 1.2 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Weighted Average Discount Rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating leases</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20241231_z3AmMpBKp8Ga" style="text-align: right" title="Weighted Average Discount Rate, Operating leases">9.2</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20231231_zzyQDnIX6sGk" style="text-align: right" title="Weighted Average Discount Rate, Operating leases">7.5</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Finance leases</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20241231_zURcXRfVh7pb" style="text-align: right" title="Weighted Average Discount Rate, Finance leases">10.4</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20231231_zKi4MRILCWhg" style="text-align: right" title="Weighted Average Discount Rate, Finance leases">2.0</td><td style="text-align: left">%</td></tr> </table> Lease Costs The table below presents certain information related to lease costs and finance and operating leases: SCHEDULE OF LEASE COSTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.75in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20240101__20241231_z6PrdKrh0Hjd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20230101__20231231_zz5i6CXt5Myc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in Thousands)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseCost_pn3n3_z5ywZJ0ol8hc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; font-weight: bold; text-align: left">Operating lease cost:</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">542</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">561</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Finance lease cost:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_pn3n3_maFLCzpkF_z2BRXyfQb2r7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Amortization of leased assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FinanceLeaseInterestExpense_pn3n3_maFLCzpkF_zjtSQvxEhau6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Interest on lease liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--FinanceLeaseCost_iT_pn3n3_mtFLCzpkF_zeDeKaSNJKjk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total finance lease cost</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">64</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">51</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_89A_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zL7qtL0yQA5d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The table below presents supplemental cash flow information related to lease: SCHEDULE OF SUPPLEMENTAL CASHFLOW INFORMATION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in Thousands)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Cash paid for amounts included in the measurement of leases liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Operating leases</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--OperatingLeasePayments_pn3n3_c20240101__20241231_zBe6qvKXskrg" style="width: 16%; text-align: right" title="Cash paid for amounts included in the measurement of leases liabilities: Operating leases">541</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--OperatingLeasePayments_pn3n3_c20230101__20231231_zG1RHixR9CA4" style="width: 16%; text-align: right" title="Cash paid for amounts included in the measurement of leases liabilities: Operating leases">573</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Finance leases</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--FinanceLeaseInterestPaymentOnLiability_pn3n3_c20240101__20241231_zcxZoi7Q6qhk" style="text-align: right" title="Cash paid for amounts included in the measurement of leases liabilities: Finance leases">64</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--FinanceLeaseInterestPaymentOnLiability_pn3n3_c20230101__20231231_zjsBmae4WTmg" style="text-align: right" title="Cash paid for amounts included in the measurement of leases liabilities: Finance leases">44</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligations:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating leases</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn3n3_c20240101__20241231_zZ3ILW9n38qe" style="text-align: right" title="Right-of-use assets obtained in exchange for lease obligations: Operating leases">405</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn3n3_c20230101__20231231_z8skcaHsHe23" style="text-align: right" title="Right-of-use assets obtained in exchange for lease obligations: Operating leases">752</td><td style="text-align: left"> </td></tr> </table> Undiscounted Cash Flows <p id="xdx_89F_ecustom--LesseeLeaseLiabilityMaturityTableTextBlock_z0zwumRTrVXh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The table below reconciles the undiscounted cash flows for each of the first five years and total of the remaining years to the finance lease liabilities and operating lease liabilities recorded on the balance sheet. SCHEDULE OF FINANCE LEASE LIABILITIES AND OPERATING LEASE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 100%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Operating Leases</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Finance Leases</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; font-weight: bold">Year ended December 31,</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: justify">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_c20241231_zcnO6Jui4U45" style="width: 16%; text-align: right" title="Operating Leases, 2024">346</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_c20241231_zLNKWBMiG8v7" style="width: 16%; text-align: right" title="Finance Lease, 2024">26</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_c20241231_zEmdFWtufzml" style="text-align: right" title="Operating Leases, 2025">342</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_c20241231_zyOCulrspp5k" style="text-align: right" title="Finance Lease, 2025">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_c20241231_zYFQ2cAyZMUj" style="text-align: right" title="Operating Leases, 2026">318</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_c20241231_zTrlAKrhAja5" style="text-align: right" title="Finance Lease, 2026">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">2027</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_c20241231_zNAAjFau6k3a" style="text-align: right" title="Operating Leases, 2027">284</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_c20241231_zcdjGLgKg4fa" style="text-align: right" title="Finance Lease, 2027">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">2028</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_c20241231_z4mHv9zH5vtk" style="text-align: right" title="Operating Leases, 2028">225</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_c20241231_zRVCUTEDoE72" style="text-align: right" title="Finance Lease, 2028">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_c20241231_zKq7tqorvHp9" style="border-bottom: Black 1pt solid; text-align: right" title="Thereafter">518</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_c20241231_z8e9I6cd0tJl" style="border-bottom: Black 1pt solid; text-align: right" title="Thereafter">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Total minimum lease payments</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pn3n3_c20241231_zjLoDIsKvdN7" style="border-bottom: Black 1pt solid; text-align: right" title="Operating Leases, Total minimum lease payments">2,033</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iI_pn3n3_c20241231_z4R2e2MfT9R5" style="border-bottom: Black 1pt solid; text-align: right" title="Finance Leases, Total minimum lease payments">26</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Less: amount of lease payments representing interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20241231_znfdNhRgoLah" style="border-bottom: Black 1pt solid; text-align: right" title="Operating Leases, Less: amount of lease payments representing interest">(491</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20241231_z26nJM0XrxVl" style="border-bottom: Black 1pt solid; text-align: right" title="Finance Lease, Less: amount of lease payments representing interest">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Present value of future minimum lease payments</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20241231_zvy0sjv4JOGc" style="border-bottom: Black 1pt solid; text-align: right" title="Operating Leases, Present value of future minimum lease payments">1,542</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--FinanceLeaseLiability_iI_pn3n3_c20241231_zrYN1QVWrQPb" style="border-bottom: Black 1pt solid; text-align: right" title="Finance Lease, Present value of future minimum lease payments">26</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Less: Current leases obligations</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pn3n3_di_c20241231_zZ89w9A6QOx5" style="border-bottom: Black 1pt solid; text-align: right" title="Operating Leases, Less: Current leases obligations">(234</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_pn3n3_di_c20241231_zXrD64GS3i8b" style="border-bottom: Black 1pt solid; text-align: right" title="Finance Lease, Less: Current leases obligations">(25</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Long-term leases obligations</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_c20241231_z1DJiYbpwspe" style="border-bottom: Black 1pt solid; text-align: right" title="Operating Leases, Long-term leases obligations">1,308</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_pn3n3_c20241231_zpox8CS1Zg7j" style="border-bottom: Black 1pt solid; text-align: right" title="Finance Lease, Long-term leases obligations">1</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> <p id="xdx_893_ecustom--ScheduleOfRightofuseAssetsByGeographicalLocation_zk54FF6Tc53h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Operating lease right-of-use assets by geographical location were as follows: SCHEDULE OF RIGHT-OF-USE ASSETS BY GEOGRAPHICAL LOCATION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Greece</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20241231__srt--StatementGeographicalAxis__country--GR_z1EcupCrji1b" style="text-align: right" title="Operating lease right-of-use assets">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20231231__srt--StatementGeographicalAxis__country--GR_zb4y4aKVPE8l" style="text-align: right" title="Operating lease right-of-use assets">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%">Israel</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20241231__srt--StatementGeographicalAxis__country--IL_zg3NRQRI4upg" style="width: 16%; text-align: right" title="Operating lease right-of-use assets">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20231231__srt--StatementGeographicalAxis__country--IL_zZWeVToz5QF3" style="width: 16%; text-align: right" title="Operating lease right-of-use assets">292</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">U.S.</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20241231__srt--StatementGeographicalAxis__country--US_zcRQcF5847xa" style="border-bottom: Black 1pt solid; text-align: right" title="Operating lease right-of-use assets">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20231231__srt--StatementGeographicalAxis__country--US_zMSJwH4ASVNa" style="border-bottom: Black 1pt solid; text-align: right" title="Operating lease right-of-use assets">59</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20241231_zMlZJdBLxwZi" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease right-of-use assets">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20231231_z5ikcbzW6gt3" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease right-of-use assets">351</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

P3Y

P10Y

P4Y

<p id="xdx_896_ecustom--LeasesOfLesseeBalanceSheetDisclosuresTableTextBlock_zYzwtWIvwEQc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The table below presents the lease-related assets and liabilities recorded on the balance sheet: SCHEDULE OF LEASE-RELATED ASSETS AND LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.75in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20241231_z0lg654iLMy7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20231231_z3NdeRoSJOX8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Operating Leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Operating lease right-of-use assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">351</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Finance Leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_iI_pn3n3_z7ZPS1qxB78d" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Property, plants and equipment, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">136</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">89</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_iNI_pn3n3_di_zaPYU1a9nKb3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(136</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(65</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_iI_pn3n3_zOFwHgs5O205" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Property and equipment, net</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">24</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Current liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Current maturities of operating leases</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">234</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">216</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FinanceLeaseLiabilityCurrent_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current maturities of long-term finance leases</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">18</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Long-term liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Non-current operating leases</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,308</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">96</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Long-term finance leases</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Weighted Average Remaining Lease Term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 6.5 years</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 1.1 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Finance leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 0.6 years</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 1.2 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Weighted Average Discount Rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating leases</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20241231_z3AmMpBKp8Ga" style="text-align: right" title="Weighted Average Discount Rate, Operating leases">9.2</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20231231_zzyQDnIX6sGk" style="text-align: right" title="Weighted Average Discount Rate, Operating leases">7.5</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Finance leases</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20241231_zURcXRfVh7pb" style="text-align: right" title="Weighted Average Discount Rate, Finance leases">10.4</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_c20231231_zKi4MRILCWhg" style="text-align: right" title="Weighted Average Discount Rate, Finance leases">2.0</td><td style="text-align: left">%</td></tr> </table>

351000

136000

89000

136000

65000

24000

234000

216000

25000

18000

1308000

96000

1000

4000

P6Y6M

P1Y1M6D

P0Y7M6D

P1Y2M12D

0.092

0.075

0.104

0.020

The table below presents certain information related to lease costs and finance and operating leases: SCHEDULE OF LEASE COSTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.75in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20240101__20241231_z6PrdKrh0Hjd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20230101__20231231_zz5i6CXt5Myc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in Thousands)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseCost_pn3n3_z5ywZJ0ol8hc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; font-weight: bold; text-align: left">Operating lease cost:</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">542</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">561</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Finance lease cost:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_pn3n3_maFLCzpkF_z2BRXyfQb2r7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Amortization of leased assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FinanceLeaseInterestExpense_pn3n3_maFLCzpkF_zjtSQvxEhau6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Interest on lease liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--FinanceLeaseCost_iT_pn3n3_mtFLCzpkF_zeDeKaSNJKjk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total finance lease cost</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">64</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">51</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

542000

561000

60000

46000

4000

5000

64000 51000

<p id="xdx_89A_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zL7qtL0yQA5d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The table below presents supplemental cash flow information related to lease: SCHEDULE OF SUPPLEMENTAL CASHFLOW INFORMATION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.75in"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in Thousands)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Cash paid for amounts included in the measurement of leases liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Operating leases</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--OperatingLeasePayments_pn3n3_c20240101__20241231_zBe6qvKXskrg" style="width: 16%; text-align: right" title="Cash paid for amounts included in the measurement of leases liabilities: Operating leases">541</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--OperatingLeasePayments_pn3n3_c20230101__20231231_zG1RHixR9CA4" style="width: 16%; text-align: right" title="Cash paid for amounts included in the measurement of leases liabilities: Operating leases">573</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Finance leases</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--FinanceLeaseInterestPaymentOnLiability_pn3n3_c20240101__20241231_zcxZoi7Q6qhk" style="text-align: right" title="Cash paid for amounts included in the measurement of leases liabilities: Finance leases">64</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--FinanceLeaseInterestPaymentOnLiability_pn3n3_c20230101__20231231_zjsBmae4WTmg" style="text-align: right" title="Cash paid for amounts included in the measurement of leases liabilities: Finance leases">44</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligations:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating leases</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn3n3_c20240101__20241231_zZ3ILW9n38qe" style="text-align: right" title="Right-of-use assets obtained in exchange for lease obligations: Operating leases">405</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn3n3_c20230101__20231231_z8skcaHsHe23" style="text-align: right" title="Right-of-use assets obtained in exchange for lease obligations: Operating leases">752</td><td style="text-align: left"> </td></tr> </table>

541000

573000

64000

44000

405000

752000

<p id="xdx_89F_ecustom--LesseeLeaseLiabilityMaturityTableTextBlock_z0zwumRTrVXh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The table below reconciles the undiscounted cash flows for each of the first five years and total of the remaining years to the finance lease liabilities and operating lease liabilities recorded on the balance sheet. SCHEDULE OF FINANCE LEASE LIABILITIES AND OPERATING LEASE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 100%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Operating Leases</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Finance Leases</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; font-weight: bold">Year ended December 31,</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: justify">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_c20241231_zcnO6Jui4U45" style="width: 16%; text-align: right" title="Operating Leases, 2024">346</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_c20241231_zLNKWBMiG8v7" style="width: 16%; text-align: right" title="Finance Lease, 2024">26</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_c20241231_zEmdFWtufzml" style="text-align: right" title="Operating Leases, 2025">342</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_c20241231_zyOCulrspp5k" style="text-align: right" title="Finance Lease, 2025">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_c20241231_zYFQ2cAyZMUj" style="text-align: right" title="Operating Leases, 2026">318</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_c20241231_zTrlAKrhAja5" style="text-align: right" title="Finance Lease, 2026">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">2027</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_c20241231_zNAAjFau6k3a" style="text-align: right" title="Operating Leases, 2027">284</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_c20241231_zcdjGLgKg4fa" style="text-align: right" title="Finance Lease, 2027">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">2028</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_c20241231_z4mHv9zH5vtk" style="text-align: right" title="Operating Leases, 2028">225</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_c20241231_zRVCUTEDoE72" style="text-align: right" title="Finance Lease, 2028">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_c20241231_zKq7tqorvHp9" style="border-bottom: Black 1pt solid; text-align: right" title="Thereafter">518</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_c20241231_z8e9I6cd0tJl" style="border-bottom: Black 1pt solid; text-align: right" title="Thereafter">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Total minimum lease payments</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pn3n3_c20241231_zjLoDIsKvdN7" style="border-bottom: Black 1pt solid; text-align: right" title="Operating Leases, Total minimum lease payments">2,033</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iI_pn3n3_c20241231_z4R2e2MfT9R5" style="border-bottom: Black 1pt solid; text-align: right" title="Finance Leases, Total minimum lease payments">26</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Less: amount of lease payments representing interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20241231_znfdNhRgoLah" style="border-bottom: Black 1pt solid; text-align: right" title="Operating Leases, Less: amount of lease payments representing interest">(491</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20241231_z26nJM0XrxVl" style="border-bottom: Black 1pt solid; text-align: right" title="Finance Lease, Less: amount of lease payments representing interest">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Present value of future minimum lease payments</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20241231_zvy0sjv4JOGc" style="border-bottom: Black 1pt solid; text-align: right" title="Operating Leases, Present value of future minimum lease payments">1,542</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--FinanceLeaseLiability_iI_pn3n3_c20241231_zrYN1QVWrQPb" style="border-bottom: Black 1pt solid; text-align: right" title="Finance Lease, Present value of future minimum lease payments">26</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Less: Current leases obligations</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pn3n3_di_c20241231_zZ89w9A6QOx5" style="border-bottom: Black 1pt solid; text-align: right" title="Operating Leases, Less: Current leases obligations">(234</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_pn3n3_di_c20241231_zXrD64GS3i8b" style="border-bottom: Black 1pt solid; text-align: right" title="Finance Lease, Less: Current leases obligations">(25</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Long-term leases obligations</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_c20241231_z1DJiYbpwspe" style="border-bottom: Black 1pt solid; text-align: right" title="Operating Leases, Long-term leases obligations">1,308</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_pn3n3_c20241231_zpox8CS1Zg7j" style="border-bottom: Black 1pt solid; text-align: right" title="Finance Lease, Long-term leases obligations">1</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

346000

26000

342000

318000

284000

225000

518000

2033000

26000

491000

1542000

26000

234000

25000

1308000

1000

<p id="xdx_893_ecustom--ScheduleOfRightofuseAssetsByGeographicalLocation_zk54FF6Tc53h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Operating lease right-of-use assets by geographical location were as follows: SCHEDULE OF RIGHT-OF-USE ASSETS BY GEOGRAPHICAL LOCATION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Greece</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20241231__srt--StatementGeographicalAxis__country--GR_z1EcupCrji1b" style="text-align: right" title="Operating lease right-of-use assets">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20231231__srt--StatementGeographicalAxis__country--GR_zb4y4aKVPE8l" style="text-align: right" title="Operating lease right-of-use assets">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%">Israel</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20241231__srt--StatementGeographicalAxis__country--IL_zg3NRQRI4upg" style="width: 16%; text-align: right" title="Operating lease right-of-use assets">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20231231__srt--StatementGeographicalAxis__country--IL_zZWeVToz5QF3" style="width: 16%; text-align: right" title="Operating lease right-of-use assets">292</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">U.S.</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20241231__srt--StatementGeographicalAxis__country--US_zcRQcF5847xa" style="border-bottom: Black 1pt solid; text-align: right" title="Operating lease right-of-use assets">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20231231__srt--StatementGeographicalAxis__country--US_zMSJwH4ASVNa" style="border-bottom: Black 1pt solid; text-align: right" title="Operating lease right-of-use assets">59</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20241231_zMlZJdBLxwZi" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease right-of-use assets">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_c20231231_z5ikcbzW6gt3" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease right-of-use assets">351</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

292000

59000

351000

NOTE 12 – COMMITMENTS AND LICENSE AGREEMENTS See Note 13 for additional commitments related to Collaborations. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">a.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Tel Hashomer Medical Research, Infrastructure and Services Ltd (“THM”)</td></tr></table> On February 2, 2012, the Company’s Israeli Subsidiary entered into a licensing agreement with THM. According to the agreement, the Israeli Subsidiary was granted a worldwide, royalty bearing, exclusive license to trans-differentiation of cells to insulin producing cells, including the population of insulin producing cells, methods of making this population, and methods of using this population of cells for cell therapy or diabetes treatment developed by Dr. Sarah Ferber of THM. As consideration for the license, the Israeli Subsidiary will pay the following to THM: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">1)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">A royalty of <span id="xdx_906_ecustom--RoyaltyOfNetSalesPercentage_pid_dp_uPure_c20120201__20120202__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_zOhG1DOIp6ub" title="Royalty of net sales, percentage">3.5% of net sales;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">2)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_907_ecustom--SublicensingFeesPercentage_pid_dp_uPure_c20120201__20120202__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_zwY1OxFhdkei" title="Sublicensing fees, percentage">16% of all sublicensing fees received;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">3)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">An annual license fee of $<span id="xdx_902_ecustom--AnnualLicenseFee_pn3n3_c20120201__20120202__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_zuNXkNqN5rm1" title="Annual license fee">15, which commenced on January 1, 2012 and shall be paid once every year thereafter. The annual fee is non-refundable, but it shall be paid each year against the royalty noted above, to the extent that such are payable, during that year; and</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">4)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Milestone payments as follows:</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">a.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">$<span id="xdx_90F_ecustom--MilestonePayments_pn3n3_c20120201__20120202__srt--StatementScenarioAxis__custom--PhaseIClinicalTrialsMember__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_zYHmpizT0ZU9" title="Milestone payments">50 on the date of initiation of Phase I clinical trials in human subjects;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">b.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">$<span id="xdx_902_ecustom--MilestonePayments_pn3n3_c20120201__20120202__srt--StatementScenarioAxis__custom--PhaseIIClinicalTrialsMember__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_zysF2m1SJ4U4" title="Milestone payments">50 on the date of initiation of Phase II clinical trials in human subjects;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">c.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">$<span id="xdx_905_ecustom--MilestonePayments_pn3n3_c20120201__20120202__srt--StatementScenarioAxis__custom--PhaseIIIClinicalTrialsMember__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_zsG5sCYZVOd6" title="Milestone payments">150 on the date of initiation of Phase III clinical trials in human subjects;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">d.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">$<span id="xdx_900_ecustom--MilestonePayments_pn3n3_c20120201__20120202__srt--StatementScenarioAxis__custom--FirstProductByTheFDAMember__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_zW7xYfdwv2J7" title="Milestone payments">750 on the date of initiation of issuance of an approval for marketing of the first product by the FDA; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">e.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">$<span id="xdx_900_ecustom--MilestonePayments_pn6n6_c20120201__20120202__srt--StatementScenarioAxis__custom--WorldwideNetSalesOfProductsMember__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_zQ1spkxGpXk" title="Milestone payments">2 million when worldwide net sales of Products (as defined in the agreement) have reached the amount of $<span id="xdx_90C_ecustom--MilestonePayments_pn6n6_c20120201__20120202__srt--StatementScenarioAxis__custom--SalesMilestoneMember__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_zBs3pVIExQ07" title="Milestone payments">150 million for the first time, (the “Sales Milestone”).</td></tr></table> As of December 31, 2024, the Israeli Subsidiary had not reached any of these milestones. In the event of closing of an acquisition of all of the issued and outstanding share capital of the Israeli Subsidiary and/or consolidation of the Israeli Subsidiary or the Company into or with another corporation (“Exit”), the THM shall be entitled to choose whether to receive from the Israeli Subsidiary a one-time payment based, as applicable, on the value of either <span id="xdx_90C_ecustom--CommitmentSharesOfCommonStock_iI_pid_c20120202__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_zGJ60NDUnXr9" title="Commitment, shares of common stock">4,636,510 shares of common stock of the Company at the time of the Exit or the value of <span id="xdx_901_ecustom--CommitmentSharesOfCommonStockOfSubsidiary_iI_pid_c20120202__custom--CollaborationAndLicenseAgreementsAxis__custom--TelHashomerMedicalResearchInfrastructureAndServicesLtdThmMember_znxfKRdeFT98" title="Commitment, shares of common stock of Israeli subsidiary">1,000 shares of common stock of the Israeli Subsidiary at the time of the Exit. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">b.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Israel-U.S. Binational Industrial Research and Development Foundation (“BIRD”)</td></tr></table> On September 9, 2015, the Israeli Subsidiary entered into a pharma Cooperation and Project Funding Agreement (CPFA) with BIRD and Pall Corporation, a U.S. company. BIRD awarded a conditional grant of up to $<span id="xdx_90B_eus-gaap--GrantsReceivableNoncurrent_iI_pn3n3_c20150909__us-gaap--RelatedPartyTransactionAxis__custom--IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember_z63MMA1M999d" title="Grants receivable, noncurrent">400 each (according to terms defined in the agreement), for a joint research and development project for the use of Autologous Insulin Producing (AIP) Cells for the Treatment of Diabetes (the “Project”). Company received a total of $<span id="xdx_906_eus-gaap--Revenues_pn3n3_c20150908__20150909__us-gaap--RelatedPartyTransactionAxis__custom--IsraelusBinationalIndustrialResearchAndDevelopmentFoundationMember_zBKU51Nb5RJc" title="Revenues, total">299 under the grant. The project was completed in 2019. The grant is to be repaid at the rate of 5% of gross sales generated from the Project. To date no sales have been generated. <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in">f.</td> <td style="text-align: justify">Sponsored Research and Exclusive License Agreement with Columbia University</td></tr> </table> Effective April 2, 2019, the Company and The Trustees of Columbia University in the City of New York, a New York corporation, (“Columbia”) entered into a Sponsored Research Agreement (the “SRA”) whereby the Company will provide financial support for studying the utility of serological tumor marker for tumor dynamics monitoring. Effective April 2, 2019, the Company and Columbia entered into an Exclusive License Agreement (the “Columbia License Agreement”) whereby Columbia granted to the Company an exclusive license to discover, develop, manufacture, sell, and otherwise distribute certain product in the field of cancer therapy. In consideration of the licenses granted under the Columbia License Agreement, the Company shall pay to Columbia (i) a royalty of <span id="xdx_907_ecustom--RoyaltyOfNetSalesPercentage_pid_dp_uPure_c20190329__20190402__custom--CollaborationAndLicenseAgreementsAxis__custom--ColumbiaLicenseAgreementMember_zCHl8oFTk837" title="Royalty of net sales, percentage">5% of net sales of any product sold which incorporates a licensed Columbia patent and (ii) <span id="xdx_90D_ecustom--RoyaltyOfNetSalesOfOtherProductsPercentage_pid_dp_uPure_c20190329__20190402__custom--CollaborationAndLicenseAgreementsAxis__custom--ColumbiaLicenseAgreementMember_z6EmxGS48k0l" title="Royalty of net sales of other product percentage">2.5% of net sales of other products. In addition, the Company shall pay a flat $<span id="xdx_90F_ecustom--PaymentOfFeeUponAchievementOfEachRegulatoryMilestone_pn3n3_c20190329__20190402__custom--CollaborationAndLicenseAgreementsAxis__custom--ColumbiaLicenseAgreementMember_ztv9ZkKE2zo3" title="Payment of fee upon the achievement of each regulatory milestone">100 fee to Columbia upon the achievement of each regulatory milestone. To date no royalty incurring sales were made. <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in">g.</td> <td style="text-align: justify">Regents of the University of California</td></tr> </table> In December 2019, the Company and the Regents of the University of California (“University”) entered into a joint research agreement in the field of therapies and processing technologies according to an agreed upon work plan. According to the agreement, the Company will pay the University royalties of up to <span id="xdx_908_ecustom--RoyaltyOfNetSalesPercentage_pid_dp_uPure_c20191201__20191231__custom--CollaborationAndLicenseAgreementsAxis__custom--CaliforniaUniversityJointResearchAgreementMember__srt--RangeAxis__srt--MaximumMember_zw8htyCAql34" title="Royalty of net sales, percentage">5% (or up to <span id="xdx_90E_ecustom--SublicensingFeesPercentage_pid_dp_uPure_c20191201__20191231__custom--CollaborationAndLicenseAgreementsAxis__custom--CaliforniaUniversityJointResearchAgreementMember__srt--RangeAxis__srt--MaximumMember_z6zXUBnbVg6i" title="Sublicensing fees, percentage">20% of sub-licensing sales) in the event of sales that includes certain types of University owned IP. To date, no royalty incurring sales were made. <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in">h.</td> <td style="text-align: justify">Caerus Therapeutics Inc</td></tr> </table> In October 2019, the Company and Caerus Therapeutics (“Caerus”), a Virginia company, concluded a license agreement whereby Caerus granted the Company an exclusive license to all Caerus IP relating to Advance Chemeric Antigen Vectors for Targeting Tumors for the development and/or commercialization of certain licensed products. In consideration for the License granted to the Company under this Agreement, the Company shall pay Caerus annual maintenance fees and royalties of sales of up to <span id="xdx_907_ecustom--RoyaltyOfNetSalesPercentage_pid_dp_uPure_c20191001__20191031__srt--RangeAxis__srt--MaximumMember__srt--OwnershipAxis__custom--CaerusTherapeuticsIncMember_z35LyV3OEwp3" title="Royalty of net sales percentage">5% and up to <span id="xdx_907_ecustom--SublicensingFeesPercentage_pid_dp_c20191001__20191031__srt--OwnershipAxis__custom--CaerusTherapeuticsIncMember__srt--RangeAxis__srt--MaximumMember_zAO42545rB46" title="Sublicensing fees percentage">18% of sub-license fees. To date, no royalty incurring sales were made. <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in">i.</td> <td style="text-align: justify">Tissue Genesis LLC</td></tr> </table> Included in the Koligo acquisition of 2020 were the assets of Tissue Genesis LLC. The Company is committed to paying the previous owners of Tissue Genesis LLC or their assignees up to $<span id="xdx_90D_ecustom--FutureMilestonePayments_iI_pn3n3_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--BusinessAcquisitionAxis__custom--TissueGenesisLLCMember_zgq3jvjjmph2" title="Future milestone payments">500 upon the achievement of certain performance milestones and earn-out payments on future sales provided that in no event will the aggregate of the earn-out payments exceed $<span id="xdx_905_eus-gaap--RoyaltyExpense_pn6n6_c20240101__20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--BusinessAcquisitionAxis__custom--TissueGenesisLLCMember_zaQtesKHN8Ra" title="Royalty expense">4 million. To date, no performance milestones have been reached. <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in">k.</td> <td style="text-align: justify">Savicell</td></tr> </table> During 2021, the Company and Savicell Ltd (“Savicell”) entered into a collaboration agreement (the “Savicell Agreement”) to collaborate in the evaluation, continued development, validation, and use of Savicell’s platform designed for the early detection and diagnosis of diseases and conditions and for quality control and monitoring purposes, in conjunction with the Company’s systems. Pursuant to the Savicell Agreement, the Company will provide to Savicell funding for the performance of certain tasks agreed upon by the parties in a work plan. In consideration for such funding, Savicell will supply the Company with products developed under the Savicell Agreement at preferential rates and grant to the Company a worldwide exclusive licence to sell such products in the Company’s point-of-care network of hospitals, clinics and institutions for quality control and monitoring of manufacturing and processing of autologous immune cells manipulated by cell and gene therapies. The Company will be required to pay a 10% royalty for all gross sales of such products developed under the Savicell Agreement. To date, no royalty incurring sales were made. <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in">l.</td> <td style="text-align: justify">Stromatis Pharma</td></tr> </table> During 2021, the Company and Stromatis Pharma Inc. (“Stromatis”) entered into a Collaboration and Sublicense Agreement (the “Stromatis Agreement”) to collaborate in refining methods for GMP manufacturing of CAR-T/CAR-NK CT109; and the development and validation of the Stromatis technology as it relates to the CAR-T/CAR-NK CT109 antibody up to and inclusive of filing of Investigational New Drug Application relating to Stromatis’ CAR-T/CAR-NK CT109 antibody (“Licensed Product”), in accordance with the agreed project plan (“Project”). The Company will fund the Project by providing Stromatis an amount of $<span id="xdx_905_ecustom--InvestedAmountForDevelopmentPlan_pn5n6_c20210101__20211231__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--StromatisAgreementMember_zqnyiXDneQAk" title="Invested amount for development">1.2 million such funding to be provided based on approved projects. Stromatis will grant the Company certain perpetual, irrevocable royalty free and fully paid-up exclusive rights to manufacture, process and supply the Licensed Product (“Manufacturing Rights”) and perpetual, irrevocable, royalty bearing exclusive rights to market and sell and offer for sale the Licensed Product within the Company’s point of care network (“Marketing Rights”). To date, no royalty incurring sales were made. Stromatis has the option to convert the exclusive Manufacturing Rights to non-exclusive rights subject to repayment by Stromatis of an amount equal to funding provided by the Company and an additional payment by Stromatis of an ongoing revenue share of five percent (5%) of revenues of any kind received by Stromatis or its affiliates from the sale or transfer of Licensed Products or license of rights under the licensed technology in relation to the Licensed Products. The Company shall pay Stromatis in consideration for the Marketing Rights and royalties equal to <span id="xdx_902_ecustom--RoyaltyOfNetSalesPercentage_pid_dp_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--StromatisAgreementMember__srt--RangeAxis__srt--MaximumMember_z0iZNnOhausd" title="Royalty of net sales percentage">12% of net revenues of Licensed Products received by the Company. The Company advanced to Stromatis an initial sum of $<span id="xdx_902_ecustom--CostOfServicesOtherResearchAndDevelopmentExpenses_pn3n3_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--StromatisAgreementMember_zoevYkuU1ms2" title="Cost of services, other research and development expenses">500 under the Stromatis Agreement, which was recorded as Cost of revenues, development services and research and development expenses. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">m.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)) (“HMGU”)-</td></tr></table> During 2021, HMGU granted an exclusive licence under HGMU owned patent rights and non-exclusive license under HGMU know how and licensed materials, to the Company in the field of certain human stem cells. In addition, payments will be due by the Company upon certain milestones. The agreement also includes payment of royalties of between <span id="xdx_907_ecustom--RoyaltyOfNetSalesPercentage_pid_dp_uPure_c20210101__20211231__dei--LegalEntityAxis__custom--HMGUMember__srt--RangeAxis__srt--MinimumMember_ztnRBdgyvBuc" title="Royalty of net sales percentage">3% and 4% on net sales of licensed product (with a minimum annual royalty of Euro 200,000, creditable against royalties on net sales incurred during such contract year) and 5% in service revenues and payment of between <span id="xdx_90A_ecustom--RoyaltyOfSubleaseRevenue_pid_dp_uPure_c20210101__20211231__dei--LegalEntityAxis__custom--HMGUMember__srt--RangeAxis__srt--MinimumMember_zaOdizVGQthd" title="Royalty percentage on sublease revenue">10% and <span id="xdx_90A_ecustom--RoyaltyOfSubleaseRevenue_pid_dp_uPure_c20210101__20211231__dei--LegalEntityAxis__custom--HMGUMember__srt--RangeAxis__srt--MaximumMember_zmiZfpR1xCQg" title="Royalty percentage on sublease revenue">18% on sublicense revenues. <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in">n.</td> <td style="text-align: justify">European Innovation Council and SMEs Executive Agency (“EISMEA”)</td></tr> </table> During the year ended December 31, 2022, the Dutch Subsidiary, together with a consortium of other entities (“Consortium”) and EISMEA entered into a grant funding agreement for the funding of the development of an artificial intelligence guided microfluidic device that standardizes the GMP production of autologous induced pluripotent stem cells (iSPSCs) at greatly reduced costs (“iPSC project”). The total grant amount is Euro <span id="xdx_907_eus-gaap--GrantsReceivable_iI_pn3n6_uEUR_c20221231__us-gaap--RelatedPartyTransactionAxis__custom--EuropeanInnovationCouncilAndSMEsExecutiveAgencyMember_zT3CMiAJfWAc" title="Grants receivable">3.999 million of which the Dutch subsidiary is eligible to receive up to Euro <span id="xdx_907_eus-gaap--Revenues_pn3n6_uEUR_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--GrantFundingAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--EuropeanInnovationCouncilAndSMEsExecutiveAgencyMember__srt--RangeAxis__srt--MaximumMember_zRimCFXk8TNh" title="Revenues">1.179 million. The project started on September 1, 2022 and is expected to end on August 31, 2026. The Dutch subsidiary is the consortium leader for the iPSC project. During the year ended 31 December 2022, the subsidiary received initial working capital in the amount of Euro <span id="xdx_901_ecustom--WorkingCapital_iI_pn2n6_uEUR_c20221231__us-gaap--TypeOfArrangementAxis__custom--GrantFundingAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--EuropeanInnovationCouncilAndSMEsExecutiveAgencyMember_zeFWqKJJTZkk" title="Working capital">1.920 million of which Euro <span id="xdx_902_ecustom--WorkingCapital_iI_pn3n6_uEUR_c20221231__us-gaap--TypeOfArrangementAxis__custom--GrantFundingAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--EuropeanInnovationCouncilAndSMEsExecutiveAgencyMember__srt--ProductOrServiceAxis__custom--GrantsFromOtherMember_zK4xaxILihlc" title="Working capital">1.338 million was received on behalf of the other members of the Consortium and recorded in restricted cash, and Euro <span id="xdx_90F_ecustom--WorkingCapital_iI_pn3n3_uEUR_c20221231__us-gaap--TypeOfArrangementAxis__custom--GrantFundingAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--EuropeanInnovationCouncilAndSMEsExecutiveAgencyMember__srt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_zHBOswqGqE4j" title="Working capital">582 for the use of the subsidiary as per the grant agreement. As at December 31, 2024, the restricted cash related to the iPSC project was $180. During the year ended December 31, 2024, the Company recognized grant income of $356 which was offset against research and development expenses.

0.035 0.16 15000 50000 50000 150000 750000 2000000 150000000 4636510 1000

400000

299000

0.05 0.025 100000 0.05 0.20 0.05 0.18 500000

4000000

0.10 1200000 0.05 0.12 500000 0.03 0.04 200000 0.05 0.10 0.18

3999000

1179000

1920000 1338000 582000

180000

356000

NOTE 13 – COLLABORATIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">a.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Adva Biotechnology Ltd.</td></tr></table> On January 28, 2018, the Company and Adva Biotechnology Ltd. (“Adva”), entered into a Master Services Agreement (“MSA”), pursuant to which the Company and/or its affiliates provided certain services relating to development of products for Adva. In consideration for and subject to the fulfillment by the Company of certain funding commitments which were completed in 2019, Adva agreed that upon completion of the development of the products, the Company and/or its affiliates and Adva shall enter into a supply agreement pursuant to which for a period of eight (8) years following execution of such supply agreement, the Company and/or its affiliates (as applicable) is entitled (on a non-exclusive basis) to purchase the products from Adva at a specified discount pricing from their then standard pricing. The Company and/or its affiliates were also granted a non-exclusive worldwide right to distribute such products, directly or indirectly. The MSA shall remain in effect for 10 years unless earlier terminated in accordance with its terms. <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in">b.</td> <td style="text-align: justify">Revised and restated joint venture agreements</td></tr> </table> In January 2023, the Company entered into updated joint venture (JV) agreements (JVAs) with Theracell Advanced Biotechnology SA, Broaden Bioscience and Technology Corp, Image Securities FZC, Cure Therapeutics, and Med Centre for Gene and Cell Therapy FZ-LLC and assigned certain rights and obligations under its JVAs to Texas Advanced Therapies LLC, a Delaware Limited Liability company (“Texas AT”) not related to the Company. Texas AT was to receive the Company’s option to require the incorporation of the JV entity, the Company’s share in the JV entity, if and when incorporated, an option to invest additional funding in the JV entity, and board and veto rights on certain critical decisions in the JV entity. The Company retained a call option to acquire the JV partner’s share in the JV entity, as well as the right to receive a royalty and a right to conclude the Manufacturing and Service Agreement with the JV entity. Pursuant to the JVAs, the Company is not entitled to the additional share of fifteen percent of the JV entity’s GAAP profit after tax granted under the previous version of the JVAs, and the Company has no further obligation to provide additional funding to the JV entities. In May 2024, the Company was advised that Texas AT was dissolved effective December 27, 2023, which terminated the JVAs between the parties. As of December 31, 2024, no JV entities had been incorporated pursuant to the JVAs. <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in">c.</td> <td style="text-align: justify">Mircod</td></tr> </table> On July 25, 2023, the Company and Mircod LLC (“Mircod”) entered into a settlement and release agreement pursuant to which they agreed to terminate the joint venture and loan agreement between themselves. Also, pursuant to the agreement, Mircod agreed to deliver all the related deliverables to the Company, and the Company agreed to pay Mircod consideration in the amount of $1,000, of which half will be paid in cash, and one half in Orgenesis shares, upon receipt of the deliverables. As of December 31, 2024, Mircod invoiced the Company $300 in respect of deliverables that it claims were delivered and this amount is included in accounts payable. <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in">d.</td> <td style="text-align: justify">Sub-license agreement</td></tr> </table> On July 25, 2023, the Company, a Sub-licensee, and the equity interest owner of that Sub-licensee (“Sub-licensee Owner”), entered into agreements whereby: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">1)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the Company sub-licensed certain of its therapies to Sub-licensee in return for royalties on future sales and payments upon the successful completion of certain milestones;</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">2)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">subject to the fulfilment certain conditions and milestones, none of which have been fulfilled to date, the Sub-licensee Owner granted the Company a call option to purchase his interests in Sub-licensee at a valuation to be determined by a third-party valuation firm of not less than $<span id="xdx_90C_eus-gaap--EquityMethodInvestmentAggregateCost_iI_pn3n3_c20230725__us-gaap--TypeOfArrangementAxis__custom--SubLicenseAgreementsMember__srt--RangeAxis__srt--MaximumMember_zNmG06PAjL64" title="Equity interest valuation">8,000 unless agreed otherwise by the parties to the option; and</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">3)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">subject to the fulfilment of certain conditions and milestones, none of which have been fulfilled to date, the Sub-licensee Owner was granted a put option to cause the Company to purchase his equity interest in Sub-licensee at a valuation to be determined by a third-party valuation firm of not less than $8,000 unless agreed otherwise by the parties to the option.</td></tr></table> The Company has received $215 from Sub-licensee as an advance on account of future license fees. No milestones have been completed to date. The Company and sub-licensee terminated this agreement in 2025 <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in">e.</td> <td style="text-align: justify">Deep Med Joint Venture agreement (JVA)</td></tr> </table> In November 2021, Deep Med IO Ltd (“Deep Med”) and Company entered into a JVA. The Parties agreed to collaborate in the development and commercialization of an AI-powered system to be used in the manufacturing and/or quality control of CGTs. The Company has the right to finance its activities under the Deep Med JVA by procuring services, advancing funds under a convertible loan agreement, or by an equity investment. The Deep Med convertible loan bears interest at the annual rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211130__dei--LegalEntityAxis__custom--DeepMedIOLtdMember__us-gaap--TypeOfArrangementAxis__custom--JointVentureAgreementMember_zgp1T8dVBcQd" title="Interest rate">6% and is repayable after <span id="xdx_90D_ecustom--LoanRepayableTerm_dtY_c20211101__20211130__dei--LegalEntityAxis__custom--DeepMedIOLtdMember__us-gaap--TypeOfArrangementAxis__custom--JointVentureAgreementMember_zlffoQSRnHI8" title="Loan repayable term">5 years. The Company has the right to convert its holdings under the loan into shares of Deep Med, or into shares of the Deep Med JV entity once established. During twelve months ended December 31, 2022, the Company transferred $<span id="xdx_90D_ecustom--JointVentureTransferredAmount_pn5n6_c20220101__20221231__dei--LegalEntityAxis__custom--DeepMedIOLtdMember__us-gaap--TypeOfArrangementAxis__custom--JointVentureAgreementMember_zJ0V98p5Mckg" title="Joint venture transferred amount">1.9 million to Deep Med as part of its commitment under the Deep Med JVA. The Company recorded the amounts paid to Deep Med under the Deep Med JVA as research and development expenses under ASC 730. During the twelve months ended December 31, 2023, the Company and Deep Med suspended all work under the work plan pending further discussions. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">c.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Germfree Asset Purchase and Strategic Collaboration Agreement.</td></tr></table> On April 5, 2024, the Company entered into an Asset Purchase and Strategic Collaboration Agreement (the “Purchase Agreement”) with Griffin Fund 3 BIDCO, Inc., (“Germfree”), for the sale by the Company of five Orgenesis Mobile Processing Units and Labs (“OMPULs”) to Germfree, which will be incorporated into Germfree’s lease fleet and leased back to the Company or to third-party lessees designated by the Company. Pursuant to the Purchase Agreement, and subject to the terms and conditions set forth therein, in consideration for the purchase of the OMPULs, the Orgenesis Quality Management Systems Framework (“OQMSF”) and related intellectual property rights, Germfree is to pay an aggregate purchase price of $8,340 subject to adjustment through a verification mechanism set forth in the Purchase Agreement. Pursuant to the Purchase Agreement, Germfree paid the Company $6,720 as of December 31, 2024. Pursuant to the Purchase Agreement, Germfree will exclusively manufacture and distribute OMPULs and supply the Company with OMPULs for use worldwide for ten years (the “Term”), under a license to all OMPUL-related intellectual property owned by the Company. The Company will also license to Germfree the necessary technical package required to manufacture the OMPULs and will provide engineering services at a standard market rate with a statement of work to be agreed upon in advance. Germfree will provide service support for OMPULs including the provision of installation, commissioning, qualification, ongoing servicing, remote monitoring, and maintenance services for the facility, OMPULs, and related equipment. All intellectual property licensed to Germfree will remain the sole and exclusive property of the Company and all intellectual property or any improvements relating to the OMPULs or the OQMSF developed by Germfree will be the sole and exclusive property of Germfree. On November 5, 2024, Germfree notified the Company of its intention not to lease any OMPULS back to the Company. Germfree confirmed that it has satisfied its obligations to the Company under the Purchase Agreement, and the Company therefore does not expect to receive any further payments thereunder. The Company therefore recognized the profit from the sale of the OMPUL as Other Income.

1000000 300000

8000000

215000

0.06

P5Y 1900000

8340000

6720000

P10Y

NOTE 14 –LOSS PER SHARE The following table sets forth the calculation of basic and diluted loss per share for the periods indicated: SCHEDULE OF BASIC AND DILUTED LOSS PER SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20240101__20241231_zCnMSjHofngf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20230101__20231231_zy67NflLdZYi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in thousands, except per share data)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Basic and diluted:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--NetIncomeLoss_iN_pn3n3_di_maNILATzerQ_zA9hf4sBFBq4" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Net loss attributable to Orgenesis Inc</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">48,165</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">55,361</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Weighted average number of common shares outstanding</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,210,839</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,900,787</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Net loss per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11.44</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">19.08</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> For the year ended December 31, 2024, and December 31, 2023, all outstanding convertible notes, options, RSUs and warrants have been excluded from the calculation of the diluted net loss per share since their effect was anti-dilutive. Diluted loss per share excludes <span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsRSUAndWarrantsMember_zB8rpS2dKOz9" title="Antidilutive securities excluded from computation of earnings per share amount">2,156,406 shares underlying outstanding options, RSUs and warrants and <span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SharesUponConversionOfConvertibleLoansMember_zo3S3JVAjfe7" title="Antidilutive securities excluded from computation of earnings per share amount">247,895 shares upon conversion of convertible loans for the year ended December 31, 2024, because the effect of their inclusion in the computation would be anti-dilutive. Diluted loss per share excludes <span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsRSUAndWarrantsMember_zAM9N1THjamf" title="Antidilutive securities excluded from computation of earnings per share amount">790,441 shares underlying outstanding options, RSUs and warrants and <span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SharesUponConversionOfConvertibleLoansMember_zicSOII49gAa" title="Antidilutive securities excluded from computation of earnings per share amount">715,775 shares upon conversion of convertible loans for the year ended December 31, 2023, because the effect of their inclusion in the computation would be antidilutive.

The following table sets forth the calculation of basic and diluted loss per share for the periods indicated: SCHEDULE OF BASIC AND DILUTED LOSS PER SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20240101__20241231_zCnMSjHofngf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20230101__20231231_zy67NflLdZYi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in thousands, except per share data)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Basic and diluted:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--NetIncomeLoss_iN_pn3n3_di_maNILATzerQ_zA9hf4sBFBq4" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Net loss attributable to Orgenesis Inc</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">48,165</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">55,361</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Weighted average number of common shares outstanding</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,210,839</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,900,787</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Net loss per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11.44</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">19.08</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

-48165000

-55361000

4210839

2900787

11.44

19.08

2156406

247895

790441

715775

NOTE 15 – STOCK-BASED COMPENSATION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">a.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Global Share Incentive Plan</td></tr></table> The Company’s stockholders have approved the 2017 Equity Incentive Plan (the “2017 Plan”) under which, the Company had reserved a pool of <span id="xdx_904_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoZeroOneSevenEquityIncentivePlanMember_zLod8Uv5iqTg" title="Number of reserved shares for common stock">1,200,000 shares of the Company’s common stock, which may be issued at the discretion of the Company’s board of directors from time to time. Under this Plan, each option is exercisable into one share of common stock of the Company. The options may be exercised after vesting and in accordance with the vesting schedule that will be determined by the Company’s board of directors for each grant. The maximum contractual life term of the options is <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--PlanNameAxis__custom--TwoZeroOneSevenEquityIncentivePlanMember_zxqMxMfBMXV8" title="Contractual life term">10 years. As of December 31, 2024, total options available for grants under this plan are <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoZeroOneSevenEquityIncentivePlanMember_zVvSvHMUhYq9" title="Stock options available for grants">841,019. On May 23, 2012, the Company’s board of directors adopted the Global Share Incentive Plan 2012 (the “2012 Plan”) under which, the Company had reserved a pool of <span id="xdx_909_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20120523__us-gaap--PlanNameAxis__custom--GlobalShareIncentivePlanTwoZeroOneTwoMember_zXheZQKlxTW2" title="Number of reserved shares for common stock">100,000 shares of the Company’s common stock, which may be issued at the discretion of the Company’s board of directors from time to time. Under this plan, each option is exercisable into one share of common stock of the Company. The options may be exercised after vesting and in accordance with the vesting schedule that will be determined by the Company’s board of directors for each grant. The maximum contractual life term of the options is <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20120521__20120523__srt--RangeAxis__srt--MaximumMember__us-gaap--PlanNameAxis__custom--GlobalShareIncentivePlanTwoZeroOneTwoMember_zMhV7V9OjoS3" title="Contractual life term">10 years. As of December 31, 2024, total options available for grants under this plan are <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--GlobalShareIncentivePlanTwoZeroOneTwoMember_z41w5ot0hXk2" title="Stock options available for grants">76,982. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">b.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Options Granted to Employees and Directors</td></tr></table> <p id="xdx_891_eus-gaap--ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zs9zHYUIyK2c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Below is a table summarizing all of the options grants to employees and Directors made during the years ended December 31, 2024, and December 31, 2023: SCHEDULE OF EMPLOYEE STOCK OWNERSHIP PLAN DISCLOSURES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="vertical-align: top; padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Year Ended</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">No. of options granted</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Vesting period</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Fair value at grant (in thousands)</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Expiration period</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 14%; text-align: center">Employees</td><td style="width: 2%"> </td> <td style="vertical-align: top; width: 10%; text-align: center">December 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zcIVGdT6Kbd" style="width: 9%; text-align: right" title="No of options granted">61,100</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember__srt--RangeAxis__srt--MinimumMember_zPTzTn71Lmw1" title="Exercise price">5-$<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember__srt--RangeAxis__srt--MaximumMember_z3hrdWlgtCH7" title="Exercise price">6.4</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 22%; text-align: center"> 67% vested quarterly over a period of two years, with the remaining amount vested quarterly over <span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zq70iHnxCaM" title="Stock options vesting period description">four years.</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zMuq7w0Y3bHg" style="width: 9%; text-align: right" title="Fair value at grant">260</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="vertical-align: top; width: 9%; text-align: center"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_z2rplhnBJcO4" title="Expiration period">10 years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center">Directors</td><td> </td> <td style="vertical-align: top; text-align: center">December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z3yWsYeH65td" style="text-align: right" title="No. of options granted">76,522</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember__srt--RangeAxis__srt--MinimumMember_zpBn4fP9FEy8" title="Exercise price">0.98-$<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember__srt--RangeAxis__srt--MaximumMember_zdMVZGv9JXSa" title="Exercise price">10.3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> 4% annually over a period of three years, 84% vests immediately, and 12% vests <span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zxxOX7wHMU3j" title="Stock options vesting period description">on the one-year anniversary.</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z2RwOcgGLpZ" style="text-align: right" title="Fair value at grant">412</td><td style="text-align: left"> </td><td> </td> <td style="vertical-align: top; text-align: center"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zyHnmkX8N9P4" title="Expiration period">10 years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center">Employees</td><td> </td> <td style="vertical-align: top; text-align: center">December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zhLCdwd17R0b" style="text-align: right" title="No of options granted">31,800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember__srt--RangeAxis__srt--MinimumMember_zRcRN36U1fSk" title="Exercise price">4.5-$<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember__srt--RangeAxis__srt--MaximumMember_zUglNLuUQ7Af" title="Exercise price">13.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">51% Quarterly over a period of two years and the rest quarterly over a period of <span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zhV4eVONgVuj" title="Stock options vesting period description">four years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zVugHjUxEQ95" style="text-align: right" title="Fair value at grant">148</td><td style="text-align: left"> </td><td> </td> <td style="vertical-align: top; text-align: center"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_z8fTpV0uul48" title="Expiration period">10 years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center">Directors</td><td> </td> <td style="vertical-align: top; text-align: center">December 31,2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zigVmthQk0ah" style="text-align: right" title="No. of options granted">8,465</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zujUbD9cuEPe" style="text-align: right" title="Exercise price">4.5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zlfjCh1ei4l2" title="Stock options vesting period description">On the one-year anniversary</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zKXHsu0TtQQi" style="text-align: right" title="Fair value at grant">26</td><td style="text-align: left"> </td><td> </td> <td style="vertical-align: top; text-align: center"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zN7yVd239LZb" title="Expiration period">10 years</td></tr> </table> The fair value of each stock option grant is estimated at the date of grant using a Black Scholes option pricing model. The volatility is based on the historical volatility of the Company, by statistical analysis of the weekly share price for past periods based on expected term. The expected option term is calculated using the simplified method, as the Company concludes that its historical share option exercise experience does not provide a reasonable basis to estimate its expected option term. The fair value of each option grant is based on the following assumptions: <p id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_z6mn1gsALQQg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> SCHEDULE OF STOCK OPTIONS, VALUATION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Value of one common share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharePrice_iI_pid_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zAYgNchuFSJf" title="Value of one common share">0.98-$<span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_ze8XFSH9wyFd" title="Value of one common share">10.3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zlxkOF7DwNWf" title="Value of one common share">4.5-$<span id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_z0Tr8CUGmv9j" title="Value of one common share">13.6</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Dividend yield</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zCd56iCYCRUj" style="width: 16%; text-align: right" title="Dividend yield">0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zBMGWrnariF5" style="width: 16%; text-align: right" title="Dividend yield">0</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected stock price volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zEMYgzQxPjVd" title="Expected stock price volatility">79%-<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zsSn73rMZgDe" title="Expected stock price volatility">110</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zwoI8OnkxLj8" title="Expected stock price volatility">70%-<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zdd3MiHYKelc" title="Expected stock price volatility">80</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zH7QXKdgTxeg" title="Risk free interest rate">3.86%-<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zh9iGWnD54Fj" title="Risk free interest rate">4.49</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zUkY72NY8FGa" title="Risk free interest rate">3.9%-<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zJmXccJrE2df" title="Risk free interest rate">4.28</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zzPSg0wGnMBl" title="Expected term (years)">2.5-<span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zOjvf97BIMCk" title="Expected term (years)">6.06</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zhwsfM01gxO1" title="Expected term (years)">5.5-<span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zdFz9OLGTsff" title="Expected term (years)">6.06</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zKAQnuzXRrj3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">A summary of the Company’s stock options granted to employees and directors as of December 31, 2024 and December 31, 2023 is presented below: SCHEDULE OF STOCK OPTIONS ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price $</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price $</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Options outstanding at the beginning of the period</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zmrCCYtrDcwe" style="width: 10%; text-align: right" title="Number of Options - Options outstanding at the beginning of the year">302,727</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_z91fEeaHaxe3" style="width: 10%; text-align: right" title="Weighted Average Exercise Price - Options outstanding at the beginning of the year">38.9</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zeqv2k1J3gMf" style="width: 10%; text-align: right" title="Number of Options - Options outstanding at the beginning of the year">303,527</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zWgUrCcwoMzj" style="width: 10%; text-align: right" title="Weighted Average Exercise Price - Options outstanding at the beginning of the year">41.7</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Changes during the period:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zRM0JrCDxU1a" style="text-align: right" title="Number of Options - Granted">137,622</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zBJMtkKOYM5k" style="text-align: right" title="Weighted Average Exercise Price - Granted">6.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zmla8PCecxFg" style="text-align: right" title="Number of Options - Granted">40,265</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zfA504m5i1Tl" style="text-align: right" title="Weighted Average Exercise Price - Granted">6.4</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Exercised*</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_fKg_____z1kEmSdMk7U" style="text-align: right" title="Number of Options - Exercised">(25,519</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_fKg_____zu54gBSoGG03" style="text-align: right" title="Weighted Average Exercise Price - Exercised">0.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_fKg_____zNCUV17KTU9i" style="text-align: right" title="Number of Options - Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_fKg_____zrve0u5e089d" style="text-align: right" title="Weighted Average Exercise Price - Exercised">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zZss4ZbNVKL" style="text-align: right" title="Number of Options - Expired">(29,059</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zGSrlKDIqNIh" style="text-align: right" title="Weighted Average Exercise Price - Expired">36.72</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_z9lTU3FeNsSh" style="text-align: right" title="Number of Options - Expired">(17,884</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zzvAMvgGfVk7" style="text-align: right" title="Weighted Average Exercise Price - Expired">49.2</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zZ0ZI9Emacdc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options - Forfeited">(14,732</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zslIkKshsC88" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price - Forfeited">9.58</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zpzh29nv2Hp4" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options - Forfeited">(23,181</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zXQ9rd9Gqmr9" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price - Forfeited">10.4</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Options outstanding at end of the period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zq4Tet4fLAF2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options - Options outstanding at the end of the year">371,039</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zY3L2orim9Jj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options outstanding at the end of the yea">30.97</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zIeIZ34yKByh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options - Options outstanding at the end of the year">302,727</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zLoW6Z5TJH74" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options outstanding at the end of the yea">38.9</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Options exercisable at end of the period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zvQaRpWHiMA7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options - Options exercisable at end of the year">321,651</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zSjQp6L0UDBl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options exercisable at end of the year">35.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zFM7wwK9r9M2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options - Options exercisable at end of the year">274,038</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zAVk8xIWv5of" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options exercisable at end of the year">41.8</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td id="xdx_F08_za4qZTqL0tcb" style="width: 15pt; text-align: right">*</td><td style="text-align: justify">During the year ended December 31, 2024, the Company received $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTlMgQUNUSVZJVFkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_pn3n3_c20240101__20241231_zKVX7J5cXvn4" title="Share-based payment arrangement, after forfeiture">13 thousand from the exercise of employee options for the purchase of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTlMgQUNUSVZJVFkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross_pid_c20240101__20241231_zlJQUDtLDBdk" title="Grants in period">25,519 shares of the Company’s Common Stock at a weighted average price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTlMgQUNUSVZJVFkgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20241231_zte0lMvRhAbg" title="Weighted average exercise price">0.50.</td> </tr></table> <p id="xdx_891_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zOs5NNtmkdj1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following table presents summary information concerning the options granted and exercisable to employees and directors outstanding as of December 31, 2024 (in thousands, except per share data): SCHEDULE OF STOCK OPTIONS EXERCISABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Exercise Price $</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Outstanding Options</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Remaining Contractual Life</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Value $</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Exercisable Options</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Exercisable Options Value $</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">(in thousands)</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">(in thousands)</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zHrmrPIFmKye" style="width: 13%; text-align: right" title="Exercise Price">0.98</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zh0cRqHRfRlg" style="width: 13%; text-align: right" title="Number of Outstanding Options">7,585</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zEbs1vU4sNE2" style="width: 13%; text-align: right" title="Weighted Average Remaining Contractual Life">9.95</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zUYwhnKVTNq5" style="width: 13%; text-align: right" title="Aggregate Intrinsic Value">7</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z8YkknA6Wfeh" style="width: 13%; text-align: right" title="Number of Exercisable Options">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zIQni4UnITSd" style="width: 13%; text-align: right" title="Aggregate Exercisable Options Value">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zrJqqv3AXg7c" style="text-align: right" title="Exercise Price">4.5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_znTwBvH2ekTj" style="text-align: right" title="Number of Outstanding Options">9,161</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zH4j2EnP7Q22" style="text-align: right" title="Weighted Average Remaining Contractual Life">8.91</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zyKAJ3UXiF22" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z5ignWMTlmJb" style="text-align: right" title="Number of Exercisable Options">6,161</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zcGI6aMdwho" style="text-align: right" title="Aggregate Exercisable Options Value">28</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zCJIhrmqGZl9" style="text-align: right" title="Exercise Price">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z0c6te4sDCIc" style="text-align: right" title="Number of Outstanding Options">17,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zxfWyEbuF4zj" style="text-align: right" title="Weighted Average Remaining Contractual Life">8.01</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zjCQgS81NR8j" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z0NTYrqk8Jee" style="text-align: right" title="Number of Exercisable Options">8,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z0c7zV8unUsd" style="text-align: right" title="Aggregate Exercisable Options Value">44</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zYc1iUNsfBN2" style="text-align: right" title="Exercise Price">6.3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zCCBXjAkSNMa" style="text-align: right" title="Number of Outstanding Options">21,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z4TO90n7F59h" style="text-align: right" title="Weighted Average Remaining Contractual Life">9.52</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zN9c0uqSG4h7" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zb56NKCslPU9" style="text-align: right" title="Number of Exercisable Options">3,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zlhh5tZXjNa9" style="text-align: right" title="Aggregate Exercisable Options Value">24</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zJhh7NJ4ZJR6" style="text-align: right" title="Exercise Price">6.4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zU1IvLVWOl15" style="text-align: right" title="Number of Outstanding Options">50,684</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zBw1OoKOx0Bi" style="text-align: right" title="Weighted Average Remaining Contractual Life">9.42</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zGSaXF2rRLge" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zxKsomPIGSbg" style="text-align: right" title="Number of Exercisable Options">37,522</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zSyaulGcHUKb" style="text-align: right" title="Aggregate Exercisable Options Value">240</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zCrXoGq8XtXj" style="text-align: right" title="Exercise Price">6.5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_znRRZxgLXEY8" style="text-align: right" title="Number of Outstanding Options">625</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zbYGSPIN7SQ9" style="text-align: right" title="Weighted Average Remaining Contractual Life">9.52</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zywrQzKXmWjd" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zZhFmXnfYyP9" style="text-align: right" title="Number of Exercisable Options">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zBec7nOCMCl2" style="text-align: right" title="Aggregate Exercisable Options Value">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_z8vlySPHob8c" style="text-align: right" title="Exercise Price">10.3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_z6Jx1pdfarMh" style="text-align: right" title="Number of Outstanding Options">32,281</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_z3jqVmYkEE73" style="text-align: right" title="Weighted Average Remaining Contractual Life">9.56</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zSSS1xgrR5bl" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zMBYnSjTMNQ6" style="text-align: right" title="Number of Exercisable Options">32,281</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zDzXvNinFfOc" style="text-align: right" title="Aggregate Exercisable Options Value">332</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z46eXlCVk10l" style="text-align: right" title="Exercise Price">13.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z1khDAA9odZ4" style="text-align: right" title="Number of Outstanding Options">2,434</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zdu5Ok5coS82" style="text-align: right" title="Weighted Average Remaining Contractual Life">7.11</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zvzHaqU9Ty2d" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zRQTZzj514a2" style="text-align: right" title="Number of Exercisable Options">1,922</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z2SIlfQgmfvi" style="text-align: right" title="Aggregate Exercisable Options Value">26</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zd5TDIC52FB6" style="text-align: right" title="Exercise Price">18.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zSSTbV0aJBwk" style="text-align: right" title="Number of Outstanding Options">8,465</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zNRsXHI9o486" style="text-align: right" title="Weighted Average Remaining Contractual Life">3.22</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zputVKKBB1a2" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zM07p0c053p4" style="text-align: right" title="Number of Exercisable Options">8,465</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_z5HLUB2wWLV8" style="text-align: right" title="Aggregate Exercisable Options Value">157</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zA7pViL6Flk1" style="text-align: right" title="Exercise Price">20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zN4fXYRIt278" style="text-align: right" title="Number of Outstanding Options">27,653</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zurq3Zdk5cy6" style="text-align: right" title="Weighted Average Remaining Contractual Life">6.16</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zs24x3QEemIl" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zuWfGtlqo648" style="text-align: right" title="Number of Exercisable Options">29,400</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zJdplyz24tb" style="text-align: right" title="Aggregate Exercisable Options Value">588</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zcFlojDmtEM9" style="text-align: right" title="Exercise Price">20.1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z9rrxGQG1eD" style="text-align: right" title="Number of Outstanding Options">4,700</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zxzpohMOMovi" style="text-align: right" title="Weighted Average Remaining Contractual Life">4.25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_za8bWWVzTvL6" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z05jJZ4M7Yel" style="text-align: right" title="Number of Exercisable Options">4,700</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zDKbmSqFQ2e8" style="text-align: right" title="Aggregate Exercisable Options Value">94</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zNyRVQvf8Afk" style="text-align: right" title="Exercise Price">28.9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zz6l1cQ2LP5c" style="text-align: right" title="Number of Outstanding Options">8,465</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zXEWdRg90Fpc" style="text-align: right" title="Weighted Average Remaining Contractual Life">2.85</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zQF9YWVSj5O8" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zgDlLbyWnvMi" style="text-align: right" title="Number of Exercisable Options">8,465</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zhtaMPR9lSUl" style="text-align: right" title="Aggregate Exercisable Options Value">245</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z0hVjUvvMyQc" style="text-align: right" title="Exercise Price">29.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z1WO3FGgGDK8" style="text-align: right" title="Number of Outstanding Options">2,800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z3PY5Kq2ytS4" style="text-align: right" title="Weighted Average Remaining Contractual Life">6.08</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zjeAyfx2BM1d" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zphiuLWlFV5e" style="text-align: right" title="Number of Exercisable Options">2,800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z88aexbcZavl" style="text-align: right" title="Aggregate Exercisable Options Value">83</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zVnC2wjV9XUl" style="text-align: right" title="Exercise Price">29.9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zm8LFxionJmg" style="text-align: right" title="Number of Outstanding Options">34,945</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_z4Rv3BKQ4mZg" style="text-align: right" title="Weighted Average Remaining Contractual Life">4.07</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zmhQ4pXtWzzf" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zI2RbpLd9Dxh" style="text-align: right" title="Number of Exercisable Options">34,945</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zmHc2RWqLOzb" style="text-align: right" title="Aggregate Exercisable Options Value">1,045</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zxcD0l0hr6Vc" style="text-align: right" title="Exercise Price">31.4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zcrXQvSUEpC5" style="text-align: right" title="Number of Outstanding Options">250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zxyaaDRKt3ui" style="text-align: right" title="Weighted Average Remaining Contractual Life">4.90</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zK8U7dwwGhli" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zp4LarX3Qdm6" style="text-align: right" title="Number of Exercisable Options">250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_z9woUyAgVAAh" style="text-align: right" title="Aggregate Exercisable Options Value">8</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zAYSN4CillSl" style="text-align: right" title="Exercise Price">45</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zfb6Px1w2g2a" style="text-align: right" title="Number of Outstanding Options">2,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zXeZJHfpMuV9" style="text-align: right" title="Weighted Average Remaining Contractual Life">4.37</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_z4I4Gqm5ck57" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zAE79Yy8YfK8" style="text-align: right" title="Number of Exercisable Options">2,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_z3XtQHhDSjvh" style="text-align: right" title="Aggregate Exercisable Options Value">90</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zBxWipmKEDy5" style="text-align: right" title="Exercise Price">46</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_z2mrwn1BK0F6" style="text-align: right" title="Number of Outstanding Options">13,080</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_ziWOePNHo6L" style="text-align: right" title="Weighted Average Remaining Contractual Life">4.01</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zizUSvjF6WP6" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zsK2RWrsMtIh" style="text-align: right" title="Number of Exercisable Options">13,080</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zPgzGbVCVTy2" style="text-align: right" title="Aggregate Exercisable Options Value">602</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zhxnwhT7iwLc" style="text-align: right" title="Exercise Price">47</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zU0c5u7e0Fe4" style="text-align: right" title="Number of Outstanding Options">625</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zV1fFeHzlY79" style="text-align: right" title="Weighted Average Remaining Contractual Life">0.49</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_ztSTwZbwNC1l" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zVyFxQoP6tA9" style="text-align: right" title="Number of Exercisable Options">625</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zHEfmvHVainh" style="text-align: right" title="Aggregate Exercisable Options Value">29</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zA5djRyE9S9l" style="text-align: right" title="Exercise Price">48</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zfAxWqKIJ1y1" style="text-align: right" title="Number of Outstanding Options">46,662</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zdsA2DGeWWq2" style="text-align: right" title="Weighted Average Remaining Contractual Life">1.45</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zyt3ihBUwFOa" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zdG21QmbePol" style="text-align: right" title="Number of Exercisable Options">46,662</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zMa81T0PYOUi" style="text-align: right" title="Aggregate Exercisable Options Value">2,240</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_zV3bBmHp7TSg" style="text-align: right" title="Exercise Price">50.2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_zlzShZeZsJu3" style="text-align: right" title="Number of Outstanding Options">2,100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_zMAhcXFhaV17" style="text-align: right" title="Weighted Average Remaining Contractual Life">3.41</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_zX0u4f9f9IXi" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_zYjVJoMVoHw" style="text-align: right" title="Number of Exercisable Options">2,100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_zvXdm19Xn7Xl" style="text-align: right" title="Aggregate Exercisable Options Value">105</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyOneMember_zEahk6CyP6w2" style="text-align: right" title="Exercise Price">50.7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyOneMember_zBsHk5plQKIi" style="text-align: right" title="Number of Outstanding Options">4,950</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyOneMember_zcu50ZANngcg" style="text-align: right" title="Weighted Average Remaining Contractual Life">2.45</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyOneMember_zwXbJ9jTApwj" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyOneMember_zDSuChzPAgdk" style="text-align: right" title="Number of Exercisable Options">4,950</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyOneMember_zUP2MXIpGiga" style="text-align: right" title="Aggregate Exercisable Options Value">251</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyTwoMember_zLPed09ax8gi" style="text-align: right" title="Exercise Price">51</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyTwoMember_ziji0lfphsi7" style="text-align: right" title="Number of Outstanding Options">2,087</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyTwoMember_zPR6eejaHFh2" style="text-align: right" title="Weighted Average Remaining Contractual Life">5.17</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyTwoMember_zcvxaNupc9Wi" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyTwoMember_zZ7X8AzrGGyk" style="text-align: right" title="Number of Exercisable Options">2,087</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyTwoMember_zQVQZLdadt3e" style="text-align: right" title="Aggregate Exercisable Options Value">106</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyThreeMember_zwjMqfmdbDil" style="text-align: right" title="Exercise Price">51.2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyThreeMember_zsdPjoUyc0m4" style="text-align: right" title="Number of Outstanding Options">7,550</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyThreeMember_zmWagHqZDdOj" style="text-align: right" title="Weighted Average Remaining Contractual Life">5.11</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyThreeMember_zp6LPOGydcI7" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyThreeMember_zPzov0PwnG6b" style="text-align: right" title="Number of Exercisable Options">7,550</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyThreeMember_zJtGTsCorJRa" style="text-align: right" title="Aggregate Exercisable Options Value">387</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyFourMember_zlh8a4fizI94" style="text-align: right" title="Exercise Price">59.9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyFourMember_zO9xEKw0GTRe" style="text-align: right" title="Number of Outstanding Options">27,155</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyFourMember_zCSwPyasF0Xg" style="text-align: right" title="Weighted Average Remaining Contractual Life">3.02</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyFourMember_zBDaM6nAHbZd" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyFourMember_zHGfcsmalQz2" style="text-align: right" title="Number of Exercisable Options">27,154</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyFourMember_zoVHGb8XGH5d" style="text-align: right" title="Aggregate Exercisable Options Value">1,626</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyFiveMember_zGBzhPFoe9ff" style="text-align: right" title="Exercise Price">68.4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyFiveMember_zd4J5TkyvVEh" style="text-align: right" title="Number of Outstanding Options">1,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyFiveMember_zfPlXwZjnSXd" style="text-align: right" title="Weighted Average Remaining Contractual Life">5.38</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyFiveMember_zJdl0FQpOUDi" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyFiveMember_zwYOZ9e4btS" style="text-align: right" title="Number of Exercisable Options">1,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyFiveMember_zkw3xZ3Hgeac" style="text-align: right" title="Aggregate Exercisable Options Value">82</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentySixMember_zR2QS6nUA7w2" style="text-align: right" title="Exercise Price">72</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentySixMember_z3FBNUNEtzu3" style="text-align: right" title="Number of Outstanding Options">8,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentySixMember_ziMtDtvAA0Y9" style="text-align: right" title="Weighted Average Remaining Contractual Life">2.43</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentySixMember_zLilMdvyawF2" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentySixMember_zWJ54t9YCrji" style="text-align: right" title="Number of Exercisable Options">8,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentySixMember_zRLkVSGDwxNj" style="text-align: right" title="Aggregate Exercisable Options Value">600</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentySevenMember_z2ige66bcmq5" style="text-align: right" title="Exercise Price">83.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentySevenMember_zamq98fElqng" style="text-align: right" title="Number of Outstanding Options">24,999</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentySevenMember_z06Qu9WEVYT2" style="text-align: right" title="Weighted Average Remaining Contractual Life">3.49</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentySevenMember_zZrd3aX71Aud" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentySevenMember_zor0X1GHxKzi" style="text-align: right" title="Number of Exercisable Options">24,999</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentySevenMember_zW9coFFDKpxk" style="text-align: right" title="Aggregate Exercisable Options Value">2,090</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyEightMember_zntqB7u1hW4a" style="padding-bottom: 1pt; text-align: right" title="Exercise Price">89.1</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyEightMember_zCv5k5RRE6ei" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Outstanding Options">1,500</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyEightMember_zm8fdcd4O2c9" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Remaining Contractual Life">3.46</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyEightMember_zNt1vioxmPQk" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyEightMember_zpj3TMdnzXD" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Exercisable Options">1,500</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyEightMember_zw42QwkOWYEa" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Exercisable Options Value">134</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zENKooya1v59" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Outstanding Options">371,039</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zuNjNqvASG7l" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Remaining Contractual Life">5.69</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zFfkfKTH93O" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value">7</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zS73WKildZZ6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Exercisable Options">321,651</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zBb3bBKkaV7l" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Exercisable Options Value">11,256</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Costs incurred with respect to stock-based compensation for employees and directors for the years ended December 31, 2024 and December 31, 2023 were $ <span id="xdx_90C_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesAndDirectorsMember_zP9XeFX4Aqa1" title="Share based compensation">640 thousand and $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesAndDirectorsMember_z71ZyhS29Nkk" title="Share based compensation">485 thousand, respectively. As of December 31, 2024, there was $ <span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn3n3_c20241231__dei--LegalEntityAxis__custom--MasthercellGlobalMember_zHwpdwwiNyNi" title="Unrecognized compensation costs">177 thousand of unrecognized compensation costs related to non-vested employees and directors stock options, to be recorded over the next <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20240101__20241231__dei--LegalEntityAxis__custom--MasthercellGlobalMember_z1MfAiKSSFDc" title="Expiration period">3.5 years. <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in">c.</td> <td style="text-align: justify">Options Granted to Consultants and service providers</td></tr> </table> <p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zNcK2vQRwXtb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Below is a table summarizing all the compensation granted to consultants and service providers during the years ended December 31, 2024 and December 31, 2023: SCHEDULE OF STOCK OPTIONS GRANTED TO CONSULTANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Year of grant</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">No. of options granted</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Exercise price</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Vesting period</td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">Fair value at grant (in thousands)</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Expiration period</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 13%">Non-employees</td><td style="width: 2%"> </td> <td style="width: 13%; text-align: center">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zR9tdy5m3VTc" style="width: 11%; text-align: right" title="Number of options granted">1,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__srt--RangeAxis__srt--MinimumMember_z7LHiFls8rY3" title="Exercise price">6.7-$<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__srt--RangeAxis__srt--MaximumMember_znAciFOTeDX2" title="Exercise price">6.7</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 12%; text-align: center">Quarterly over a period of <span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriodDescription_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zBGNeFvWRNj3" title="Vesting peirod description">two years</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zvZ1tI9rUYx2" style="width: 10%; text-align: right" title="Fair value at grant">9</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="text-align: right; width: 12%"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z9I2FnTlAxf6" title="Expiration period">10 years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Non-employees</td><td> </td> <td style="text-align: center">2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zaVBLmSQVeUe" style="text-align: right" title="Number of options granted">833</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zVQgoQXdCxUg" style="text-align: right" title="Exercise price">13.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">Annually over a period of <span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriodDescription_dtY_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zsZnZ1GIDtF5" title="Vesting peirod description">five years</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zsYZVpmd5rIi" style="text-align: right" title="Fair value at grant">9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zh4c6k1PAqH5" title="Expiration period">10 years</td></tr> </table> The fair value of options granted during 2024 and 2023 to consultants and service providers, was computed using the Black-Scholes model. The fair value of each stock option grant is estimated at the date of grant using a Black Scholes option pricing model. The volatility is based on the historical volatility of the Company, by statistical analysis of the weekly share price for past periods based on the expected term period, the expected term is the contractual term of each grant. The underlying data used for computing the fair value of the options are as follows: <p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zltf98yyNEO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">SCHEDULE OF STOCK OPTIONS, VALUATION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Value of one common share</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_903_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zVkeZUJPJ6G6" title="Value of one common share">6.7</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zC2p1CmYPiHd" title="Value of one common share">13.6</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zSrAHgo7qAhf" style="text-align: right" title="Dividend yield">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zomkpPTiecPc" style="text-align: right" title="Dividend yield">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected stock price volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zy9FJGYKkhD" title="Expected stock price volatility">87</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zahKrLGPEtd9" title="Expected stock price volatility">80</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zY0R1OlUt1d4" title="Risk free interest rate">3.71%-<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z3K6N4pfFyh5" title="Risk free interest rate">3.76</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zLt6e28ZMdRj" title="Risk free interest rate">4.07</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z57XNHAamJTd" title="Expected term (years)">10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zKhzEH1Hir0f" title="Expected term (years)">10</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zHXFoc41Ruuk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">A summary of the Company’s stock options granted to consultants and service providers as of December 31, 2024, and December 31, 2023 is presented below: SCHEDULE OF STOCK OPTIONS ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Options </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price $ </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price $ </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">Options outstanding at the beginning of the year</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zgdNpeU9aJy2" style="width: 10%; text-align: right" title="Number of Options - Options outstanding at the beginning of the year">26,703</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z8LVQcJeGoZf" style="width: 10%; text-align: right" title="Weighted Average Exercise Price - Options outstanding at the beginning of the year">50.7</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zHzJls1yOAd2" style="width: 10%; text-align: right" title="Number of Options - Options outstanding at the beginning of the year">51,714</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zawz4IPKRj6c" style="width: 10%; text-align: right" title="Weighted Average Exercise Price - Options outstanding at the beginning of the year">48.8</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Changes during the year:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zir9qYxlwgd4" style="text-align: right" title="Number of Options - Granted">1,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z03L0sr313Ka" style="text-align: right" title="Weighted Average Exercise Price - Granted">6.7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zdF8ZGZPdYyc" style="text-align: right" title="Number of Options - Granted">833</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z8ZWjuxo5XM6" style="text-align: right" title="Weighted Average Exercise Price - Granted">13.6</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zBxqF6lBwuF1" style="text-align: right" title="Number of Options - Expired">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zyYNIpvxwWGa" style="text-align: right" title="Weighted Average Exercise Price - Expired">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zjC0MIJYlrw9" style="text-align: right" title="Number of Options - Expired">(2,333</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zeR8d9ebcNm5" style="text-align: right" title="Weighted Average Exercise Price - Expired">60.4</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z08LZpc1lEL6" style="text-align: right" title="Number of Options - Forfeited">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z3dJA0mFN21c" style="text-align: right" title="Weighted Average Exercise Price - Forfeited">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zl1Z6lwCPWQ4" style="text-align: right" title="Number of Options - Forfeited">(23,511</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zlFO9ZxdKbZ8" style="text-align: right" title="Weighted Average Exercise Price - Forfeited">44.2</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1pt">Cancelled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_iN_pid_di_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zoDS71iHkLya" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options - Cancelled">(1,500</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z0pGjbf78kO6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price - Cancelled">53.00</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_iN_pid_di_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_ziJ0xfjC5lTk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options - Cancelled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z25cSAYUUvcg" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price - Cancelled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Options outstanding at end of the year</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z3Z6CqMzy6jk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options - Options outstanding at the end of the year">26,703</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zLPRhfm38sNe" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options outstanding at the end of the yea">48.13</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zQJF8kw0jjy7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options - Options outstanding at the end of the year">26,703</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zhyuEalg2hs8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options outstanding at the end of the yea">50.7</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Options exercisable at end of the year</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zFuDUPRxtnUg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options - Options exercisable at end of the year">22,104</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zRfWK03ZenR5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options exercisable at end of the year">51.70</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zSCFf92t8T5b" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options - Options exercisable at end of the year">20,606</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zcpYtGgDmhEe" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options exercisable at end of the year">57.1</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_898_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zDs6ETrBVYw6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">The following table presents summary information concerning the options granted and exercisable to consultants and service providers outstanding as of December 31, 2024 (in thousands, except per share data): SCHEDULE OF STOCK OPTIONS EXERCISABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Exercise Price $</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Outstanding Options</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Remaining Contractual Life</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Value $</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Exercisable Options</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Exercisable Options Value $</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">(in thousands)</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">(in thousands)</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_znCdglwF0fK8" style="width: 13%; text-align: right" title="Exercise Price">6.7</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z1uCzhu7lVT2" style="width: 13%; text-align: right" title="Number of Outstanding Options">1,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z8fCQ1kiR1da" style="width: 13%; text-align: right" title="Weighted Average Remaining Contractual Life">9.68</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z6X8EAv7PiC1" style="width: 13%; text-align: right" title="Aggregate Intrinsic Value">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zOdIJz06fag4" style="width: 13%; text-align: right" title="Number of Exercisable Options">1,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zZs3E0fVdtN7" style="width: 13%; text-align: right" title="Aggregate Exercisable Options Value">7</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zaTvQQXspzf5" style="text-align: right" title="Exercise Price">13.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zAPyC12kVaHk" style="text-align: right" title="Number of Outstanding Options">833</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zBEWxZFy7JSk" style="text-align: right" title="Weighted Average Remaining Contractual Life">8.44</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zshpTGUx8jtc" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zklKMJBYKVk6" style="text-align: right" title="Number of Exercisable Options">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zn9gho8VN2Yd" style="text-align: right" title="Aggregate Exercisable Options Value">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zIkpHqhu6RN1" style="text-align: right" title="Exercise Price">20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z6l5Jpubr3eb" style="text-align: right" title="Number of Outstanding Options">2,833</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z6aRRz8MaEpi" style="text-align: right" title="Weighted Average Remaining Contractual Life">7.46</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zVvzGgLZzGgb" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z2TnJbcz29L6" style="text-align: right" title="Number of Exercisable Options">2,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zlUwD5l4Tnqd" style="text-align: right" title="Aggregate Exercisable Options Value">40</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z9dy7DCwNN3l" style="text-align: right" title="Exercise Price">29.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zmU0pbyjlZ12" style="text-align: right" title="Number of Outstanding Options">750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zcw8CO9vYbOf" style="text-align: right" title="Weighted Average Remaining Contractual Life">6.96</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zCpsFa9iap16" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zvfuFiLvDxKe" style="text-align: right" title="Number of Exercisable Options">750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zN5o6ZmV8w39" style="text-align: right" title="Aggregate Exercisable Options Value">22</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zN5edpg3MOOh" style="text-align: right" title="Exercise Price">29.9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z3VOQTwo91na" style="text-align: right" title="Number of Outstanding Options">2,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zvu6VbJI36Ef" style="text-align: right" title="Weighted Average Remaining Contractual Life">5.22</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zK3m5U2gHiM" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zlluHuHZ5Kjl" style="text-align: right" title="Number of Exercisable Options">2,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zwa3zjmxxeya" style="text-align: right" title="Aggregate Exercisable Options Value">60</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zHptSYgHVGme" style="text-align: right" title="Exercise Price">40.9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zSe5JZUmBil5" style="text-align: right" title="Number of Outstanding Options">2,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zWuVTh7WAJm2" style="text-align: right" title="Weighted Average Remaining Contractual Life">4.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zZj8AuDNpy2j" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zQP4NaZRvOo3" style="text-align: right" title="Number of Exercisable Options">2,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zJoPC6A6VtMb" style="text-align: right" title="Aggregate Exercisable Options Value">102</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zCxPIOvIzzie" style="text-align: right" title="Exercise Price">44.2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zXwHHvhhnZAd" style="text-align: right" title="Number of Outstanding Options">512</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zdF6HZDTzI7j" style="text-align: right" title="Weighted Average Remaining Contractual Life">2.93</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zkpYCyiXSeD3" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zzmAs8mnKUll" style="text-align: right" title="Number of Exercisable Options">512</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zWMtPYkErsGe" style="text-align: right" title="Aggregate Exercisable Options Value">23</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z6cYRHB36QQe" style="text-align: right" title="Exercise Price">45</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zNC4dGeXbmti" style="text-align: right" title="Number of Outstanding Options">1,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zDdwDcW3hyef" style="text-align: right" title="Weighted Average Remaining Contractual Life">4.53</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zKv6VtUHXK6h" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z0oroYOT3kXi" style="text-align: right" title="Number of Exercisable Options">500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_znluuLABjfp6" style="text-align: right" title="Aggregate Exercisable Options Value">23</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_z6GXIxGmCssk" style="text-align: right" title="Exercise Price">46</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_z1fZsGps5SH4" style="text-align: right" title="Number of Outstanding Options">2,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zEDGO0b3kOMb" style="text-align: right" title="Weighted Average Remaining Contractual Life">5.96</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zMo4hD3GJQD9" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zwILrnPxtzvf" style="text-align: right" title="Number of Exercisable Options">400</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zJhk5vMmvKYb" style="text-align: right" title="Aggregate Exercisable Options Value">18</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z33uYt5inWn" style="text-align: right" title="Exercise Price">48</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zpVmB4ytn1Z" style="text-align: right" title="Number of Outstanding Options">833</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z4JrMYnhfl9l" style="text-align: right" title="Weighted Average Remaining Contractual Life">1.94</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z007anisd59e" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zGzGKJT43SBd" style="text-align: right" title="Number of Exercisable Options">833</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zgViOJBb1YS1" style="text-align: right" title="Aggregate Exercisable Options Value">40</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zJ0UprJWXghe" style="text-align: right" title="Exercise Price">50.7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zEo1uvSEXlBa" style="text-align: right" title="Number of Outstanding Options">500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z0f7jyGryIZd" style="text-align: right" title="Weighted Average Remaining Contractual Life">4.19</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zT8YmFvpXmUc" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z3WQRo6g21Tk" style="text-align: right" title="Number of Exercisable Options">500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zrhbip85STs8" style="text-align: right" title="Aggregate Exercisable Options Value">25</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_z6zmXl9u9Pb2" style="text-align: right" title="Exercise Price">59.9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zWXmTn1KptO2" style="text-align: right" title="Number of Outstanding Options">1,666</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zNRYTm43Tawe" style="text-align: right" title="Weighted Average Remaining Contractual Life">3.81</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zuf9njhmq3Nk" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zOmjyE0ZWNel" style="text-align: right" title="Number of Exercisable Options">1,666</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_ztTCHKommUlk" style="text-align: right" title="Aggregate Exercisable Options Value">100</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zRN6Vl1CrW09" style="text-align: right" title="Exercise Price">68.4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z9l9RUrnctL2" style="text-align: right" title="Number of Outstanding Options">750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zizQcuqJInO8" style="text-align: right" title="Weighted Average Remaining Contractual Life">5.38</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zLOXe4TiRAn7" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zjZfELCubqcg" style="text-align: right" title="Number of Exercisable Options">750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zR5OrVKax7Gh" style="text-align: right" title="Aggregate Exercisable Options Value">51</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zd61N1C49Apb" style="text-align: right" title="Exercise Price">70</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zVW8ghHp8P0h" style="text-align: right" title="Number of Outstanding Options">7,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zV1G0YhTeV27" style="text-align: right" title="Weighted Average Remaining Contractual Life">4.83</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zHi9oKlq74J" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zyFof0GUwOXh" style="text-align: right" title="Number of Exercisable Options">7,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zWPp3Vgrepg1" style="text-align: right" title="Aggregate Exercisable Options Value">490</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zcCB0JZLl10k" style="text-align: right" title="Exercise Price">83.4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zMZk6paIRCli" style="text-align: right" title="Number of Outstanding Options">860</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zgzTwKq3z1u8" style="text-align: right" title="Weighted Average Remaining Contractual Life">3.52</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zEN4MZ1Fbtbl" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zs5HqXIJM28i" style="text-align: right" title="Number of Exercisable Options">860</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zXFPaZoWBR45" style="text-align: right" title="Aggregate Exercisable Options Value">72</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zmNMOJilZb9d" style="padding-bottom: 1pt; text-align: right" title="Exercise Price">84.3</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zmLb7B8r8Ovd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Outstanding Options">833</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zHdw1vemiK48" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Remaining Contractual Life">3.04</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zDKgF8fx6YV9" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zSigO8mVqgbk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Exercisable Options">833</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zgLMHfw1nY59" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Exercisable Options Value">70</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zA1x44e4tJ44" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Outstanding Options">26,703</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_ztLPNvV0cSZd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Remaining Contractual Life">5.36</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zAMVzOw8hFV8" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zmEEuDFktJA4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Exercisable Options">22,104</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zvrF0vTPRoFd" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Exercisable Options Value">1,143</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Costs incurred with respect to options granted to consultants and service providers for the years ended December 31, 2024 and December 31, 2023 were $ <span id="xdx_907_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zfiDIUyERwu2" title="Stock-based compensation">41 and $<span id="xdx_901_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z4bbATQ3S19k" title="Stock-based compensation">63, respectively. As of December 31, 2024, there was $ <span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zuYjBnjsY9fb" title="Unrecognized compensation costs">17 of unrecognized compensation costs related to non-vested consultants and service providers, to be recorded over the next <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zcVKXFVlZFBb" title="Expiration period">3.07 years. <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in">d.</td> <td style="text-align: justify">Restricted Stock Units (“RSUs”) Granted to Employees</td></tr> </table> <p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdrxulUZOzp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Below is a table summarizing all the RSUs grants to employees and made during the years ended December 31, 2024: SCHEDULE OF STOCK OPTIONS GRANTED TO EMPLOYEES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">No. of options granted</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Vesting period</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Fair value at grant (in thousands)</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 18%; text-align: center">Employees</td><td style="width: 3%"> </td> <td style="width: 18%; text-align: center">December 31, 2024</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zR4sxZaqaCxd" style="width: 16%; text-align: right" title="Number of options granted">8,250</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 17%; text-align: center">Quarterly over a period of <span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriodDescription_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkC4SpyUTCma" title="Vesting period description">two years</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfEwyHsFvmGi" style="width: 15%; text-align: right" title="Fair value at grant">44</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">Employees</td><td> </td> <td style="text-align: center">December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zwNXPHI3clud" style="text-align: right" title="Number of options granted">14,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">Quarterly over a period of <span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriodDescription_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zApSi19Bqihk" title="Vesting period description">two years</td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDTGMseKlxyj" style="text-align: right" title="Fair value at grant">50</td><td style="text-align: left"> </td></tr> </table> The fair value of each RSUs grant is estimated based on the market value of the underlying stock at the date of grant. A summary of the Company’s RSUs granted to employees as of December 31, 2024 is presented below: SCHEDULE OF STOCK OPTIONS ACTIVITY GRANTED TO EMPLOYEES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of RSUs</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of RSUs</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Options outstanding at the beginning of the period</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrgdGEOKmZl2" style="width: 16%; text-align: right" title="Number of RSUs - Options outstanding at the beginning of the year">14,200</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zyaeWVrp54zg" style="width: 16%; text-align: right" title="Number of RSUs - Options outstanding at the beginning of the year">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Changes during the period:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zL5G6qmuCtY2" style="text-align: right" title="Number of RSUs - Granted">8,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ziXnWp41ZfL7" style="text-align: right" title="Number of RSUs - Granted">14,200</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRAINBMBAjVl" style="text-align: right" title="Number of RSUs - Expired">(12,410</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCskZAmRCdE9" style="text-align: right" title="Number of RSUs - Expired">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBzfpsFyxLj" style="border-bottom: Black 1pt solid; text-align: right" title="Number of RSUs - Forfeited">(1,306</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzr9wnRhhk72" style="border-bottom: Black 1pt solid; text-align: right" title="Number of RSUs - Forfeited">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Options outstanding at end of the period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zWnRZ4ekjbN9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of RSUs - Options outstanding at the end of the year">8,734</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zcqoOIBME0T" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of RSUs - Options outstanding at the end of the year">14,200</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_894_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJTFm9GRoeFk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following table presents summary information concerning the options granted and exercisable to employees and directors outstanding as of December 31, 2024 (in thousands, except per share data): SCHEDULE OF STOCK OPTIONS EXERCISABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">year</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Outstanding RSUs</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Remaining Contractual Life</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Value $</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td colspan="2" style="text-align: center">(in thousands)</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 22%; text-align: right">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdf07hnA94Sk" style="width: 22%; text-align: right" title="Number of Outstanding Options">2,434</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQ5EokymPVM1" style="width: 22%; text-align: right" title="Weighted Average Remaining Contractual Life">9.56</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1kl05csZvxh" style="width: 22%; text-align: right" title="Aggregate Intrinsic Value">5</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right">2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7CiKiPlYZJg" style="text-align: right" title="Number of Outstanding Options">6,300</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBXM2fX3hzYa" style="text-align: right" title="Weighted Average Remaining Contractual Life">8.99</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zD1TGLjuxWzj" style="text-align: right" title="Aggregate Intrinsic Value">12</td><td style="text-align: left"> </td></tr> </table> Costs incurred with respect to RSUs compensation for employees for the years ended December 31, 2024 and December 31, 2023 were $46 and $0. As of December 31, 2024, there was $36 of unrecognized compensation costs related to non-vested employees RSUs, to be recorded over the next <span id="xdx_901_ecustom--EmployeeServiceSharebasedCompensationNonvestedTotalCompensationCostNotYetRecognizedAndPeriodForRecognitionInYears_dtY_c20240101__20241231_zt4R3KbX44mg" title="RSUs, to be recorded term">1.39 years. e. Shares and warrants issued to advisors. Below is a table summarizing the shares and warrants grants to advisers during the period from January 1, 2024 to December 31, 2024: SCHEDULE OF SHARES AND WARRANTS GRANTS TO ADVISORS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Date of issue of share or warrant</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Reason for issue of share or warrant</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Consideration</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise price of warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrant vesting (subject to continued service provided to Company)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrant expiry date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 13%; text-align: justify; padding-bottom: 1pt">March 7, 2024</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="width: 13%; text-align: justify; padding-bottom: 1pt">Strategic advisor agreement</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="width: 20%; text-align: justify; padding-bottom: 1pt">50,000 shares of Common Stock and warrants to purchase 50,000 shares of Common Stock</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; width: 1%; text-align: left">$</td><td style="padding-bottom: 1pt; width: 10%; text-align: right">10.3</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="width: 20%; text-align: justify; padding-bottom: 1pt">One third on March 7, 2024, one third on June 5, 2024, and one third on September 3, 2024.</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="width: 12%; text-align: justify; padding-bottom: 1pt">March 6, 2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">April 18, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">Strategic advisor agreement</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">Warrants to purchase 50,000 shares of Common Stock</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right">10.3</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">One third on April 18, 2024, one third on July 18, 2024, and one third on October 18, 2024.</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">April 17, 2029</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">April 23, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">Strategic advisor agreement</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">Warrants to purchase 50,000 shares of Common Stock</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right">10.3</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">One third on April 16, 2024, one third on July 16, 2024, and one third on October 16, 2024.</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">April 22, 2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">May 22, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">Strategic advisor agreement</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">Warrants to purchase 47,500 shares of Common Stock</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right">10.3</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">One third on May 21, 2024, one third on August 21, 2024, and one third on November 21, 2024.</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">May 21, 2029</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">July 14, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">Strategic advisor agreement</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">Warrants to purchase 20,000 shares of Common Stock</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right">10.3</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">One third on July 14, 2024, one third on October 14, 2024, and one third on January 14, 2024.</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">July 13, 2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">September 5, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">Strategic advisor agreement</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">50,000 shares of Common</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right">10.3</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: justify">No. of Warrants Granted</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Vesting Period</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: justify">Fair Value at Grant (in thousands)</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: justify">Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYeThSqDJdmh" style="width: 14%; text-align: right" title="Number of options granted">217,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 14%; text-align: justify"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYIVAGhGVa15" title="Restricted stock unit vesting period description">Over a period of nine months</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqRAoRSo7wZ" style="width: 14%; text-align: right" title="Fair value at grant">646</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Shares</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231_zZFYz5NVUzGc" style="text-align: right" title="Number of shares granted">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: justify">N/A</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20240101__20241231_zdZPauFGzO12" style="text-align: right" title="Fair value at grant">350</td><td style="text-align: left"> </td></tr> </table> The fair valuation of these shares grants is based on the market value of the share at the date of grant. The fair valuation of these warrants grants is based on the following assumptions: SCHEDULE OF WARRANTS GRANTS ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the period ended December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Value of one common share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5.1-$8.4</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 80%; text-align: justify">Dividend yield</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zktrYHheBlyb" style="width: 16%; text-align: right" title="Dividend yield">0</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected stock price volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zMYKfZM5HbS6" title="Expected stock price volatility">87%-<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_za8o6qJPyil1" title="Expected stock price volatility">91</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zeGMPCNp0ey1" title="Risk free interest rate">4.07%-<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zlY1ieIY5LZ" title="Risk free interest rate">4.68</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zy3YqulKhMzi" title="Expected term (years)">5</td><td style="text-align: left"> </td></tr> </table>

1200000

P10Y

841019

100000

P10Y

76982

<p id="xdx_891_eus-gaap--ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zs9zHYUIyK2c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Below is a table summarizing all of the options grants to employees and Directors made during the years ended December 31, 2024, and December 31, 2023: SCHEDULE OF EMPLOYEE STOCK OWNERSHIP PLAN DISCLOSURES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="vertical-align: top; padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Year Ended</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">No. of options granted</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Vesting period</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Fair value at grant (in thousands)</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Expiration period</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 14%; text-align: center">Employees</td><td style="width: 2%"> </td> <td style="vertical-align: top; width: 10%; text-align: center">December 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zcIVGdT6Kbd" style="width: 9%; text-align: right" title="No of options granted">61,100</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember__srt--RangeAxis__srt--MinimumMember_zPTzTn71Lmw1" title="Exercise price">5-$<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember__srt--RangeAxis__srt--MaximumMember_z3hrdWlgtCH7" title="Exercise price">6.4</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 22%; text-align: center"> 67% vested quarterly over a period of two years, with the remaining amount vested quarterly over <span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zq70iHnxCaM" title="Stock options vesting period description">four years.</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zMuq7w0Y3bHg" style="width: 9%; text-align: right" title="Fair value at grant">260</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="vertical-align: top; width: 9%; text-align: center"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_z2rplhnBJcO4" title="Expiration period">10 years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center">Directors</td><td> </td> <td style="vertical-align: top; text-align: center">December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z3yWsYeH65td" style="text-align: right" title="No. of options granted">76,522</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember__srt--RangeAxis__srt--MinimumMember_zpBn4fP9FEy8" title="Exercise price">0.98-$<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember__srt--RangeAxis__srt--MaximumMember_zdMVZGv9JXSa" title="Exercise price">10.3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> 4% annually over a period of three years, 84% vests immediately, and 12% vests <span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zxxOX7wHMU3j" title="Stock options vesting period description">on the one-year anniversary.</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z2RwOcgGLpZ" style="text-align: right" title="Fair value at grant">412</td><td style="text-align: left"> </td><td> </td> <td style="vertical-align: top; text-align: center"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zyHnmkX8N9P4" title="Expiration period">10 years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center">Employees</td><td> </td> <td style="vertical-align: top; text-align: center">December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zhLCdwd17R0b" style="text-align: right" title="No of options granted">31,800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember__srt--RangeAxis__srt--MinimumMember_zRcRN36U1fSk" title="Exercise price">4.5-$<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember__srt--RangeAxis__srt--MaximumMember_zUglNLuUQ7Af" title="Exercise price">13.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">51% Quarterly over a period of two years and the rest quarterly over a period of <span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zhV4eVONgVuj" title="Stock options vesting period description">four years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zVugHjUxEQ95" style="text-align: right" title="Fair value at grant">148</td><td style="text-align: left"> </td><td> </td> <td style="vertical-align: top; text-align: center"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_z8fTpV0uul48" title="Expiration period">10 years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center">Directors</td><td> </td> <td style="vertical-align: top; text-align: center">December 31,2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zigVmthQk0ah" style="text-align: right" title="No. of options granted">8,465</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zujUbD9cuEPe" style="text-align: right" title="Exercise price">4.5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1Description_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zlfjCh1ei4l2" title="Stock options vesting period description">On the one-year anniversary</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zKXHsu0TtQQi" style="text-align: right" title="Fair value at grant">26</td><td style="text-align: left"> </td><td> </td> <td style="vertical-align: top; text-align: center"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zN7yVd239LZb" title="Expiration period">10 years</td></tr> </table>

61100

6.4

four years 260000 P10Y

76522

0.98

10.3

on the one-year anniversary 412000 P10Y

31800

4.5

13.6

four years 148000 P10Y

8465

4.5

On the one-year anniversary 26000 P10Y

<p id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_z6mn1gsALQQg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> SCHEDULE OF STOCK OPTIONS, VALUATION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Value of one common share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharePrice_iI_pid_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zAYgNchuFSJf" title="Value of one common share">0.98-$<span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_ze8XFSH9wyFd" title="Value of one common share">10.3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zlxkOF7DwNWf" title="Value of one common share">4.5-$<span id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_z0Tr8CUGmv9j" title="Value of one common share">13.6</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Dividend yield</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zCd56iCYCRUj" style="width: 16%; text-align: right" title="Dividend yield">0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zBMGWrnariF5" style="width: 16%; text-align: right" title="Dividend yield">0</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected stock price volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zEMYgzQxPjVd" title="Expected stock price volatility">79%-<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zsSn73rMZgDe" title="Expected stock price volatility">110</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zwoI8OnkxLj8" title="Expected stock price volatility">70%-<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zdd3MiHYKelc" title="Expected stock price volatility">80</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zH7QXKdgTxeg" title="Risk free interest rate">3.86%-<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zh9iGWnD54Fj" title="Risk free interest rate">4.49</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zUkY72NY8FGa" title="Risk free interest rate">3.9%-<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zJmXccJrE2df" title="Risk free interest rate">4.28</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zzPSg0wGnMBl" title="Expected term (years)">2.5-<span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zOjvf97BIMCk" title="Expected term (years)">6.06</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zhwsfM01gxO1" title="Expected term (years)">5.5-<span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zdFz9OLGTsff" title="Expected term (years)">6.06</td><td style="text-align: left"> </td></tr> </table>

0.98

10.3

4.5

13.6

0.79

1.10

0.70

0.80

0.0386

0.0449

0.039

0.0428

P2Y6M

P6Y21D

P5Y6M

P6Y21D

<p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zKAQnuzXRrj3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">A summary of the Company’s stock options granted to employees and directors as of December 31, 2024 and December 31, 2023 is presented below: SCHEDULE OF STOCK OPTIONS ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price $</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price $</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Options outstanding at the beginning of the period</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zmrCCYtrDcwe" style="width: 10%; text-align: right" title="Number of Options - Options outstanding at the beginning of the year">302,727</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_z91fEeaHaxe3" style="width: 10%; text-align: right" title="Weighted Average Exercise Price - Options outstanding at the beginning of the year">38.9</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zeqv2k1J3gMf" style="width: 10%; text-align: right" title="Number of Options - Options outstanding at the beginning of the year">303,527</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zWgUrCcwoMzj" style="width: 10%; text-align: right" title="Weighted Average Exercise Price - Options outstanding at the beginning of the year">41.7</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Changes during the period:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zRM0JrCDxU1a" style="text-align: right" title="Number of Options - Granted">137,622</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zBJMtkKOYM5k" style="text-align: right" title="Weighted Average Exercise Price - Granted">6.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zmla8PCecxFg" style="text-align: right" title="Number of Options - Granted">40,265</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zfA504m5i1Tl" style="text-align: right" title="Weighted Average Exercise Price - Granted">6.4</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Exercised*</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_fKg_____z1kEmSdMk7U" style="text-align: right" title="Number of Options - Exercised">(25,519</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_fKg_____zu54gBSoGG03" style="text-align: right" title="Weighted Average Exercise Price - Exercised">0.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_fKg_____zNCUV17KTU9i" style="text-align: right" title="Number of Options - Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_fKg_____zrve0u5e089d" style="text-align: right" title="Weighted Average Exercise Price - Exercised">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zZss4ZbNVKL" style="text-align: right" title="Number of Options - Expired">(29,059</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zGSrlKDIqNIh" style="text-align: right" title="Weighted Average Exercise Price - Expired">36.72</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_z9lTU3FeNsSh" style="text-align: right" title="Number of Options - Expired">(17,884</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zzvAMvgGfVk7" style="text-align: right" title="Weighted Average Exercise Price - Expired">49.2</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zZ0ZI9Emacdc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options - Forfeited">(14,732</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zslIkKshsC88" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price - Forfeited">9.58</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zpzh29nv2Hp4" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options - Forfeited">(23,181</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zXQ9rd9Gqmr9" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price - Forfeited">10.4</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Options outstanding at end of the period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zq4Tet4fLAF2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options - Options outstanding at the end of the year">371,039</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zY3L2orim9Jj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options outstanding at the end of the yea">30.97</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zIeIZ34yKByh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options - Options outstanding at the end of the year">302,727</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zLoW6Z5TJH74" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options outstanding at the end of the yea">38.9</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Options exercisable at end of the period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zvQaRpWHiMA7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options - Options exercisable at end of the year">321,651</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zSjQp6L0UDBl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options exercisable at end of the year">35.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zFM7wwK9r9M2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options - Options exercisable at end of the year">274,038</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zAVk8xIWv5of" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options exercisable at end of the year">41.8</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

302727

38.9

303527

41.7

137622

6.75

40265

6.4

25519

0.50

29059

36.72

17884

49.2

14732

9.58

23181

10.4

371039

30.97

302727

38.9

321651

35.00

274038

41.8

13000

25519

0.50

<p id="xdx_891_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zOs5NNtmkdj1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following table presents summary information concerning the options granted and exercisable to employees and directors outstanding as of December 31, 2024 (in thousands, except per share data): SCHEDULE OF STOCK OPTIONS EXERCISABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Exercise Price $</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Outstanding Options</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Remaining Contractual Life</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Value $</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Exercisable Options</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Exercisable Options Value $</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">(in thousands)</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">(in thousands)</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zHrmrPIFmKye" style="width: 13%; text-align: right" title="Exercise Price">0.98</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zh0cRqHRfRlg" style="width: 13%; text-align: right" title="Number of Outstanding Options">7,585</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zEbs1vU4sNE2" style="width: 13%; text-align: right" title="Weighted Average Remaining Contractual Life">9.95</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zUYwhnKVTNq5" style="width: 13%; text-align: right" title="Aggregate Intrinsic Value">7</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z8YkknA6Wfeh" style="width: 13%; text-align: right" title="Number of Exercisable Options">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zIQni4UnITSd" style="width: 13%; text-align: right" title="Aggregate Exercisable Options Value">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zrJqqv3AXg7c" style="text-align: right" title="Exercise Price">4.5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_znTwBvH2ekTj" style="text-align: right" title="Number of Outstanding Options">9,161</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zH4j2EnP7Q22" style="text-align: right" title="Weighted Average Remaining Contractual Life">8.91</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zyKAJ3UXiF22" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z5ignWMTlmJb" style="text-align: right" title="Number of Exercisable Options">6,161</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zcGI6aMdwho" style="text-align: right" title="Aggregate Exercisable Options Value">28</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zCJIhrmqGZl9" style="text-align: right" title="Exercise Price">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z0c6te4sDCIc" style="text-align: right" title="Number of Outstanding Options">17,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zxfWyEbuF4zj" style="text-align: right" title="Weighted Average Remaining Contractual Life">8.01</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zjCQgS81NR8j" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z0NTYrqk8Jee" style="text-align: right" title="Number of Exercisable Options">8,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z0c7zV8unUsd" style="text-align: right" title="Aggregate Exercisable Options Value">44</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zYc1iUNsfBN2" style="text-align: right" title="Exercise Price">6.3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zCCBXjAkSNMa" style="text-align: right" title="Number of Outstanding Options">21,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z4TO90n7F59h" style="text-align: right" title="Weighted Average Remaining Contractual Life">9.52</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zN9c0uqSG4h7" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zb56NKCslPU9" style="text-align: right" title="Number of Exercisable Options">3,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zlhh5tZXjNa9" style="text-align: right" title="Aggregate Exercisable Options Value">24</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zJhh7NJ4ZJR6" style="text-align: right" title="Exercise Price">6.4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zU1IvLVWOl15" style="text-align: right" title="Number of Outstanding Options">50,684</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zBw1OoKOx0Bi" style="text-align: right" title="Weighted Average Remaining Contractual Life">9.42</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zGSaXF2rRLge" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zxKsomPIGSbg" style="text-align: right" title="Number of Exercisable Options">37,522</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zSyaulGcHUKb" style="text-align: right" title="Aggregate Exercisable Options Value">240</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zCrXoGq8XtXj" style="text-align: right" title="Exercise Price">6.5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_znRRZxgLXEY8" style="text-align: right" title="Number of Outstanding Options">625</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zbYGSPIN7SQ9" style="text-align: right" title="Weighted Average Remaining Contractual Life">9.52</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zywrQzKXmWjd" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zZhFmXnfYyP9" style="text-align: right" title="Number of Exercisable Options">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zBec7nOCMCl2" style="text-align: right" title="Aggregate Exercisable Options Value">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_z8vlySPHob8c" style="text-align: right" title="Exercise Price">10.3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_z6Jx1pdfarMh" style="text-align: right" title="Number of Outstanding Options">32,281</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_z3jqVmYkEE73" style="text-align: right" title="Weighted Average Remaining Contractual Life">9.56</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zSSS1xgrR5bl" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zMBYnSjTMNQ6" style="text-align: right" title="Number of Exercisable Options">32,281</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zDzXvNinFfOc" style="text-align: right" title="Aggregate Exercisable Options Value">332</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z46eXlCVk10l" style="text-align: right" title="Exercise Price">13.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z1khDAA9odZ4" style="text-align: right" title="Number of Outstanding Options">2,434</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zdu5Ok5coS82" style="text-align: right" title="Weighted Average Remaining Contractual Life">7.11</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zvzHaqU9Ty2d" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zRQTZzj514a2" style="text-align: right" title="Number of Exercisable Options">1,922</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z2SIlfQgmfvi" style="text-align: right" title="Aggregate Exercisable Options Value">26</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zd5TDIC52FB6" style="text-align: right" title="Exercise Price">18.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zSSTbV0aJBwk" style="text-align: right" title="Number of Outstanding Options">8,465</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zNRsXHI9o486" style="text-align: right" title="Weighted Average Remaining Contractual Life">3.22</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zputVKKBB1a2" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zM07p0c053p4" style="text-align: right" title="Number of Exercisable Options">8,465</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_z5HLUB2wWLV8" style="text-align: right" title="Aggregate Exercisable Options Value">157</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zA7pViL6Flk1" style="text-align: right" title="Exercise Price">20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zN4fXYRIt278" style="text-align: right" title="Number of Outstanding Options">27,653</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zurq3Zdk5cy6" style="text-align: right" title="Weighted Average Remaining Contractual Life">6.16</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zs24x3QEemIl" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zuWfGtlqo648" style="text-align: right" title="Number of Exercisable Options">29,400</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zJdplyz24tb" style="text-align: right" title="Aggregate Exercisable Options Value">588</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zcFlojDmtEM9" style="text-align: right" title="Exercise Price">20.1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z9rrxGQG1eD" style="text-align: right" title="Number of Outstanding Options">4,700</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zxzpohMOMovi" style="text-align: right" title="Weighted Average Remaining Contractual Life">4.25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_za8bWWVzTvL6" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z05jJZ4M7Yel" style="text-align: right" title="Number of Exercisable Options">4,700</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zDKbmSqFQ2e8" style="text-align: right" title="Aggregate Exercisable Options Value">94</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zNyRVQvf8Afk" style="text-align: right" title="Exercise Price">28.9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zz6l1cQ2LP5c" style="text-align: right" title="Number of Outstanding Options">8,465</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zXEWdRg90Fpc" style="text-align: right" title="Weighted Average Remaining Contractual Life">2.85</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zQF9YWVSj5O8" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zgDlLbyWnvMi" style="text-align: right" title="Number of Exercisable Options">8,465</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zhtaMPR9lSUl" style="text-align: right" title="Aggregate Exercisable Options Value">245</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z0hVjUvvMyQc" style="text-align: right" title="Exercise Price">29.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z1WO3FGgGDK8" style="text-align: right" title="Number of Outstanding Options">2,800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z3PY5Kq2ytS4" style="text-align: right" title="Weighted Average Remaining Contractual Life">6.08</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zjeAyfx2BM1d" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zphiuLWlFV5e" style="text-align: right" title="Number of Exercisable Options">2,800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z88aexbcZavl" style="text-align: right" title="Aggregate Exercisable Options Value">83</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zVnC2wjV9XUl" style="text-align: right" title="Exercise Price">29.9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zm8LFxionJmg" style="text-align: right" title="Number of Outstanding Options">34,945</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_z4Rv3BKQ4mZg" style="text-align: right" title="Weighted Average Remaining Contractual Life">4.07</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zmhQ4pXtWzzf" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zI2RbpLd9Dxh" style="text-align: right" title="Number of Exercisable Options">34,945</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zmHc2RWqLOzb" style="text-align: right" title="Aggregate Exercisable Options Value">1,045</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zxcD0l0hr6Vc" style="text-align: right" title="Exercise Price">31.4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zcrXQvSUEpC5" style="text-align: right" title="Number of Outstanding Options">250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zxyaaDRKt3ui" style="text-align: right" title="Weighted Average Remaining Contractual Life">4.90</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zK8U7dwwGhli" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zp4LarX3Qdm6" style="text-align: right" title="Number of Exercisable Options">250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_z9woUyAgVAAh" style="text-align: right" title="Aggregate Exercisable Options Value">8</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zAYSN4CillSl" style="text-align: right" title="Exercise Price">45</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zfb6Px1w2g2a" style="text-align: right" title="Number of Outstanding Options">2,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zXeZJHfpMuV9" style="text-align: right" title="Weighted Average Remaining Contractual Life">4.37</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_z4I4Gqm5ck57" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zAE79Yy8YfK8" style="text-align: right" title="Number of Exercisable Options">2,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_z3XtQHhDSjvh" style="text-align: right" title="Aggregate Exercisable Options Value">90</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zBxWipmKEDy5" style="text-align: right" title="Exercise Price">46</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_z2mrwn1BK0F6" style="text-align: right" title="Number of Outstanding Options">13,080</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_ziWOePNHo6L" style="text-align: right" title="Weighted Average Remaining Contractual Life">4.01</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zizUSvjF6WP6" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zsK2RWrsMtIh" style="text-align: right" title="Number of Exercisable Options">13,080</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSeventeenMember_zPgzGbVCVTy2" style="text-align: right" title="Aggregate Exercisable Options Value">602</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zhxnwhT7iwLc" style="text-align: right" title="Exercise Price">47</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zU0c5u7e0Fe4" style="text-align: right" title="Number of Outstanding Options">625</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zV1fFeHzlY79" style="text-align: right" title="Weighted Average Remaining Contractual Life">0.49</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_ztSTwZbwNC1l" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zVyFxQoP6tA9" style="text-align: right" title="Number of Exercisable Options">625</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEighteenMember_zHEfmvHVainh" style="text-align: right" title="Aggregate Exercisable Options Value">29</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zA5djRyE9S9l" style="text-align: right" title="Exercise Price">48</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zfAxWqKIJ1y1" style="text-align: right" title="Number of Outstanding Options">46,662</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zdsA2DGeWWq2" style="text-align: right" title="Weighted Average Remaining Contractual Life">1.45</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zyt3ihBUwFOa" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zdG21QmbePol" style="text-align: right" title="Number of Exercisable Options">46,662</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineteenMember_zMa81T0PYOUi" style="text-align: right" title="Aggregate Exercisable Options Value">2,240</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_zV3bBmHp7TSg" style="text-align: right" title="Exercise Price">50.2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_zlzShZeZsJu3" style="text-align: right" title="Number of Outstanding Options">2,100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_zMAhcXFhaV17" style="text-align: right" title="Weighted Average Remaining Contractual Life">3.41</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_zX0u4f9f9IXi" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_zYjVJoMVoHw" style="text-align: right" title="Number of Exercisable Options">2,100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyMember_zvXdm19Xn7Xl" style="text-align: right" title="Aggregate Exercisable Options Value">105</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyOneMember_zEahk6CyP6w2" style="text-align: right" title="Exercise Price">50.7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyOneMember_zBsHk5plQKIi" style="text-align: right" title="Number of Outstanding Options">4,950</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyOneMember_zcu50ZANngcg" style="text-align: right" title="Weighted Average Remaining Contractual Life">2.45</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyOneMember_zwXbJ9jTApwj" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyOneMember_zDSuChzPAgdk" style="text-align: right" title="Number of Exercisable Options">4,950</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyOneMember_zUP2MXIpGiga" style="text-align: right" title="Aggregate Exercisable Options Value">251</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyTwoMember_zLPed09ax8gi" style="text-align: right" title="Exercise Price">51</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyTwoMember_ziji0lfphsi7" style="text-align: right" title="Number of Outstanding Options">2,087</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyTwoMember_zPR6eejaHFh2" style="text-align: right" title="Weighted Average Remaining Contractual Life">5.17</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyTwoMember_zcvxaNupc9Wi" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyTwoMember_zZ7X8AzrGGyk" style="text-align: right" title="Number of Exercisable Options">2,087</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyTwoMember_zQVQZLdadt3e" style="text-align: right" title="Aggregate Exercisable Options Value">106</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyThreeMember_zwjMqfmdbDil" style="text-align: right" title="Exercise Price">51.2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyThreeMember_zsdPjoUyc0m4" style="text-align: right" title="Number of Outstanding Options">7,550</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyThreeMember_zmWagHqZDdOj" style="text-align: right" title="Weighted Average Remaining Contractual Life">5.11</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyThreeMember_zp6LPOGydcI7" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyThreeMember_zPzov0PwnG6b" style="text-align: right" title="Number of Exercisable Options">7,550</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyThreeMember_zJtGTsCorJRa" style="text-align: right" title="Aggregate Exercisable Options Value">387</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyFourMember_zlh8a4fizI94" style="text-align: right" title="Exercise Price">59.9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyFourMember_zO9xEKw0GTRe" style="text-align: right" title="Number of Outstanding Options">27,155</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyFourMember_zCSwPyasF0Xg" style="text-align: right" title="Weighted Average Remaining Contractual Life">3.02</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyFourMember_zBDaM6nAHbZd" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyFourMember_zHGfcsmalQz2" style="text-align: right" title="Number of Exercisable Options">27,154</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyFourMember_zoVHGb8XGH5d" style="text-align: right" title="Aggregate Exercisable Options Value">1,626</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyFiveMember_zGBzhPFoe9ff" style="text-align: right" title="Exercise Price">68.4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyFiveMember_zd4J5TkyvVEh" style="text-align: right" title="Number of Outstanding Options">1,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyFiveMember_zfPlXwZjnSXd" style="text-align: right" title="Weighted Average Remaining Contractual Life">5.38</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyFiveMember_zJdl0FQpOUDi" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyFiveMember_zwYOZ9e4btS" style="text-align: right" title="Number of Exercisable Options">1,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyFiveMember_zkw3xZ3Hgeac" style="text-align: right" title="Aggregate Exercisable Options Value">82</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentySixMember_zR2QS6nUA7w2" style="text-align: right" title="Exercise Price">72</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentySixMember_z3FBNUNEtzu3" style="text-align: right" title="Number of Outstanding Options">8,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentySixMember_ziMtDtvAA0Y9" style="text-align: right" title="Weighted Average Remaining Contractual Life">2.43</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentySixMember_zLilMdvyawF2" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentySixMember_zWJ54t9YCrji" style="text-align: right" title="Number of Exercisable Options">8,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentySixMember_zRLkVSGDwxNj" style="text-align: right" title="Aggregate Exercisable Options Value">600</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentySevenMember_z2ige66bcmq5" style="text-align: right" title="Exercise Price">83.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentySevenMember_zamq98fElqng" style="text-align: right" title="Number of Outstanding Options">24,999</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentySevenMember_z06Qu9WEVYT2" style="text-align: right" title="Weighted Average Remaining Contractual Life">3.49</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentySevenMember_zZrd3aX71Aud" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentySevenMember_zor0X1GHxKzi" style="text-align: right" title="Number of Exercisable Options">24,999</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentySevenMember_zW9coFFDKpxk" style="text-align: right" title="Aggregate Exercisable Options Value">2,090</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyEightMember_zntqB7u1hW4a" style="padding-bottom: 1pt; text-align: right" title="Exercise Price">89.1</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyEightMember_zCv5k5RRE6ei" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Outstanding Options">1,500</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyEightMember_zm8fdcd4O2c9" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Remaining Contractual Life">3.46</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyEightMember_zNt1vioxmPQk" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyEightMember_zpj3TMdnzXD" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Exercisable Options">1,500</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwentyEightMember_zw42QwkOWYEa" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Exercisable Options Value">134</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zENKooya1v59" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Outstanding Options">371,039</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zuNjNqvASG7l" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Remaining Contractual Life">5.69</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zFfkfKTH93O" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value">7</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zS73WKildZZ6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Exercisable Options">321,651</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToEmployeesMember_zBb3bBKkaV7l" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Exercisable Options Value">11,256</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

0.98

7585000

P9Y11M12D

7000

4.5

9161000

P8Y10M28D

6161000

28000

17500000

P8Y3D

8750000

44000

6.3

21250000

P9Y6M7D

3750000

24000

6.4

50684000

P9Y5M1D

37522000

240000

6.5

625000

P9Y6M7D

10.3

32281000

P9Y6M21D

32281000

332000

13.6

2434000

P7Y1M9D

1922000

26000

18.6

8465000

P3Y2M19D

8465000

157000

27653000

P6Y1M28D

29400000

588000

20.1

4700000

P4Y3M

4700000

94000

28.9

8465000

P2Y10M6D

8465000

245000

29.6

2800000

P6Y29D

2800000

83000

29.9

34945000

P4Y25D

34945000

1045000

31.4

250000

P4Y10M24D

250000

8000

2000000

P4Y4M13D

2000000

90000

13080000

P4Y3D

13080000

602000

625000

P0Y5M26D

625000

29000

46662000

P1Y5M12D

46662000

2240000

50.2

2100000

P3Y4M28D

2100

105000

50.7

4950000

P2Y5M12D

4950000

251000

2087000

P5Y2M1D

2087000

106000

51.2

7550000

P5Y1M9D

7550000

387000

59.9

27155000

P3Y7D

27154000

1626000

68.4

1200000

P5Y4M17D

1200000

82000

8333000

P2Y5M4D

8333000

600000

83.6

24999000

P3Y5M26D

24999000

2090000

89.1

1500000

P3Y5M15D

1500000

134000

371039

P5Y8M8D

7000

321651

11256000

640000

485000

177000

P3Y6M

<p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zNcK2vQRwXtb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Below is a table summarizing all the compensation granted to consultants and service providers during the years ended December 31, 2024 and December 31, 2023: SCHEDULE OF STOCK OPTIONS GRANTED TO CONSULTANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Year of grant</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">No. of options granted</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Exercise price</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Vesting period</td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">Fair value at grant (in thousands)</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Expiration period</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 13%">Non-employees</td><td style="width: 2%"> </td> <td style="width: 13%; text-align: center">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zR9tdy5m3VTc" style="width: 11%; text-align: right" title="Number of options granted">1,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__srt--RangeAxis__srt--MinimumMember_z7LHiFls8rY3" title="Exercise price">6.7-$<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__srt--RangeAxis__srt--MaximumMember_znAciFOTeDX2" title="Exercise price">6.7</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 12%; text-align: center">Quarterly over a period of <span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriodDescription_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zBGNeFvWRNj3" title="Vesting peirod description">two years</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zvZ1tI9rUYx2" style="width: 10%; text-align: right" title="Fair value at grant">9</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="text-align: right; width: 12%"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z9I2FnTlAxf6" title="Expiration period">10 years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Non-employees</td><td> </td> <td style="text-align: center">2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zaVBLmSQVeUe" style="text-align: right" title="Number of options granted">833</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zVQgoQXdCxUg" style="text-align: right" title="Exercise price">13.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">Annually over a period of <span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriodDescription_dtY_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zsZnZ1GIDtF5" title="Vesting peirod description">five years</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zsYZVpmd5rIi" style="text-align: right" title="Fair value at grant">9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodExpirationPeriod_dtY_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zh4c6k1PAqH5" title="Expiration period">10 years</td></tr> </table>

1500

6.7

two years 9000 P10Y

833

13.6

five years 9000 P10Y

<p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zltf98yyNEO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">SCHEDULE OF STOCK OPTIONS, VALUATION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Value of one common share</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_903_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zVkeZUJPJ6G6" title="Value of one common share">6.7</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zC2p1CmYPiHd" title="Value of one common share">13.6</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zSrAHgo7qAhf" style="text-align: right" title="Dividend yield">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zomkpPTiecPc" style="text-align: right" title="Dividend yield">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected stock price volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zy9FJGYKkhD" title="Expected stock price volatility">87</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zahKrLGPEtd9" title="Expected stock price volatility">80</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zY0R1OlUt1d4" title="Risk free interest rate">3.71%-<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z3K6N4pfFyh5" title="Risk free interest rate">3.76</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zLt6e28ZMdRj" title="Risk free interest rate">4.07</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z57XNHAamJTd" title="Expected term (years)">10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zKhzEH1Hir0f" title="Expected term (years)">10</td><td style="text-align: left"> </td></tr> </table>

6.7

13.6

0.87

0.80

0.0371

0.0376

0.0407

P10Y

<p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zHXFoc41Ruuk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">A summary of the Company’s stock options granted to consultants and service providers as of December 31, 2024, and December 31, 2023 is presented below: SCHEDULE OF STOCK OPTIONS ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Options </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price $ </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price $ </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">Options outstanding at the beginning of the year</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zgdNpeU9aJy2" style="width: 10%; text-align: right" title="Number of Options - Options outstanding at the beginning of the year">26,703</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z8LVQcJeGoZf" style="width: 10%; text-align: right" title="Weighted Average Exercise Price - Options outstanding at the beginning of the year">50.7</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zHzJls1yOAd2" style="width: 10%; text-align: right" title="Number of Options - Options outstanding at the beginning of the year">51,714</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zawz4IPKRj6c" style="width: 10%; text-align: right" title="Weighted Average Exercise Price - Options outstanding at the beginning of the year">48.8</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Changes during the year:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zir9qYxlwgd4" style="text-align: right" title="Number of Options - Granted">1,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z03L0sr313Ka" style="text-align: right" title="Weighted Average Exercise Price - Granted">6.7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zdF8ZGZPdYyc" style="text-align: right" title="Number of Options - Granted">833</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z8ZWjuxo5XM6" style="text-align: right" title="Weighted Average Exercise Price - Granted">13.6</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zBxqF6lBwuF1" style="text-align: right" title="Number of Options - Expired">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zyYNIpvxwWGa" style="text-align: right" title="Weighted Average Exercise Price - Expired">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zjC0MIJYlrw9" style="text-align: right" title="Number of Options - Expired">(2,333</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zeR8d9ebcNm5" style="text-align: right" title="Weighted Average Exercise Price - Expired">60.4</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z08LZpc1lEL6" style="text-align: right" title="Number of Options - Forfeited">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z3dJA0mFN21c" style="text-align: right" title="Weighted Average Exercise Price - Forfeited">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zl1Z6lwCPWQ4" style="text-align: right" title="Number of Options - Forfeited">(23,511</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zlFO9ZxdKbZ8" style="text-align: right" title="Weighted Average Exercise Price - Forfeited">44.2</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1pt">Cancelled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_iN_pid_di_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zoDS71iHkLya" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options - Cancelled">(1,500</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z0pGjbf78kO6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price - Cancelled">53.00</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_iN_pid_di_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_ziJ0xfjC5lTk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options - Cancelled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z25cSAYUUvcg" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price - Cancelled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Options outstanding at end of the year</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_z3Z6CqMzy6jk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options - Options outstanding at the end of the year">26,703</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zLPRhfm38sNe" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options outstanding at the end of the yea">48.13</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zQJF8kw0jjy7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options - Options outstanding at the end of the year">26,703</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zhyuEalg2hs8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options outstanding at the end of the yea">50.7</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Options exercisable at end of the year</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zFuDUPRxtnUg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options - Options exercisable at end of the year">22,104</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zRfWK03ZenR5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options exercisable at end of the year">51.70</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zSCFf92t8T5b" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options - Options exercisable at end of the year">20,606</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zcpYtGgDmhEe" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price - Options exercisable at end of the year">57.1</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

26703

50.7

51714

48.8

1500

6.7

833

13.6

2333

60.4

23511

44.2

1500 53.00

26703

48.13

26703

50.7

22104

51.70

20606

57.1

<p id="xdx_898_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_hus-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zDs6ETrBVYw6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">The following table presents summary information concerning the options granted and exercisable to consultants and service providers outstanding as of December 31, 2024 (in thousands, except per share data): SCHEDULE OF STOCK OPTIONS EXERCISABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Exercise Price $</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Outstanding Options</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Remaining Contractual Life</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Value $</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Exercisable Options</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Exercisable Options Value $</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">(in thousands)</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">(in thousands)</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_znCdglwF0fK8" style="width: 13%; text-align: right" title="Exercise Price">6.7</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z1uCzhu7lVT2" style="width: 13%; text-align: right" title="Number of Outstanding Options">1,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z8fCQ1kiR1da" style="width: 13%; text-align: right" title="Weighted Average Remaining Contractual Life">9.68</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z6X8EAv7PiC1" style="width: 13%; text-align: right" title="Aggregate Intrinsic Value">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zOdIJz06fag4" style="width: 13%; text-align: right" title="Number of Exercisable Options">1,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zZs3E0fVdtN7" style="width: 13%; text-align: right" title="Aggregate Exercisable Options Value">7</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zaTvQQXspzf5" style="text-align: right" title="Exercise Price">13.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zAPyC12kVaHk" style="text-align: right" title="Number of Outstanding Options">833</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zBEWxZFy7JSk" style="text-align: right" title="Weighted Average Remaining Contractual Life">8.44</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zshpTGUx8jtc" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zklKMJBYKVk6" style="text-align: right" title="Number of Exercisable Options">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zn9gho8VN2Yd" style="text-align: right" title="Aggregate Exercisable Options Value">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zIkpHqhu6RN1" style="text-align: right" title="Exercise Price">20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z6l5Jpubr3eb" style="text-align: right" title="Number of Outstanding Options">2,833</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z6aRRz8MaEpi" style="text-align: right" title="Weighted Average Remaining Contractual Life">7.46</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zVvzGgLZzGgb" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z2TnJbcz29L6" style="text-align: right" title="Number of Exercisable Options">2,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zlUwD5l4Tnqd" style="text-align: right" title="Aggregate Exercisable Options Value">40</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z9dy7DCwNN3l" style="text-align: right" title="Exercise Price">29.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zmU0pbyjlZ12" style="text-align: right" title="Number of Outstanding Options">750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zcw8CO9vYbOf" style="text-align: right" title="Weighted Average Remaining Contractual Life">6.96</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zCpsFa9iap16" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zvfuFiLvDxKe" style="text-align: right" title="Number of Exercisable Options">750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zN5o6ZmV8w39" style="text-align: right" title="Aggregate Exercisable Options Value">22</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zN5edpg3MOOh" style="text-align: right" title="Exercise Price">29.9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z3VOQTwo91na" style="text-align: right" title="Number of Outstanding Options">2,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zvu6VbJI36Ef" style="text-align: right" title="Weighted Average Remaining Contractual Life">5.22</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zK3m5U2gHiM" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zlluHuHZ5Kjl" style="text-align: right" title="Number of Exercisable Options">2,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zwa3zjmxxeya" style="text-align: right" title="Aggregate Exercisable Options Value">60</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zHptSYgHVGme" style="text-align: right" title="Exercise Price">40.9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zSe5JZUmBil5" style="text-align: right" title="Number of Outstanding Options">2,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zWuVTh7WAJm2" style="text-align: right" title="Weighted Average Remaining Contractual Life">4.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zZj8AuDNpy2j" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zQP4NaZRvOo3" style="text-align: right" title="Number of Exercisable Options">2,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zJoPC6A6VtMb" style="text-align: right" title="Aggregate Exercisable Options Value">102</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zCxPIOvIzzie" style="text-align: right" title="Exercise Price">44.2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zXwHHvhhnZAd" style="text-align: right" title="Number of Outstanding Options">512</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zdF6HZDTzI7j" style="text-align: right" title="Weighted Average Remaining Contractual Life">2.93</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zkpYCyiXSeD3" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zzmAs8mnKUll" style="text-align: right" title="Number of Exercisable Options">512</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zWMtPYkErsGe" style="text-align: right" title="Aggregate Exercisable Options Value">23</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z6cYRHB36QQe" style="text-align: right" title="Exercise Price">45</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zNC4dGeXbmti" style="text-align: right" title="Number of Outstanding Options">1,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zDdwDcW3hyef" style="text-align: right" title="Weighted Average Remaining Contractual Life">4.53</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zKv6VtUHXK6h" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z0oroYOT3kXi" style="text-align: right" title="Number of Exercisable Options">500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_znluuLABjfp6" style="text-align: right" title="Aggregate Exercisable Options Value">23</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_z6GXIxGmCssk" style="text-align: right" title="Exercise Price">46</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_z1fZsGps5SH4" style="text-align: right" title="Number of Outstanding Options">2,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zEDGO0b3kOMb" style="text-align: right" title="Weighted Average Remaining Contractual Life">5.96</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zMo4hD3GJQD9" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zwILrnPxtzvf" style="text-align: right" title="Number of Exercisable Options">400</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zJhk5vMmvKYb" style="text-align: right" title="Aggregate Exercisable Options Value">18</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z33uYt5inWn" style="text-align: right" title="Exercise Price">48</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zpVmB4ytn1Z" style="text-align: right" title="Number of Outstanding Options">833</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z4JrMYnhfl9l" style="text-align: right" title="Weighted Average Remaining Contractual Life">1.94</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z007anisd59e" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zGzGKJT43SBd" style="text-align: right" title="Number of Exercisable Options">833</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zgViOJBb1YS1" style="text-align: right" title="Aggregate Exercisable Options Value">40</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zJ0UprJWXghe" style="text-align: right" title="Exercise Price">50.7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zEo1uvSEXlBa" style="text-align: right" title="Number of Outstanding Options">500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z0f7jyGryIZd" style="text-align: right" title="Weighted Average Remaining Contractual Life">4.19</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zT8YmFvpXmUc" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z3WQRo6g21Tk" style="text-align: right" title="Number of Exercisable Options">500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zrhbip85STs8" style="text-align: right" title="Aggregate Exercisable Options Value">25</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_z6zmXl9u9Pb2" style="text-align: right" title="Exercise Price">59.9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zWXmTn1KptO2" style="text-align: right" title="Number of Outstanding Options">1,666</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zNRYTm43Tawe" style="text-align: right" title="Weighted Average Remaining Contractual Life">3.81</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zuf9njhmq3Nk" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zOmjyE0ZWNel" style="text-align: right" title="Number of Exercisable Options">1,666</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_ztTCHKommUlk" style="text-align: right" title="Aggregate Exercisable Options Value">100</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zRN6Vl1CrW09" style="text-align: right" title="Exercise Price">68.4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z9l9RUrnctL2" style="text-align: right" title="Number of Outstanding Options">750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zizQcuqJInO8" style="text-align: right" title="Weighted Average Remaining Contractual Life">5.38</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zLOXe4TiRAn7" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zjZfELCubqcg" style="text-align: right" title="Number of Exercisable Options">750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zR5OrVKax7Gh" style="text-align: right" title="Aggregate Exercisable Options Value">51</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zd61N1C49Apb" style="text-align: right" title="Exercise Price">70</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zVW8ghHp8P0h" style="text-align: right" title="Number of Outstanding Options">7,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zV1G0YhTeV27" style="text-align: right" title="Weighted Average Remaining Contractual Life">4.83</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zHi9oKlq74J" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zyFof0GUwOXh" style="text-align: right" title="Number of Exercisable Options">7,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zWPp3Vgrepg1" style="text-align: right" title="Aggregate Exercisable Options Value">490</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zcCB0JZLl10k" style="text-align: right" title="Exercise Price">83.4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zMZk6paIRCli" style="text-align: right" title="Number of Outstanding Options">860</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zgzTwKq3z1u8" style="text-align: right" title="Weighted Average Remaining Contractual Life">3.52</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zEN4MZ1Fbtbl" style="text-align: right" title="Aggregate Intrinsic Value">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zs5HqXIJM28i" style="text-align: right" title="Number of Exercisable Options">860</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFifteenMember_zXFPaZoWBR45" style="text-align: right" title="Aggregate Exercisable Options Value">72</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zmNMOJilZb9d" style="padding-bottom: 1pt; text-align: right" title="Exercise Price">84.3</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zmLb7B8r8Ovd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Outstanding Options">833</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zHdw1vemiK48" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Remaining Contractual Life">3.04</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zDKgF8fx6YV9" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zSigO8mVqgbk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Exercisable Options">833</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixteenMember_zgLMHfw1nY59" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Exercisable Options Value">70</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zA1x44e4tJ44" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Outstanding Options">26,703</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_ztLPNvV0cSZd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Remaining Contractual Life">5.36</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zAMVzOw8hFV8" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zmEEuDFktJA4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Exercisable Options">22,104</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember_zvrF0vTPRoFd" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Exercisable Options Value">1,143</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

6.7

1500

P9Y8M4D

1000

7000

13.6

833

P8Y5M8D

2833

P7Y5M15D

2000

40000

29.6

750

P6Y11M15D

750

22000

29.9

2000

P5Y2M19D

2000

60000

40.9

2500

P4Y9M

2500

102000

44.2

512

P2Y11M4D

512

23000

1333

P4Y6M10D

500

23000

2000

P5Y11M15D

400

18000

833

P1Y11M8D

833

40000

50.7

500

P4Y2M8D

500

25000

59.9

1666

P3Y9M21D

1666

100000

68.4

750

P5Y4M17D

750

51000

7000

P4Y9M29D

7000

490000

83.4

860

P3Y6M7D

860

72000

84.3

833

P3Y14D

833

70000

26703

P5Y4M9D

22104

1143000

41000

63000

17000

P3Y25D

<p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdrxulUZOzp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Below is a table summarizing all the RSUs grants to employees and made during the years ended December 31, 2024: SCHEDULE OF STOCK OPTIONS GRANTED TO EMPLOYEES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">No. of options granted</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Vesting period</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Fair value at grant (in thousands)</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 18%; text-align: center">Employees</td><td style="width: 3%"> </td> <td style="width: 18%; text-align: center">December 31, 2024</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zR4sxZaqaCxd" style="width: 16%; text-align: right" title="Number of options granted">8,250</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 17%; text-align: center">Quarterly over a period of <span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriodDescription_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkC4SpyUTCma" title="Vesting period description">two years</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfEwyHsFvmGi" style="width: 15%; text-align: right" title="Fair value at grant">44</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">Employees</td><td> </td> <td style="text-align: center">December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zwNXPHI3clud" style="text-align: right" title="Number of options granted">14,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">Quarterly over a period of <span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodVestingPeriodDescription_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zApSi19Bqihk" title="Vesting period description">two years</td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDTGMseKlxyj" style="text-align: right" title="Fair value at grant">50</td><td style="text-align: left"> </td></tr> </table>

8250

two years 44000

14200

two years 50000

A summary of the Company’s RSUs granted to employees as of December 31, 2024 is presented below: SCHEDULE OF STOCK OPTIONS ACTIVITY GRANTED TO EMPLOYEES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of RSUs</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of RSUs</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Options outstanding at the beginning of the period</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrgdGEOKmZl2" style="width: 16%; text-align: right" title="Number of RSUs - Options outstanding at the beginning of the year">14,200</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zyaeWVrp54zg" style="width: 16%; text-align: right" title="Number of RSUs - Options outstanding at the beginning of the year">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Changes during the period:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zL5G6qmuCtY2" style="text-align: right" title="Number of RSUs - Granted">8,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ziXnWp41ZfL7" style="text-align: right" title="Number of RSUs - Granted">14,200</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRAINBMBAjVl" style="text-align: right" title="Number of RSUs - Expired">(12,410</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCskZAmRCdE9" style="text-align: right" title="Number of RSUs - Expired">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBzfpsFyxLj" style="border-bottom: Black 1pt solid; text-align: right" title="Number of RSUs - Forfeited">(1,306</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzr9wnRhhk72" style="border-bottom: Black 1pt solid; text-align: right" title="Number of RSUs - Forfeited">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Options outstanding at end of the period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zWnRZ4ekjbN9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of RSUs - Options outstanding at the end of the year">8,734</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zcqoOIBME0T" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of RSUs - Options outstanding at the end of the year">14,200</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

14200

8250

14200

12410

1306

8734

14200

<p id="xdx_894_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJTFm9GRoeFk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following table presents summary information concerning the options granted and exercisable to employees and directors outstanding as of December 31, 2024 (in thousands, except per share data): SCHEDULE OF STOCK OPTIONS EXERCISABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">year</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Outstanding RSUs</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Remaining Contractual Life</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Value $</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td colspan="2" style="text-align: center">(in thousands)</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 22%; text-align: right">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdf07hnA94Sk" style="width: 22%; text-align: right" title="Number of Outstanding Options">2,434</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQ5EokymPVM1" style="width: 22%; text-align: right" title="Weighted Average Remaining Contractual Life">9.56</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1kl05csZvxh" style="width: 22%; text-align: right" title="Aggregate Intrinsic Value">5</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right">2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7CiKiPlYZJg" style="text-align: right" title="Number of Outstanding Options">6,300</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBXM2fX3hzYa" style="text-align: right" title="Weighted Average Remaining Contractual Life">8.99</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn3n3_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zD1TGLjuxWzj" style="text-align: right" title="Aggregate Intrinsic Value">12</td><td style="text-align: left"> </td></tr> </table>

2434

P9Y6M21D

5000

6300

P8Y11M26D

12000

46000

36000

P1Y4M20D

Below is a table summarizing the shares and warrants grants to advisers during the period from January 1, 2024 to December 31, 2024: SCHEDULE OF SHARES AND WARRANTS GRANTS TO ADVISORS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Date of issue of share or warrant</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Reason for issue of share or warrant</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Consideration</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise price of warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrant vesting (subject to continued service provided to Company)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrant expiry date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 13%; text-align: justify; padding-bottom: 1pt">March 7, 2024</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="width: 13%; text-align: justify; padding-bottom: 1pt">Strategic advisor agreement</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="width: 20%; text-align: justify; padding-bottom: 1pt">50,000 shares of Common Stock and warrants to purchase 50,000 shares of Common Stock</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; width: 1%; text-align: left">$</td><td style="padding-bottom: 1pt; width: 10%; text-align: right">10.3</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="width: 20%; text-align: justify; padding-bottom: 1pt">One third on March 7, 2024, one third on June 5, 2024, and one third on September 3, 2024.</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="width: 12%; text-align: justify; padding-bottom: 1pt">March 6, 2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">April 18, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">Strategic advisor agreement</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">Warrants to purchase 50,000 shares of Common Stock</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right">10.3</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">One third on April 18, 2024, one third on July 18, 2024, and one third on October 18, 2024.</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">April 17, 2029</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">April 23, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">Strategic advisor agreement</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">Warrants to purchase 50,000 shares of Common Stock</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right">10.3</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">One third on April 16, 2024, one third on July 16, 2024, and one third on October 16, 2024.</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">April 22, 2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">May 22, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">Strategic advisor agreement</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">Warrants to purchase 47,500 shares of Common Stock</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right">10.3</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">One third on May 21, 2024, one third on August 21, 2024, and one third on November 21, 2024.</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">May 21, 2029</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">July 14, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">Strategic advisor agreement</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">Warrants to purchase 20,000 shares of Common Stock</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right">10.3</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">One third on July 14, 2024, one third on October 14, 2024, and one third on January 14, 2024.</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">July 13, 2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">September 5, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">Strategic advisor agreement</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">50,000 shares of Common</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td style="padding-bottom: 1pt; text-align: right">10.3</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: justify">No. of Warrants Granted</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Vesting Period</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: justify">Fair Value at Grant (in thousands)</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: justify">Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYeThSqDJdmh" style="width: 14%; text-align: right" title="Number of options granted">217,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 14%; text-align: justify"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYIVAGhGVa15" title="Restricted stock unit vesting period description">Over a period of nine months</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqRAoRSo7wZ" style="width: 14%; text-align: right" title="Fair value at grant">646</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Shares</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231_zZFYz5NVUzGc" style="text-align: right" title="Number of shares granted">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: justify">N/A</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_pn3n3_c20240101__20241231_zdZPauFGzO12" style="text-align: right" title="Fair value at grant">350</td><td style="text-align: left"> </td></tr> </table>

Strategic advisor agreement

50000

10.3

One third on March 7, 2024, one third on June 5, 2024, and one third on September 3, 2024.

2029-03-06

Strategic advisor agreement

50000

10.3

One third on April 18, 2024, one third on July 18, 2024, and one third on October 18, 2024.

2029-04-17

Strategic advisor agreement

50000

10.3

One third on April 16, 2024, one third on July 16, 2024, and one third on October 16, 2024.

2029-04-22

Strategic advisor agreement

47500

10.3

One third on May 21, 2024, one third on August 21, 2024, and one third on November 21, 2024.

2029-05-21

Strategic advisor agreement

20000

10.3

One third on July 14, 2024, one third on October 14, 2024, and one third on January 14, 2024.

2029-07-13

Strategic advisor agreement

50000

10.3

217500

Over a period of nine months

646000

50000

350000 The fair valuation of these warrants grants is based on the following assumptions: SCHEDULE OF WARRANTS GRANTS ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the period ended December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Value of one common share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5.1-$8.4</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 80%; text-align: justify">Dividend yield</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zktrYHheBlyb" style="width: 16%; text-align: right" title="Dividend yield">0</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected stock price volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zMYKfZM5HbS6" title="Expected stock price volatility">87%-<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_za8o6qJPyil1" title="Expected stock price volatility">91</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zeGMPCNp0ey1" title="Risk free interest rate">4.07%-<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zlY1ieIY5LZ" title="Risk free interest rate">4.68</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis__custom--OptionsGrantedToNonEmployeesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zy3YqulKhMzi" title="Expected term (years)">5</td><td style="text-align: left"> </td></tr> </table>

5.1

8.4

0.87

0.91

0.0407

0.0468

P5Y

NOTE 16 – TAXES <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in">a.</td> <td style="text-align: justify">Corporate taxation in the U.S.</td></tr> </table> The corporate U.S. Federal Income tax rate applicable to the Company and its US subsidiaries is <span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20240101__20241231__srt--StatementGeographicalAxis__country--US_z5oCAKvgsZff" title="Effective income tax rate reconciliation, at income tax rate">21%. As of December 31, 2024, the Company has an accumulated tax loss carryforward of approximately $48 million (as of December 31, 2023, approximately $36 million). For U.S. federal income tax purposes, net operating losses (“NOLs”) arising in tax years beginning after December 31, 2017, the Internal Revenue Code of 1986, as amended (the “Code”) limits the ability to utilize NOL carryforwards to 80% of taxable income in tax years beginning after December 31, 2018. In addition, NOLs arising in tax years ending after December 31, 2017 can be carried forward indefinitely, but carryback is generally prohibited. NOLs generated in tax years beginning before January 1, 2018 will not be subject to the taxable income limitation, and NOLs generated in tax years ending before January 1, 2018 will continue to have a two-year carryback and twenty-year carryforward period. Deferred tax assets for NOLs will need to be measured at the applicable tax rate in effect when the NOL is expected to be utilized. The changes in the carryforward/carryback periods as well as the new limitation on use of NOLs may significantly impact the Company’s valuation allowance assessments for NOLs generated after December 31, 2017. In addition, utilization of the NOLs may be subject to substantial annual limitation under Section 382 of the Code due to an “ownership change” within the meaning of Section 382(g) of the Code. An ownership change subjects pre-ownership change NOL carryforwards to an annual limitation, which significantly restricts the ability to use them to offset taxable income in periods following the ownership change. In general, the annual use limitation equals the aggregate value of the Company’s stock at the time of the ownership change multiplied by a specified tax-exempt interest rate. <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.5in">b.</td> <td style="text-align: justify">Corporate taxation in Israel</td></tr> </table> The Israeli Subsidiaries are taxed in accordance with Israeli tax laws. The corporate tax rate applicable to 2024 and 2023 are <span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20240101__20241231__srt--StatementGeographicalAxis__country--IL_z11G5O3sMRue" title="Effective income tax rate reconciliation, at income tax rate"><span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20230101__20231231__srt--StatementGeographicalAxis__country--IL_z0mVVdjKpV51" title="Effective income tax rate reconciliation, at income tax rate">23%. As of December 31, 2024, the Israeli Subsidiary has an accumulated tax loss carryforward of approximately $10 million (as of December 31, 2023, approximately $10 million). Under the Israeli tax laws, carryforward tax losses have no expiration date. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">c.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Deferred Taxes</td></tr></table> The following table presents summary of information concerning the Company’s deferred taxes as of the years ending December 31, 2024 and December 31, 2023: SCHEDULE OF DEFERRED TAX ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20241231_zhAKOqZwy0c3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20231231_zJbEPvCqogBa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">(U.S. dollars in thousands)</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; text-align: left">Deferred tax assets (liabilities), net:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGz5nL_zvO5MZb1ESY" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Net operating loss carry forwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">13,048</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">12,331</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGz5nL_zc2HyVFJKIWl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Research and development expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,466</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,932</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGz5nL_zrbpkpoDzpR6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Equity compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,357</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,563</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_iI_pn3n3_maDTAGz5nL_zXXhNjpxN9Lj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Employee benefits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">70</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_iNI_pn3n3_di_msDTAGz5nL_z1u6FftjxA79" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Property, plants and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(19</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(26</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_ecustom--DeferredTaxAssetsLeasesAsset_iI_pn3n3_maDTAGz5nL_zFqxSWTY7uu3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Leases asset</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">66</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--DeferredTaxLiabilitiesLeaseLiability_iNI_pn3n3_di_msDTAGz5nL_zOBn7DQOm6G7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lease liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(67</td><td style="text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsInvestments_iI_pn3n3_maDTAGz5nL_z7Aibo6wgnY1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Partnership Investment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,627</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_pn3n3_di_msDTAGz5nL_zk1hQODL4dJa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,455</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,629</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_ecustom--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssetsBadDebtAllowance_iI_pn3n3_maDTAGz5nL_zlnZj94VJWWc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Bad debt allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,910</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">575</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGz5nL_zfo2Wu8zy6D8" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,024</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,088</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGz5nL_msDTLzXIZ_z9XNzH9jV9I9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Deferred tax assets gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21,442</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">26,530</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_maDTLzXIZ_zqC7uYMOIkNe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(21,442</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(26,530</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxLiabilities_iTI_pn3n3_mtDTLzXIZ_zY3XQp5BBD67" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Realization of deferred tax assets is contingent upon sufficient future taxable income during the period that deductible temporary differences and carry forwards losses are expected to be available to reduce taxable income. As the achievement of required future taxable income is not considered more likely than not achievable, the Company and all its subsidiaries have recorded full valuation allowance. The changes in valuation allowance are comprised as follows: SCHEDULE OF VALUATION ALLOWANCE ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">(U.S dollars in thousands)</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 1pt">Balance at the beginning of year</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--DeferredTaxAssetsValuationAllowance_iNS_pn3n3_di_c20240101__20241231_zIO49BP72FOb" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Balance at the beginning of year">(26,530</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DeferredTaxAssetsValuationAllowance_iNS_pn3n3_di_c20230101__20231231_zodYL2GpEPQ8" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Balance at the beginning of year">(14,753</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Deconsolidation of Octomera</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--DeferredTaxAssetsValuationAllowanceDeconsolidation_pn3n3_c20240101__20241231_zWzk18gOW57" style="text-align: right" title="Deconsolidation of Octomera">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--DeferredTaxAssetsValuationAllowanceDeconsolidation_pn3n3_c20230101__20231231_zfsdeHPUOtPb" style="text-align: right" title="Deconsolidation of Octomera">1,252</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Change during the year</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn3n3_c20240101__20241231_zC44r3fwLzWe" style="border-bottom: Black 1pt solid; text-align: right" title="Change during the year">5,088</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn3n3_c20230101__20231231_zmDtWGdyJ20i" style="border-bottom: Black 1pt solid; text-align: right" title="Change during the year">(13,029</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Balance at end of year</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_pn3n3_di_c20240101__20241231_zKMkqkd3tQGk" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at end of year">(21,442</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_pn3n3_di_c20230101__20231231_zSn4wp5G4A4l" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at end of year">(26,530</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">d.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Reconciliation of the Theoretical Tax Expense to Actual Tax Expense</td></tr></table> The main reconciling item between the statutory tax rate of the Company and the effective rate is the provision for valuation allowance with respect to tax benefits from carry forward tax losses. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">e.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Uncertain Tax Provisions</td></tr></table> ASC Topic 740, “Income Taxes” requires significant judgment in determining what constitutes an individual tax position as well as assessing the outcome of each tax position. Changes in judgment as to recognition or measurement of tax positions can materially affect the estimate of the effective tax rate and consequently, affect the operating results of the Company. As of December 31, 2024, the Company has not accrued a provision for uncertain tax positions.

0.21

48000000

36000000

0.23

10000000

The following table presents summary of information concerning the Company’s deferred taxes as of the years ending December 31, 2024 and December 31, 2023: SCHEDULE OF DEFERRED TAX ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20241231_zhAKOqZwy0c3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20231231_zJbEPvCqogBa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">(U.S. dollars in thousands)</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; text-align: left">Deferred tax assets (liabilities), net:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGz5nL_zvO5MZb1ESY" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Net operating loss carry forwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">13,048</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">12,331</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGz5nL_zc2HyVFJKIWl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Research and development expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,466</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,932</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGz5nL_zrbpkpoDzpR6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Equity compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,357</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,563</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_iI_pn3n3_maDTAGz5nL_zXXhNjpxN9Lj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Employee benefits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">70</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_iNI_pn3n3_di_msDTAGz5nL_z1u6FftjxA79" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Property, plants and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(19</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(26</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_ecustom--DeferredTaxAssetsLeasesAsset_iI_pn3n3_maDTAGz5nL_zFqxSWTY7uu3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Leases asset</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">66</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--DeferredTaxLiabilitiesLeaseLiability_iNI_pn3n3_di_msDTAGz5nL_zOBn7DQOm6G7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lease liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(67</td><td style="text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsInvestments_iI_pn3n3_maDTAGz5nL_z7Aibo6wgnY1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Partnership Investment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,627</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_pn3n3_di_msDTAGz5nL_zk1hQODL4dJa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,455</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,629</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_ecustom--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssetsBadDebtAllowance_iI_pn3n3_maDTAGz5nL_zlnZj94VJWWc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Bad debt allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,910</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">575</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGz5nL_zfo2Wu8zy6D8" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,024</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,088</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGz5nL_msDTLzXIZ_z9XNzH9jV9I9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Deferred tax assets gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21,442</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">26,530</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_maDTLzXIZ_zqC7uYMOIkNe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(21,442</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(26,530</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxLiabilities_iTI_pn3n3_mtDTLzXIZ_zY3XQp5BBD67" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

13048000

12331000

4466000

3932000

1357000

1563000

80000

70000

19000

26000

66000 67000

31000

8627000

1455000

1629000

2910000 575000

1024000

1088000

21442000

26530000

21442000

26530000

The changes in valuation allowance are comprised as follows: SCHEDULE OF VALUATION ALLOWANCE ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">(U.S dollars in thousands)</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 1pt">Balance at the beginning of year</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--DeferredTaxAssetsValuationAllowance_iNS_pn3n3_di_c20240101__20241231_zIO49BP72FOb" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Balance at the beginning of year">(26,530</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DeferredTaxAssetsValuationAllowance_iNS_pn3n3_di_c20230101__20231231_zodYL2GpEPQ8" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Balance at the beginning of year">(14,753</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Deconsolidation of Octomera</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--DeferredTaxAssetsValuationAllowanceDeconsolidation_pn3n3_c20240101__20241231_zWzk18gOW57" style="text-align: right" title="Deconsolidation of Octomera">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--DeferredTaxAssetsValuationAllowanceDeconsolidation_pn3n3_c20230101__20231231_zfsdeHPUOtPb" style="text-align: right" title="Deconsolidation of Octomera">1,252</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Change during the year</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn3n3_c20240101__20241231_zC44r3fwLzWe" style="border-bottom: Black 1pt solid; text-align: right" title="Change during the year">5,088</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn3n3_c20230101__20231231_zmDtWGdyJ20i" style="border-bottom: Black 1pt solid; text-align: right" title="Change during the year">(13,029</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Balance at end of year</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_pn3n3_di_c20240101__20241231_zKMkqkd3tQGk" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at end of year">(21,442</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_pn3n3_di_c20230101__20231231_zSn4wp5G4A4l" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at end of year">(26,530</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

26530000

14753000

1252000

5088000

-13029000

21442000

26530000

NOTE 17 – REVENUES Disaggregation of Revenue The following table disaggregates the Company’s revenues by major revenue streams. SCHEDULE OF DISAGGREGATION OF REVENUE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Revenue stream:</td><td> </td> <td style="text-align: left"> </td><td id="xdx_49A_20240101__20241231_z1FUhwGHUPf1" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_498_20230101__20231231_z90GcMQpXEp9" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Revenue stream:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--CellProcessDevelopmentServicesAndHospitalServicesMember_z9Wf5bI1RWNl" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Cell process development services and hospital services</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,020</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">515</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--LicenseFeesMember_z1eQWUfMXbxj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">License fees</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">15</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">15</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zapr2vWlMOp" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,035</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">530</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_894_ecustom--ScheduleOfBreakdownOfRevenuesPerCustomerTableTextBlock_zSsBD02kbdT" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">A breakdown of the revenues per customer what constituted at least 10% of revenues is as follows: SCHEDULE OF BREAKDOWN OF REVENUES PER CUSTOMER <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20240101__20241231_zf9nlHdBTCBe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20230101__20231231_zZm8RElRKzv3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Revenue earned:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--MajorCustomersAxis__custom--CustomerAMember__srt--StatementGeographicalAxis__country--US_zEqfa3V8FL98" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify">Customer A (United States)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">492</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--MajorCustomersAxis__custom--CustomerBMember__srt--StatementGeographicalAxis__country--US_zqhXG31KlANi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Customer B (United States)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">280</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--MajorCustomersAxis__custom--CustomerCMember__srt--StatementGeographicalAxis__country--US_zCHkgH2tNN99" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Customer C (United States)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">90</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--MajorCustomersAxis__custom--CustomerDMember__srt--StatementGeographicalAxis__country--US_zy3KNHLCLjl1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Customer D (United States)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">280</td><td style="text-align: left"> </td></tr> </table> Contract Assets and Liabilities Contract assets are mainly comprised of accounts receivable net of allowance for doubtful debts, which includes amounts billed and currently due from customers. <p id="xdx_89A_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_zNKsZgxXRUIc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">The activity for accounts receivable is comprised of: SCHEDULE OF ACTIVITY FOR TRADE RECEIVABLES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20240101__20241231_zKn5hmyiXpn5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20230101__20231231_zhgtnlioqpef" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40E_eus-gaap--AccountsReceivableNetCurrent_iS_pn3n3_zEnXVy16Ui3h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Balance as of beginning of period</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">88</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">36,183</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--AccountsReceivableDeconsolidation_iN_pn3n3_di_zlEF7u996Ptb" style="vertical-align: bottom; background-color: White"> <td>Deconsolidation of Octomera</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">82</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,985</td><td style="text-align: left">)</td></tr> <tr id="xdx_402_ecustom--AccountsReceivableAdditions_iI_pn3n3_zN4Qwlppvtge" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Additions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">670</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">560</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--AccountsReceivableCollections_pn3n3_zyUN6kzq65me" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Collections</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,268</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6,230</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_ecustom--AccountsReceivableAllowancesForDoubtfulAccounts_pn3n3_zMNUi8ilktUb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Allowances for credit losses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">469</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(24,388</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_ecustom--ExchangeRateDifferencesOfAccountsReceivable_pn3n3_zGOnoh9I513g" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Exchange rate differences</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(52</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--AccountsReceivableNetCurrent_iE_pn3n3_zl15gTNAQQ9j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance as of end of period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">40</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">88</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_89D_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zvcFLaYaKxXa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">The activity for contract liabilities is comprised of: SCHEDULE OF ACTIVITY FOR CONTRACT LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20240101__20241231_zRkFHBFg8fu3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20230101__20231231_zeibohvCBydl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40D_eus-gaap--ContractWithCustomerLiabilityCurrent_iS_pn3n3_zEZOzezf2PRb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Balance as of beginning of period</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">200</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">70</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--ContractWithCustomerLiabilityReconsolidationAndDeconsolidation_pn3n3_zf3xBx49sOq4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Reconsolidation (deconsolidation) of Octomera</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">110</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(106</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_ecustom--ContractWithCustomerLiabilityDeconsolidation_iN_pn3n3_di_zki7hSJ82kMa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Deconsolidation of OBI</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(60</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--IncreaseDecreaseInContractWithCustomerLiability_pn3n3_zr2n06ipaAl1" style="vertical-align: bottom; background-color: White"> <td>Additions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">236</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--ContractWithCustomerLiabilityRealizations_iN_pn3n3_di_zE1LDMeuojw6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Realizations</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(445</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ContractWithCustomerLiabilityCurrent_iE_pn3n3_zoGp4YpnSYJ9" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance as of end of period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">105</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">200</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

The following table disaggregates the Company’s revenues by major revenue streams. SCHEDULE OF DISAGGREGATION OF REVENUE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Revenue stream:</td><td> </td> <td style="text-align: left"> </td><td id="xdx_49A_20240101__20241231_z1FUhwGHUPf1" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_498_20230101__20231231_z90GcMQpXEp9" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Revenue stream:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--CellProcessDevelopmentServicesAndHospitalServicesMember_z9Wf5bI1RWNl" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Cell process development services and hospital services</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,020</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">515</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--LicenseFeesMember_z1eQWUfMXbxj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">License fees</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">15</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">15</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zapr2vWlMOp" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,035</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">530</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1020000

515000

15000

1035000

530000

<p id="xdx_894_ecustom--ScheduleOfBreakdownOfRevenuesPerCustomerTableTextBlock_zSsBD02kbdT" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">A breakdown of the revenues per customer what constituted at least 10% of revenues is as follows: SCHEDULE OF BREAKDOWN OF REVENUES PER CUSTOMER <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20240101__20241231_zf9nlHdBTCBe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20230101__20231231_zZm8RElRKzv3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Revenue earned:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--MajorCustomersAxis__custom--CustomerAMember__srt--StatementGeographicalAxis__country--US_zEqfa3V8FL98" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify">Customer A (United States)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">492</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--MajorCustomersAxis__custom--CustomerBMember__srt--StatementGeographicalAxis__country--US_zqhXG31KlANi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Customer B (United States)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">280</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--MajorCustomersAxis__custom--CustomerCMember__srt--StatementGeographicalAxis__country--US_zCHkgH2tNN99" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Customer C (United States)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">90</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--MajorCustomersAxis__custom--CustomerDMember__srt--StatementGeographicalAxis__country--US_zy3KNHLCLjl1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Customer D (United States)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">280</td><td style="text-align: left"> </td></tr> </table>

492000

300000

280000

90000

150000

280000

<p id="xdx_89A_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_zNKsZgxXRUIc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">The activity for accounts receivable is comprised of: SCHEDULE OF ACTIVITY FOR TRADE RECEIVABLES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20240101__20241231_zKn5hmyiXpn5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20230101__20231231_zhgtnlioqpef" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40E_eus-gaap--AccountsReceivableNetCurrent_iS_pn3n3_zEnXVy16Ui3h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Balance as of beginning of period</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">88</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">36,183</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--AccountsReceivableDeconsolidation_iN_pn3n3_di_zlEF7u996Ptb" style="vertical-align: bottom; background-color: White"> <td>Deconsolidation of Octomera</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">82</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,985</td><td style="text-align: left">)</td></tr> <tr id="xdx_402_ecustom--AccountsReceivableAdditions_iI_pn3n3_zN4Qwlppvtge" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Additions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">670</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">560</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--AccountsReceivableCollections_pn3n3_zyUN6kzq65me" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Collections</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,268</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6,230</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_ecustom--AccountsReceivableAllowancesForDoubtfulAccounts_pn3n3_zMNUi8ilktUb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Allowances for credit losses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">469</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(24,388</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_ecustom--ExchangeRateDifferencesOfAccountsReceivable_pn3n3_zGOnoh9I513g" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Exchange rate differences</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(52</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--AccountsReceivableNetCurrent_iE_pn3n3_zl15gTNAQQ9j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance as of end of period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">40</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">88</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

88000

36183000

-82000 5985000 670000 560000 -1268000 -6230000 469000 -24388000 -1000 -52000

40000

88000

<p id="xdx_89D_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zvcFLaYaKxXa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">The activity for contract liabilities is comprised of: SCHEDULE OF ACTIVITY FOR CONTRACT LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20240101__20241231_zRkFHBFg8fu3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20230101__20231231_zeibohvCBydl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40D_eus-gaap--ContractWithCustomerLiabilityCurrent_iS_pn3n3_zEZOzezf2PRb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Balance as of beginning of period</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">200</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">70</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--ContractWithCustomerLiabilityReconsolidationAndDeconsolidation_pn3n3_zf3xBx49sOq4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Reconsolidation (deconsolidation) of Octomera</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">110</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(106</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_ecustom--ContractWithCustomerLiabilityDeconsolidation_iN_pn3n3_di_zki7hSJ82kMa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Deconsolidation of OBI</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(60</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--IncreaseDecreaseInContractWithCustomerLiability_pn3n3_zr2n06ipaAl1" style="vertical-align: bottom; background-color: White"> <td>Additions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">236</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--ContractWithCustomerLiabilityRealizations_iN_pn3n3_di_zE1LDMeuojw6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Realizations</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(445</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ContractWithCustomerLiabilityCurrent_iE_pn3n3_zoGp4YpnSYJ9" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance as of end of period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">105</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">200</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

200000

70000

110000 -106000 60000

300000

236000

445000

105000

200000

NOTE 18 – COST OF DEVELOPMENT SERVICES AND RESEARCH AND DEVELOPMENT EXPENSES <p id="xdx_899_eus-gaap--ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_zSwZZ62Giwx7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center"> </td> <td style="padding-bottom: 1pt; text-align: center"> </td><td id="xdx_49F_20240101__20241231__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zIYu7BuaMyYd" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center"> </td> <td style="padding-bottom: 1pt; text-align: center"> </td><td id="xdx_493_20230101__20231231__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zr0ZQZ9hGE57" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td colspan="5" style="border-bottom: Black 1pt solid; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center"> </td> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center"> </td> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td colspan="5" style="text-align: center">(in thousands)</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--SalariesWagesAndOfficersCompensation_pn3n3_maRADEz0Eo_zqC0q8e2RjH" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Salaries and related expenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">6,300</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,800</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_maRADEz0Eo_zUlsVy1h5jDe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">158</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">210</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ProfessionalFees_pn3n3_maRADEz0Eo_zhFRQedV2XQj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Subcontracting, professional and consulting services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">745</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,662</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--LabExpenses_pn3n3_maRADEz0Eo_zwscW6dqoehg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lab expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">113</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">377</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--Depreciation_pn3n3_maRADEz0Eo_zQT4pFV72MJb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Depreciation expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">620</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">312</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OtherResearchAndDevelopmentExpense_pn3n3_maRADEz0Eo_zFnTdRi3O2I1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other research and development expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,043</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,542</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--GrantAmount_iN_pn3n3_di_msRADEz0Eo_zgGFGhHVuwR2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less – grant</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(357</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(280</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--ResearchAndDevelopmentExpense_iT_pn3n3_mtRADEz0Eo_zEWYLLxSBd63" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">9,622</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">10,623</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">d.</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Asset Purchase Agreement with Broaden.</td></tr></table> On July 10, 2024, the Company entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Broaden Bioscience and Technology Corp. (“Broaden”) for the purchase by the Company of the following assets (the “Assets”): The process and algorithms developed by Broaden for processing CAR-T, RACE CAR-T and all oncology products that will enable the Company to develop and sell treatments to third parties, which include Broaden’s rights, title and interests in and to all intellectual property, including, but not limited to, patents, patent applications, know-how, materials, licenses, permits and approvals related thereto. Pursuant to the Purchase Agreement, in consideration for the purchase of the Assets, the Company will pay Broaden an amount equal to the value of the Assets established with the assistance of a third party valuation firm not to exceed $<span id="xdx_90A_ecustom--IntangiableAssetPurchasePriceValuedByThirdParty_iI_pn3n3_uUSD_c20240710__dei--LegalEntityAxis__custom--BroadenMember_zihawgXmHeXc" title="Intangiable asset purchase price valued by third party">11,000 (the “Consideration”), less a debt adjustment relating to $10,767 owed to the Company by Broaden for work performed and invoiced (but fully impaired in the Company’s financial statements) between August 2022 and May 2023 (the “Debt”), as detailed in the Purchase Agreement. The Consideration that exceeds the Debt will be payable at the election of the Company in shares of the Company’s common stock at a price of $30.0 per share or 10% above the market price at such time it is paid, whichever is higher, or a note with amortization in 24 months from the date of the Purchase Agreement, including prepayment provisions. The Company accounted for the Purchase agreement by recording the difference between the Consideration and Debt as research and development expenses, and the consideration that exceeds the debt was recorded in other long-term liabilities. Asset Purchase Agreement with Theracell. On July 12, 2024, the Company entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Theracell Advanced Biotechnology S.A, Theracell Advanced Biotechnology LTD and IDNA Genomics Public Limited (collectively, “Theracell”) for the purchase by the Company of the following assets (the “Assets”) owned by Theracell: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">50% of the outstanding ownership rights and equity interests in Theracell Laboratories IKE (“Theracell IKE”) not currently owned by the Company so that the Company shall own 100% of the outstanding equity interests of Theracell IKE; and</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Certain products (the “Products”), which include: (i) the manufacturing processes, algorithms, work instructions, test methods, standard operating procedures and specifications for producing Tumor Infiltrating Lymphocytes (“TILs”) that meet current Good Manufacturing Practice (cGMP) requirements that will enable the Company to potentially use this product as a platform for treating a wide variety of solid tumors; (ii) a 3rd generation GMP lentivirus production process, which is part of a therapy manufacturing process that will enable the Company to potentially treat Beta Thalassemia therapies; (iii) an oncolytic virus cell carrier platform which will enable the Company to potentially develop treatments for an array of cancers; (iv) a process for the potential treatment of mesenchymal stem cells for kidney disorders; (v) a process for controlled isolation of regenerative EVs derived from mesenchymal stem cells for the potential treatment of kidney disorders; and (vi) bioxome encapsulated APIs for improved transdermal delivery and bioavailability for the potential treatment of atopic dermatitis/wound healing; including Theracell’s rights, title and interests in and to all intellectual property, including, but not limited to, patents, patent applications, know-how, materials, licenses, permits and approvals relating to Products as further described in the Purchase Agreement.</td></tr></table> Pursuant to the Purchase Agreement, in consideration for the purchase of the Assets, the Company will pay Theracell an aggregate purchase price of $<span id="xdx_904_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_uUSD_c20240712__20240712__dei--LegalEntityAxis__custom--TheracellMember_zQMJG15OubH4" title="Intangible asset purchase price valued by third party">13,000 (the “Consideration”), which is equal to the value of the Assets established with the assistance of a third-party valuation firm, less a debt adjustment in the amount of $10,324 which was owed (but fully impaired in the Company’s financial statements) by Theracell to the Company (the “Debt”). The aggregate Consideration will be paid by the Company as follows: (i) $400 will be paid to Theracell within 60 days after signing of the Purchase Agreement, (ii) $250 will be paid to Theracell within one year after signing of the Purchase Agreement, and (iii) the remaining amount (less any Debt) will be paid to Theracell in four equal annual payments beginning on December 30, 2025 and ending on December 30, 2028. As of the date of this annual report on Form 10-K, the Company had paid Theracell $243. The Company accounted for the Purchase agreement by recording the difference between the Consideration and Debt as research and development expenses, and the consideration that exceeds the debt was recorded in short term or other long-term liabilities as appropriate.

<p id="xdx_899_eus-gaap--ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_zSwZZ62Giwx7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center"> </td> <td style="padding-bottom: 1pt; text-align: center"> </td><td id="xdx_49F_20240101__20241231__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zIYu7BuaMyYd" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center"> </td> <td style="padding-bottom: 1pt; text-align: center"> </td><td id="xdx_493_20230101__20231231__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zr0ZQZ9hGE57" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td colspan="5" style="border-bottom: Black 1pt solid; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center"> </td> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center"> </td> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td colspan="5" style="text-align: center">(in thousands)</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--SalariesWagesAndOfficersCompensation_pn3n3_maRADEz0Eo_zqC0q8e2RjH" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Salaries and related expenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">6,300</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,800</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_maRADEz0Eo_zUlsVy1h5jDe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">158</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">210</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ProfessionalFees_pn3n3_maRADEz0Eo_zhFRQedV2XQj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Subcontracting, professional and consulting services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">745</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,662</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--LabExpenses_pn3n3_maRADEz0Eo_zwscW6dqoehg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lab expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">113</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">377</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--Depreciation_pn3n3_maRADEz0Eo_zQT4pFV72MJb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Depreciation expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">620</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">312</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OtherResearchAndDevelopmentExpense_pn3n3_maRADEz0Eo_zFnTdRi3O2I1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other research and development expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,043</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,542</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--GrantAmount_iN_pn3n3_di_msRADEz0Eo_zgGFGhHVuwR2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less – grant</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(357</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(280</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--ResearchAndDevelopmentExpense_iT_pn3n3_mtRADEz0Eo_zEWYLLxSBd63" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">9,622</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">10,623</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

6300000

4800000

158000

210000

745000

3662000

113000 377000

620000

312000

2043000

1542000

357000 280000

9622000

10623000

11000000

10767000

30.0

0.10

50% of the outstanding ownership rights and equity interests in Theracell Laboratories IKE (“Theracell IKE”) not currently owned by the Company so that the Company shall own 100% of the outstanding equity interests of Theracell IKE; and

13000000

10324000

The aggregate Consideration will be paid by the Company as follows: (i) $400 will be paid to Theracell within 60 days after signing of the Purchase Agreement, (ii) $250 will be paid to Theracell within one year after signing of the Purchase Agreement, and (iii) the remaining amount (less any Debt) will be paid to Theracell in four equal annual payments beginning on December 30, 2025 and ending on December 30, 2028. As of the date of this annual report on Form 10-K, the Company had paid Theracell $243. The Company accounted for the Purchase agreement by recording the difference between the Consideration and Debt as research and development expenses, and the consideration that exceeds the debt was recorded in short term or other long-term liabilities as appropriate.

NOTE 19 – FINANCIAL EXPENSES, NET SCHEDULE OF FINANCIAL EXPENSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_49B_20240101__20241231_zdbvt2Wb7rxc" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_49F_20230101__20231231_zBm8vKWSBxxh" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td colspan="5" style="border-bottom: Black 1pt solid; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td colspan="5" style="border-bottom: Black 1pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--InterestExpenseOnConvertibleLoans_pn3n3_maTFEzElv_zpiMX5VPcGJ4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Interest expense on convertible loans</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,737</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,167</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_ecustom--ForeignCurrencyTransactionsGainLossRealized_pn3n3_maTFEzElv_zhYV1qLmm2Fi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Foreign exchange loss, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">782</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">325</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OtherIncome_iN_pn3n3_di_msTFEzElv_zyZirQKH4gA6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Other expense</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(11</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">7</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--FinancialExpenses_iT_pn3n3_mtTFEzElv_zMSrYNYWplh" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,508</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,499</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

SCHEDULE OF FINANCIAL EXPENSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_49B_20240101__20241231_zdbvt2Wb7rxc" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_49F_20230101__20231231_zBm8vKWSBxxh" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td colspan="5" style="border-bottom: Black 1pt solid; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td colspan="5" style="border-bottom: Black 1pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--InterestExpenseOnConvertibleLoans_pn3n3_maTFEzElv_zpiMX5VPcGJ4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Interest expense on convertible loans</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,737</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,167</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_ecustom--ForeignCurrencyTransactionsGainLossRealized_pn3n3_maTFEzElv_zhYV1qLmm2Fi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Foreign exchange loss, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">782</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">325</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OtherIncome_iN_pn3n3_di_msTFEzElv_zyZirQKH4gA6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Other expense</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(11</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">7</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--FinancialExpenses_iT_pn3n3_mtTFEzElv_zMSrYNYWplh" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,508</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,499</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

3737000 2167000 782000 325000

11000

-7000

4508000 2499000 NOTE 20 – DECONSOLIDATION OF SUBSIDIARIES Deconsolidation of Orgenesis Biotech Israel Limited (“OBI”) On February 14, 2024, following a claim for payment by employees of OBI of past salaries due, the district court in Haifa, Israel appointed a trustee to run the affairs of OBI. As a result of this appointment, effective February 14, 2024, the Company no longer controlled OBI and has ceased to consolidate the results of OBI into its consolidated results. The Company recognized a loss as a result of the deconsolidation of $<span id="xdx_907_eus-gaap--DeconsolidationGainOrLossAmount_iN_pn3n3_di_c20240101__20241231__us-gaap--BusinessAcquisitionAxis__custom--OrgenesisBiotechIsraelLimitedMember_zWBPXSM8gts5" title="Recognized loss from deconsolidation">66. The Company does not currently believe that rehabilitation is possible and purchased certain OBI equipment. The Company recorded $<span id="xdx_900_eus-gaap--AccountsPayableCurrent_iI_pn3n3_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--BusinessAcquisitionAxis__custom--OrgenesisBiotechIsraelLimitedMember_zZS3X79Dfmga" title="Accounts payable related parties">2,695 being what it owes to OBI under Accounts payable related Parties on the balance sheet of December 31, 2024. <p id="xdx_89B_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_hus-gaap--BusinessAcquisitionAxis__custom--OrgenesisBiotechIsraelLimitedMember_gL3SOBABATB-JBO_zZfFE1UCsfab" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">The following table summarizes the deconsolidated assets and liabilities as of February 14, 2024: SCHEDULE OF DECONSOLIDATE ASSETS AND LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49E_20240214__us-gaap--BusinessAcquisitionAxis__custom--OrgenesisBiotechIsraelLimitedMember_zpqwGfIqCpdd" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify">Total assets acquired:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_pn3n3_maBCRIAznti_zVwFdg6mdCLi" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 80%; text-align: justify">Cash and cash equivalents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_iI_pn3n3_maBCRIAznti_zfcWjalvnKqa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Property, plants and equipment, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,884</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_iI_pn3n3_maBCRIAznti_zwNPnt4QQQ6a" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Other Assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,422</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iTI_pn3n3_mtBCRIAznti_maBCRIAzz4h_z8BnU5V4dSW2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Total assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">4,310</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iI_pn3n3_msBCRIAzz4h_zMlUBd1WvCH6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify; padding-bottom: 1pt">Total liabilities:</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">4,244</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iTI_pn3n3_mtBCRIAzz4h_maDLAz1yo_z1ywCgtj9WSj" style="vertical-align: bottom; background-color: White"> <td style="font-style: italic; text-align: justify; padding-bottom: 1pt">Total Net Assets deconsolidated</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">66</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--DeconsolidationLossAmount_iTI_pn3n3_mtDLAz1yo_zaxjCo9DJzC1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify">Loss from deconsolidation of OBI</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">66</td><td style="text-align: left"> </td></tr> </table> Deconsolidation of Korea, Belgium, Services Deconsolidation of Orgenesis Korea During 2024, following a claim for payment by employees of Orgenesis Korea of past salaries due, the court in Korea ordered the liquidation of Orgenesis Korea. As a result of thereof, effective October 1, 2024 , the Company no longer controlled Orgenesis Korea and has ceased to consolidate the results of Orgenesis Korea into its consolidated results. The Company recognized a profit as a result of the deconsolidation of $<span id="xdx_900_eus-gaap--DeconsolidationGainOrLossAmount_iN_pn3n3_di_c20240101__20241231__us-gaap--BusinessAcquisitionAxis__custom--OrgenesisKoreaMember_z0QX3NwE4RB9" title="Recognized loss from deconsolidation">1,335. <div id="xdx_C0A_gL3SOBABATB-JBO_zpcZrvyc2B7b"> <table cellpadding="0" cellspacing="0" id="xdx_30A_134_zyq9YmCrOyfk" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - SCHEDULE OF DECONSOLIDATE ASSETS AND LIABILITIES (Details)"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20241001__us-gaap--BusinessAcquisitionAxis__custom--OrgenesisKoreaMember_zzUYctnzT8k" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify">Total assets acquired:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_pn3n3_maBCRIAznti_zmTgCGoFS6I9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 80%; text-align: justify">Cash and cash equivalents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_iI_pn3n3_maBCRIAznti_zcrwly1xZWL6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Property, plants and equipment, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_iI_pn3n3_maBCRIAznti_z2cSXHmLgENi" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Other Assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">40</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iTI_pn3n3_mtBCRIAznti_maBCRIAzz4h_zdPZ26Ednc66" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Total assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">41</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iI_pn3n3_msBCRIAzz4h_zmkxR35Yvd5f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify; padding-bottom: 1pt">Total liabilities:</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">749</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iNTI_pn3n3_di_mtBCRIAzz4h_maDLAz1yo_zYnoP7f0tyok" style="vertical-align: bottom; background-color: White"> <td style="font-style: italic; text-align: justify">Total Net liabilities deconsolidated</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">708</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--AccumulatedOtherComprehensiveIncomeDeconsolidated_iI_pn3n3_maDLAz1yo_zzmNs5VIHXTl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify; padding-bottom: 1pt">Total accumulated other comprehensive income deconsolidated</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">627</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--DeconsolidationProfitAmount_iTI_pn3n3_mtDLAz1yo_zfxcSyYflk6i" style="vertical-align: bottom; background-color: White"> <td style="font-style: italic; text-align: justify">Profit from deconsolidation of Orgenesis Korea</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,335</td><td style="text-align: left"> </td></tr> </table> </div> Deconsolidation of Orgenesis Belgium SRL and Orgenesis Services SRL (“the Belgian subsidiaries”) On December 20, 2024, the Liège Business Court in Belgium appointed provisional liquidators for the Belgian subsidiaries. The Belgian subsidiaries had, on November 8, 2024, petitioned the Liège Business Court to allow a judicial reorganization pursuant to Article XX.41 of the Belgian Code of Economic Law. The petition followed the inability of the Belgian subsidiaries to pay employee payroll expenses and accounts payable. As a result of thereof, effective December 20, 2024, the Company no longer controlled the Belgian subsidiaries and has ceased to consolidate their results into its consolidated results. The Company recognized a profit as a result of the deconsolidation of $<span id="xdx_90D_eus-gaap--DeconsolidationGainOrLossAmount_iN_pn3n3_di_c20240101__20241231__us-gaap--BusinessAcquisitionAxis__custom--OrgenesisBelgiumSRLAndOrgenesisSRLMember_zVAOq47zmhY" title="Recognized loss from deconsolidation">3,213. <div><div> <table cellpadding="0" cellspacing="0" id="xdx_302_134_zyUi1kuYhU1l" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - SCHEDULE OF DECONSOLIDATE ASSETS AND LIABILITIES (Details)"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20241220__us-gaap--BusinessAcquisitionAxis__custom--OrgenesisBelgiumSRLMember_zJPCRdYKTZ42" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify">Orgenesis Belgium SRL</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-style: italic; text-align: justify">Total assets acquired:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_pn3n3_maBCRIAznti_z7yNLbq7b7Ll" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Cash and cash equivalents</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_iI_pn3n3_maBCRIAznti_zMiqqzRQ6ij5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 80%; text-align: justify">Property, plants and equipment, net</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">13</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_iI_pn3n3_maBCRIAznti_z61AraFUVDZe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Other Assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">91</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iTI_pn3n3_mtBCRIAznti_maBCRIAzz4h_zzJLhdluxCqa" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Total assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">104</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iI_pn3n3_msBCRIAzz4h_zb4snZVDxBlg" style="vertical-align: bottom; background-color: White"> <td style="font-style: italic; text-align: justify">Total liabilities assumed:</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,453</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iNTI_pn3n3_di_mtBCRIAzz4h_maDLAz1yo_zmvQIcxZKzkk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify">Total net liabilities deconsolidated</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,349</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--AccumulatedOtherComprehensiveIncomeDeconsolidated_iI_pn3n3_zr9nw6PcyYy8" style="vertical-align: bottom; background-color: White"> <td style="font-style: italic; text-align: justify">Total Accumulated Other Comprehensive income deconsolidated</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">82</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--DeconsolidationProfitAmount_iTI_pn3n3_mtDLAz1yo_zDUla7xfq98f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify">Profit from deconsolidation of Orgenesis Belgium SRL</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,431</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_490_20241220__us-gaap--BusinessAcquisitionAxis__custom--OrgenesisServicesSRLMember_z4VrCNmgS1ri" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify">Orgenesis Services SRL</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-style: italic; text-align: justify">Total assets acquired:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_pn3n3_maBCRIAznti_zaGyZgUkYuhk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 80%; text-align: justify">Cash and cash equivalents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_iI_pn3n3_maBCRIAznti_zMgdkUhE6tg2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Property, plants and equipment, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">768</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_iI_pn3n3_maBCRIAznti_zcihM4QQBBEh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Other Assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">124</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iTI_pn3n3_mtBCRIAznti_maBCRIAzz4h_zlXR8d54eEBa" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Total assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">897</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iI_pn3n3_msBCRIAzz4h_zK4Cm7asAikk" style="vertical-align: bottom; background-color: White"> <td style="font-style: italic; text-align: justify">Total liabilities assumed:</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,852</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iNTI_pn3n3_di_mtBCRIAzz4h_maDLAz1yo_zNplTBDpNgMi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify">Total net liabilities deconsolidated</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">955</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--AccumulatedOtherComprehensiveIncomeDeconsolidated_iI_pn3n3_zQFnm8MbngKf" style="vertical-align: bottom; background-color: White"> <td style="font-style: italic; text-align: justify">Total Accumulated Other Comprehensive loss deconsolidated</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(175</td><td style="text-align: left">)</td></tr> <tr id="xdx_40E_ecustom--DeconsolidationProfitAmount_iTI_pn3n3_mtDLAz1yo_zXdnfbZxVaE1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify">Profit from deconsolidation of Orgenesis Services SRL</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">782</td><td style="text-align: left"> </td></tr> </table> </div></div> The deconsolidation of the Belgian subsidiaries is described in this note. For related legal proceedings, including the appointment of provisional liquidators by the Liège Business Court, see note 22.

-66000

2695000

<p id="xdx_89B_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_hus-gaap--BusinessAcquisitionAxis__custom--OrgenesisBiotechIsraelLimitedMember_gL3SOBABATB-JBO_zZfFE1UCsfab" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">The following table summarizes the deconsolidated assets and liabilities as of February 14, 2024: SCHEDULE OF DECONSOLIDATE ASSETS AND LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49E_20240214__us-gaap--BusinessAcquisitionAxis__custom--OrgenesisBiotechIsraelLimitedMember_zpqwGfIqCpdd" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify">Total assets acquired:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_pn3n3_maBCRIAznti_zVwFdg6mdCLi" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 80%; text-align: justify">Cash and cash equivalents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_iI_pn3n3_maBCRIAznti_zfcWjalvnKqa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Property, plants and equipment, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,884</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_iI_pn3n3_maBCRIAznti_zwNPnt4QQQ6a" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Other Assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,422</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iTI_pn3n3_mtBCRIAznti_maBCRIAzz4h_z8BnU5V4dSW2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Total assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">4,310</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iI_pn3n3_msBCRIAzz4h_zMlUBd1WvCH6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify; padding-bottom: 1pt">Total liabilities:</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">4,244</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iTI_pn3n3_mtBCRIAzz4h_maDLAz1yo_z1ywCgtj9WSj" style="vertical-align: bottom; background-color: White"> <td style="font-style: italic; text-align: justify; padding-bottom: 1pt">Total Net Assets deconsolidated</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">66</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--DeconsolidationLossAmount_iTI_pn3n3_mtDLAz1yo_zaxjCo9DJzC1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify">Loss from deconsolidation of OBI</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">66</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" id="xdx_30A_134_zyq9YmCrOyfk" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - SCHEDULE OF DECONSOLIDATE ASSETS AND LIABILITIES (Details)"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20241001__us-gaap--BusinessAcquisitionAxis__custom--OrgenesisKoreaMember_zzUYctnzT8k" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify">Total assets acquired:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_pn3n3_maBCRIAznti_zmTgCGoFS6I9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 80%; text-align: justify">Cash and cash equivalents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_iI_pn3n3_maBCRIAznti_zcrwly1xZWL6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Property, plants and equipment, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_iI_pn3n3_maBCRIAznti_z2cSXHmLgENi" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Other Assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">40</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iTI_pn3n3_mtBCRIAznti_maBCRIAzz4h_zdPZ26Ednc66" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Total assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">41</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iI_pn3n3_msBCRIAzz4h_zmkxR35Yvd5f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify; padding-bottom: 1pt">Total liabilities:</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">749</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iNTI_pn3n3_di_mtBCRIAzz4h_maDLAz1yo_zYnoP7f0tyok" style="vertical-align: bottom; background-color: White"> <td style="font-style: italic; text-align: justify">Total Net liabilities deconsolidated</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">708</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--AccumulatedOtherComprehensiveIncomeDeconsolidated_iI_pn3n3_maDLAz1yo_zzmNs5VIHXTl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; text-align: justify; padding-bottom: 1pt">Total accumulated other comprehensive income deconsolidated</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">627</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--DeconsolidationProfitAmount_iTI_pn3n3_mtDLAz1yo_zfxcSyYflk6i" style="vertical-align: bottom; background-color: White"> <td style="font-style: italic; text-align: justify">Profit from deconsolidation of Orgenesis Korea</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,335</td><td style="text-align: left"> </td></tr> </table>

4000

2884000

1422000

4310000

4244000

66000

-1335000

1000

40000

41000

749000

-708000

627000 1335000

-3213000

13000

91000

104000

2453000

-2349000

82000 2431000

5000

768000

124000

897000

1852000

-955000

-175000 782000

NOTE 21 – RELATED PARTIES TRANSACTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">a.</td><td style="font: 10pt Times New Roman, Times, Serif">Related Parties presented in the consolidated statements of comprehensive loss</td></tr></table> SCHEDULE OF RELATED PARTY TRANSACTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td colspan="5" style="border-bottom: Black 1pt solid; text-align: center">Years ended December 31,</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td colspan="5" style="border-bottom: Black 1pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 2.5pt">Stock-based compensation expenses to executive officers</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20241231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_z3WFHZEWMHW2" style="border-bottom: Black 2.5pt double; width: 16%; text-align: right" title="Stock Based Compensation">89</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_z1MkVGkZc3Cb" style="border-bottom: Black 2.5pt double; width: 16%; text-align: right" title="Stock Based Compensation">78</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Stock-based compensation expenses to Board Members</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20241231__us-gaap--RelatedPartyTransactionAxis__custom--BoardMembersMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_fKg_____z4JkVUdyjIAj" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock Based Compensation">405</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20231231__us-gaap--RelatedPartyTransactionAxis__custom--BoardMembersMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_fKg_____zPLgPuQZK1S9" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock Based Compensation">99</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Compensation of executive officers</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--OfficersCompensation_pn3n3_c20240101__20241231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_zvAVs1CoXGt3" style="border-bottom: Black 2.5pt double; text-align: right" title="Compensation">323</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--OfficersCompensation_pn3n3_c20230101__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_z1b6mEEfCh7h" style="border-bottom: Black 2.5pt double; text-align: right" title="Compensation">690</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Management and consulting fees to Board Members</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_c20240101__20241231__us-gaap--RelatedPartyTransactionAxis__custom--BoardMembersMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_zhN9lxDYufJd" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and consulting fees">277</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_c20230101__20231231__us-gaap--RelatedPartyTransactionAxis__custom--BoardMembersMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_zWq392TLAn6j" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and consulting fees">380</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="width: 0.5in">b.</td> <td>Related Parties presented in the consolidated balance sheets</td></tr> </table> <p id="xdx_89E_ecustom--ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsTableTextBlock_zrqZ2vYfORmg" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">SCHEDULE OF RELATED PARTIES PRESENTED IN CONSOLIDATED BALANCE SHEETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">(in thousands)</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Executive officers’ payables</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--OtherLiabilities_iI_pn3n3_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ExecutiveOfficerMember_zJueO7QCNMOd" style="width: 16%; text-align: right" title="Related parties payables">225</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--OtherLiabilities_iI_pn3n3_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ExecutiveOfficerMember_zEzK58G2epeb" style="width: 16%; text-align: right" title="Related parties payables">150</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Non-executive directors’ payable</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--OtherLiabilities_iI_pn3n3_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonexecutiveDirectorsMember_zXpkWw8QVnle" style="text-align: right" title="Related parties payables">543</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--OtherLiabilities_iI_pn3n3_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonexecutiveDirectorsMember_zBemyAiR5Cij" style="text-align: right" title="Related parties payables">938</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Amounts payable Orgenesis Biotech Israel Ltd</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--AccountsPayableCurrent_iNI_pn3n3_di_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--ConsolidatedEntitiesAxis__custom--OrgenesisBiotechIsraelLimitedMember_zwz5ChSZrGc6" style="text-align: right" title="Related parties payables">(2,695</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--AccountsPayableCurrent_iNI_pn3n3_di_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--ConsolidatedEntitiesAxis__custom--OrgenesisBiotechIsraelLimitedMember_z5ivvDTKa23a" style="text-align: right" title="Related parties payables">-</td><td style="text-align: left"> </td></tr> </table>

SCHEDULE OF RELATED PARTY TRANSACTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td colspan="5" style="border-bottom: Black 1pt solid; text-align: center">Years ended December 31,</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td colspan="5" style="border-bottom: Black 1pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 2.5pt">Stock-based compensation expenses to executive officers</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20241231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_z3WFHZEWMHW2" style="border-bottom: Black 2.5pt double; width: 16%; text-align: right" title="Stock Based Compensation">89</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_z1MkVGkZc3Cb" style="border-bottom: Black 2.5pt double; width: 16%; text-align: right" title="Stock Based Compensation">78</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Stock-based compensation expenses to Board Members</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20241231__us-gaap--RelatedPartyTransactionAxis__custom--BoardMembersMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_fKg_____z4JkVUdyjIAj" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock Based Compensation">405</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20231231__us-gaap--RelatedPartyTransactionAxis__custom--BoardMembersMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_fKg_____zPLgPuQZK1S9" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock Based Compensation">99</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Compensation of executive officers</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--OfficersCompensation_pn3n3_c20240101__20241231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_zvAVs1CoXGt3" style="border-bottom: Black 2.5pt double; text-align: right" title="Compensation">323</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--OfficersCompensation_pn3n3_c20230101__20231231__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember__us-gaap--RelatedPartyTransactionAxis__srt--ExecutiveOfficerMember_z1b6mEEfCh7h" style="border-bottom: Black 2.5pt double; text-align: right" title="Compensation">690</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Management and consulting fees to Board Members</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_c20240101__20241231__us-gaap--RelatedPartyTransactionAxis__custom--BoardMembersMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_zhN9lxDYufJd" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and consulting fees">277</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_c20230101__20231231__us-gaap--RelatedPartyTransactionAxis__custom--BoardMembersMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_zWq392TLAn6j" style="border-bottom: Black 2.5pt double; text-align: right" title="Management and consulting fees">380</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

89000

78000

405000

99000

323000

690000

277000

380000

<p id="xdx_89E_ecustom--ScheduleOfRelatedPartiesPresentedInConsolidatedBalanceSheetsTableTextBlock_zrqZ2vYfORmg" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">SCHEDULE OF RELATED PARTIES PRESENTED IN CONSOLIDATED BALANCE SHEETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">(in thousands)</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Executive officers’ payables</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--OtherLiabilities_iI_pn3n3_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ExecutiveOfficerMember_zJueO7QCNMOd" style="width: 16%; text-align: right" title="Related parties payables">225</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--OtherLiabilities_iI_pn3n3_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ExecutiveOfficerMember_zEzK58G2epeb" style="width: 16%; text-align: right" title="Related parties payables">150</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Non-executive directors’ payable</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--OtherLiabilities_iI_pn3n3_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonexecutiveDirectorsMember_zXpkWw8QVnle" style="text-align: right" title="Related parties payables">543</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--OtherLiabilities_iI_pn3n3_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NonexecutiveDirectorsMember_zBemyAiR5Cij" style="text-align: right" title="Related parties payables">938</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Amounts payable Orgenesis Biotech Israel Ltd</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--AccountsPayableCurrent_iNI_pn3n3_di_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--ConsolidatedEntitiesAxis__custom--OrgenesisBiotechIsraelLimitedMember_zwz5ChSZrGc6" style="text-align: right" title="Related parties payables">(2,695</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--AccountsPayableCurrent_iNI_pn3n3_di_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--ConsolidatedEntitiesAxis__custom--OrgenesisBiotechIsraelLimitedMember_z5ivvDTKa23a" style="text-align: right" title="Related parties payables">-</td><td style="text-align: left"> </td></tr> </table>

225000

150000

543000

938000

2695000

NOTE 22 – LEGAL PROCEEDINGS On January 18, 2022, a complaint (the “Complaint”) was filed in the Tel Aviv District Court (the “Court”) against the Company, Orgenesis Ltd (“the Israeli Subsidiary”), Prof. Sarah Ferber, Vered Caplan and Dr. Efrat Asa Kunik (collectively, the “defendants”) by plaintiffs the State of Israel, as the owner of Chaim Sheba Medical Center at Tel Hashomer (“Sheba”), and Tel Hashomer Medical Research, Infrastructure and Services Ltd. (collectively, the “plaintiffs”). In the Complaint, the plaintiffs are seeking that the Court issue a declaratory remedy whereby the defendants are required to pay royalties to the plaintiffs at the rate of 7% of the sales and 24% of any and all revenues in consideration for sublicenses related to any product, service or process that contain know-how and technology of Sheba and any and all know-how and technology either developed or supervised by Prof. Ferber in the field of cell therapy, including in the category of the point-of-care platform and any and all services and products in relation to the defendants’ CDMO activity. In addition, the plaintiffs seek that the defendants provide financial statements and pay NIS 10,000 to the plaintiffs due to the royalty provisions of the license agreement, dated February 2, 2012, between the Israeli subsidiary and Tel Hashomer Medical Research, Infrastructure and Services Ltd. (the “License Agreement”). The Complaint alleges that the Company and the Israeli subsidiary used know-how and technology of Sheba and know-how and technology either developed or supervised by Prof. Ferber while employed by Sheba in the field of cell therapy, including in the category of the point-of-care platform and the services and products in relation to the defendants’ CDMO activity and are entitled to the payment of certain royalties pursuant to the terms of the License Agreement. The defendants have filed their statements of defense responding to this Complaint, the Plaintiffs filed their response and the parties are now conducting disclosure proceedings in accordance with Israel’s civil regulations. In accordance with Israel’s civil regulations, the parties considered alternative means to resolve at least some of the disputes and have consented to engage the services of a mutually agreeable mediator. The mediation is currently taking place. According to management’s estimation, since a loss is not considered probable, no provision was made in the financial statements. On September 6, 2023, a claim (the “Claim”) was filed in the Tel Aviv District Court (the “Court”) against the Company, the Israeli Subsidiary, Octomera LLC, Orgenesis Biotech Israel Ltd, Theracell Laboratories Private Company and Vered Caplan (collectively, the “defendants”) by Ehud Almon (Plaintiff) for certain finders’ fees and / or royalties related to sales made by an Octomera subsidiary to a Greek entity in the amount of $896 and also for other means of compensation. The Israeli Subsidiary and Vered Caplan filed their statement of defense on January 28, 2024 claiming, inter alia, that the Plaintiff did not serve as a broker, but rather served as the Greek entity’s representative and as such he is not entitled to compensation of any kind from the defendants. It was also clarified that the defendants did not enter into a finder’s agreement with the Plaintiff. Additionally, the Israeli subsidiary and Vered Caplan claimed that the Plaintiff concealed material information from the court, including the signed partnership agreement between the Greek entity’s owner and the Plaintiff, as well as certain criminal charges brought against him in Greece. On February 22, 2024, the Plaintiff filed a request for service of process to deliver the Claim to the Company and the other defendants incorporated outside of Israel. This request was denied on the same day. An appeal filed by the Plaintiff on the aforementioned decision was denied. On May 27, 2024, the Plaintiff filed a new request for service of process to deliver the Claim to the Company and the other defendants incorporated outside of Israel. On May 28, 2024 the request was accepted. The court ruled that the Claim be delivered via courier to the Company and Octomera LLC, and delivered in accordance with the Hague Convention to Theracell Laboratories. After requesting a continuance, on September 18, 2024, the Plaintiff filed an update that the Claim was delivered to the Company and Octomera LLC on August 16, 2024. On the same day, the Claimant also filed a motion, petitioning that the Claim will be delivered to Theracell Laboratories via the Company or via Vered Caplan, in order to minimize the costs of translating and delivering the Claim to Greece. On October 7, 2024 Vered Caplan filed her opposition to the abovementioned motion, claiming that there is no legal basis for the Claimant’s request, especially since the ruling regarding the service of process was made per the Plaintiff’s request. On October 10, 2024 the Company filed its opposition to the request, on the same basis, mentioning, inter alia, that the claim itself has no connection to Israel and that the Israeli courts are not the appropriate forum for the Plaintiff’s claims. Ruling on the abovementioned motion is pending. According to management’s estimation, since the likelihood of the Plaintiff winning the case is less than fifty percent, no provision was made in the financial statements. On October 26, 2023, a complaint was filed in the Supreme Court of the State of New York by plaintiffs Southern Israel Bridging Fund Two LP and Mr. Amir Hasidim, against the Company, seeking the payment of $<span id="xdx_901_eus-gaap--LossContingencyDamagesSoughtValue_c20231025__20231026__dei--LegalEntityAxis__custom--SouthernIsraelBridgingFundTwoLPMember__srt--TitleOfIndividualAxis__custom--MrAmirHasidimMember_z5nyWeu7Zrv1" title="Seeking payment">1,150 together with interest in the amount of <span id="xdx_90A_ecustom--LitigationSettlementInterestPercentage_dp_uPure_c20231025__20231026__dei--LegalEntityAxis__custom--SouthernIsraelBridgingFundTwoLPMember__srt--TitleOfIndividualAxis__custom--MrAmirHasidimMember_z1wzC06nMC1e" title="Litigation settlement interest percentage">6%. In the Complaint plaintiffs alleged the amount provided to the Company was based on a Convertible Loan Agreement dated May 17, 2022, which provided for a loan amount of $5,000. Notwithstanding the Convertible Loan Agreement, on August 21, 2023, Company sent the plaintiffs an offset notice in light of the plaintiffs’ breach of obligations under the Convertible Loan Agreement and the damages caused to the Company as a result of said breach. The Company counter sued as well, seeking damages for Plaintiff’s breach of contract, fraud and harassment. Accordingly, the Company disputes whether it owes plaintiffs the amount sought in the Complaint. On November 1, 2023, a claim (the “Claim”) was filed in the Tel Aviv District Court (the “Court”) against the Company, the Israeli Subsidiary, and Vered Caplan (collectively, the “Defendants”) by Fidelity Venture Capital Ltd. and Dror Atzmon (together – the “Plaintiffs”). The claim is based on two agreements the Company entered into with the Plaintiffs on November 2, 2016: (a) an unsecured convertible note agreements for an aggregate amount of NIS 1 million ($280). The loan bears a monthly interest rate of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231101__us-gaap--TypeOfArrangementAxis__custom--UnsecuredConvertibleNoteAgreementsMember_zJ57iXfoeiEk" title="Monthly interest rate">2% and will mature on May 1, 2017, unless converted earlier and (b) a consultation agreement which awarded the Plaintiffs 80 thousand warrants. The exercise price of the warrants and conversion price were fixed at $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231101__us-gaap--TypeOfArrangementAxis__custom--ConsultationAgreementMember_zpjwKYZAirn6" title="Warrants exercise price">5.2 per share (pre-reverse stock split implemented by the Company in November 2017). On April 27, 2017, and November 2, 2017, the Company entered into extension agreements through November 2, 2017 and May 2, 2018, respectively, in connection with the convertible note agreements. In March 2018, the Plaintiffs submitted a notice of their intention to convert into shares the Company’s common stock, the principal amount of the loan, and accrued interest of approximately $<span id="xdx_90E_eus-gaap--DebtInstrumentPeriodicPayment_pn3n3_c20180331__20180331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zndwdODxSRU7" title="Principal amount of the loan and accrued interest">383 outstanding. In addition, the Plaintiffs exercised all the warrants awarded in the consultation agreement. In light of the reverse stock split which took place in November 2017, the Company disagreed with the plaintiffs’ calculations regarding the number of issuable shares of Common Stock. The Company responded to the notice and rejected these contentions in their entirety. In April 2018, the Company terminated the agreements based on several claims, including mistake, intentional misrepresentation and bad faith. Therefore, the Company deposited the shares in total amount of 10,798 issued under those agreements and the principal amount and accrued interest of the loan in an escrow account. The deposit of the principal amount and accrued interest presented as restricted cash in the balance sheet as of December 31, 2024. Based on the calculation difference, in their Claim, the Plaintiffs request damages in the amount of NIS 40,143, and the issuance of 1,186,960 shares of the Company. The Defendants filed their statement of defense on April 15, 2024, in which they raised, among others, the aforementioned claims and additional procedural and substantial claims, including laches. The parties have agreed to start mediation proceeding in connection with the Claim. The mediation is currently taking place. According to management’s estimation, since the likelihood of the Plaintiffs winning the case is less than fifty percent, no provision was made in the financial statements. On July 11, 2024, the Israeli subsidiary (Declared bankrupt by Israeli district court in August 2025) reached a settlement agreement regarding unpaid rentals sanctioned by the Tel Aviv Magistrate’s court pursuant to which the subsidiary will pay the amount of NIS <span id="xdx_903_eus-gaap--LitigationSettlementAmountAwardedFromOtherParty_uNIS_c20240711__20240711__us-gaap--TypeOfArrangementAxis__custom--UnsecuredConvertibleNoteAgreementsMember_zHJUAYPpEZYi" title="Litigation settlement, amount awarded from other party">427,000 (approximately $<span id="xdx_903_eus-gaap--GainLossRelatedToLitigationSettlement_pn3n3_uUSD_c20240711__20240711__us-gaap--TypeOfArrangementAxis__custom--UnsecuredConvertibleNoteAgreementsMember_zxsycSZ0pCS" title="Gain loss related to litigation settlement">114) including VAT to the lessor of leased premises no later than September 30, 2024, which includes a grace period for late payments. As of the date of this annual report on Form 10-K, the Company had paid all of the settlement amount less $<span id="xdx_905_eus-gaap--GainLossRelatedToLitigationSettlement_pn3n3_uUSD_c20241101__20241130__us-gaap--TypeOfArrangementAxis__custom--UnsecuredConvertibleNoteAgreementsMember_z95xpIYcObR2" title="Gain loss related to litigation settlement">47, and the lessor agreed to defer payment of the $<span id="xdx_90D_eus-gaap--GainLossRelatedToLitigationSettlement_pn3n3_uUSD_c20241101__20241130__us-gaap--TypeOfArrangementAxis__custom--UnsecuredConvertibleNoteAgreementsMember_zLF161J1aF6j" title="Gain loss related to litigation settlement">47 to December 28, 2024. In the event that the Company fails to meet all of its obligations under the settlement agreement, the Company may be liable to pay an additional NIS <span id="xdx_900_ecustom--AdditionalAmountToBePaidForFailureLitigationSettlementAmountAwardedFromOtherParty_uNIS_c20240711__20240711__us-gaap--TypeOfArrangementAxis__custom--UnsecuredConvertibleNoteAgreementsMember_zZ1qsdWVRWY" title="Additional amount to be paid for failure litigation settlement amount awarded from other party">211,000 (approximately $<span id="xdx_903_eus-gaap--GainLossRelatedToLitigationSettlement_pn3n3_uUSD_c20240711__20240711__us-gaap--TypeOfArrangementAxis__custom--UnsecuredConvertibleNoteTwoAgreementsMember_zAO5WwGw9gmg" title="Gain loss related to litigation settlement">57) over and above the amount still due, in respect of claims for unpaid rentals made by the lessor. On December 20, 2024, the Liège Business Court in Belgium appointed provisional liquidators for Orgenesis Belgium SRL and Orgenesis Services SRL (“the Belgian subsidiaries”). The Belgian subsidiaries had, on November 8, 2024, petitioned the Liège Business Court to allow a judicial reorganization pursuant to Article XX.41 of the Belgian Code of Economic Law. The petition followed the inability of the Belgian subsidiaries to pay employee payroll expenses and accounts payable. On December 19, 2024, Murray Bacal filed a complaint against Orgenesis, Inc. in the circuit court of the eleventh judicial circuit in and for Miami-Dade County, Florida claiming non-payment for services provided pursuant to terms of a strategic advisor agreement. On June 8, 2025, the court entered a default final judgment against the Company for damages calculated to be $<span id="xdx_90B_eus-gaap--LossContingencyDamagesSoughtValue_pn3n3_c20250608__20250608__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z66exGJcBJP2" title="Plaintiffs request damages amount">512 plus post-judgment interest. The Company has filed a motion to vacate the default final judgment as void for non-service of the complaint on the defendant. On March 4, 2026, the Court vacated the default final judgment in its entirety. On January 30, 2026, the Company, via service of process to the New York Secretary of State, was served with a complaint captioned “Newtech Investment Holdings, LLC, Ariel Malik, and Guy Hoffman vs. Orgenesis Inc. and Theracell Advanced Biotechnology Ltd.” The complaint requests specific performance. The complaint alleges that the Company and Theracell Advanced Biotechnology Ltd. entered into a Joint Venture Agreement dated December 25, 2022, and that rights previously assigned by the Company to Texas Advanced Therapies LLC were transferred to the plaintiffs upon the dissolution of Texas Advanced Therapies LLC. The Company disputes that the dissolution transferred those rights to the plaintiffs without the Company’s consent and intends to contest the claim vigorously, furthermore the JV Agreement contains a clause that in the event of a dissolution of any party to the agreement the JV agreement is terminated. On March 10, 2026, the court denied Plaintiffs’ motion to seal the Joint Venture Agreement in its entirety and directed the clerk to unseal the filed agreement. Except as described above, the Company is not involved in any pending material legal proceedings.

In the Complaint, the plaintiffs are seeking that the Court issue a declaratory remedy whereby the defendants are required to pay royalties to the plaintiffs at the rate of 7% of the sales and 24% of any and all revenues in consideration for sublicenses related to any product, service or process that contain know-how and technology of Sheba and any and all know-how and technology either developed or supervised by Prof. Ferber in the field of cell therapy, including in the category of the point-of-care platform and any and all services and products in relation to the defendants’ CDMO activity.

10000000

896000

1150

0.06

5000

1000000

280000

0.02

80000

5.2

383000

10798

40143000000

1186960

427000

114000

47000

211000

57000

512000

NOTE 23 – SUBSEQUENT EVENTS On January 22, 2025, the Company entered into an Equity Purchase Agreement (the “Equity Purchase Agreement”) with Williamsburg Venture Holdings, LLC, a Nevada limited liability company (“Investor”), pursuant to which the Investor agreed to invest up to $5,000,000 over a 24-month period (unless otherwise determined therein) in accordance with the terms and conditions of an Equity Purchase Agreement, dated as of January 22, 2025, by and between Orgenesis and the Investor. In connection with the Equity Purchase Agreement, the parties also entered into a Registration Rights Agreement (the “Registration Rights Agreement”) pursuant to which the Company agreed to register with the SEC the ordinary shares issuable under the Equity Purchase Agreement, among other securities. The Investor agrees to fund $<span id="xdx_900_eus-gaap--Investments_iI_c20250122__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementMember_z3TRNVjGCKjb">750,000 upon the Registration Statement being deemed effective by the SEC. During the remaining term, the Company shall be entitled to put to the Investor, and the Investor shall be obligated to purchase, such number of ordinary shares of Orgenesis (such shares, the “Put Shares”) and at such price as are determined in accordance with the Equity Purchase Agreement. The per share purchase price for the Put Shares shall be 90% of the market price defined as the average of the two (2) lowest Volume-Weighted Average Price (VWAP) for the five (5) consecutive trading days immediately preceding the relevant Clearing Date (defined therein), as reported by Bloomberg Finance L.P. or other reputable source. At the Company’s option, under an Accelerated Purchase Notice (defined therein), the Company may deliver a put notice by 11:00 AM on a particular day with a per share purchase price that would be the lowest traded price on that day. Further, in consideration of Orgenesis’ Put rights, the Investor shall be entitled to <span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20250122__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember_z7be2ixJrKG3">168,182 ordinary shares of Orgenesis from the date of the Equity Purchase Agreement and pursuant to the Equity Purchase Agreement, the Investor may not acquire at any point, more than <span id="xdx_90E_eus-gaap--BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_iI_pid_dp_c20250122__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--WilliamsburgVentureHoldingsLLCMember_zrOTmVZYjYEa">9.99% of the outstanding ordinary shares of Orgenesis. On February 28, 2025, the Company entered into an Agreement (the “Asset Purchase Agreement”) with Neurocords, LLC. (“Neurocords”) for the purchase by the Company of certain intellectual property assets and all development product, deliverables and data related thereto in the field of advanced regenerative medicine therapies for spinal cord injuries (SCI) (the “Assets”). In addition, Neurocords and Company entered into mutual releases against all future claims, and terminated certain licensing and related agreements previously entered into. In addition, the Company will have a three-month option at no further cost to receive an assignment of the William Rice University Option Agreement, dated November 24, 2024. Pursuant to the Asset Purchase Agreement, in consideration for the purchase of the Assets, the Company issued to Neurocords <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20250228__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_ztFQaMdUc5Rc" title="Ordinary shares">1,200,000 shares of common stock, free and clear of any trading restrictions after the initial 6-month restricted period, or any other restrictions or third-party rights. On August 9, 2025, Yaron Adler and Adam Pelavin notified Orgenesis Inc. (the “Company”), of their decision to resign as directors of the Company, effective immediately. Mr. Adler and Mr. Pelavin’s resignations were not the result of any disagreement with the Company, or its management on any matter relating to the Company’s operations, policies or practices. On August 18, 2025, Santhosh Nagaraja notified Orgenesis Inc. (the “Company”), of his decision to resign as director of the Company, effective immediately. Mr. Nagaraja’s resignation was not the result of any disagreement with the Company, or its management on any matter relating to the Company’s operations, policies or practices. On August 21, 2055, Ashish Nanda notified Orgenesis Inc. (the “Company”), of his decision to resign as director of the Company, effective immediately. Mr. Nanda’s resignation was not the result of any disagreement with the Company, or its management on any matter relating to the Company’s operations, policies or practices. On August 6, 2025, the district court in Lod, Israel declared Orgenesis Limited, the Israeli subsidiary, bankrupt and ordered it to be dissolved. On June 13, 2025 the Company and Germfree reached a settlement thus resolving any remaining differences between themselves. On September 10, 2025, Theracell Laboratories IKE (“Theracell”), a subsidiary of Octomera LLC, which is a subsidiary of the Company, entered into a Convertible Loan Agreement (the “Agreement”) with Alpha Prosperity Fund SPC, acting on behalf of and for the account of Segregated Portfolio P (the “Lender”). Pursuant to the Agreement, the Lender agreed to provide Theracell with an initial loan in the principal amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20250910__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zaxjqbiWVy75" title="Principal amount">1,000,000 (the “Loan”). The Loan will bear simple interest at a rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20250910__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zM1NrUoVYfk4" title="Interest rate">10% per annum and has a maturity of 36 months. For the first 30 days following the effective date, the Borrower may prepay the Loan without the consent of the Lender. Thereafter, repayment requires the Lender’s prior approval. Beginning after 30 days and continuing until maturity, the Lender has the option, at its sole discretion, to convert the outstanding amount into equity of either the Company or Theracell, such that the Lender would hold up to 80% of the outstanding share capital of the applicable entity. The conversion of the Loan into shares of the Company is subject to shareholder approval of the issuance of the required shares. In addition, the Agreement provides that the Lender will be issued a warrant to purchase <span id="xdx_90C_ecustom--WarrantsToPurchasePercentage_pid_dp_c20250910__20250910__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zRupOdGhxWQ3" title="Warrants purchase percentage">15% of the fully diluted share capital of either the Company or Theracell, at the Lender’s discretion, for an aggregate exercise price of $<span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstanding_iI_dp_c20250910__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zG2LtOBwdGod" title="Warrants purchase">250,000 and exercisable for three years from issuance. The issuance of shares upon exercise of the warrant is likewise subject to shareholder approval of the issuance of such shares. Additional warrants would be issued in connection with each cumulative drawdown of an additional $<span id="xdx_903_ecustom--AdditionalWarrants_iI_dp_c20250910__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zAGS71UGHi0g" title="Additional warrants">1,000,000 under the credit facility referenced below. <span id="xdx_90C_eus-gaap--LineOfCreditFacilityDescription_dp_c20250910__20250910__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zXX6Zfrq4Vn6" title="Credit facility description">The Agreement further provides Theracell with access to a credit facility of up to $10,000,000, available in tranches with the Lender’s prior written approval in its sole discretion. Drawdowns under the facility are subject to the same terms as the Loan, other than the conversion feature. Theracell has drawn $10,000,000 under the credit facility as well as $775,000 paid over and above the $10,000,000 credit line amount as of the date of this annual report on Form 10-K. The previously outstanding debt facilities from Newtech Investment Holdings, LLC and Ariel Malik totaling $6,083,857 were repaid from the proceeds of the facility. The Agreement also provides that, following the lapse of 30 days from the Effective Date and subject to the receipt of all necessary corporate and legal approvals, the Lender may appoint three members to the Company’s Board of Directors, which appointments will be subject to the disclosure and filing requirements of the Securities Exchange Act of 1934 and the rules of the Securities and Exchange Commission. On January 9th, 2026, the Company issued to Lender a warrant (the “Alpha Warrant”) exercisable for <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20260109__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zy73hMmcRBcj" title="Warrant issued">3,289,490 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), with a three year expiration and an aggregate exercise price equal to $250,000. The Alpha Warrant and the shares of Common Stock issuable upon exercise of such Warrant have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), and shall be exempt from registration under Section 4(a)(2) of the Securities Act as a transaction not involving a public offering. On August 8, 2025, Mr. Victor Miller, the Chief Financial Officer, Treasurer and Secretary of the Company, resigned effective immediately from all positions he held with the Company to pursue other opportunities. Mr. Miller’s decision to resign did not result from any disagreement with the Company, its management or its board of directors on any matter, whether related to the Company’s operations, policies, practices or otherwise. On March 10, 2026, the Company’s Board of Directors elected Adam Pelavin and Yaron Adler to serve as members of the Board, effective immediately, with terms expiring at the Company’s 2026 annual meeting of stockholders and thereafter until their successors are duly elected and qualified, or until earlier death, resignation, or removal. In connection with these elections, the Board approved fixing the size of the Board at four members. Mr. Pelavin was appointed to the audit committee, and Mr. Adler was appointed to the compensation committee. On March 10, 2026, the Company appointed Douglas Karriker as its Chief Financial Officer, effective March 10, 2026. Mr. Karriker previously served in roles at the Company and has relevant employment experience. There is no arrangement or understanding pursuant to which he was selected as an officer, and the Company is not aware of any related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.

5000000

750000

168182

0.0999

1200000

1000000

0.10

0.15

2500

10000

The Agreement further provides Theracell with access to a credit facility of up to $10,000,000, available in tranches with the Lender’s prior written approval in its sole discretion. Drawdowns under the facility are subject to the same terms as the Loan, other than the conversion feature. Theracell has drawn $10,000,000 under the credit facility as well as $775,000 paid over and above the $10,000,000 credit line amount as of the date of this annual report on Form 10-K. The previously outstanding debt facilities from Newtech Investment Holdings, LLC and Ariel Malik totaling $6,083,857 were repaid from the proceeds of the facility. The Agreement also provides that, following the lapse of 30 days from the Effective Date and subject to the receipt of all necessary corporate and legal approvals, the Lender may appoint three members to the Company’s Board of Directors, which appointments will be subject to the disclosure and filing requirements of the Securities Exchange Act of 1934 and the rules of the Securities and Exchange Commission.

3289490

0.0001

P3Y

250000

Represents an amount lower than $1 Excluding Depreciation, amortization and impairment expenses Relates to impairment expenses on certain property, plant and equipment. Excluding Depreciation, amortization and impairment expenses Including impairment expense for the years ended December 31, 2024 and December 31, 2023 were $8,375 thousand and $0 thousand, respectively (see note 1). Weighted average interest. The terms of the loan were amended on January 1, 2024. Under the new terms, the loan became convertible into shares of Common Stock and the lender agreed to extend the maturity date to December 31, 2024. In consideration for such extension, the Company issued to the lender warrants to purchase 36,000 shares of the Company’s Common Stock at a price of $8.5 per share and granted lender the right to convert any part of the outstanding balance of the loan into Common Stock of the Company at the conversion rate of $8.5 per share. Based on its analysis, the Company concluded that this change in terms should be accounted for as a modification. This loan was converted as per the debt exchange agreement. See note 10. Following the balance sheet date, the maturities of the loans were extended to dates in 2025. The conversion price is not fixed and is contingent on the terms under the loan agreement. Was not yet paid by December 31, 2023. During the year ended December 31, 2024, the Company received $13 thousand from the exercise of employee options for the purchase of 25,519 shares of the Company’s Common Stock at a weighted average price of $0.50.